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The deleterious effects of Type 2 diabetes on the brain have been shown to 
result in a greater prevalence of age-associated cognitive impairment and an 
enhanced risk of age-related cognitive decline in older diabetic populations. Type 2 
diabetes is a complex metabolic disorder. Apart from the negative impact of 
abnormalities intrinsic to diabetes, diabetes-associated cerebral microvascular 
disease may contribute to this accelerated cognitive ageing.  
 
Direct in vivo evaluation of the cerebral microcirculation is difficult in 
humans and the vessels themselves are too small to permit detailed visualisation with 
current neuroimaging methods. The microvasculature of the retina may offer a 
window into such vascular status of the brain as there is considerable homology 
between the retina and cerebral microcirculations. Moreover, the retinal vasculature 
is known to be affected by a wide range of systemic pathologies and is unique in that 
it is the only vasculature that can be directly visualised and photographed.  
 
Retinal microvascular abnormalities (RMAs) have been understudied risk 
factors in cognitive ageing epidemiological research. Few reports have 
comprehensively examined cognitive function in relation to diabetic retinopathy. 
Also the relationship between cognitive function and quantitative aspects of retinal 
vascular network geometry has not been investigated in people with Type 2 diabetes. 
The results of a systematic review reported in this thesis showed inconsistent 
findings on the importance of the association between retinal microvascular 
abnormalities and cognitive dysfunction in predominantly non-diabetic populations. 
This may have reflected substantial differences between studies regarding the choice 
of population under study, the methods applied for measuring and defining RMAs, 
the types of neuropsychological tests administered for assessing cognitive function, 
and the approach taken in data analysis.  
 
The principal aim of the original research described in this thesis was to 
examine the associations of cognitive test performance with severity of diabetic 
retinopathy and quantitative parameters of retinal vascular network in a 
population-based sample of older people with Type 2 diabetes. Objective, 
reproducible and computerized retinal image analysis was used to quantify retinal 
vessel calibres and arteriolar bifurcation geometry in order to detect subtle changes 
in retinal vascular network. A valid estimation of peak prior cognitive ability allowed 
the further exploration of the impact of retinal microvascular abnormalities on 
imputed cognitive decline from best-ever levels of cognitive function to that 
measured in old age. 
 
The analysis was based on a cohort of 547 men and 519 women aged 60-75 
 iv 
years with Type 2 diabetes, randomly sampled from the Lothian Diabetes Register, 
Scotland, in 2006/2007 (the Edinburgh Type 2 Diabetes Study). A battery of seven 
cognitive tests was administered and standard 7-field binocular digital retinal 
photography undertaken. The Mill Hill Vocabulary Scale was used to estimate 
pre-morbid cognitive ability. Diabetic retinopathy was evaluated independently by 
two optometrists using a standardised grading protocol (a modification of the Early 
Treatment of Diabetic Retinopathy Scale). Quantitative retinal vascular parameters 
were measured by myself from a digital image of field 1 using semi-automated, 
computer-based methods. Retinal vessel calibres were summarised as the central 
retinal arteriolar and venular equivalents (CRAE and CRVE, respectively) and 
arterio-venous ratio (AVR). Retinal arteriolar bifurcation geometry was expressed as 
arteriolar bifurcation angles (BA), arterial branching coefficient (BC), and 
sub-optimality (degree of deviation from optimality) of the retinal arteriolar angles. 
The statistical analyses were based on the 1,044 study participants who had both 
gradable retinal images and cognitive testing. 
 
Both general cognition, as indexed by a general cognitive factor reflecting 
the variance common to all the cognitive tests used, and most of the individual 
cognitive tests were negatively affected in participants with diabetic retinopathy 
relative to those without. These cognitive measures also showed a significant 
relationship with increasing severity of diabetic retinopathy (none, mild, and 
moderate-severe). Those with moderate-severe diabetic retinopathy had worst 
performances on general cognitive function, executive function, information 
processing speed, non-verbal memory and mental flexibility. When lifetime decline 
was estimated from peak, prior cognitive level, severity of diabetic retinopathy was 
significantly associated with a greater decline in information processing speed, 
non-verbal memory and mental flexibility and, in men for general cognition and 
executive function. The associations of severity of diabetic retinopathy with general 
cognition, executive function and information processing speed were independent of 
socio-demographic characteristics, cardiovascular risk factors, macrovascular disease, 
mood and hyperglycaemia. The associations with estimated decline in specific 
cognitive measures resulted principally from the impact of diabetic retinopathy on 
general cognitive ability.  
 
The study also showed that larger retinal arteriolar and venular calibres were 
both significantly associated with lower test scores on verbal memory in men. 
Multiple linear regression analyses demonstrated larger retinal arteriolar calibre was 
associated with a significantly greater decline in verbal memory after possible 
confounding by retinal venular calibre and vascular risk factors and disease was 
taken into account. In contrast, the study did not support an independent association 
between retinal venular calibre and cognitive decline in men or in women with Type 
2 diabetes. Parameters of retinal arteriolar bifurcation geometry were not associated 
with cognitive outcome. 
 v 
Overall, these findings support the hypothesis that cerebral microvascular 
disease associated with Type 2 diabetes, reflected by the presence and severity of 
diabetic retinopathy, may exacerbate the effects of ageing on cognitive function. In 
particular, alterations in the blood-brain barrier may be an important 
pathophysiological mechanism in the occurrence of cognitive dysfunction in diabetic 
patients. They further may be added to the knowledge that gained from previous 
pathologic and brain imaging investigations demonstrating a relationship between 
markers of cerebral microvascular disease and cognitive dysfunction in diabetes. The 
role of quantitative parameters of retinal vascular network geometry in 
diabetes-related cognitive impairment is less clear. Prospective studies are required to 
clarify the temporal sequence of these associations and the eventual clinical 
significance of these small, early cognitive function changes. Such a follow-up 
project involving the present study population is underway. From a clinical 
perspective, if the above findings are substantiated, diabetes-associated cognitive 
dysfunction may be amenable to treatment and preventive strategies specifically 
targeted at protecting the cerebral microvasculature and reducing the risk of 
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General Background to Type 2 Diabetes, Cognitive 
Dysfunction and Retinal Microvascular Abnormalities 
 
1.1. Introduction 
Ongoing demographic changes resulting in global ageing of the general 
population mean that cognitive impairment and dementia are becoming increasingly 
important contributors to morbidity and mortality in elderly people. According to the 
2003 World Health Report Global Burden of disease estimates, dementia accounted 
for 11.2% of all years lived with disability among people aged 60 years and over, 
which was greater than stroke (9.5%) or cardiovascular disease (5.0%) (WHO, 2003). 
Currently in the UK, dementia affects nearly 700,000 people over the age of 65 years 
old and is expected to increase more than 100% in incidence by the year 2051 
(Knapp et al., 2007). Even in individuals without frank dementia, cognitive 
impairment, which manifests itself as mild to severe dysfunctions across different 
cognitive domains, limits people‘s quality of life and survival, and constitutes a 
major determinant of long-term institutionalization and dependency in old age 
(Waldstein and Elias, 2003). Furthermore, people with cognitive impairment are at 
greater risk of developing dementia over time. Owing to their increasing prevalence 
and devastating impact on ageing populations, cognitive impairment and dementia 
are placing a large burden of support on carers and society more widely. A major 
public health challenge is therefore to identify people at high risk of cognitive 
impairment so that they might benefit from preventive measures and therapeutic 
interventions (Price et al., 2006).  
   
When the brain undergoes neurodegenerative changes associated with 
ageing, marked variation between individuals indicates that clinically relevant 
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cognitive decrements may occur due to specific pathologies, for example vascular 
disease. One of the most important risk factors for vascular disease is Type 2 diabetes, 
which has been associated with an accelerated rate of cognitive decline in addition to 
a higher incidence of stroke and dementia. As early as 1976, diabetes mellitus was 
considered ‗a special kind of accelerated aging‘ because it increases an individual‘s 
susceptibility to degenerative disease (Kent, 1976). More recently, diabetes has been 
shown to confer a two-fold or greater increase in risk of vascular dementia as well as 
a 1.2 to 2.3 times greater risk of Alzheimer‘s disease (Cukierman et al., 2005; 
Biessels et al., 2006). Despite the probable role of diabetes in accelerated brain 
ageing, there is no clear evidence to date that diabetes management affects the rate or 
nature of cognitive dysfunction (Cukierman et al., 2005).  
 
Worldwide estimates suggest that Type 2 diabetes will increase in 
prevalence to 366 million by the year 2030 (Wild et al., 2004). With increased early 
diagnosis and improved glycaemic control, the mortality rate resulting from 
diabetes-related complications has decreased. However, as people with diabetes live 
longer, the incidence of diabetes-related cognitive impairment in elderly people will 
rise and become increasingly evident, underscoring the importance of furthering our 
knowledge of the mechanisms underlying these disruptions. Potential risk factors, if 
appropriately identified and modified, may pave the way for delaying the onset and 
reducing the burden of cognitive impairment attributable to Type 2 diabetes. 
 
As a progressive, life-long condition, Type 2 diabetes is a complex 
metabolic disorder and is associated with the development of both macro and 
microvascular diseases. Current interventions aimed at reducing the impact of 
macrovascular disease in non-diabetic populations (reduction of blood pressure, 
lipid-lowering therapy, use of aspirin and anti-oxidant vitamins) have had little effect 
on cognitive decline, except by preventing major strokes (PROGRESS Collaborative 
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Group, 2001; Heart Protection Study Collaborative Group, 2002a,b; Kang et al., 
2007). 
 
Microvascular disease is the hallmark of chronic hyperglycaemia which is 
characterised by structural changes in the capillary walls, occurring in eyes, kidney 
and peripheral nervous system. Based on findings from neuropathological and 
neuroimaging studies, microvascular disease in the brain may also play a role in 
cognitive dysfunction. However, investigation of potential links between 
microvascular diasease and cognitive impairment in Type 2 diabetes has been 
restricted to small and clinic-based studies because direct in vivo evaluation of the 
cerebral microcirculation is difficult in humans and requires sophisticated 
neuroimaging techniques (Strachan et al., 2008a). The microvasculature of the retina 
therefore provides a possible and more accessible window into the status of the small 
vessels of the brain given that the two vasculatures are developmentally related, of 
similar size and share physiologic characteristics (Patton et al., 2005). Changes in the 
retinal vasculature may reflect the analogous changes in the cerebral vasculature and 
the retinal vasculature can be directly visualised and photographed.  
 
This thesis explores the association between measures of retinal 
microvasculature and cognitive function in older people with Type 2 diabetes. Figure 
1 illustrates a hypothesised role of retinal microvascular abnormalities as proxy 
indicators of cerebral microvascular disease in the aetiology of cognitive dysfunction 
in Type 2 diabetes. The first, introductory chapter, provides general background 
information on the epidemiology of Type 2 diabetes and cognitive impairment, 
following which is a review of studies investigating the relationships between Type 2 
diabetes, diabetes-related risk factors, and cognitive dysfunction in older people. An 
overview of retinal microvascular abnormalities and their associations with major 
vascular risk factors, cerebro- and cardio-vascular disease is also provided and 
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methods for evaluation of retinal microvascular abnormalities associated with 

















Figure 1: Diagram of potential relationships between retinal microvascular 
abnormalities as ‗surrogate‘ markers of cerebral microvascular disease and cognitive 
dysfunction in Type 2 diabetes 
 
Chapter 2 focuses on retinal microvascular abnormalities that may serve as 
surrogate markers of cerebral microvascular disease and provides a systematic 
review on the association between these abnormalities and cognitive dysfunction. 
Chapter 3 describes the background and objectives of the present thesis. The 
methodology of the original research project and current study is described in 
Chapter 4, and the results in Chapter 5. Chapter 6 is a discussion of the main findings 
and methodological issues arising in the study. In Chapter 7, the conclusions of the 
study are summarised, followed by the recommendations for future research. 
Diabetic retinopathy or other 
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1.2. Type 2 diabetes 
 
1.2.1. Definition  
The concept ‗Diabetes Mellitus‘ is used as a general term for describing a 
group of metabolic diseases, characterised by chronic hyperglycaemia, due to either 
insulin deficiency or to the impaired effectiveness of insulin action, or a combination 
of both. Hyperglycaemia in turn causes damage to many organs, in particular blood 
vessels and nerves. Type 2 diabetes (formerly known as ‗non-insulin-dependent‘) is 
the most common form of diabetes caused by varying degrees of defects in both 
insulin secretion and action, accounting for as much as 90 to 95% of all cases of 
diabetes. The term ‗non-insulin-dependent‘ diabetes has been replaced in favor of an 
aetiological classification rather than by treatment modality. Other former terms 
‗adult-onset‘, and ‗maturity-onset‘ diabetes have less specificity (since Type 2 
diabetes may also occur in children and adolescents) and are therefore no longer in 
use. This thesis focuses on Type 2 diabetes in older adults. 
 
1.2.2. Pathophysiology  
 
Normal glucose homeostasis 
In healthy people, blood glucose levels are normally maintained within a 
narrow range by the harmonization between glucose absorption, uptake and 
metabolism by peripheral tissues and hepatic glucose production (Saltiel and Kahn, 
2001). Insulin is the main hormone for the regulation of blood glucose levels. It is 
secreted by pancreaticβ-cells in response to elevated blood glucose, and exerts its 
major biological effects by binding to and activating a specific plasma membrane 
receptor in peripheral target tissues. Insulin stimulates uptake in muscle and fat cells 
by translocating glucose transporter-4 from intracellular sites to the cell surface. 
Thereafter, insulin promotes glycolysis as well as storage of glucose and other 
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substances by stimulating glycogen, lipid and protein synthesis. In hepatocytes, 
insulin stimulates lipid and glycogen synthesis and inhibits the production and 
release of glucose by suppressing glycogenolysis and gluconeogenesis (Alberti and 
Zimmet, 1998; Kahn, 2003; Lyssenko et al., 2005).    . 
 
Insulin resistance and β-cell dysfunction 
An array of metabolic alterations have been identified to explain the gradual 
deterioration of glucose homeostasis leading to Type 2 diabetes, including peripheral 
insulin resistance, overproduction of glucose in the liver, and progressive 
abnormalities in pancreatic β -cells function (Kahn 2003; Katsilambros and 
Tentolouris, 2003; Lyssenko et al. 2005). These defects could be attributable to the 
interplay of environmental risk factors (e.g. obesity) with a genetic susceptibility and 
are exacerbated by hyperglycaemia itself which can damage the β -cell 
(‗glucotoxicity‘) (Katsilambros and Tentolouris, 2003). 
 
Insulin resistance 
Insulin resistance refers to a metabolic condition in which physiological 
concentrations of insulin fail to produce their biological effects occurring in all 
insulin-dependent tissues, primarily skeletal muscles, adipose tissue and the liver. 
Specifically, in skeletal muscle, which accounts for more than 80% of 
insulin-stimulated glucose use, insulin resistance is manifested by decreased glucose 
uptake and impaired glucose use by non-oxidative glucose disposal (e.g. glycogen 
formation). In the liver, insulin resistance is characterised by failure to suppress 
glucose output, leading to an overproduction of glucose. In adipose tissue, rates of 
lipolysis and production of circulating non-esterified fatty acids (NEFAs) are not 
inhibited due to impaired ability of insulin, which further stimulates gluconeogenesis, 
triglyceride synthesis and glucose production in the liver as well as impairing 
glucose utilization by skeletal muscle (McGarry, 2002; Katsilambros and Tentolouris, 
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2003). Figure 2 shows the impact of insulin resistance on glucose homeostasis. 
Several possible mechanisms could be involved in the loss of insulin sensitivity. 
These include a decrease in glucose transport due to a defect in the insulin-signaling 
pathway in target tissues, or to an excessive release of NEFAs and an over-secretion 
of inflammatory cytokines and adipokines from the adipose tissue (Virally et al., 
2007). In addition to active fatty acid oxidation in liver, an over-secretion of 
glucagon may also contribute to increased gluconeogenesis. There are a number of 
factors associated with insulin sensitivity, such as age, ethnicity, other genetic and 
environmental factors as well as the interaction between them (Kahn, 2003). Among 
these, lifestyle changes could, at least in part, explain insulin resistance, including 
overall or intra-abdominal obesity, smoking, physical inactivity and some dietary 
factors (Kahn, 2003; Parillo and Riccardi, 2004).  
 
Figure 2: Impact of insulin resistance on glucose homeostasis. Blood glucose tends 
to rise because of both increased hepatic glucose production and decreased 
insulin-mediated uptake and use of glucose by peripheral tissues (Reproduced from 
Katsilambros and Tentolouris, 2003)  
 
In addition to impaired glucose tolerance, insulin resistance is often 
accompanied by a cluster of other metabolic abnormalities, such as central obesity 
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(overweight with fat deposits mainly around the waist), dyslipidaemia, hypertension, 
hypercoagulability and microalbuminuria (Reaven, 1988). This combination of risk 
factors is referred to as ‗metabolic syndrome‘, ‗insulin resistance syndrome’or 
‗syndrome X‘ (Isomaa, 2003). 
 
β-cell dysfunction 
β-cell dysfunction refers to a decrease in the sensitivity of β-cells in 
response to glycaemic stimuli and/or a reduction of insulin secretion, including 
abnormalities in pulsatile insulin release and in insulin secretion kinetics, quantitative 
and qualitative abnormalities of insulin, β-cell loss and its progression (Virally et 
al., 2007). As a consequence, insulin responses during an oral glucose tolerance test 
are delayed and reduced (Alberti and Zimmet, 1998; Kahn, 2003). Possible 
mechanisms have been proposed to explain the progressive reduction in insulin 
response, including genetic defects in β-cell mass or function, abnormalities in the 
secretory process due to prolonged exposure to increased levels of glucose 
(glucotoxicity) or NEFAs (lipotoxicity), or both, and amyloid deposition in the islets 
(El-Assaad et al., 2003; Stumvoll et al., 2005). 
 
Given the complexity as well as the long-term nature of Type 2 diabetes, the 
metabolic pathways and the sequence of underlying defects leading to the condition 
have remained elusive. The prevailing view is that insulin resistance is compensated 
for by the adaptive capacity of theβ-cells to increase insulin concentrations, but if 
insulin resistance worsens, a progressively elevated insulin demand results inβ-cell 
exhaustion in susceptible individuals, leading to a subclinical stage of glucose 
intolerance (Kahn, 2003; Lyssenko et al., 2005). However, abnormalities of insulin 
secretion without impairment of insulin sensitivity have been demonstrated in 
first-degree relatives of individuals with Type 2 diabetes (Pimenta et al., 1995). As 
well as during the course of the disease, the relative contributions of insulin 
resistance and β-cell dysfunction in the pathophysiology of T2DM may also differ by 
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ethnic background (Alberti and Zimmet, 1998; Kahn 2003). 
 
1.2.3. Clinical manifestations 
As a direct result of high glucose concentrations, diabetes may present with 
characteristic symptoms such as thirst and polyuria. However, Type 2 diabetes starts 
for many individuals early in life and remains asymptomatic for a long period of time. 
It may be noted only after certain medical complications appear. The long term 
complications include progressive development of disease of the capillaries of the 
kidney and retina, damage to the peripheral nerves and excessive atherosclerosis 
(Ekoé et al., 2001). The clinical manifestations of these complications therefore 
include nephropathy that may lead to renal failure, retinopathy with potential 
blindness, neuropathy with risk of foot ulcers, amputation and automatic dysfunction. 
These individuals have a greatly increased risk of cardiovascular, peripheral vascular 
and cerebrovascular disease but rarely experience ketoacidosis following an episode 
of extreme hyperglycaemia. In contrast to Type 1 diabetes due to an absolute lack of 
insulin, many patients with Type 2 diabetes can control their blood glucose levels by 
losing weight, modifying diet, or taking oral anti-diabetic agents that stimulate 
insulin secretion or enhance insulin action in muscle and the liver. Daily exogenous 
insulin injections are usually required only when metabolic control is extremely poor 
or diet and oral medication regimens have failed (Ryan, 2001).  
 
1.2.4. Diagnostic criteria  
Diagnosis of diabetes is based on blood glucose levels from either a fasting 
or random plasma glucose test and/or an oral glucose tolerance test. The fasting 
plasma glucose (FPG) test is based on the blood glucose concentration after an 
overnight fast (no caloric intake for at least 8 hours), in contrast to a random plasma 
glucose test where fasting is not required. The oral glucose tolerance test (OGTT) is 
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based on the intake of 75-g glucose in 250-300mL water by a fasting subject, with 
measurement of blood glucose both after fasting and 2 hours after the glucose intake. 
The revised World Health Organization (WHO) diagnostic criteria posed in 1999 are 
currently used in the diagnosis of DM (Figure 3). In these updated criteria (compared 
with the old WHO 1980, 1985 criteria) diabetes is clinically defined as a FPG level 
≥7.0 mmol/L on two separate occasions or following the OGTT, a 2 hour 
post-prandial glucose level (2hPPG) ≥11.0 mmol/L (WHO, 1999; WHO, 2006). 
These diagnostic thresholds have been shown to have high sensitivity and specificity 
for identifying people with and without microvascular complications (e.g. 
retinopathy and nephropathy) of diabetes associated with chronic hyperglycaemia 
(McCane et al., 1994; Engelgau et al., 1997; Expert Committee on the Diagnosis and 
Classification of Diabetes Mellitus, 1997). 
 
One abnormal laboratory value is diagnostic in symptomatic patients; two values are required 
in asymptomatic subjects. 
 
Fasting Plasma Glucose (FPG)               ≥7.0 mmol/L (126mg/dL)     or 
Random Plasma Glucose (RPG)              ≥11.0 mmol/L (200mg/dL) 
 
The Glucose Tolerance Test is only required for borderline cases using the above tests 
Fasting Plasma Glucose (FPG)               ≥7.0 mmol/L (126mg/dL)    and/or  
2hr Oral Glucose Tolerance Test (OGTT)       ≥11.0 mmol/L (200mg/dL) 
 
Figure 3: World Health Organization (WHO) diagnostic criteria 1999 for diabetes 
mellitus (Reproduced from Cichowska, 2004). 
 
For epidemiological studies, the WHO recommends the use of the 2-h 
glucose criteria alone as the best method largely due to the concerns about ensuring 
the fasting status of subjects (WHO 1985; WHO 1999). Although similar to the 
WHO diagnostic criteria, the American Diabetes Association recommends in 
epidemiological studies, using the fasting glucose testing only in the interest of 
standardisation and facilitation of field work as well as less costs (Expert Committee 
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on the diagnosis and classification of diabetes mellitus, 1997). Recent studies have 
shown that if the FPG test alone is used, up to 31% of the diabetic subjects are not 
being diagnosed compared with the practice of using both the FPG test and the 
OGTT (DECODE 1999; DECODE 2003). Questions have been raised though 
whether these recommendations are valid as studies have also shown that fasting and 
2-h glucose criteria do not identify the same groups of individuals (DECODE 2003). 
For example, young and obese subjects are more likely to have diagnostic FPG 
values than diagnostic 2-h glucose values, whereas women and elderly subjects are 
more likely to have raised isolated OGTT levels (Shaw et al., 1999; DECODE 1999; 
DECODE 2003). The differences between subjects may reflect the fact that the two 
tests represent physically different aspects of glucose metabolism and are therefore 
likely to be influenced differently by the ageing process and other factors (Anderson 
and Gale, 2002). Using only one of the criteria could probably introduce bias to 
studies and therefore impact on the estimated prevalence of diabetes. 
 
1.2.5. Prevalence and incidence 
Type 2 diabetes (T2DM) is a relatively common disease affecting many 
adults and has reached epidemic proportions worldwide (Zimmet et al., 2001). This 
increase in prevalence of T2DM has accelerated due to a rise in incidence which is 
mainly driven by increasing obesity rates globally and ageing population structures 
in developed countries, increased migration of susceptible populations accompanied 
by shifts in lifestyle and improved survival in people with diabetes (Lipscombe and 
Hux, 2007).  
 
The concept of ‗diabetes of the elderly‘ groups together aging long-term 
diabetic patients and older diabetic patients in whom diabetes has recently been 
identified. Different sources of data can provide population-based estimates of the 
prevalence and incidence of T2DM in elderly populations, including national 
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statistics and population surveys. Overall, the estimated prevalence based on 
self-report or doctor-diagnosed disease from interviews/questionnaires or registers 
are underestimates of the total prevalence of diabetes, which includes individuals 
with both known and undiagnosed T2DM. The prevalence of undiagnosed DM can 
only be estimated from biochemical testing of blood samples and is highly dependent 
on the actual measurements used, such as a fasting blood glucose or oral glucose 
tolerance test, and the type of blood specimen taken. In general the prevalence of 
T2DM varies due to these methodological differences and the diagnostic criteria used 
to define the disease as well as the risk factor profile of the cohort (e.g. obesity, 
physical activity, deprivation and genetic differences) and by geographical regions or 
countries. An overview of population studies on the total prevalence and incidence of 
both diagnosed and undiagnosed T2DM, in particular in people aged 60 years and 
over is given below. 
 
In the general population people aged 60 years and older, prevalence of 
T2DM was higher than in any other age category. Patients within this age range 
accounted for more than half (54%) of the total Type 2 diabetes population (The 
International Diabetes Federation, 2006). Table 1 lists the large scale studies that 
have estimated the prevalence of T2DM. The prevalence of diagnosed T2DM 
assessed by recall of a previous doctor‘s diagnosis of DM on questionnaire varied 
from 6.6% to 24.7% in men aged 60 years or over and from 5.1% to 22.4% in 
women of the same age. The estimated total T2DM prevalence (diagnosed and 
undiagnosed) ranged from 13.0% to 41.0% in men and from 10.6% to 34.6% in 
women, with Asian Indians having the highest prevalences in both sexes. The 
proportion of undiagnosed T2DM in these aged populations was as high as 60%. For 
example, in the combined cohort of 8,538 individuals aged 60-79 years from the 
British Regional Heart study and the British Women‘s Heart and Health study, the 
prevalence of undiagnosed T2DM using the fasting glucose criteria alone was 5.4% 
and the total prevalence was 11.8% in mixed subjects (Thomas et al., 2005). The use 
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of the 2-h glucose criteria has resulted in higher prevalence rates of undiagnosed 
T2DM than those observed by using fasting glucose criteria. In the KORA survey 
(Rathmann et al., 2003), for example, age-specific prevalence rates for men were as 
follows: 8.1% in men aged 60-64 years, 8.9% in those aged between 65 and 69 years, 
and 13.3% in men 70 years and older. For women, the proportions with undiagnosed 
DM were 7.3%, 8.2% and 7.1%, respectively. As Table 1 shows, although in subjects 
older than 60 years of age there is some evidence that total prevalence rates are 
slightly higher in females than in males, gender differences have not been observed 
in other studies. 
 
Incidence may not be a particularly useful concept in T2DM given that the 
disease remains asymptomatic for a considerable time and the time at which the 
disease process commenced is unknown for almost all the cases. There are far fewer 
reports on the incidence of T2DM than on prevalence. In the Hoorn Study, the 
incidence of T2DM was based on both fasting and 2-h glucose measurements in 610 
men and 732 women aged 50-75 years. The 6-year cumulative incidence was 
estimated at 10.5% for men and 9.4% for women (de Vegt et al., 2001). In the 
Atherosclerosis Risk in Communities (ARIC) Study of 12,107 subjects aged 45-64 
years, after 9 years, the incidence per 1000 person-years was 23.4 in men and 25.1 in 
women among African Americans, and 15.9 in men and 10.4 in women among white 
adults (Brancati et al., 2000). These results demonstrate that as with prevalence the 
incidence in populations varies depending on age structure and characteristics of the 
populations as well as the diagnostic methods used. However, most studies show that 
the incidence rates of T2DM are higher in older people than in younger people. 
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Table 1: Prevalence of diagnosed and undiagnosed T2DM defined by 2hPG and/or FPG criteria in older people from different population studies 
Reference           Location          Population & N             Age group  
                                   (age in years)              (≥60yrs) 
 
         Undiagnosed T2DM (%)  Diagnosed             Total 
T2DM (%)           T2DM(%) 
 
FPG ≥7.0 and/or 2h      FPG≥7.0      Criteria   
 PG≥11.1 (mmol/l)        (mmol/l)      
Dunstan et al. (2002) Australia Total in study 11,247 both sexes 
(25+)               M/F 
                  
























Total in study 1653 both sexes 




















DECODE  Study 
Group ( 2003) 
 




Total in study 15,606 both sexes 
(30-89)               M/F 
 























DECODA  Study 
Group ( 2003) 
 




Total in study 24,335 both sexes 
(30-89)               M/F 
  (Chinese & Japanese) 






































Thomas et al. (2005)  UK 4252 M, 4286 F (60-79)   M/F              60-79  5.7/5.2 ADA 7.6/5.1 13.0/10.6 




 (20+)                 M/F    
FPG: Fasting Plasma Glucose; M: Male, F: Female; N: Number; ADA: American Diabetes Association; WHO: World Health Organization; DECODE: Diabetes 
Epidemiology: Collaborative analysis of Diagnostic Criteria in Europe; DECODA: Diabetes Epidemiology: Collaborative analysis of Diagnostic Criteria in Asia; NHANES: 
National Health and Nutrition Examination Survey
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1.3. Cognitive dysfunction 
 
1.3.1. Cognitive function and neuropsychological assessment 
Cognition or cognitive function is defined as conscious mental activity that 
is not principally sensory or emotional, comprising a large range of higher brain 
functions related to the selection, acquisition, storage, manipulation and organization 
of information (Deary and Batty, 2007). Different aspects of mental function can be 
conceptualized, measured, and sometimes correlated with underlying 
neuroanatomical systems (Lezak, 1983). The pragmatic approach taken by most 
people when measuring cognitive function is to use validated neuropsychological 
tests (also referred to as cognitive or mental tests), which have been derived by using 
comparisons between patients with circumscribed brain lesions and normal controls 
(Woodruff-Pak, 1997). In epidemiological studies, neuropsychological assessments 
have been applied to determine cognitive aspects that are disproportionately affected 
either by normal ageing or other pathological processes. Individual 
neuropsychological tests have been proven to be sufficiently sensitive and specific to 
diagnose more severe cognitive deficits such as dementia (Lezak, 1995). However, 
these individual tests are normally designed to assess a single major aspect or 
‗domain‘ of intellectual function and some tests are not sensitive enough to detect the 
more subtle changes in cognitive function due to a limited range of scores. Therefore, 
a comprehensive cognitive examination with multiple neuropsychological tests is 
often required in studies to address a wide range of cognitive function and domains.  
 
Though each individual may have strengths in specific areas, consistent 
empirical findings from large, representative population samples reveal that all 
cognitive tests tend to correlate positively with one another. People who perform 
well on one mental task are more likely to do well on most others, despite large 
variations in the tests‘ contents (Deary, 2000). Overall cognitive abilities can be 
summarized by a common factor resting on the correlations among test scores, 
namely general intelligence or g. This was discovered by Spearman in 1904, who 
invented the factor analytic method which enabled the determination of the degree to 
which each of the cognitive measures correlated with the general cognitive factor 
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(Spearman, 1904). A general factor may then be defined as the first unrotated 
principal component (or factor) from a correlation matrix of a battery of cognitive 
tests administered to a sample of population (Deary and Batty, 2007).  
 
With the subsequent addition of cognitive test data as well as introduction of 
more sophisticated statistical methods, the central role of the general intelligence 
factor has not changed but only been reinforced (Detterman, 2006). In particular, 
there is a growing consensus on a hierarchical model of cognitive ability with g at the 
pinnacle and group factors of ability (which describe major correlated domains of 
cognitive ability, such as memory, verbal and visuospatial) at the next lower level 
(Carroll, 1993). The g-factor was considered to be general in the sense that it was 
likely to be present to some degree in nearly all measures of cognitive ability (Caroll, 
1993). More recently, there is empirical evidence that the g factor from very different 
test batteries is almost perfectly correlated (Johnson et al., 2008), and it is the g 
factor that carries most of the predictive power of mental tests (Deary et al., 2010), 
lending further support on the consistency and accuracy of its measurement. Further 
detailed description of the ‗hierarchical model‘ of cognitive abilities led to the 
proposal of two yet substantially correlated aspects of general intelligence, fluid and 
crystallised abilities (Horn, 1994).  
 
1.3.2. Age-associated cognitive decline 
Cognitive impairment is generally taken to mean either decreased ability 
relative to the population norm (e.g. their age cohort) at a point in time, or a decline 
in the cognitive abilities of an individual comparing their current with their prior 
ability. While some individuals are able to maintain high levels of cognitive function 
into extreme old age, it is more common for older people to experience cognitive 
decline. The shift from mild age-associated changes, to a subclinical state of 
cognitive impairment, to more severe form of clinical dementia, is a continuous 
spectrum of cognitive abilities without defined boundaries.  
 
The term age-associated cognitive decline or normal (non-pathological) 
cognitive ageing is used to describe the commonly noted changes in cognitive ability 
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that are inherent to the ageing process. Several other terms, which are thought to be a 
variant of normal ageing rather than a distinct pathological entity have also been 
developed, including ‗Benign Senescent Forgetfulness‘, ‗Age-Associated Memory 
Impairment‘ (AAMI) and ‗Age-Consistent Memory Impairment‘ (ACMI) (Ritchie et 
al., 2001; Bischkopf et al., 2002; Petersen, 2004). 
 
In general, these cognitive changes may present in four major patterns. First, 
there is little age-associated decline in some mental functions (crystallised 
intelligence), such as general knowledge, vocabulary, and arithmetic ability, which 
may remain stable or even increase with age through the influences of education and 
cultural experience. However, other aspects of mental capabilities begin to decline 
during adulthood, with some further acceleration of decline in very old age (Hedden 
and Gabrieli, 2004; Park and Reuter-Lorenz, 2009). These cognitive processes, 
collectively called ‗fluid‘ abilities, include memory, reasoning, processing speed and 
executive functions which may be particularly vulnerable to biological ageing as well 
as neurological damage (Anstey and Christensen, 2000; Salthouse, 2001). 
Furthermore, when one fluid mental domain declines others are likely to do so also, 
and some of the age-related declines could be underpinned by a decline in the 
general cognitive factors (Wilson et al., 2002; Deary et al., 2009). Secondly, in all 
affected cognitive domains, slowed information processing speed appears to 
contribute largely to age-associated decline and the slowing has begun by the early 
adulthood (Der and Deary, 2006). Thirdly, rather than presenting an abrupt shift from 
stable to declining cognitive performance, many of these cognitive abilities that 
decline with age appear to do so in a gradual and linear trend or more complex 
manner (Salthouse, 1991). Also, the cognitive ageing process manifests as significant 
inter-individual differences in both the level of cognitive ability and rate of decline, 
in which age explained less than one sixth of the total variance (Salthouse, 1991). 
The individual differences in cognitive ability in old age may reflect not only 
differences in the degree to which change (typically deterioration) has taken place 
but also differences in prior cognitive ability (Deary et al., 2009). The latter is an 
enduring feature of mental life throughout adulthood. Indeed, recent empirical data 
have shown that childhood intelligence accounts for at least 50% of the variance in 
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cognitive ability in old age in people without dementia, which in turn is largely 
determined by genetic factors (Deary et al., 2009).  
 
1.3.3. Neurobiological mechanisms of age-associated 
cognitive decline 
Both hereditary and environmental factors could contribute to normal 
cognitive ageing. Although there is a putative link between age-associated changes in 
brain structure and cognitive ageing, the exact neurobiological mechanism 
underlying age-associated cognitive decline is unknown. Several possible 
explanations have been proposed, in particular highlighting individual differences in 
normal cognitive ageing. 
 
Overall structural changes in brain ageing involve a steady decrease in the 
weight and volume of the brain, and the latter is balanced by an increase in 
ventricular spaces and cerebrospinal fluid. The manners in which the shrinkage 
occurs are less clear but may reflect a reduction in neuronal size and number and a 
decrease in dendritic synapses or loss of synaptic plasticity (i.e. connections with 
other neurons) (Raz et al, 2005). Compared with the brain on the whole, 
age-associated shrinkage is much smaller but does not occur to the same extent in the 
cerebral parenchyma. For example, the prefrontal cortex is most affected and the 
occipital least, showing an anterior–posterior gradient (Raz and Rodrigue, 2006). 
Also brain atrophy is steadier in grey matter (the neuron cell bodies) and cortical 
thickness than in white matter (the nerve fibres connecting different brain areas) 
(Deary et al., 2009). Furthermore, cerebral dopamine receptor density declines with 
age, which relates to neurotransmitter levels and plays a central role in regulating 
attention and in modulating response to contextual stimuli (Hedden and Gabrieli, 
2004). These normative age-associated changes in brain structure could be 
attributable to the effects of oxidative stress, recurrent inflammation reactions, 
age-related vascular and microvascular changes and stress-related corticosteroid 
levels (Whalley et al., 2004; Raz and Rodrigue, 2006). 
 
The loss of white matter integrity particularly in the prefrontal region has 
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also been proposed to play a crucial role in normal cognitive ageing, since it leads to 
impaired information transfer between different cortical areas, from a loss of transfer 
speed in the case of demyelination to complete disconnection when axonal 
disruptions occur (Deary et al., 2009). Interactions between distant cortical areas are 
considered as crucial for the emergence of higher cognitive functions (Sullivan and 
Prefferbaum, 2006). Recent structural and functional neuroimaging studies supported 
the effect of white matter lesions in cognitive ageing (Frisoni et al., 2007). 
 
       Two major assumptions pertaining to cognitive reserve have been widely 
used in an attempt to explain how, in the face of normative age-associated structural 
brain changes, individuals vary greatly in the process of cognitive ageing (Stern, 
2009). The first is neural reserve, defined as the brain‘s capacity to buffer the effects 
of insults, and which may differ between people. The second assumption, namely 
neural compensation, is that the ageing brain may compensate structural losses in 
functional areas by recruiting previously unrelated parts of the brain to take over 
cognitive function roles (Hedden and Gabrieli, 2004; Sullivan and Prefferbaum, 
2006). The main determinants of cognitive reserve are early life cognitive ability, 
educational attainment and occupational status, with the former being a strong 
predictor of the latter two (Whalley et al., 2004; Salthouse, 2009). 
 
1.3.4. Dementia 
Relative to normal levels of intellectual function, at the opposite end of the 
cognitive continuum in old age are the severe cognitive deficits associated with 
dementia. Rather than a single biological condition or disease, dementia represents a 
constellation of symptoms, characterised by a chronic or progressive decline in 
cortical and/or subcortical functions including memory, reasoning and 
communication skills. As the condition progresses, complex cognitive impairment 
occurs, such as a gradual loss in ability to carry out daily activities (Ritchie and 
Lovestone, 2002; van der Flier and Scheltens, 2005). Moreover, these dementia 
symptoms are usually accompanied by disturbance of mood, behavior and 
personality. Different types of dementia have been identified and the most common 
forms are Alzheimer‘s disease (AD) and vascular dementia (VaD). 
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AD is a degenerative disorder and typically begins with difficulty recalling 
recently learned material only, worsening over time to further loss of memory and 
decrements in other cognitive and functional abilities. Pathologically, AD is 
characterised by the presence of neuritic amyloid plaques and neurofibrillary tangles 
of hyperphosphorylated tau protein, seen upon post-mortem examination of the brain. 
Although a definitive diagnosis can only be made with evidence of neuropathologic 
features at autopsy, the accuracy (positive predictive value) of different clinical 
criteria for AD is found to be reasonably high (above 80%) when compared with a 
neuropathologic diagnosis (Graves, 2004). Currently, standardised diagnostic criteria 
for AD involve the development of memory impairment, accompanied by 
impairment of at least one of the other cognitive domains, including aphasia, apraxia, 
agnosia or a disturbance of executive functioning, which cannot be explained by 
other neurologic or psychiatric disorders (American Psychiatric Association, 2000) 
 
Vascular dementia is a heterogeneous term for a wide variety of vascular 
lesions including large -and small-vessel disease of extra –and intra-cranial arteries 
that result in dementia because of cerebral infarction, hypoperfusion or haemorrhage 
(Román, 2002; van der Flier and Scheltens, 2005). Large vessel VaD is usually 
thrombo-embolic in nature and may result in cerebral damage either through multiple 
discrete cerebral infarcts (multi-infarct dementia) leading to a stepwise deterioration 
in frontal lobe executive function, or a single major infarct in a critical area of the 
brain (strategic infarct dementia). The most common form is a consequence of 
cerebral small vessel disease (subcortical ischaemic VaD) and is associated with the 
presence of lacunar infarcts and white matter lesions (Román et al., 2002; Chui, 
2007). Because of these different vascular pathologies underlying VaD, no single set 
of clinical criteria have become universally accepted for its diagnosis (Graves, 2004). 
Currently, the clinical diagnosis of VaD requires that patients fulfill criteria for 
‗dementia‘ and present evidence of cerebrovascular disease based on clinical 
information reflecting vascular risk profile and/or neuroimaging. Given that the 
criteria for AD formed the basis of criteria for all dementia, this approach to the 
diagnosis of VaD is likely to be overly biased towards AD, emphasizing memory 
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loss and progressive, irreversible decline as the primary symptoms rather than the 
pattern of motor slowing and executive deficits typically associated with VaD 
(Rockwood, 2002; Selnes and Vinters, 2006). Moreover, the severity and type of 
lesions on neuroimaging required for a diagnosis of VaD remain controversial 
(Selnes and Vinters, 2006). These obstacles prevent a clear separation between AD 
and VaD in epidemiological investigations. Another major complication to the study 
of specific dementia subtypes is the increasing recognition of mixed dementia. 
Vascular dementia frequently co-exists with AD in the same patient and the two 
conditions possibly share underlying risk factors and neuropathological features 
(Ritchie and Lovestone, 2002). 
 
1.3.5. Subclinical cognitive impairment 
Assuming a continuous spectrum between normal cognitive function and 
dementia, another category of ‗mild cognitive impairment (MCI)‘ has been 
introduced in an attempt to characterise an immediate or transitional state of 
cognitive impairment i.e. one which falls outside the limits of normal ageing but is 
insufficient for the diagnosis of dementia. Other alternative terms have also been 
proposed, including mild cognitive decline, ‗cognitive impairment, no dementia‘ 
(CIND) and Mild Cognitive Disorder (MCD), but MCI is widely favoured as the 
diagnostic entity of subclinical cognitive impairment (Davis and Rockwood, 2004). 
Clinically, MCI is a syndrome characterised by decline in one or more cognitive 
domains (usually memory) greater than expected for an individual‘s age and 
education level but to a degree that does not interfere notably with activities of daily 
living (Petersen, 2004). Based on the type of neuropsychological profile, the clinical 
subsets of MCI include non-amnestic and amnestic MCI and the latter is further 
categorized as single or multiple domains (Petersen, 2004; Portet et al., 2006). 
Amnestic MCI has greater rates of progression to dementia, particularly to AD and 
could constitute a prodromal stage of this disorder (Fisher et al., 2007; Gauthier et al., 
2006; Petersen, 2004). 
 
However, the suitability of the concept of MCI in large population-based 
studies has been questioned. The consensus criteria for the diagnosis of MCI 
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incorporate clinical judgment as shown in Figure 4 and are not derived just from 
neuropsychological test cut points. Thus, the concept of MCI may be more reliable 
within a clinical context as most of the work attempting to characterise it has been 
carried out in the memory clinics, where participants would already be experiencing 
sufficient memory challenges to require consultation with a clinician (McDowell, 
2004). While subjects in clinic samples typically show uniform progression of 
cognitive decline, in four large population studies, MCI failed to demonstrate 
temporal stability as a large proportion (from 26 to 32%) of the participants initially 
identified as having MCI were subsequently classified as having no cognitive 
impairment at follow-up (from 1 to 5 years) (Ritchie et al. 2001; Larrieu et al., 2002; 
Fisk et al., 2003; Fisk and Rockwood, 2005). Furthermore, MCI has been shown to 
be a relatively poorer predictor for the onset of dementia in the general population 
(Ritchie et al., 2001).  
 
1. Cognitive complaint (usually memory), preferably corroborated by an informant 
2. Cognitive impairment (usually memory) for age and education 
3. Essentially normal general cognitive function 
4. Largely preserved activities of daily living 
5. Not demented 
Figure 4: Clinical criteria for mild cognitive impairment (Reproduced from Kelley 
and Petersen, 2007). 
 
More recently, the term ‗Vascular cognitive impairment‘ (VCI) has received 
increasing attention. VCI was proposed to define the whole spectrum of mild to 
severe cognitive impairment that shares presumed cerebrovascular morbidity 
(O‘Brien et al., 2003). The cognitive profile of VCI was also suggested to be specific 
and predominantly subcortical, with relatively preserved memory but impaired 
psychomotor and executive functions (Selnes and Vinters, 2006). However, VCI is 
an umbrella term comprising heterogeneous groups, and developing a single, 
uniform set of diagnostic criteria that apply to all subtypes of VCI has been 
challenging (Selnes and Vinters, 2006; Moorhouse and Rockwood, 2008).  
 
1.3.6. Prevalence and incidence of cognitive impairment and 
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dementia 
The difficulties in distinguishing between normative and non-normative 
cognitive ageing, and the inconsistencies in defining cognitive impairment are a 
severe challenge to measuring prevalence and incidence. In particular, prevalence 
estimates of subclinical cognitive impairment vary considerably depending upon 
which definitional classification is used as well as the population sampling and 
assessment procedures. For example, subtle changes to the ‗stringent diagnostic 
criteria‘ such as removing the stipulation of a subjective memory complaint or 
normal activities of daily living, have been shown to significantly increase the 
prevalence of MCI (Fisk et al., 2003). Estimates of MCI have ranged from 3% to 
19% in those aged 65 years and older because of various assessment criteria applied 
(Gauthier et al., 2006). The prevalence estimates for age-associated cognitive decline 
(AACD) have ranged from 21% in those aged 60 and older (Ritchie et al., 2001), to 
27% in those aged 65 and older (Hanninen et al., 1996). In general subclinical 
cognitive impairment is common in the older population and can increase in 
prevalence with the steadily ageing population. However, due to conflicting findings, 
it is not clear whether prevalence varies by sex. Similarly, the incidence rates of MCI 
have ranged greatly from 8 to 58 per 1000 per year in the general elderly population 
(Gauthier et al., 2006), depending on diagnostic criteria, sample structure, follow-up 
and cognitive measures. Furthermore, annual conversion rates from MCI to dementia 
have been found to be high in clinic samples ranging from 10% to 15% but are often 
substantially lower in population-based studies (i.e., 3.8%-6.3%) (Farias et al., 2009).  
 
Despite the use of different methodologies for case identification and 
definition between studies, increases in the prevalence and incidence of dementia 
with age have been consistently reported (Graves, 2004). For example, in an analysis 
of data from the UK, the prevalence of dementia from all causes ranged from 1.3% to 
2.9% among those 65-74 years of age, between 5.9% and 12.2% among those 75-84 
years of age, and from 20.3% to 32.5% in those aged 85 years or above (Knapp et al., 
2007). An age-related trend in dementia prevalence was observed for both sexes. 
Further analyses demonstrated the AD was the dominant type of dementia, 
accounting for 62% of all cases (and was more common in women), while VaD and 
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mixed dementia, accounting for nearly one third (27%) of all cases (and was more 
common in men). Similarly, among participants in the Cardiovascular Health Study, 
a steady increase in the incidence of dementia with age was noted in both men and 
women (Fitzpatrick et al., 2004). Whereas further analyses of subtypes showed a 
steep increase in the incidence of both AD and VaD with age, the incidence rates did 
not vary by sex or race.  
 
1.3.7. Estimated lifetime cognitive change 
Cognitive ability is a measurement of cognitive function at a specific point 
in time. In older people, performance at any single point in time on age-sensitive 
(fluid) cognitive tests reflects both a person‘s prior cognitive state together with the 
extent to which their cognitive state has declined with age or age-associated 
pathologies. The detection and quantification of cognitive impairment simply by 
comparing an individual‘s current test performance with test norms relative to their 
peers cannot therefore give an accurate measure of an individual‘s degree of 
cognitive decline during ageing. Rather, measurement of age-related cognitive 
decline requires a comparison of an individual‘s cognitive ability in old age with 
their prior level of cognitive ability from a period preceding the point at which the 
decline is thought to commence (Crawford, 1992). However, such prior cognitive 
data especially while individuals are still in good health are rarely available (Deary et 
al., 2004a). As a result, prior or premorbid mental ability is commonly estimated by 
using vocabulary and knowledge-based tests, including the Wechsler Test of Adult 
Reading (WTAR) test (Wechsler, 2001), the Mill Hill Vocabulary Scale (MHVS) 
(Raven et al., 1998) and the National Adult Reading Test (NART) (Nelson and 
Willison, 1991), with the latter two being used more frequently. The MHVS requires 
the subject to underline which of six words is closest in meaning to a target word. 
The NART requires the subject to read aloud 50 words, none of which follow normal 
English rules of grapheme-phoneme correspondence and/or stress (Deary and Batty, 
2007). As measures of crystallised intelligence, these types of test scores vary little 
with age, and are relatively resistant to the effects of neurological or psychiatric 
morbidity (Crawford, 1992; Crawford, 2003; Salthouse, 2004). Their use as 
indicators of peak prior cognitive ability has been validated. For example, the NART 
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remained stable before and after identification of mild dementia and showed high 
inter-rater and test-retest reliability (Crawford, 1992; McGurn et al, 2004). Moreover, 
the score in old age correlated highly with childhood IQ (Crawford et al, 2001). 
Good retrospective validity in healthy old people (Deary et al., 2004a) means that the 
estimation of lifetime best cognitive ability from these test scores can be compared 
with the results on fluid intelligence tests to assess the difference and degree of 
potentially clinically significant cognitive decline. For instance, by using linear 
regression, adjusting scores on a fluid mental test for NART has been shown to be a 
valid, instantaneous measure of relative lifetime cognitive change or cognitive 
decline (Deary et al., 2004a). 
 
1.4. Cognitive dysfunction associated with Type 2 
diabetes 
This section provides an overview of empirical studies investigating the 
relationship between Type 2 diabetes and cognitive function. The potential 
mechanisms leading to cognitive impairment in people with Type 2 diabetes are 
described first followed by a description of the extent and the pattern of cognitive 
impairment in people with Type 2 diabetes in late adulthood. In recognition of the 
probable importance of the complications and comorbidities associated with Type 2 
diabetes, including vascular disease, in diabete-related cognitive impairment, a 
further review is presented of studies examining the influence of these and specific 
characteristics on cognitive function.  
 
The aforementioned literature review included only epidemiological studies 
published in the English language and identified primarily by searching MEDLINE. 
Searches used combinations of key words relating to Type 2 diabetes, 
diabetes-related risk factors and diseases of interest (e.g. hypertension, 
hyperlipidemia, cardiovascular disease) and to cognitive function (e.g. cognitive 
decline, cognitive impairment or cognitive performance). References cited in the 
articles identified through the MEDLINE search were also examined. 
 
 27 
1.4.1. Possible pathophysiological mechanisms of cognitive 
dysfunction in people with Type 2 diabetes 
Given that Type 2 diabetes is a complex disorder, it is likely that multiple 
different, synergistic processes intrinsic or related to diabetes may interact to initiate 
and promote cognitive decrements (Strachan et al., 2008b). Apart from genetic 
predisposition (e.g. through variation in the apolipoprotein E gene), a number of 
pathophysiological mechanisms have been proposed to explain the association 
between diabetes and accelerated cognitive decline in older adults. 
 
Ischaemic cerebrovascular disease  
 
Macroangiopathy 
Type 2 diabetes is known to contribute to macroangiopathy in the intra and 
extracranial arteries, including formation of atherosclerotic plaques, ulceration of the 
intima, thickening of the arterial media and calcifications (Mazzone et al., 2008). The 
large-vessel atherosclerosis may lead to cerebral hypoperfusion, infarction and 
commonly results in artery-to-artery embolic stroke (Manschot et al., 2007). 
Ischaemic stroke (embolic or non-embolic) in the brain may be confined to the 
cerebral cortex, the underlying white matter, or both. Thus depending on the area 
affected within the nervous system, focal or lateralized symptoms of cognitive 
dysfunction might occur due to ischaemic injuries to the territory supplied by a given 
cerebral artery. This stroke-related cognitive impairment might not only be 
attributable to diabetes, but also to diabetes associated risk factors for vascular 
comorbidity (Mankovsky and Ziegler 2004; Almdal et al., 2004). Type 2 diabetes 
typically develops in the context of a cluster of vascular and metabolic risk factors, 
including obesity, insulin resistance, atherogenic dyslipidaemia, hypertension, and 
prothrombotic and proinflammatory states. Several risk factors from the metabolic 
syndrome might be predictors of cerebrovascular disease, ischaemic stroke and 
accelerated cognitive decline and dementia (Kalmijn et al., 1996; Kuusisto et al., 
1997; Yaffe et al., 2004a; Whitmer et al., 2005). These risk factors in the metabolic 




At the level of the microvasculature, Type 2 diabetes is associated with 
pathological changes in its principal components including endothelial cells and the 
capillary basement membrane (Lorenzi and Cagliero, 1991). While much is known 
about diabetes-induced microangiopathy in kidney, retinal and peripheral nerves, the 
contribution of diabetes to cerebral microvascular pathogenesis and cognitive 
dysfunction is less clear. Functional properties of the blood-brain barrier (BBB) 
decline with age (Farkas and Luiten, 2001). Recently, using magnetic resonance 
imaging on patients with Type 2 diabetes, increased BBB permeability has been 
suggested to play a role in the increased levels of cognitive impairment in diabetes 
(Starr et al., 2003). Additionally, chronic exposure to hyperglycaemia in diabetes has 
been shown to disturb vascular homeostasis and result in abnormalities of cerebral 
capillaries, such as basement membrane thickening (Gispen and Biessels, 2000; 
Biessels et al., 2002). These microvascular changes might lead to chronic and 
insidious ischaemia of the brain (Bissels et al., 2006). Unlike causing circumscribed 
vascular lesions, diabetes might evoke more generalized and widespread 
microvascular disease in the brain, causing microinfarcts, probably leading to brain 
atrophy, lacunar infarcts and white matter lesions that have been demonstrated in 
neuroimaging studies (Bissels et al., 2006; van Harten et al., 2006). 
 
Glucose toxicity 
Similar to the role of aberrant glucose metabolism in other long-term 
complications of diabetes, ‗toxic‘ effects of hyperglycaemia have also been suggested 
in slowly progressive functional and structural abnormalities in the brain (Gispen and 
Biessels, 2000). Chronic hyperglycaemia ‗toxicity‘ could thus be one of the 
determinants of cognitive changes in people with diabetes. Animal studies have 
demonstrated that induced hyperglycaemia via administration of streptozotocin to 
impair production and secretion of insulin from beta cells in the pancreas, is 
associated with cognitive impairment and abnormalities in synaptic plasticity and 
neuronal density (Biessels et al., 2002). Several mechanisms have been suggested 
through which high glucose concentrations might mediate this effect, including an 
increased glucose flux through the polyol and hexosamine pathways, disturbances of 
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intracellular neurotransmitter second messenger pathways, an imbalance in the 
generation and scavenging of reactive oxygen species, and an accumulation of 
advanced glycation end products (AGEs) or proteins (Brownlee, 2001). These 
processes can affect brain tissue directly, as well as leading to microvascular disease. 
Given that some of these mechanisms, such as oxidative stress, increased formation 
of AGEs and microvascular pathology have also been implicated in the ageing 
process of the brain, the glucose-mediated effects on brain structure and cognition 
are likely to accelerate brain ageing and could certainly reduce the threshold for 
cognitive impairment and dementia in combination with other pathological 
alterations (Bissels et al., 2006).  
 
Insulin changes and amyloid metabolism 
Insulin resistance, at least in the early stages of Type 2 diabetes contributes 
to compensatory hyperinsulinaemia and the latter has been identified as a risk factor 
for accelerated cognitive decline and dementia (Kalmijn et al., 1995; Kuusisto et al., 
1997; Luchsinger et al., 2004). Part of this association between high insulin 
concentrations and increased risk of cognitive dysfunction is likely to be mediated 
through vasoactive effects of insulin on vascular disease (Baron, 1994). In addition, 
insulin might have direct effects on the brain. Insulin is transported directly across 
the blood-brain barrier and can be produced locally in the brain. Insulin receptors are 
distributed widely within the brain, in particular with dense amounts in the 
hippocampus and the cortex. Insulin modulates homoeostasis of food intake and 
energy in the brain and could also play a role in learning and memory (Zhao and 
Alkon, 2001). Ageing is associated with changes in insulin and its receptors in the 
brain and activation of the insulin receptors has been found to be impaired in autopsy 
samples of patients with Alzheimer‘s disease (Frölich et al., 1998).  
 
Similar to the toxic effects of hyperglycaemia on amyloid metabolism by 
the formation of AGEs, alternations in insulin homoeostasis could affect the 
metabolism of amyloid-β peptide (Aβ) by changes of insulin and its receptors in the 
brain (Craft and Watson, 2004). Aβ is derived from the amyloid precursor and forms 
neuritic senile plaques with other proteins. Excessive Aβ can be cleared through 
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processes involving insulin-degrading enzyme (Farris et al., 2003). 
Hyperinuslinaemia in Type 2 diabetes has been suggested to stimulate Aβ secretion 
and inhibit the extracellular degradation of Aβ by competition for insulin-degrading 
enzyme (Gasparini and Xu, 2003).  
 
1.4.2. Frequency and patterns of cognitive impairment in 
people with Type 2 diabetes 
There have been a number of published reviews describing and analysing 
the impact of Type 2 diabetes on cognitive functions. Strachan (Strachan et al., 1997) 
published in 1997 a critical analysis of the literature before the majority of the 
longitudinal studies were finished, which included mainly cross-sectional studies 
using clinic-based samples. Stewart (Stewart and Liolitsa, 1999) later on in 1999 
added more evidence to the link explaining all the possible mechanisms of this 
association. Awad (Awad et al., 2004) revisited the studies included in these reviews 
as well as those more recently published, and estimated effect sizes showing poorer 
domain-specific cognitive performance of Type 2 diabetic groups compared with 
performance of control groups. Cukierman (Cukierman et al., 2005) systematically 
reviewed and summarized twenty-five prospective studies relating Type 2 diabetes 
status to decline in cognitive function over time. Overall, these studies clearly 
showed that Type 2 diabetes was associated with moderate reductions in cognitive 
performance and with accelerated cognitive decline 
 
The majority of cross-sectional studies have demonstrated that older adults 
with Type 2 diabetes perform more poorly than controls without diabetes on a variety 
of cognitive function tests. In particular, cognitive measures assessing psychomotor 
efficiency, frontal/executive function, and learning and memory skills are most often 
affected (Stewart and Liolitsa, 1999; Awad et al., 2004; van Harten et al., 2006). The 
cognitive performance of patients with Type 2 diabetes relative to controls is often 
reported using effect size estimates, which show between-group differences in 
standard deviation units. Moderate to large effect sizes on affected domains are 
observed in people with diabetes older than 65 years. These range from 0.4SD to 




 percentile of reference values (e.g. reduced 
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performance with an effect size of 1SD places the mean performance of the diabetic 
group around the 15
th
 percentile of the control group) (Stewart and Liolitsa, 1999; 
Awad et al., 2004). Smaller effect sizes (<0.5SD) are found in relatively younger 
adults (<60 years old) with Type 2 diabetes (Stewart and Liolitsa, 1999; Awad et al., 
2004). This cognitive profile is suggestive of accelerated ageing and may reflect 
difficulty in processing unstructured information, which would particularly affect 
performance in cognitively demanding situations that require rapid information 
processing or divided attention (Brands et al., 2007; Biessels et al., 2007). 
 
The longitudinal, population-based studies included in the systematic review 
by Cukierman demonstrating that Type 2 diabetes was a risk factor for accelerated 
age-related cognitive decline (Cukierman et al., 2005), used cognitive screening 
instruments for assessing global cognitive function or batteries of more 
comprehensive neuropsychological tests (mostly including the Digit Symbol 
Substitution test, DSST). DSST is a primary measure of psychomotor speed and a 
secondary measure of working memory function (Joy et al., 2004), given that 
processing speed includes encoding and retrieval speed, the speed with which 
information is processed in working memory, as well as response speed, the speed of 
executing a motor response (Kyllonen and Christal, 1990). As a pooled estimate, 
compared with people without diabetes, people with Type 2 diabetes were 1.2 times 
more likely to experience cognitive decline as measured by a global functioning test 
such as the Mini-Mental State Exam (95%CI 1.1, 1.4) and 1.7 times more likely to 
develop cognitive decline as measured by the DSS (95%CI 1.3, 2.3). Taken together, 
all available data indicate that the rate of cognitive decline due to ageing is increased 
1.5-fold to 2.0-fold in older individuals with Type 2 diabetes (Cukierman et al., 
2005). However, a recent study examining the effect of Type 2 diabetes on cognition 
in the oldest old (age at study entry 85 years) did not find an association between 
diabetes and accelerated cognitive decline (van den Berg et al., 2006). Whether this 
was an artifact due to survivor effect or another phenomenon is unknown. Studies 
evaluating clinically significant cognitive impairment and diabetes have also shown 
that individuals with Type 2 diabetes are more likely to develop mild cognitive 
impairment (odds ratio 1.4 to 1.8) independent of age and co-morbid diseases (Yaffe 
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et al., 2004b; Luchsinger et al., 2007).  
 
Although there is compelling evidence that cognitive impairment and/or 
decline are potential complications of diabetes, the risk factors for cognitive 
decrements in older individuals with Type 2 diabetes are still uncertain. Above the 
age of 60 gradually progressive cognitive decline in people with diabetes mostly 
occurs in the context of neurodegenerative processes of the brain and develops over 
many years (Biessels et al., 2007). Diabetes-specific risk factors affecting cognitive 
ability before the clinical onset of frank dementia need to be identified. Most of the 
currently available studies addressing this issue are cross sectional, relating cognition 
to concurrent vascular and metabolic risk factors and often suffer from 
methodological limitations, including small sample sizes, bias in recruitment of 
subjects and failure to adjust for confounding factors. Even in large-scale, 
prospective studies, a very narrow range of diabetes-specific information is available. 
It is important to note that many of the potential risk factors for age-related cognitive 
decline may affect cognitive ageing through mediating effects on each other, and that 
the two conditions may share common risk factors. Although there are mechanistic 
studies that provide pathophysiological leads, it remains unclear which of these are 
clinically relevant.      
 
1.4.3. Diabetes-related risk factors, comorbidities and 
cognitive function 
There are various characteristics of people with Type 2 diabetes, such as 
hyperglycaemia, macro- and micro vascular disease which could be essential in 
explaining their increased risk of cognitve impairment. These risk factors are also 
potentially amenable to treatment or prevention. However, there are few 
epidemiological studies addressing whether or not such risk factors are actually    
important. Most studies were not specifically designed to assess the effects of 
diabetes on the risk of cognitive impairment, but rather aimed to identify risk factors 
for cognitive impairment in older people in a broader sense. 
 
This section provides an overview of current epidemiological evidence for 
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the effects of diabetes-related risk factors and co-morbid conditions on cognitive 
functioning in people with Type 2 diabetes as well as relevant evidence from general 
population samples.  
 
Non-modifiable risk factors 
 
Age 
Although normal ageing has a global effect on cognitive changes, it 
disproportionately influences certain aspects of cognitive function. Crystallised 
functions seem quite resistant to the ageing process, whereas fluid intelligence 
acquired as a result of genetic factors may be particularly susceptible (Deary and 
Batty, 2007). These patterns are supported by population-based epidemiological 
studies on the relation between chronological age and cognitive function in older 
cohorts. In cross-sectional and longitudinal studies, older age (at baseline) has been 
associated with a downward shift in the distribution of global cognitive ability scores, 
such as the MMSE and with an increased risk of progressive decline on the MMSE 
over time (Brayne et al., 1998; Comijs et al., 2004). Administration of a cognitive 
test battery in the Massachusetts Male Ageing Study showed an inverse, linear 
association between chronological age and performance on measures of working 
memory, speed and attention and spatial relations in 981 middle-aged to older men 
(Fonda et al., 2005). Similarly, in cross-sectional data from the Seattle Longitudinal 
Study, notable age differences from age 25 to age 81 were observed on a number of 
different cognitive tasks (Schaie, 1996). Older subjects tended to perform relatively 
poorly on the measures of perceptual speed, verbal memory, spatial orientation and 
reasoning. In 7-year longitudinal comparisons, linear age-related declines were 
observed from age 60 to 88. Conversely, in both occasions, older subjects up to their 
late 70s obtained equivalent or higher scores on verbal ability compared with 
younger subjects (Schaie, 1996; Hultsch et al., 1998; Zelinski and Burnight, 1997). 
 
It is matter of debate as to whether the observed patterns of cognitive 
decline during ageing occur as a result of ageing itself, due to the effects of 
concomitant age-associated pathologies, or both (Hedden and Gabrieli, 2004). 
Another possible explanation is that age differences in cognition, especially detected 
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in a cross-sectional data set, are inextricably confounded with birth cohort effects  
in which individuals from different birth cohorts would have variations in cognitive 
function even if they are of the same age. This is due to different past exposures to 
unmeasured risk factors. Failure to consider the age-associated pathologies could 
lead to an underestimation of their impact and lead to the false assumption that 
ageing per se is the underlying cause of the observed cognitive decline. Indeed, the 
effects of Type 2 diabetes on the brain and cognitive function are most marked in the 
elderly and mimic the effects of ageing. This may pose a major challenge in 
distinguishing the effects of diabetes from those of ‗normal ageing‘. In a study of 113 
people with Type 2 diabetes and 51 control subjects, age was inversely associated 
with performance on the measures of attention and executive function, information 
processing speed and memory within the Type 2 diabetic group, and there was a 
significant interaction between age and group for the memory domain (Manschot et 
al., 2006). This pointed to an interaction between Type 2 diabetes and cognitive 
ageing, and therefore the latter may be accelerated by diabetes. Furthermore, it has 
been observed in longitudinal studies of older adults that Type 2 diabetes is 




Findings from population-based epidemiological studies on differences in 
cognition between men and women are mixed and somewhat contradictory. Some 
cross-sectional analyses have suggested that women may outperform men on 
memory and vocabulary tasks (Barrett-Connor and Kritz-Silverstein, 1999; Aartsen 
et al., 2004). Conversely, men scored better on measures of visuospatial speed and 
visuoconstructive performance in another Finnish study (Portin et al., 1995). Other 
studies failed to find a sex difference in general ability as indexed by the sum of a 
cognitive test battery (Portin et al., 1995; Cullum et al., 2000). Results from 
longitudinal analyses showed no sex differences in 4-year risk of cognitive decline 
on any of the eight CAMCOG subscales in the CC75C study (Cullum et al., 2000) or 
in the rate of decline over six years on several measures of speed tasks in the 
Longitudinal Aging Study Amsterdam (Aartsen et al. 2004). Where sex differences 
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have been observed, several hypotheses have been proposed in an attempt to account 
for these, including male-female differences in brain reserve and differential 
susceptibility to normal or pathological age-associated changes (van Exel et al., 
2001). However, differences in cognitive function between men and women remain 
unclear based on current evidence. 
 
Similarly very little is known about the effect of sex on cognitive function in 
people with Type 2 diabetes. There are no available data directly comparing older 
diabetic men and women and only limited data comparing diabetes as a risk factor 
for cognitive dysfunction in men versus women. It has been hypothesized that 
diabetes may be a more-potent risk factor for cognitive dysfunction in women than in 
men, given their higher risk of diabetes-related cardiovascular disease (subclinical 
and clinical vascular disease) and early loss of possible protective effects of estrogen 
due to earlier menopause on cognitive functioning (Coker and Shumaker, 2003). 
However, what evidence does exist generally supports a similar relationship between 
Type 2 diabetes and cognition in men and women. A cross-sectional analysis of the 
Framingham Study cohort found no evidence of interactions between diabetes status 
and sex on multiple measures of cognitive test scores in 551 men (mean age=65.7 
years) and 872 women (mean age=67.2 years) (Elias et al., 2005). In a larger sample 
of approximately 6,000 older community–dwelling men from the Physicians‘ Health 
Study II and more than 6,000 similar women from the Women‘s Health Study, there 
was no evidence of interactions between sex and Type 2 diabetes status on 2-year 
cognitive decline for general cognition and verbal memory (Okereke et al., 2008).  
 
Duration of diabetes 
Another variable, closely related to age, which may affect cognition and has 
been investigated in a number of recent epidemiological studies is the period of time 
an individual has had diabetes. Such duration of diabetes is normally calculated by 
subtracting age at diagnosis from current age. Because people with diabetes may 
have the disease many years before diagnosis, the true duration of diabetes is often 
difficult to estimate precisely and may therefore be underestimated. Furthermore it 
can be challenging to determine whether duration of disease per se or age of onset of 
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diabetes has the more effect on cognitive changes. Despite these difficulties, there is 
increasing evidence from recent studies suggesting longer duration of diabetes may 
be an important risk factor for cognitive dysfunction in older people with Type 2 
diabetes. 
 
In an early observational study of the Framingham Study cohort, Elias (Elias 
et al., 1997) examined the development and duration of Type 2 diabetes at biennial 
visits over a period of 30 years in 1, 811 men and women (187 subjects with Type 2 
diabetes and 1,624 nondiabetic subjects). Administering a battery of eight cognitive 
tests at the end of follow-up (aged 55-88 years), the investigators showed that 
duration of diabetes was associated with an increased odds of impairment 
(standardised Z scores below the 25
th
 percentile) on tests of verbal memory and 
abstract reasoning (similarities of WAIS). In a more recent study, compared with 
normoglycaemics, people with Type 2 diabetes more that 15 years had significantly 
slower processing speed and poorer executive performance. These cognitive abilities 
were intermediate in the group with diabetes of less than 15 years (Saczynski et al., 
2008). In cross-sectional analyses, increasing duration of diabetes has been 
associated with poorer scores on measures of verbal memory, information processing 
speed and motor speed (Cosway et al., 2001; Manschot et al., 2006; van Harten et al., 
2007) in people with Type 2 diabetes. In large, longitudinal cohorts of older adults, 
longer duration of diabetes was associated with greater 2-year cognitive decline in 
general cognition and verbal memory in men and women after multivariate 
adjustment (Okereke et al., 2008). 
 
Duration of diabetes represents a composite measure of the physiological 
insult of hyperglycaemia and other diabetes comorbidities, such as hypertension, 
macro- and microvascular disease. Thus, association between duration of diabetes 
and diminished cognitive function may reflect either direct and/or indirect effects (eg. 
through a mediating role of clinical and subclinical cardiovascular disease) of 
diabetes on cognition. Whether a clustering of these diabetes-associated risk factors 
or shared underlying pathophysiological mechanisms contribute to the increased risk 
of cognitive dysfunction needs to be further clarified.  
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Major modifiable risk factors 
 
Glycaemic control  
In people with diabetes, the aim of treatment is to maintain normal glucose 
levels and utilization in order to prevent vascular and other complications that result 
from hyperglycaemia. Glycaemic control is the ability to keep glucose levels in the 
normal range. Glycated haemoglobin (GHb) percentage is a measure of integrated 
glycaemic control over the past 2-3 months, with extra weighting for the past one 
month. This percentage reflects the proportion of haemoglobin that has become 
glycosylated because glucose is attached to it by a slow non-enzymatic process. 
Because blood cells live for about 2-3 months, GHb levels reveal the average levels 
of glucose during that period. In clinical practice, HbA1c is one of the GHb species 
most often measured, which is present in the largest amounts and results from the 
attachment of glucose to the N-terminal amino acid valine of the β-chain of 
haemoglobin. Higher HbA1c has been found to be associated with an increased risk 
of micro- and macrovascular complication in diabetes (DCCT 1993; UKPDS34, 
1998). Normal levels of HbA1c are 4-6% whereas HbA1c levels suggesting poor 
glycaemic control are between 8-11.9% (American Diabetes Association, 2002). 
Although HbA1c has been widely used as an index of long-term glycaemic control, 
its use as a diagnostic tool for Type 2 diabetes has been limited due to lack of the 
standardised measurements between laboratories, which makes results difficult to 
compare.  
 
Current literature on the relationship between HbA1c levels and 
neuropsychological functions is limited and results are inconsistent. An analysis 
based on nearly 2,000 postmenopausal women observed an increased risk (OR= 1.4; 
95% CI 1.0, 1.9) of mild cognitive impairment over four years for every 1% increase 
in HbA1c at baseline after adjusting for age, education, race, depression, alcohol use 
and medication. Those with HbA1c of more than 7% had a nearly 4-fold increase in 
developing MCI (Yaffe et al., 2006). Another investigation, involving 5,632 elderly 
men and women from the Italian Longitudinal Study on Aging, found higher HbA1c 
levels were associated with risk of 8-year cognitive decline, particularly in memory 
(Maggi et al., 2009). In some cross-sectional studies of people with Type 2 diabetes, 
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an inverse relationship between HbA1c and global cognition (van Harten et al., 
2007), working memory (Pelmuter et al., 1990; Munshi et al., 2006), executive 
functioning (Munshi et al., 2006), learning (Reaven et al., 1990) and psychomotor 
performance (Reaven et al., 1990; Ryan and Geckle, 2000; Manschot et al., 2006) 
has been shown. By contrast, other studies failed to demonstrate a relationship 
whether in people with diabetes (Cosway et al., 2001; Manschot et al., 2007; 
Umegaki et al., 2008; Ruis et al., 2009) or in a general population (van den Berg et 
al., 2006; Saczynski et al., 2008). It has been argued that the lack of association in 
these studies may reflect relatively well-controlled diabetes in the study sample, as 
evident from the participants‘ HbA1c level, or a negative effect of HbA1c on 
cognition after longer diabetes duration.  
 
Results from clinical trials lend further support to a negative association 
between HbA1c and intellectual functioning. Early trials, which were limited by 
small size and short duration of follow-up (<7 months) reported that improved 
glycaemic control caused improved cognitive test performance mainly in the areas of 
attention, learning, and complex psychomotor function (Gradman et al., 1993; 
Meneilly et al., 1993; Naor et al., 1997). More recently, Ryan et al. (Ryan et al., 2006) 
conducted a multi-centre randomized double-blind clinical trial of rosiglitazone vs. 
glyburide therapy in a larger sample of 145 older adults with Type 2 diabetes, and 
found that better glycaemic control may improve working memory function over a 
6-month period.  
 
Despite the inconsistency in findings from epidemiological studies, several 
mechanisms have been proposed whereby HbA1c may affect cognition. For example, 
chronic hyperglycaemia per se could cause cognitive impairment by direct neuronal 
damage possibly caused by advanced glycosylated endproducts (AGEs), leading to 
its degeneration as reflected in global and hippocampal atrophy as well as 
neuropathologic markers of Alzheimer‘s disease. It is also possible that 
hyperglycaemia has an indirect impact on neuronal damage via cerebral 




One of the most studied risk factors for cognitive decline in later life is high 
blood pressure, given that blood pressure is easily measured, potentially modifiable 
and a major risk factor for cerebrovascular disease. However, so far results from 
epidemiological studies in general populations have been mixed—some studies 
reported a negative effect of high blood pressure on cognition and others reported no 
association. Variation in findings may be partially explained by age and timing of 
blood pressure assessment. Also nowadays a substantial proportion of older 
individuals have been taking anti-hypertensive medication, and it is unclear how 
accurately the measured blood pressure values actually reflect long-term cumulative 
exposure levels (Herbert et al., 2004). These issues have been addressed in a series of 
recent large-scale longitudinal studies which have shown that higher blood pressure 
levels during middle-age, especially if not treated effectively predict poorer cognitive 
outcomes in old age. In these studies, cognitive tests were administered to untreated 
hypertensive patients and test scores were linked to blood pressure levels determined 
in mid-life (Elias et al., 1993; Launer et al., 1995; Kilander et al., 1998; Qiu et al., 
2005). For example, in the Framingham study, measurements of blood pressure were 
obtained at five biennial examinations during the period 1956-1964 when few 
hypertensive participants received treatment (Elias et al., 1993). Blood pressure 
values were based on the average of five measurements. With cognitive function 
assessed 20 years later, the results for the total sample showed a negative, linear 
relationship between both SBP and DBP and performance on a global composite 
score and several subtests of WAIS (the Logical Memory immediate and delayed 
recall, the Visual Reproductions, and the Digits Backward). Each 10mmHg increase 
in blood pressure was associated with a decline of 0.04 to 0.07 standard deviations in 
the composite score. Similar results were found in sub-analyses of participants who 
were untreated at the time of blood pressure measurement or throughout the entire 
study period.  
 
There is less evidence that the same negative effect of hypertension on 
cognition is present in later life and in particular, three studies have reported a 
U-shaped relation between SBP and cognitive function (Guo et al., 1997; Glynn et al., 
1999; Bohannon et al., 2002). Findings suggest that midlife levels of hypertension 
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may contribute to individual differences in cognitive function in late adulthood, 
whereas blood pressure in old age may bear a relatively weaker relation to cognitive 
impairment or decline over and above that of other morbidity (Swan et al., 1998). 
Waldstein suggested that non-significant associations between hypertension and 
cognitive function in old age might reflect selective attrition (Waldstein, 1995).  
 
Recent analyses of data from a sub-sample of 1,811 subjects (mean age=67 
years) participating in the Framingham Heart Study, demonstrated significant 
synergistic interactive effects of hypertension and Type 2 diabetes. In the total 
sample, each 10-mmHg increase in blood pressure was significantly associated with 
higher risk of performing below the 25
th
 percentile for verbal memory (OR: 1.29 
95%CI 1.10, 1.52). Within the diabetic group (n=187), each 10-mmHg increase in 
blood pressure was associated with ‗highest‘ levels of risk of poor performance on a 
composite cognitive test score (OR: 2.03 95%CI 1.12, 3.71) as well as on 
visuospatial measures (OR: 1.68 95%CI 1.04, 2.69). The highest risk for poor 
performance were also associated with a diagnosis of Type 2 diabetes in the presence 
of hypertension (n=576) (i.e. OR=1.97 and 1.82 for the composite and visuo-spatial 
scores respectively (Elias et al., 1997). The comorbid effect of diabetes and 
hypertension on cognitive function has been reported in other studies (Kuusisto et al., 
1993; Posner et al., 2002; Hassing et al. 2004; Manschot et al., 2007). For example, 
an analysis based on 258 older adults (mean age=83 years) in the OCTO-Twin Study 
observed a steeper 6-year decline (by an additional 0.29 points per 2-year interval) in 
global cognitive function related to Type 2 diabetes at baseline but not related to 
hypertension. However, there was a significant interaction between diabetes and 
hypertension in rate of change in MMSE such that those with both diseases had 
greatest decline (additionally by 0.42 points per 2-year interval) compared with those 
free from both (Hassing et al., 2004). In contrast, another two population-based 
studies failed to find the modulating effect of hypertension on cognitive function in 
Type 2 diabetes (Kanaya et al., 2004; Fontbonne et al., 2001). 
 
Dyslipidaemia/serum lipids 
Given that the brain has a very high lipid content, there is considerable 
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biological plausibility for a positive association between serum lipids and intellectual 
functioning. Low circulating lipid levels, perhaps resulting from chronic morbidity 
and/or poor nutrition intake or absorption in old age, may directly affect neuronal 
metabolism, neurotransmitter systems, and cognitive processes. However, the current 
literature of the relationship between serum lipid levels and cognitive functioning in 
late-life has been inconsistent as to whether high or low serum cholesterol 
concentrations are associated with cognition or indeed at all.  
 
A recent systematic review examined population-based longitudinal data on 
the relation of serum lipids with cognitive decline or impairment (Anstey et al., 
2008). Three of the seven studies included found that higher total serum cholesterol 
(TC) in older individuals was associated with a decreased risk of both cognitive 
decline and cognitive impairment (Wada et al., 1997; Hyman et al., 1996; Solfrizzi et 
al., 2004). However, no relationship was observed between TC levels and cognitive 
performance in another three studies, including one with a large sample size 
(n=1,147) (Kalmijn et al., 1996; Karlamangla et al., 2004; Reitz et al., 2005). In 
addition, neither high density lipoprotein (HDL) nor LDL-cholesterol levels were 
associated with the cognitive outcome in these studies. 
 
However, several other studies have demonstrated a negative association 
between blood lipid levels and cognition. One large-scale study included in Anstey‘s 
systematic review (Kivipelto et al., 2001), involving 1,352 elderly Finnish men and 
women, found that higher mid-life (mean age=50 years) TC increased the risk of 
mild cognitive impairment (OR1.9 95%CI 1.2, 3.0) over a 21 year follow-up period. 
Moreover, in other investigations, beneficial effects of satin use or lipid-lowering 
drugs were noted either on IQ change from childhood to old age in dementia-free 
older survivors of the Scottish Mental Health Survey (Starr et al., 2004), or on 
estimated lifetime cognitive decline in older patients with Type 2 diabetes (Manschot 
et al., 2007). In elderly people with diabetes, hypertriglyceridemia was also related to 
poorer performance on the measures of verbal fluency, reaction times and backward 
digit span (Perlmuter et al., 1990; Helkala et al., 1995). It is possible that the inverse 
relationship of blood lipid levels with cognitive function may be partly or fully 




Obesity is not only associated with metabolic disturbances such as 
hypertension, Type 2 diabetes and dyslipidaemia, but also is an independent risk 
factor for cardiovascular disease and mortality, including stroke. In this context, a 
relationship may also exist between obesity and cognition. Also, obesity could have a 
more direct effect on cognitive dysfunction through its subclinical inflammatory 
potential (Jeong et al., 2005), eventually leading to structural changes in the brain 
(Jagust et al., 2005). Despite the biological plausibility of such an association, 
current literature relating obesity to cognition has been limited to relatively few 
reports in older adults.  
 
A sex-specific analysis based on data from the Framingham Heart Study 
showed worse cognitive ability in obese individuals (Body Mass Index (BMI) ≥ 30 
kg/m
2
) (Elias et al., 2005). After adjusting for socio-demographic and cardiovascular 
risk factors, obese men performed relatively worse compared with those non-obese 
men on a global composite score, and on individual tests of visual reproductions and 
digit span forward. In another population-based study, obesity was assessed at 
mid-life time (mean age 53 years) and cognitive function was measured 8 years later. 
Highest baseline quartile of waist to hip ratio, but not BMI, was associated with 
worse cognitive performance on visual memory, executive function and visual motor 
skills (Wolf et al., 2007). Contrary to these findings, two studies involving large 
number of older individuals either failed to establish an association between waist 
circumference (abdominal obesity) and cognition or found an inverted U-shaped 
relationship between BMI and cognition (Kuo et al., 2006; Dik et al., 2007). A more 
recent study based on older patients with Type 2 diabetes did not find an association 
between BMI and estimated lifetime cognitive change (Ruis et al., 2009).          
 
Smoking 
Smoking is a major modifiable risk factor for impaired pulmonary function 
and vascular disease. Smoking may also affect cognition either being mediated via an 
effect on vascular or pulmonary pathologies or through a more direct effect on the 
central nervous system, such as disturbing blood flow in the brain. Results from early 
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epidemiological studies on the relationship between smoking and cognition were 
inconclusive. Many of them were cross-sectional, with smoking assessed by 
self-report which is more prone to recall bias and which may be influenced by 
cognitive status at the time of assessment, especially in elderly people (Woodward, 
2002). These limitations have been at least partially addressed in a number of more 
recent studies.  
 
In a longitudinal analysis based on 9, 209 participants aged 65 years and 
older, both male and female current smokers declined at greater rate on MMSE 
scores compared with those who had never smoked over a mean period of 2.3 years. 
Moreover, a higher number of pack-years of smoking, reflecting higher lifetime 
exposure levels, were weakly but significantly associated with the greatest rate of 
cognitive decline (Ott et al., 2004). Another investigation based on middle-aged men 
and women from the British 1946 birth cohort study, fully controlled for people‘s 
prior mental ability (at age 15 years) in addition to a range of possible confounders. 
There was a significant trend between the number of cigarettes smoked at age 43 and 
the rate of 10-year decline in verbal memory (Richards et al., 2003).  
 
A beneficial effect of smoking cessation on reduced age-related cognitive 
decline has also been noted in some studies (Richards et al., 2003). In the 
Honolulu-Asia Aging study, the likelihood of scoring poorly on the CASI instrument 
was inversely related to the time since giving up smoking in elderly 
Japanese-American men (Galanis et al., 1997). In another analysis based on older 
people with evidence of asymptomatic atherosclerosis, former female smokers had 
better performance on the age-sensitive Auditory Verbal Learning and the Trail 
Making tests compared with current smokers (Stewart et al., 2006).  
 
Despite these findings in general populations, very few investigations have 
linked smoking status to cognition in large numbers of people with Type 2 diabetes 
(Arvanitakis et al., 2006; Umegaki et al., 2008; Ruis et al., 2009) and results are also 
conflicting. Whether smoking status could modify the relation of Type 2 diabetes to 
cognitive function (people with Type 2 diabetes who smoked performed worse than 
those with diabetes who did not smoke), needs to be explored.   
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Other modifiable risk factors 
 
Alcohol intake 
Despite chronic alcohol abuse causing progressive neurodegenerative 
disease, recent epidemiological studies have paid more attention to the long term 
effects of regular light to moderate alcohol intake on cognitive function. Moderate 
alcohol consumption has been found to be associated with lower risk for coronary 
heart disease and stroke (Pearson, 1996; Mukamal et al, 2006; Elkind et al., 2006) in 
the general populations. Also, moderate drinking in older adults was reported to 
stimulate appetite and improve mood. Given the beneficial effects on physical health, 
it is plausible that moderate alcohol intake could be protective against impaired 
cognitive function. However, findings from epidemiological studies have so far been 
mixed. In a recent meta-analysis (Peters et al., 2008), the pooled estimates from 
seven population-based prospective studies (aged ≥65 years) failed to demonstrate an 
association between moderate amounts of alcohol consumption and risk of cognitive 
decline (RR: 0.89 95%CI: 0.67 to 1.17). As there was significant heterogeneity 
between the available studies, the authors of the review stated that the results should 
be interpreted with caution. Indeed, the included studies varied in the populations 
examined, methods of assessing exposure to alcohol, classification of alcohol use, 
follow-up periods, neuropsychological tests and controlling for potential 
confounding factors. A J-shaped curve between the level of alcohol consumed and 
cognitive performance was seen in the majority of the studies although with wide 
confidence intervals and lack of statistical significance (Peters et al., 2008). In 
particular, there was a lack of standardisation regarding the operational definition of 
moderate amount of alcohol intake, which varied widely between studies. Also some 
studies used ‗non-drinkers‘ as the reference category for comparison, including both 
lifetime abstainers as well as quitters, whereas others either preferred the lowest 
intake category excluding abstainers or chose infrequent/less than one drink per 
month as their reference level. 
    
It has also been speculated that there may be a sex difference in the 
relationship of alcohol with cognitive function, given that patterns of alcohol use and 
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alcohol metabolism are likely to differ for men and women (Dufouil et al., 1997; 
Elias et al., 1999; Kalmijn et al., 2002; McGuire et al., 2007). However, a recent 
study found both male and female current drinkers performed better on a task of 
global cognitive ability relative to abstainers and former drinkers (Bond et al., 2004).  
 
The effects of alcohol intake have also been investigated in people with 
Type 2 diabetes (although the same methodological limitations apply). Among adults 
with Type 2 diabetes, moderate alcohol consumption has been associated with a 
reduced risk of cardiovascular disease, metabolic syndrome and levels of 
inflammation and endothelial dysfunction markers (Wakabayashi wt al., 2002; 
Freiberg et al., 2004; Howard et al., 2004; Shai et al., 2004). Consistent with these 
findings, in a cross-sectional study of 119 men with Type 2 diabetes, Fan et al. (2008) 
found that moderate alcohol drinkers who had at least 1 drink per month to no more 
than 2 drinks per day, scored significantly better on Digit Span Backward, Digit 
Symbol and Trail Making B tests, compared with abstainers after controlling for 
various diabetes-related, psycho-social and vascular factors. Heavy drinkers (more 
than 3 drinks a day) were excluded from the study. More recently, the Nurses‘ Health 
Study examined 1,698 women aged 71-80 years with Type 2 diabetes and found that 
at baseline, moderate alcohol drinkers (those consuming 1.0-9.9 g of alcohol or about 
1 drink per day) had higher mean scores on a general cognition test compared with 
abstainers (Townsend et al., 2009). The association was unchanged after excluding 
women who decreased their alcohol drink after the diagnosis of diabetes. However, 
moderate alcohol consumption was not associated with 4-year cognitive decline. 
Higher alcohol consumption (10-30 g of alcohol per day) was not associated with 
either initial cognition or cognitive decline.  
 
Depression 
Depression is a common mental disorder in the elderly. Unlike the normal 
day-to-day fluctuations of moods, clinical depression or major depressive disorder is 
a persistent and profound syndrome that is characterised by symptoms of depressed 
mood, loss of interest or enjoyment, and physical symptoms such as fatigue, loss of 
energy and sleeping difficulties. The specific diagnostic criteria for clinical dementia 
are shown in Figure 5.  
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A. Five (or more) of the following symptoms have been present nearly everyday during the same 2-week 
period and represent a change from previous functioning; at least one of the symptoms is either depressed 
mood or loss of interest or pleasure. 
(1) depressed mood 
(2) markedly diminished interest or pleasure in all, or almost all, activities 
(3) significant weight loss when not dieting or weight gain, or decrease or increase in appetite 
(4) insomnia or hypersomnia 
(5) psychomotor agitation or retardation 
(6) fatigue or loss of energy 
(7) feelings of worthlessness or excessive or inappropriate guilt (which may be delusional) 
(8) diminished ability to think or concentrate, or indecisiveness 
(9) recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without a specific plan, 
or a suicide attempt or a specific plan for committing suicide 
 
B. The symptoms cause clinically significant distress or impairment in social, occupational, or other 
important areas of functioning.   
C. The symptoms are not due to the direct physiological effects of a substance or a general medical 
condition or mood-incongruent hallucinations. 
D. The symptoms are not better accounted for by bereavement. 
Figure 5: Clinical diagnostic criteria for Major Depressive Disorder (American 
Psychiatric Association, 1994) 
 
There is growing evidence in the literature suggesting depression may also be 
an important and treatable risk factor for cognitive dysfunction in the elderly. Despite 
the different subtypes of depression, individuals with depression are likely to share 
the main symptoms of depressed mood, including the difficulty in initiating 
responses, maintaining effort in attention or concentration, which may be particularly 
pertinent to cognitive task performance in information processing speed, learning, 
memory and executive function (Herrmann et al., 2007). A negative cross-sectional 
association between depression and cognitive function has been consistently 
observed in large-population based studies (Fuhrer et al., 1992; Baune et al., 2006). It 
is possible that depression may initiate or accelerate the cognitive ageing process. 
Given that depression and cognitive impairment often co-exist, it is also possible that 
impaired cognitive function may present during a depressive episode because of 
diminished attention and motivation, and may be directly related to the disease itself 
and its neuropathological aspects. Alternatively, depressive symptoms could be 
simply a psychological reaction to perceived deterioration in cognitive function. 
However, the observed association often persists after clinical recovery of depression 
(Butters et al., 2000; Butters et al., 2004). 
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Reverse causation (depression caused as a result of cognitive impairment) is 
also unlikely to account for recent findings from longitudinal studies relating 
depression to late-life cognitive decline in time (Yaffe et al., 1999; Paterniti et al., 
2002; Wilson et al., 2004). For example, Wilson and associates (2004) found that 
increased self-reported depressive symptoms at baseline predicted annual rate of 
cognitive decline in a composite score independently of baseline cognitive function. 
In addition, results were unchanged after excluding those with cognitive impairment 
at baseline. In an earlier study involving elderly women without dementia, a 
significant dose-related association between the number of self-reported depressive 
symptoms and the rate of 4-year decline in performance on three cognitive tasks (the 
MMSE, the WAIS Digit Symbol and the Trail-Making test B) was reported, after 
controlling for a number of possible confounders including baseline cognitive ability 
(Yaffe et al., 1999). 
 
Although the precise basis of the association between cognitive impairment 
and depression in late-life remains unclear, several neurobiological mechanisms have 
been proposed. A shared nervous system pathology underlying both depression and 
cognitive dysfunction has been suggested, in particular involving the impact of 
cerebral microvascular disease, such as white matter hyper-intense lesions shown on 
magnetic resonance imaging (Thomas and O‘Brien, 2008). Another possibility is that 
both cognitive deficits and depression may be associated with higher levels of 
cortisol and dysregulation of the hypothalamic-pituitary-adrenal axis (HPA). In 
particular, elevated glucocorticoid levels may have deleterious effects on the 
structure and function of the hippocampus, a key locus for cognitive function 
including learning and memory. The hippocampus is also a core region in the limbic 
system and has widespread connections to diverse cortical areas which are known to 
constitute the neuroanatomical network of mood regulations (Drevets, 2000). 
 
The prevalence of depressive symptoms is higher in older adults with Type 2 
diabetes relative to the general population, and the presence of depression and 
diabetes has been noted to worsen the course of both, particularly through diabetic 
complications, poorer glycaemic control and a great number of depressive relapses. 
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Thus depression may also increase vulnerability to and/or exacerbate existing 
cognitive deficits. So far only a few studies have evaluated the effect of depression 
on cognition in people with Type 2 diabetes (Lowe et al., 1994; Gregg et al., 2000; 
Watari et al., 2006). Although results are mixed, these studies suggest that depression 
does not account for all of the cognitive decrements associated with diabetes.  
 
Premorbid cognitive ability 
As mentioned earlier, the concept of ‗cognitive reserve‘ maintains that there 
are aspects of brain structure and function (e.g. neural plasticity and efficiency of 
neural networks) that buffer the effects of neuropathology such that the greater the 
reserve, the more severe the pathology must be to produce functional impairment 
(Richards and Deary, 2005). Within the context of the reserve hypothesis, there is 
individual variation in the development of clinical impairment of cognitive function, 
and some individuals may have some physical brain structures and/or cognitive 
strategies that serve as protective reserves against clinical level of deterioration. 
There is a wide range of putative indices of cognitive reserve, chief among which is 
pre-morbid (early life) cognitive ability (Whalley et al., 2004; Stern et al., 2006). It 
has been noted that the level of cognitive ability in old age is substantially (about 
50%) determined by childhood mental ability.  
 
It is possible that a higher premorbid or childhood ability indicates greater 
cognitive reserve, providing greater resistance to the effects of diverse pathological 
insults. A number of studies have demonstrated a relation of child or early life 
cognitive ability, as estimated from mental test scores in the first two decades of life, 
with diverse health outcomes in late life. For example, higher ability levels are 
related to lower rates of total and cardiovascular disease mortality and morbidity 
(Hart et al., 2004; Deary et al., 2004b; Batty et al., 2005; Batty et al., 2007), lower 
frailty (Deary et al., 2004b), higher quality of life (Bain et al., 2003), and reduced 
rates of major psychiatric disease (Walker et al., 2002; Zammit et al., 2004; Batty et 
al., 2005). Moreover, higher ability is associated with less cognitive decline or 
improved performance in later adulthood and old age (Snowdon et al., 1996; 
Richards et al., 2004; Bourne et al., 2007). For instance, a follow-up study of the UK 
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1946 birth cohort examined the relation between cognitive ability at age 15 years and 
cognitive decline from 43 to 53 years in men and women (Richards et al., 2004). 
Participants with higher childhood ability experienced less cognitive decline on tasks 
of memory and search speed. More importantly, these results were observed after 
accounting for later-life educational attainment, social class and a range of health 
indicators.  
 
In turn, pre-morbid ability is also influenced by diverse biological influences 
including a genetic component as well as early exposure to social and material 
environmental factors. For example, advantageous socio-economic conditions in 
childhood may directly affect cognitive development, possibly through a greater 
exposure to cognitive stimuli (Everson-Rose et al., 2003).  
 
As an alternative to the ‗cognitive reserve‘ hypothesis, the ‗use it or lose it‘ 
hypothesis has been proposed to explain the relationship between premorbid ability 
and cognitive function in later life, suggesting that use-dependent processes afford 
cognitive protection. Those with high childhood mental ability may have received 
more education and worked at more intellectually demanding tasks, which further 
enable them to acquire a repertoire of life skills that support a mentally stimulating 
and socially engaged life style, thus ‗exercising‘ their mental faculties more 
throughout the life-course than those who were initially less cognitively able 
(Christensen and Henderson., 1991; Staff et al., 2004; Bourne et al., 2007).  
 
Education level 
There is now a large body of literature on the relationship between early-age 
educational attainment and cognitive function in later life. In population-based 
studies, a strong positive association has consistently been observed between years of 
formal education and better cognitive performance, but the findings on the 
association with cognitive decline have been mixed (Wight et al., 2002; Anstey et al., 
2003; Lee et al., 2003; Seeman et al., 2005). It has been argued that even with 
statistical adjustments, change in cognitive function between two time points is hard 
to distinguish from level of function at either time point, especially when the 
predictor of interest such as education, is highly correlated with the cognitive 
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outcome. Thus multiple cognitive assessments in time are needed to separate initial 
level of cognition from rate of change. However, fewer such studies are available and 
some of them have failed to find an association between education level earlier in life 
and cognitive decline associated with ageing (Christensen et al., 2001; Gerstorf et al., 
2006; Van Dijk et al., 2008).  
 
In addition, the specific pattern of what aspects of cognition may be 
involved and protected is yet not clear and possibly due to difference in study 
populations, cognitive tasks and frequency of consecutive assessments. For example, 
in an analysis of 865 elderly men and women from the MacArthur Studies of 
Successful Aging with three phases of cognitive assessment, formal educational 
attainment was highly positively associated with performance on all five measures of 
both crystallised and fluid abilities over a 7-year follow-up period (Seeman et al., 
2005). However, data from the Australia Longitudinal Study of Ageing spanning an 
8-year period with three phases of cognitive assessment showed an inverse 
association between level of education and cognitive decline in cognitive processing 
speed but not in verbal ability and memory (Anstey et al., 2003). In another study 
covering 6 years with 5 cognitive assessments showed slower decline on a measure 
of general cognitive mental status for higher level of education but not on 
domain-specific cognitive tests (Alley et al., 2007).  
 
Proposed mechanisms for a protective effect of education on subsequent 
cognitive decline in older age include confounding with other education-related 
factors. It is speculated that education may act as a marker for general socioeconomic 
conditions such as general health status and health-related lifestyles. However, in 
most studies, education has been shown to be significantly and independently 
associated with cognition after statistical control of factors such as health and 
life-style related variables. A second hypothesis (consistent with ‗use it or lose it‘ 
proposal) is that education could lead to occupations, social environment or leisure 
activities that entail greater ongoing mental cognitive stimulation over the lifetime. 
This theory has been supported by findings from some studies in which individuals 
who engage in leisure activities and continued education have better cognitive ability 
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in mid to late life, although the benefits of such activities may be most evident in 
those with least formal education (Wight et al., 2002; Rafnsson., 2006). Finally, it is 
possible that education may have more direct effects on the brain and cognitive 
processes by promoting brain development resulting in greater dentritic branching 
and eventually leading to greater ‗brain reserve‘ capacity.     
 
Macrovascular disease 
Atherosclerosis is a progressive disease of large and medium-sized arteries 
characterised by the accumulation of lipids and fibrous elements in the arterial wall 
(Ross, 1999; Lusis, 2000). Atherosclerotic lesions begin as fatty streaks and may 
eventually progress into more advanced lesions of atherosclerotic plaques. Plaques 
often become gradually more complex with calcification, ulceration and 
haemorrhage. Although these lesions can grow large and block blood flow, the most 
important and common complication is the rupture of the atherosclerotic plaque and 
the formation of thrombus (Lusis, 2000).  
 
Atherosclerosis can affect several arterial beds. The term ‗macrovascular 
disease‘ collectively refers to atherosclerotic disease that obstructs the blood supply 
to the heart (e.g. coronary heart disease), brain (e.g. cerebrovascular disease) and the 
lower limbs (e.g. peripheral arterial disease). As highlighted earlier, large-vessel 
atherosclerosis of intra and extracranial arteries may lead to cerebral hypoperfusion 
and commonly results in artery-to-artery embolic stroke. On the other hand, cerebral 
blood flow is autoregulated by intracranial mechanisms of altering blood vessel 
diameters in response to cerebral hypofusion. However, if systemic blood pressure 
levels fall below the autoregulative window, cerebral blood flow follows perfusion 
pressure and hypoxia may occur (Vingerhoets, 2001). In addition to cerebrovascular 
insufficiency, as a generalized systemic process, either symptomatic or significant 
but yet clinically unrecognized atherosclerotic disease may co-exist within the same 
individual, and one manifestation of macrovascular disease should promote 
investigation of the similar disease in other arterial beds (Phillips, 2001). In fact, 
evidence of coronary artery disease has frequently been reported in patients who 
have had transient ischaemic attacks (TIA) and cerebral stroke (Russell, 1983), and is 
also found in up to 90% of individuals with symptomatic peripheral arterial disease 
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(Vogt et al., 1992). Furthermore, in coronary heart disease, such as myocardial 
infarction, atherosclerosis-induced cardiac pathology may predispose to cardiogenic 
cerebral emboli and possibly reduced ventricular function which may lead to either 
acute or chronic state of cerebral hypoxia and hypo-perfusion.  
 
From these perspectives, different major clinical types of macrovascular 
disease may be associated with impaired neuropsychological functioning. To date, 
however, this potential source of variance in cognitive ability has generated 
somewhat limited interest in population-based studies. Specifically, longitudinal data 
on the pattern of cognitive decline in older individuals with macrovascular disease 
are lacking. Based on current investigations, findings are contradictory. For example, 
in survivors of stroke, some cross-sectional data showed reduced performance on 
both global (Zhu et al., 1998; Kase et al., 1998) and domain-specific tasks including 
verbal memory and executive function (Rafnsson et al., 2007) relative to stroke-free 
or healthy controls, whilst others failed to provide evidence in support of deficits in 
specific cognitive domains (Srikanth et al., 2003). Stroke has also been found to be 
associated with an increased decline in global cognitive function (Kalmijn et al., 
1996; Kase et al., 1998; Haan et al., 1999). In the Zutphen Elderly Study, elderly 
male stroke patients were at 4.3 times increased odds of a decline in MMSE scores 
over three years after adjusting for age, education and baseline MMSE test scores 
(Kalmijn et al., 1996). Moreover, in the Cardiovascular Health Study (Haan et al., 
1999), elderly subjects with prevalent stroke declined faster over a period of seven 
years in mean digit symbol test scores, compared with stroke-free participants (-1.96 
points vs. -0.28). These effects were independent of age, sex, race, education and 
incident stroke.  
 
A more recent investigation was based on 452 elderly men and women in 
the Edinburgh Artery Study, who were cognitively tested on two separate occasions, 
at baseline and four years later (Rafnsson et al., 2007). When compared with subjects 
free of any cardiovascular disease (CVD), and after adjusting for demographic 
characteristics, depression and major vascular risk factors, subjects with prevalent or 
incident stroke showed a significantly steeper 4-year decline in verbal memory 
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performance, but not on tasks assessing other domains, including nonverbal 
reasoning, executive function and processing speed. Contrary to these findings, an 
analysis based on 1224 older adults in the Longitudinal Aging Study Amsterdam did 
not find an association between stroke and 3-year cognitive decline in any 
domain-specific tests (Dik et al., 2000).  
 
Given the inconsistencies in the relationship between stroke and cognitive 
function, a number of methodological limitations need to be noted. For example, 
apart from incomplete neuropsychological assessment, the timing of cognitive testing 
relative to the onset of stroke varies across studies. Although compared with 
hospitalized patients, population-recruited stroke survivors may be considered as 
having milder stroke pathology, particularly high rates of impairment may be 
observed where cognitive testing is performed very early following the event, which 
is largely influenced by acute confusional or sensorimotor state. In addition, brain 
imaging data have been collected in only a very few studies. As a result, specific 
information on aetiological type, lesion size and location of the stroke is generally 
not available. Despite assumed ischaemic stroke in the majority of cases, it is 
possible that subtype and lesion site may affect cognitive outcomes to a different 
extent. In some analyses, TIA patients have been included whereas elsewhere these 
have been deliberately excluded. The result of their inclusion may be dilution of any 
cognitive effects seen among cases.  
 
Relatively few studies have examined cognitive function in the context of 
macro-vascular pathology other than stroke. In population samples, different indices 
of coronary heart disease (CHD), such as the presence of angina, myocardial 
infarction (MI) or CHD, have cross-sectionally been associated with worse 
performance on mental status tests in some studies (Breteler et al., 1994; Elwood et 
al., 2002) but not in others (Petrovitch et al., 1998; Ahto et al., 1999; Tilvis et al., 
2004). Negative effects of CHD on measures of specific cognitive function, 
including verbal, mathematical reasoning and executive functioning have been found 
in other cross-sectional studies (Elwood et al., 2002; Verhaeghen et al., 2003). 
Furthermore, in most population-based follow-up studies, cognitive assessment has 
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been limited to global cognitive measures alone, such as the MMSE (Zhu et al., 1998; 
Haan et al., 1999; Eslinger et al., 2003; Piguet et al., 2003; Tilvis et al., 2004). No 
association between CHD and cognitive decline has been observed in the majority of 
these studies (Zhu et al., 1998; Eslinger et al., 2003; Piguet et al., 2003).  
 
Only three studies have collected longitudinal data using a battery of 
cognitive tests. Haan et al. (1999) found a steeper 7-year decline in digit symbol test, 
in the presence of either major ECG abnormalities or cognitive heart failure at 
baseline. In contrast, neither clinically verified angina nor MI at baseline or 
follow-up was found to be associated with a greater 4-year decline in 
domain-specific measures of fluid intelligence (Rafnsson et al., 2007). A similar null 
finding was observed in another study (Verhaeghen et al., 2003). It should be noted 
that few studies have adequately taken into account the potential overlap between 
different CHD syndrome groups or between subjects with other manifestations of 
atherosclerotic disease and thus the possibility of confounding by previous stroke has 
not always been sufficiently excluded. Moreover, on several occasions, control 
subjects have not been entirely free of clinical vascular disease.  
 
Studies of cognitive function in people with PAD are also scarce and most 
early studies were not designed to study cognitive function in relation to PAD per se. 
In population-based samples, the presence of PAD has been determined either from 
clinical symptoms of arterial narrowing in the lower limbs (intermittent claudication  
(IC)), or from measurements of the ankle brachial index (ABI). Intermittent 
claudication has been found to be cross sectionally associated with worse 
performance on global (Tilvis et al., 2004) and domain-specific tasks (Singh-Manoux 
et al., 2003). However, another cross-sectional report failed to show the effects of IC 
on cognitive test (Elwood et al., 2002). Similarly in longitudinal data, the findings of 
association between IC and decline in global mental status were conflicting (Piguet 
et al., 2003; Tilvis et al., 2004). More recently, in Edinburgh Artery Study, among 
stroke-free subjects, elderly individuals with symptomatic PAD (IC) had a 
significantly greater 4-year decline in verbal memory functioning (Rafnsson et al., 
2007). An inverse association between ABI and cognitive performance on non-verbal 
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intelligence, executive function and information processing speed has also been 
observed in a cross-sectional study (Price et al., 2006). ABI has also been associated 
with a progressive decline in global mental status (Breteler et al., 1994; Haan et al., 
1999). These studies may suffer from confounding by concomitant vascular risk 
factors. For example, disease categories are non-mutually exclusive of other 
manifestations of macrovascular disease, including stroke. As with studies on CHD, 
only on rare occasions have control subjects been free of any clinical cardiovascular 
disease.    
 
Very few previous studies have presented detailed data on the relation 
between macrovascular disease and cognitive function in people with Type 2 
diabetes. In a recent study, the presence of any macrovascular atherosclerotic disease 
appeared to be the most consistent determinant of impaired cognition on a composite 
score in Type 2 diabetetic patients (Manschot et al., 2007). Another cross-sectional 
analysis (Umegaki et al., 2008), involving 907 elderly Japanese people with diabetes, 
also showed the presence of stroke was associated with cognitive impairment 
(defined as an MMSE score of 24 or less) (OR 3.01, 95%CI 1.58, 5.75). Given the 
established relationship of Type 2 diabetes and macrovascular disease, it is important 
to determine the role of concomitant atherosclerotic disease, cerebrovascular or 
otherwise, on the cognitive function of people with Type 2 diabetes. 
 
Microvascular disease 
It has been shown that up to one-third of symptomatic stroke can be 
attributed to disease of the small arteries/arterioles of the cerebral circulation 
(Greenberg, 2006). People with Type 2 diabetes are especially prone to ischaemic 
strokes due to small vessel disease, which result in a different stroke pattern from 
non-diabetic subjects (Bell, 1994; Megherbi et al., 2003; Karapanayiotides et al., 
2004). Cerebral microvascular disease is commonly characterised by stenosis or 
occlusion of small penetrating arteries with sudden or chronic ischaemia leading to 
complete infarction (lacunar infarcts) and/or incomplete infarction of cerebral white 
matter. These end arteries tend to arise directly from the large arteries and have few, 
if any, branches or distal collateral supply. However, morphological changes of these 
microvessels are difficult to visualise in life and clinical features develop insidiously 
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(Farrall and Wardlaw, 2009). Postmortem findings generally reflect late-stage 
changes which mask the earlier events.  
 
Two major pathological changes have been described which contribute to 
occlusion or hypoperfusion of small vessels, resulting in cerebral ischaemia. Similar 
to atherosclerosis in large vessels, the first and more frequent is arteriosclerosis in 
arterioles which further leads to a number of pathophysiological alterations, such as 
thickening of vessel walls, disturbance of the blood brain barrier and drop of 
perfusion rate. As a result, ‗incomplete infarctions‘ may develop, producing 
ischaemic demyelination, astrogliosis, oligodendrocyte and axonal loss. The second 
is lipohyalinosis which manifests as a progressive disorganization of small artery 
walls, with subintimal deposits of a hyaline fibrinoid substance (Fisher, 1968; 
Lammie, 2000; Román et al., 2002). This is considered to be the major pathological 
feature leading to lacunar infarction (Lammie, 2002).  
 
Although the initial steps in the development of microvascular disease 
remain unclear, increased permeability of the blood-brain barrier has been proposed 
to play an important role, in which vascular leakage caused by microvascular 
endothelial dysfunction and damage may allow plasma components of the blood to 
enter into the arteriolar wall (with damage, thickening and eventual disintegration), 
followed by perivascular oedma-related lesions in brain parenchyma (Farrall and 
Wardlaw, 2009). 
 
On magnetic resonance imaging (MRI) of the brain, cerebral microvascular 
disease can be frequently observed, particularly in adults over the age of 60. White 
matter lesions or abnormalities are seen as focal and diffuse hyperintensities on 
T2-weighted MRI scans, typically located in the extensive periventricular areas and 
the deep regions of anterior limb of the internal capsule. This is possibly related to 
local cerebral blood flow being lowest in periventricular and deep white-matter 
regions, as these are perfused by long, narrow, non-collateral end-arterioles (de 
Pantoni et al., 1996). The severity of white-matter lesions (WML) is directly 
proportional to the degree of stenosis of the multiple medullary arterioles due to 
arteriosclerosis. Lacunar infarcts or lacunes are small cavitated ischaemic infarcts, 
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resulting from occlusion of the lenticulostriate, thalamo-perforating and long 
medullary arterioles (Fisher, 1982). They are typically located in the thalamus, 
caudate nucleus, globus pallidus, internal capsule and frontal white matter. They are 
found in 10% to 31% of all symptomatic strokes, but most lacunes are clinically 
silent (Fisher, 1965; Sacco et al., 1991; Longstreth et al., 1998). Lacunar infarcts may 
be silent, but they may contribute to gradual cognitive decline (Patton, 2006). Further, 
lacunar infarcts in the white matter and brainstem can be distinguished from white 
matter lesions of hypodensity on T1-weighted MRI. 
 
Both lacunar infarcts and WML associated with small vessel disease are 
predominantly found in the sub-cortical associative areas of the brain, involving the 
basal ganglia, cerebral white matter and the brain stem. Thus these ischaemic lesions 
may particularly interrupt the prefrontal subcortical loops and disconnect the 
prefrontal cortex or anterior cingulated cortices from their basal ganglia or 
thalamocortical connections, which lead to impaired prefrontal lobe/executive 
functioning, including impaired information processing (Mori, 2002). Apart from 
having a direct effect on cognitive function, lacunes and WML are frequently found 
in the presence of Alzheimer‘s disease and these lesions may also affect cognition by 
interacting with neurodegenerative pathology such as amyloid plaques and 
neurofibrillary tangles. 
 
There is growing evidence from population-based studies that cerebral small 
vessel disease, as visualised on MRI as WML load or progression and/or lacunar 
infarcts may contribute to cognitive impairment (Longstreth et al., 1996; de Groot et 
al., 2000; Au et al., 2006) and cognitive decline associated with ageing (Garde et al., 
2000; Garde et al., 2005; Prins et al., 2005; Schmidt et al., 2005; van den Heuvel et 
al., 2006). Conventional MRI is unlikely to identify the full spectrum of small vessel 
disease related cerebral damage. More sophisticated techniques, such as diffusion 
tensor and magnetization transfer-imaging (MTI) have proved superior regarding the 
detection and quantification of subtle loss of white matter tract integrity, especially in 
the so-called normal-appearing white matter, which has been related to cognitive 
decline in elderly individuals (Schmidt et al., 2005; Shenkin et al., 2005). Another 
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pathological correlate of cognitive impairment in subjects with small vessel disease 
which eludes detection by MRI is microinfarcts in the gray matter (Kövari et al., 
2007). 
 
These neuro-imaging techniques have provided invaluable tools in 
advancing our understanding of cerebral vascular pathology. However, they are often 
expensive and available only in highly specialized settings, and therefore are not 
suitable candidates for more widespread screening of large numbers of ostensibly 
healthy people from the general population. Moreover, cerebral small vessels 
themselves are too small to visualise in detail using current neuro-imaging methods. 
A simpler, more accessible and sensitive technique is required. Small vessel disease 
is not restricted to the brain, but as an expression of a systemic condition, also affects 
other organs such as the retina and the kidney (Thompson and Hakim, 2009). In 
particular, the retinal vasculature can be directly visualised non-invasively in vivo 
and also photographed with ease because of its essential two-dimensional nature. 
More importantly, retinal and cerebral small vessels share similar embryological 
origin, size (50-250µm), structure (endarteries lacking anastomoses), and the 
blood-brain and blood-retinal barrier (Patton et al., 2005; Lloyd et al., 1995; Wong 
and Mitchell, 2007). As a consequence, there is increasing interest on the role of 
retinal microvascular abnormalities as a phenotypic marker of the condition of the 
cerebral microvasculature and their relationship with cognitive dysfunction. The 
association of these retinal vascular signs with cognitive dysfunction is 
systematically reviewed in the next chapter.   
  
1.5. Overview of retinal microvascular abnormalities 
The retina and the brain are highly metabolically active tissues with 
demanding requirements on metabolites via specialised vascular networks (Patton et 
al., 2005). From an embryological perspective, the retina is an extension of the 
diencephalon, and both organs share a similar pattern of vasculisation during 
development. There is a close anatomical correlation between both macrovascular 
and microvascular blood supply to the brain and to the retina. Both vascular 
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networks have similar vascular regulatory processes (Patton et al., 2005). Retinal 
blood vessels are the only structures that are visible by clinical examination because 
they convey erythrocytes containing the visible pigment haemoglobin. Abnormalities 
of the retinal circulation frequently highlight perturbation of the systemic circulation 
due to conditions such as diabetes and hypertension. In the last decades, advances in 
digital retinal photography and imaging techniques have allowed precise 
characterisation of subtle retinal vascular changes in large populations. This section 
provides a brief overview of the anatomical and physiological homology between the 
retinal and cerebral microvasculatures. It also describes the classification, 
pathophysiology and epidemiology of various retinal microvascular abnormalities, in 
particular, those which are related to diabetes.  
 
1.5.1. The normal retinal and microvascular arrangement 
The human eye functions similarly to a camera. Light comes in through the 
cornea, pupil and lens at the front of the eye just as the lens of the camera lets in light 
to the film (Osareh, 2004). The light is then focused on the retina like the film of a 
camera. This information will then be processed and sent to the brain via the optic 
nerve, connecting the eye to the brain, and finally the image is perceived in the brain 
(Osareh, 2004). Figure 6 illustrates a cross section of the human eye and highlights 




Figure 6: A cross section of the human eye with various ocular components (Sources: 
http://www.freedomscientific.com/resources/vision-anatomy-eye.asp) 
 
The retina is a thin multi-layered neural sensory tissue between the retinal 
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pigmented epithelium and the vitreous body, covering the inside wall at the back of 
the eye. The retina has four major types of cells: neurons (photoreceptors, bipolar 
cells, amacrine and ganglion cells), vascular (pericytes and endothelial), macroglial 
cells (Muller cells and astrocytes), and microglia (which act as phagocytes). The 
photoreceptor cells (mainly the rods and cones) are responsible for translating the 
light beams they receive into electrical impulses and then chemical signals, 
eventually transmitting this neural information to the brain where they are interpreted 
into images. The outlying parts of the retina are responsible for peripheral vision 
while the central and round area, called the macula, is in charge of detailed central 
vision which allows us to see detail and perform tasks that require central vision such 
as reading (Osareh, 2004). Within the macula is a small depression called the fovea, 
which corresponds to the region of the retina with highest sensitivity. The optic disc 
or optic nerve head is the entry and exit site of blood vessels and optic nerve fibres 
from the retina to the optic nerve (Osareh, 2004). It is a brighter region than the rest 
of the ocular fundus with a usually round shape. In the centre of the optic disc, there 
is a depression called the optic cup. Figure 7 shows highlighted regions of macular, 
fovea and optic disc components in a normal fundus image.  
 
 
           
Figure 7: Posterior pole of the eye showing macular, fovea and optic disc 
(Reproduced from Osareh, 2004) 
 
In humans, the retinal vessels occupy and nourish the inner half of the 
neural retina. They are highly organised and have two distinct layers of microvessels: 
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the superficial layer in the nerve fibre/ganglion cell layer, and the deeper layer 
extending into the inner nuclear and outer plexiform layers (Figure 8). The retinal 
vasculature is separated from the surrounding neural components by the cytoplasm of 
Muller cells and glial cells. In general, the retinal blood vessels are derived from the 
central retinal artery and vein and extend outward from the optic disc in all directions 
spreading their network across the retina. The retinal circulation is a relatively 
low-flow and high-oxygen-extraction system. Retinal vessel density is greater in the 
central retina and decreases towards the retinal periphery with the extreme part 
avascular and also sparing the fovea. Specific regions of the retina identified as 
dominating the oxygen requirements of the retina include the inner segments of the 
photoreceptors and the inner and outer plexiform layers.  
 
 
Figure 8: Organisation and structure of retina showing different cell types. The 
retinal vessels comprise two layers of microvessels: a superficial layer in the 
ganglion cell layer and a deep layer in the inner and outer plexiform layers (Adapted 
from Gardner and Aiello, 2000) 
 
The central retinal artery is a direct branch of the ophthalmic artery arising 
from bifurcations adjacent to the optic disc to form an intraretinal, end artery 
microvascular system. The retinal branch ‗arteries‘ lack an internal elastic lamina and 
therefore they are arterioles anatomically (Archer et al., 2007). These arterioles are 
around 200 µm in diameter and bifurcate to third and fourth orders in the peripheral 
Light 




  Outer plexiform layer 
Blood vessels 
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retina and finally to pre-capillary arterioles. Contrary to this arrangement, in the 
central retina small pre-capillary arterioles appear abruptly from the larger radial 
arteries. It is also notable that retinal arterioles often present 90
o
 vascular branching 
patterns, in which the smaller arterioles tend to come off at right angles from the 
parent stem (Cogan and Kuwabara, 1984). Although the arrangement of retinal 
vessels is unique for each person, the large blood vessels, in general, occupy the 
innermost portion of the retina while smaller blood vessels, the capillaries are found 
between the nerve fibre and inner nuclear layers. The diameter of the capillary 
network varies in different parts of the retina: the deep outer mesh ranges from 
15-130µm while the superficial network averages about 65µm (Wise et al., 1971). 
The retinal capillary wall is lined by a monolayer of endothelial cells encompassed 
by a basement membrane and surrounded by pericytes.  
 
The capillaries drain blood flow into the venular system, which is localized 
in the deeper retina (inner plexiform layer), and eventually to the retinal veins 
(Archer et al., 2007). Due to the lack of a well-developed smooth muscle covering, 
they have a larger diameter than arteries ranging from 30 to 300µm (Archer et al., 
2007). The central retinal vein lies within the optic disc and is drained by the 
ophthalmic vein and cavernous sinus. As retinal blood vessels are end arteries in 
nature without anastomotic connections, occlusion of these vessels leads to cessation 
of retinal blood flow and subsequent destruction of the inner layers of the retina 
(Patton et al., 2005). Figure 9 shows a normal human retinal image from the right eye 
with different structures including blood vessels and the optic disc.  
 
        
               (a)                      (b) 
Figure 9: A normal retinal image from the right eye. Diagram of the retinal (a) and 
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retinal image (b) (Reproduced from Osareh, 2004) 
The main retinal components numbered in Figure 9 are as follows: 
1- Superior temporal blood vessels; 2- Superior nasal blood vessels; 3- Fovea; 4- 
Optic disc; 5- Inferior temporal blood vessels; 6- Inferior nasal blood vessels 
 
 
1.5.2. Anatomical and physiological similarities of the 
cerebral and retinal microcirculation 
 
‘Barrier’ circulations 
The intraretinal circulation is structurally and functionally analogous to the 
cerebral microcirculation in that they both have similar and important properties of 
‗barrier‘ endothelia (Patton et al., 2005). This barrier function serves to prevent 
non-specific permeation of the neuronal milieu by macromolecules and restrict the 
transfer of small hydrophilic and blood cells, yet facilitates exchange of respiratory 
gases, amino acids, salts, sugars and some peptides, and helps buffer variations in 
blood composition in the brain and retina (Archer et al., 2007). The endothelial cells 
of the cerebral and retinal capillaries form a continuous and single layer around the 
capillary lumen. They are non-fenestrated with each cell being fused to juxtaposed 
neighbours by tight junctional complexes, which are composed of several proteins, 
such as occludin, junctional adhesion molecules and zonulae occludens. These tight 
junctions form the mechanical component of the blood-brain and inner blood-retinal 
barriers (Patton et al., 2005). In addition, instead of static lipid membrane barriers, 
barrier endothelia are dynamic interfaces with specific and elective membrane 
transport acting as a metabolic component of the barrier. They have specific 
carrier-mediated transport proteins, providing transport of nutrients such as glucose 
and amino acids across the tight junctions, as well as enzymatic degradation of 
molecules crossing the blood-brain and blood-retinal barriers. 
 
This barrier is thought to be maintained in part by other constituents of the 
cerebral and retinal microvasculaures, including pericytes, basement membranes and 
the surrounding neuroglia, that promote tight junction integrity and the 
non-fenestrated phenotype of the endothelium. For example, pericytes, which are 
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embedded within a common basement membrane with the endothelial cell, provide 
structural support to the microvasculature as well as having contractile properties by 
acting as the capillary counterparts of vascular smooth muscle cells. Retinal pericytes 
occur in a 1:1 ratio with endothelial cells, which is greater than in their counterparts 
of cerebral capillaries and is also a unique feature of this microvasculature in humans. 
The basement membrane, a connective tissue sheath surrounds the capillaries and 
anchors vessels to adjacent tissues (Patton et al., 2005). Both cerebral and retinal 
astrocytes (known as perivascular end feet) may not only play a role in the 
development of endothelial zonule occludens and specific barrier proteins, but also in 
angiogenesis, inducing endothelial cell and pericyte differentiation (Patton et al., 
2005). Figure 10 illustrates the mechanical and metabolic components of the 





Figure 10: Schematic diagram of the mechanical and metabolic components of the 
blood-brain and blood-retinal barriers and the influence of glial cells on these 
barriers (Reproduced from Patton et al., 2005) 
 
 
Regulation of cerebral and retinal circulations 
The retinal vasculature lacks autononomic innervation (except for the 
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choroidal circulation extending into the outer layers of the retina) and therefore blood 
flow into the capillary beds is not under neurogenic control but autoregulated via 
local myogenic and metabolic mechanisms. Likewise, there is no autonomic 
innervation to the cerebral microvasculature and the local process of control or 
autoregulation is a property of both circulations. More specifically, the perfusion 
pressure of the cerebral or retinal circulation is related to systemic blood pressure and 
tissue pressure by the following relationship (Figure 11): 
Cerebral/ocular blood flow = (mean arterial blood pressure-intracranial/intraocular 
pressure)/ vascular resistance 
 
   





Figure 11: Schematic diagram of the retinal microvessel and ocular blood flow (OBF) 
as an example (Reproduced from Patton et al., 2005) 
 
In order for the retinal and cerebral circulations to maintain a constant flow 
over a range of systemic blood pressures, their vascular resistance has to be altered 
accordingly. This is largely mediated by the vascular smooth muscle of the arterioles 
and pericytes, resulting in changes in luminal diameters. In particular, in response to 
a high intraocular or intracranial pressure, the myogenic capacity of both vascular 
smooth muscles and pericytes to contract produces increased vascular tone and 
facilitates a sensitive decrease of luminal diameter in retinal and cerebral blood 
vessels. In addition, cerebral and retinal blood flow is related to local metabolic 
needs, which depends on regional neuronal activity (Patton et al., 2005). For example, 
in the retina, blood flow has been found to be greater in the temporal retinal 
(containing the metabolically active macula) than in the nasal retina (Patton et al., 
Intraocular Pressure (IOP) Vascular Resistance 





2005). This metabolic-driven activity in parenchyma can also be achieved by the 
sensitivity of the component smooth muscle cells in the arterioles to endothelial 
generated vasodilators and constrictors, such as nitric oxide (NO), endothelins and 
bradykinin. The degree of autoregulation within the retinal vascular circulation varies 
with region supplied by the superficial capillary bed being better regulated than the 
deeper capillary bed (Yu et al., 1994).  
 
1.5.3. Classification of retinal microvascular abnormalities 
The retinal vasculature offers an opportunity to examine the effects of 
various systemic and metabolic diseases on the microcirculation. With the 
development of retinal photographic techniques, including high-resolution digital 
imaging, subtle retinal vascular changes can be assessed with accuracy and high 
reproducibility. Broadly these retinal changes in older people can be divided into 
three groups:  
1) classic retinal vascular changes in diabetes and hypertension (i.e., diabetic and 
hypertensive retinopathy) 
2) isolated retinopathy signs in individuals without clinical diabetes or hypertension 
(e.g., microaneurysms, retinal haemorrhags, or cotton-wool spot)  
3) changes in retinal vascular network geometry, which include arteriolar and 
venular calibre changes, and changes in retinal vascular architecture (e.g., retinal 
tortuosity, arteriolar bifurcation angles) 
 
Of the various retinal microvascular abnormalities, only the spectrum of 
retinal vascular changes related to Type 2 diabetes is reviewed in this thesis as this is 
most relevant to the original research work undertaken. 
 
1.5.4. Pathophysiology of retinal vascular changes in Type 2 
diabetes 
In Type 2 diabetes, chronic hyperglycaemia triggers a cascade of molecular 
events that cause microvascular damage. In particular, persistent hyperglycaemia in 
poorly controlled diabetes may result in biochemical alterations and altered 
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hemodynamics of the retinal vasculature, which lead to chronic hypoxia. When 
compensatory pathways fail to resolve this retinal hypoxia, a spectrum of 
pathological processes may develop. Diabetic retinopathy is primarily a disorder of 
the retinal circulation that compromises the delivery of oxygen and nutrients to meet 
the high metabolic demands of the retina. It is one of the most common 
microvascular complications of diabetes that can lead to irreversible visual loss. 
Even in diabetic people without clinical retinopathy, retinal microvasculature may 
have been affected, such as the ‗dynamic‘ or ‗static‘ changes of the retinal vascular 
calibre size. In turn, these distinct and subtle changes may provide prognostic 
information regarding the risk of diabetic retinopathy. The pathophysiological 
changes and possible mechanisms underlying diabetic retinopathy and variation of 
retinal vascular calibre are described. 
 
Diabetic retinopathy  
The pathophysiology of diabetic retinopathy (DR) is complex. The vascular 
disruptions of diabetic retinopathy are primarily characterised by abnormal vascular 
flow, increased vessel permeability, and/or occlusion or closure of capillaries. 
Histologically, a hallmark of early DR is the change in the structure and cellular 
composition of the microvasculature, including endothelia cell damage, loss of 
intramural pericytes and thickening of capillary basement membrane. As a 
consequence, breakdown of the inner blood-retinal barrier may occur, resulting in 
accumulation of extracellular fluid and plasma proteins. Loss of contractile function 
in pericytes may weaken the vessel wall as well as disturb blood flow pattern. 
Another common feature in early DR is the presence of acellular capillaries, which 
are degenerate and non-perfused capillaries with only a basement membrane tube 
remaining (Kern and Mohr, 2007). When patches of these capillaries increase and 
become confluent, the terminal arterioles that supply these capillaries often become 
occluded. In addition, local accumulation of leukocytes, platelets and erythrocytes 
may also contribute to capillary occlusion. As a result of occluded capillaries, retinal 
ischaemia stimulates a pathologic neovascularisation mediated by angiogenic factors, 
such as vascular endothelial growth factor (VEGF). Endothelial proliferation occurs 
following ischaemia with the subsequent preretinal new vessel proliferation in an 
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attempt to supply oxygenated blood to the hypoxic retina. This neovascularisation is 
the predominant feature of later, advanced stage of DR. Hemorrhaging of new 
vessels into the vitreous may also lead to tractional retinal detachment. 
 
Cytotoxic effects of glucose 
The exact mechanisms by which elevated glucose initiates the vascular 
disruption in DR remain poorly defined and several pathways have been implicated 
(Figure 12). For instance, hyperglycaemia may trigger apoptosis in endothelial cells. 
Retinal capillary endothelial cells and pericytes have been found to die by an 
apoptotic-like process in diabetic humans, and in diabetic or experimentally 
galactosemic rats (Mizutani et al., 1996). High ambient glucose levels increase 
glucose flux though the polyol pathway, which operates in both endothelium and 
pericytes that express aldose reductase (Knott and Forrester, 2003). Thus glucose 
may also be toxic by generating free redicals whose activity is increased because of 
depletion of glutathione (a powerful free-redical scavenger) by polyol pathway 
overactivity (Knott and Forrester, 2003). Excessive production of free radicals may 
lead to oxidative stress, changes in blood rheology and haemodynamics. In addition, 
increased intracellular glucose levels may activate protein kinase C, which can have 
various deleterious effects, such as basement membrane thickening and prolonged 
retinal circulation time. For example, activation of PKC could alter the expression of 
endothelium-derived vasoactive factors, leading to an increase of vascocontrictor 
actions of endothelin-1 and a decrease in the vasodilatory function of NO. Such 
alterations in vascoreactivity may further promote retinal vasoconstriction and 
increased resistance to blood flow, thus prolonging retinal circulation time (Way et 
al., 2001). More importantly, activation of PKC can induce endothelial cells to 
release entothelin-1, which is a potent vasoconstrictor that may decrease retinal 
perfusion, and vascular endothelial growth factors (VEGFs) that may break down the 
blood-brain barrier and also lead to neovascularisation  (Knott and Forrester, 2003). 
Further, VEGF is thought to act via its receptor to phosphorylate specific 
tight-junction proteins, leading to separation of the tight junctions and eventually the 
break-down of the blood-retina barrier. Increased blood glucose concentration can 
also lead to formation of advanced glycation end-products (AGEs) by non enzymatic 
binding of glucose to protein side chains. Glycation of basement membrane 
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components may alter the membrane‘s electrochemical charge characteristics leading 
to increased vascular permeability, and also affect endothelial function. 
 
Inflammatory mechanisms 
There is increasing evidence that inflammation may also play an important 
role in the pathogenesis of DR (Ciulla et al., 2003). The stimulus for these 
inflammatory-like changes may be high glucose concentration. Leukostasis is an 
important component of the inflammatory process, and adhesion of leukocytes to the 
vascular wall has been found to be significantly increased in retinas of diabetic 
animals (Miyamoto and Ogura, 1999). Diabetes has been reported to increase 
expression of ICAM-1 (intracellular adhesion molecule-1) in the retina and 
interaction of this protein with the CD18 adhesion molecule on monocytes and 
neutrophils contributed to the diabetes-induced increase in leukostasis within retinal 
vessels (Joussen et al., 2002). Leukostasis has been postulated to be an important 
factor in death of retinal endothelial cells in diabetes (Miyamoto and Ogura, 1999; 
Joussen et al., 2001; Joussen et al., 2004). Large leukocytes cannot pass through 
unobstructured capillary beds and become logged in the narrow lumen, resulting in 
blockage of the affected capillary and reducing the retinal perfusion. In particular, 
leukocytes in diabetes are less deformable (Miyamoto and Ogura, 1999) and this, 
together with their inappropriate adherence and inherent capacity to produce toxic 
superoxide radicals has important implications for capillary non-perfusion, 
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Figure 12. Possible pathways of glucose-induced damages in retinal vascular cells in 
diabetic retinopathy. VEGF, vascular endothelium-derived growth factor; ICAM, 
intracellular adhesion molecule. 
 
 
Retinal vascular calibre changes 
As described earlier, the end-artery system of the retina lacks any obvious 
autonomic nerve supply, and blood flow into the capillary beds is tightly regulated in 
response to the metabolic needs of the retinal parenchyma. This is achieved, in large 
part, by the regulatory capacity of the component smooth muscle cells (VSMc) in the 
retinal arteries and arterioles, which are highly sensitive to endothelial-generated 
vasodilators and vasocontrictors (Gardiner et al., 2007). Downstream from the 
precapillary arteriole, pericytes of the retinal capillary possess contractile properties. 
Together with VSMc, pericytes exert a major impact on retinal hemodynamics and 
fine control of blood flow through the capillaries (Gardiner et al., 2007). 
 
Persistent dilatation of retinal arterioles has been well observed in diabetes 
(Kristinsson et al. 19997). Although the precise mechanisms through which diabetes 
triggers retinal arteriolar dilation remains unclear, Gardiner and his colleagues 
(Gardiner et al., 2007; Curtis et al., 2003) have proposed that the retinal arteriolar 
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smooth muscle cells become resistant to the vasoconstricting actions of endothelin-1. 
Retinal arteriolar dilation in diabetes may be further promoted by an inhibition of 
Ca
+2
 influx channels on smooth muscle cells and this occurs via 
hyperglycaemia-mediated overactivation of protein kinase C (Curtis and Scholfield, 
2004). Arteriolar dilation and the associated increase in retinal blood flow may be 
exacerbated in the later stages of diabetic retinopathy through a drop in retinal 
oxygen tension secondary to capillary non-perfusion (Gardiner et al., 2007). 
According to the laws of Poiseuille‘s, arteriolar dilation decreases resistance to flow 
and increases hydrostatic pressure in the capillaries and venules, leading to increase 
in the rate of fluid movement from the vessel into the tissue (Gardiner et al., 2007). 
In this scenario, retinal arteriolar dilation may also account, at least in part, for early 
increases in retinal capillary permeability in diabetes. Furthermore hemodynamic 
abnormalities associated with diabetes can be accentuated by the increases in the 
retinal capillary and venular diameters that are seen in people with diabetes. These 
possibly represent a direct consequence of arteriolar dysfunction. Alternatively, 
retinal venular dilation may also reflect inflammatory processes implicated in the 
pathogenesis of impaired glucose metabolism or be related to endothelial dysfunction, 
reflecting an increased production of nitric oxide secondary to higher levels of 
cytokines (Caballero, 2005; Kolodjaschna et al., 2004; Wilkinson-Berka, 2004).  
 
Most recently, it has been argued that before the onset of diabetic 
retinopathy, there is an early reduction in retinal perfusion and arteriolar calibre, 
followed by a gradual increase in both as the complication progresses (Curtis et al., 
2009). Perhaps the discrepancy is due to different definitions of ‗early‘, according to 
TA Gardiner (personal communication, 20 November 2009). The early dilatation 
which Gardiner referred to in the original studies was based on observation in human 
studies (perhaps several years of diabetes) and that was always in conflict with the 
very early observations of constriction observed in diabetic rats (only weeks after 
induction of diabetes). Alternatively, at the early stage there may be tissue hypoxia 
induced by arteriolar constriction that in the later stages progresses to hypoxia due to 
vessel loss. The normal vascular response to hypoxia is dilatation but in very early 
diabetic retinopathy the hypoxia is actually the result of arteriolar constriction and 
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vessels that do not respond to the hypoxia that they are causing. That constriction and 
failure to respond to the resultant hypoxia is due to hyperglycaemia-induced 
arteriolar dysfunction (Curtis et al., 2009).  
 
1.5.5. Clinical stages and features of diabetic retinopathy 
The natural history of diabetic retinopathy has been classically divided into 
an early, nonproliferative stage, and a later, proliferative stage, including a spectrum 
of retinal vascular signs. Currently it can be diagnosed either through 
ophthalmoscopy or retinal photography. Although there is a lack of pathognomonic 
signs, the individual features are associated in distinct diagnostic patterns. Except for 
microaneurysms, it is unusual for one clinical sign to occur independently (Towler 
and Lightman, 2003).  
 
Nonproliferative diabetic retinopathy 
In this stage, microaneurysms and other individual lesions caused by 
microvascular leakage, including hard exudates and haemorrhages, are the features 
of so-called ‗background diabetic retinopathy‘. They may appear and regress without 
obvious warning signs. Unless maculopathy coexists, affecting the vision, patients 
are often unaware that they suffer from the disease until it progresses to more severe 
levels. When microvascular occlusion becomes more extensive, lesions including 
venous beading or looping, intraretinal microvascular abnormalities (IRMAs) and 
abundant cotton-wool spots are common. These changes, previously termed 
‗preproliferative retinopathy‘ indicate worsening retinal ischaemia and carry a high 
risk of progression to neovascularization and the proliferative phrase of diabetic 
retinopathy (Towler and Lightman, 2003).  
 
Microaneurysms 
Microaneurysms are outpouchings of capillaries and are the earliest 
clinically detectable signs of diabetic retinopathy. They arise mostly due to 
asymmetrical dilatations of weakened capillary walls or endothelial buds attempting 
to revascularise an ischemic retina. They appear as tiny red spots, varying in size 
from 10 to 150 µm and commonly temporal to the macula (Figure 13 (b)). Although 
microaneurysms are not static features and may even disappear, sudden appearance 
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of numerous microaneurysms is an indication of worsening retinal ischaemia. 
Haemorrhages 
       Haemorrhages occur due to the rupture of weakened capillaries. They 
appear either as small red dots or blots indistinguishable from microaneurysms or as 
larger flame-shaped haemorrhages (Figure 13 (b)). The former are often present 
within the densely packed deeper layers of the retina while the latter occur in the 
more superficial nerve fiber layer. As the retinal vessels become more damaged and 
leaky, their numbers increase. 
Hard exudates  
Hard exudates (HE) are the result of precipitation of lipoproteins and other 
circulating proteins through abnormally leaky retinal vessels including 
microaneurysms. They are typically manifested as random yellowish/white patches 
of varying sizes, shapes and locations (Figure 13 (c)). These are either seen as 
individual spots, clusters, or are found in large rings around leaking capillaries. Hard 
exudates encroaching upon the macula may severely compromise vision.
 
Although 
exudates may absorb spontaneously, they usually tend to increase in volume in an 
untreated retina 
Cotton-wool spots 
Cotton-wool spots (CWS) come about due to occlusion of retinal 
pre-capillary arterioles supplying the nerve fibre layer, with concurrent swelling of 
local nerve fibre axons. These abnormalities usually appear as little fluffy round or 
oval areas in the retina with a whitish colour, usually adjacent to an area of 
haemorrhage (Figure 13 (c)). 
Intraretinal microvascular abnormalities  
Intraretinal microvascular abnormalities (IRMAs) are clusters of irregular 
vascular segments within the retina (Figure 13 (d)). They may result from dilated 
preexisting capillaries or represent limited new vessel formation. They often arise 
within large areas of capillary non-perfusion and when several are present they 
indicate severe non-proliferative diabetic retinopathy that may rapidly progress to the 
proliferative stage.  
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Venous changes: venous beading, looping or reduplication 
Venous beading (VB) occurs where there is widespread capillary ischaemia 
adjacent to a vein and may represent foci of endothelial cell proliferation that have 
failed to develop into new vessels. It consists of localised dilatation in venous calibre 
with an appearance resembling a string of sausages (Figure 13(e)), which is often 
found adjacent to IRMA. Venous beading is a sign of severe non-proliferative 
diabetic retinopathy and a strong predictor of neovascularisation. Venous loops, also 
known as omega loops, appear as an abrupt, curving deviation of a vein from its 
normal path. They are less frequent than beading. Venous reduplication may arise 
from revascularisation around areas of venous occlusion. They appear as dilatation of 
a pre-existing channel or the proliferation of a new channel of similar calibre 
adjacent to the original vein. 
 
Proliferative retinopathy 
This stage is characterised by new vessel formation which appears as arcade 
of abnormal structures normally occuring on the optic disc (new vessel disc or NVD) 
or elsewhere on the retina (new vessel elsewhere or NVE). Abnormal new 
vasculature may threaten vision due to bleeding which causes complications such as 
preretinal haemorrhage and glucoma. Fibrous tissue and haemorrhages may also 
accompany and can lead to tractional retinal detachment. NVD carries a worse 
prognosis than NVE and if left untreated often leads to vitreous haemorrhage and an 
increased chance of blindness.  
New vessels elsewhere or on the disc  
New vessel formation is stimulated by retinal ischaemia of its inner layers 
secondary to regional closure of the capillary bed. Retinal hypoxia triggers a variety 
of vasoproliferative factors, such as vascular endothelia growth factors (VEGFs), 
resulting in a neovascular response locally and by diffusing through the vitreous to 
other areas of retina, to the optic disc and into the anterior chamber. New vessels 
elsewhere (NVE) are on the surface of the retina or further forward in the vitreous 
cavity. They appear as very fine, branching or loops of vessels that develop from the 
venous sides of the capillary network adjacent to an area of retinal ischaemia (Figure 
13 (f)). In the absence of stereo biomicroscopic examination, it may be difficult to 
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distinguish subtle new vessels from IRMA. New vessels on the disc (NVD) lie on the 
disc or within 1 disc diameter of its margin.  
 
Fibrous proliferation elsewhere or on the disc  
This fibrous tissue occurs as a supportive cellular matrix accompanying 
retinal neovascularization, which persists even if the new vessels involute. They 
appear as grayish-white sheets or fine strands opaque enough to be definitely seen 
(Figure 13 (g)). 
Preretinal haemorrgage  
Preretinal haemorrhages (PRH) are located just anterior to the retina or 
under the internal limiting membrane. They may remain encapsulated and appear as 
round, oval or linear patches, or boat-shaped haemorrhages with a fluid level which 
obscures the underlying retina (Figure 13 (h)). They may reabsorb slowly or may 
need laser or surgical treatment. 
Vitreous haemorrhage  
Vitreous haemorrhages (VH) extend further forward into the vitreous cavity 
than PRH (Figure 13 (i)). They arise from bleeding from new vessels anterior to the 
retina as well as fibrovascular proliferations. 
 
Diabetic maculopathy 
       Diabetic maculopathy is characterised by macular oedema and/or ischaemia. 
It can accompany any stage of DR and may affect central vision (Hudson, 2008). 
Clinically significant macular oedema comprises any one of the following: 1) Retinal 
thickening within 500 µm of the fovea; 2) Hard exudates within 500 µm of the fovea; 
3) Retinal thickening that is larger than one disc diameter, any part of which is within 
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Figure 13: Normal and abnormal diabetic retinopathy (DR) images. A typical normal 
retinal image (a), DR showing microaneurysms and haemorrhages (b), DR with 
cotton wool spots and exudates (c), intraretinal microvascular abnormalities (IRMAs) 
(d), venous beading (e), new vessels elsewhere (f), fibrous tissue elsewhere (g), 
preretinal haemorrhage (the uncoagulated blood) (h), and vitreous haemorrhage 





1.5.6. Prevalence and incidence of diabetic retinopathy 
The prevalence and incidence of DR in diabetic populations have been 
measured in several epidemiological studies using a variety of ascertainment 
methods. Some have used direct opthalmoloscopic examination whereas others have 
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employed a number of different retinal photographic techniques (e.g. stereoscopic vs. 
nonstereoscopic, the number of fields taken). More reports have combined the results 
of Type 1 and Type 2 diabetes, although most have concentrated on Type 2. Few 
studies have focused on older people with diabetes. In general, the prevalence of DR 
varies with the age of the diabetic cohort studied, diabetes duration, the risk factor 
profile of the cohort, the grading systems used to measure DR and definitions for 
diabetes and DR severity.  
 
Many epidemiological studies have assessed the prevalence of DR by using 
the modified Airlie House classification and its extension of the Early Treatment 
Diabetic Retinopathy Study (ETDRS) classification systems (ETDRS Report No.10, 
1991). Overall, the estimated prevalence of DR (of any level of severity) assessed by 
using this classification system ranges from 18.2 to 54.1% (Varma et al., 2004). For 
example, in the Beaver Dam Study of 445 diabetic individuals aged 43-86 years the 
prevalence of any DR was 36.8%, with 1.8% of subjects having proliferative 
retinopathy (PDR) (Klein et al., 1992a). Similarly, the Los Angeles Latino Eye Study 
on over 1187 diabetic individuals (age ≥ 40 years) estimated the prevalence of any 
DR at 45.8% and PDR at 5.6% (Varma et al., 2004). The Wisconsin Epidemiologic 
Study of Diabetic Retinopathy (WESDR) reported a higher prevalence of 50% for 
people who had a diagnosis of diabetes aged between 50 and 69 years (Klein et al., 
1984). This higher prevalence may reflect poorer diabetes management and the late 
diagnosis of diabetes in the earlier years. Table 2 lists the population-based studies 
that have estimated the prevalence of DR using the ETDRS classification system or 
other method in people with Type 2 diabetes. This shows that the prevalence of any 
DR varied across studies with an overall increase according to mean duration of 
diabetes in study participants. For example, the prevalence of any DR in people with 
newly diagnosed diabetes was lower than in those with known diabetes and varied 
from 1.5 to 15.8%. The differences in reported prevalences of retinopathy in people 
with newly discovered Type 2 diabetes may be in part due to variations in the time 
between onset and detection of DM, reflecting variations in the access to and 




Age- and gender- related differences have not been reported consistently 
and in most reports, it was difficult to seperate out the influence of Type 1 diabetes, 
as the results were not stratified by type of diabetes. Based on data from the Los 
Angeles Latino Eye study (Varma et al., 2004) in which Type 1 diabetes (n=30) 
made up only 2.5% of all diabetics (n=1217), the prevalence of any DR and PDR 
rose steadily with every 10-year increase in age from the age of 40 years (from 40.7 
to 55.0% for DR, 4.4 to 8.2% for PDR) whereas a decrease in prevalence of any DR 
or PDR was seen among those aged 80 years and older (40.0% and 3.3% 
respectively). The age-adjusted prevalence of any DR was similar in men (49.6%) 
compared with women (45.0%). In support of these findings, Leske (Leske et al. 
1999) reported 28.9% prevalence of any DR in men and 28.2% in women and there 
was no age-specific difference when a very small percentage of Type 1 diabetics 
(1.9%) were included. A lower prevalence of DR in age groups over 80 relative to 
younger age groups in the Latino Eye study may stem from either increased mortality 
in diabetic patients with the most severe disease and complications, or could reflect a 
reduced prevalence of DR in older diabetics with newly diagnosed diabetes. With 
respect to race, in the National Health and Nutrition Examination Survey (NHANES) 
III, Whites had a lower prevalence rate of any DR relative to either Hispanics or 
African Americans. Specifically Hispanics experienced the highest prevalence rates 
irrespective of duration of diabetes (Harris et al., 1998; Varma et al., 2004). 
 
Compared with prevalence studies, there are far fewer reports on the 
incidence and progression of diabetic retinopathy in population-based studies. In the 
WESDR, incidence of any DR was based on 533 diabetic patients diagnosed at age 
30 years or older and DR was assessed by 7-field retinal photographs using ETDRS 
protocols. The 10-year cumulative incidence of DR was 73% and progression to 
PDR was 17% for patients who were free of DR at the baseline examination (Klein et 
al., 1994a). In the Liverpool Diabetic Eye study of 3742 patients with Type 2 
diabetes aged 56-72 years old the 5-year cumulative incidence of any DR was 30.5% 
based on 3-field photographic gradings (Younis et al., 2003). In another study in 
Taiwan, of 471 Chinese diabetic patients aged over 40 years old, the 4-year 
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cumulative incidence of any DR was 4.8% and progression to PDR 1.5% when DR 
was determined by opthalmoscopy (Chen et al., 1995). These results show that the 
incidence in populations may vary greatly depending on geographical regions, 
socioeconomic factors and characteristics of the diabetic population as well as the 
epidemiological methods used, such as definition of diabetes and detection and 
classification of DR (The Eye Disease Prevalence Research Group, 2004). Whether 
there is a variation with age or gender remains unclear based on the limited data. 
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Diagnosed with DR only; DR: diabetic retinopathy; Dx: diagnosed; M: men; W: women; NHANES III:Third National Health and Nutrition 
Examination Survey; WESDR: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. 
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1.6. Diabetic retinopathy, retinal vascular calibre 
and systemic factors 
Two decades ago, the Framingham Heart and Eye Study proposed that 
diabetic retinopathy signs may reflect generalised microangiopathic processes that 
affect not only the eyes but also organs elsewhere in the body (Hiller et al., 1988). In 
recent years, using standardised and advanced retinal photographic methods such as 
high-resolution digital imaging to evaluate retinal vascular changes in diabetes, 
population-based studies have more precisely quantified the associations of these 
retinal vascular changes with a diverse range of environmental and genetic factors as 
well as systemic vascular complications. It has now become evident that diabetic 
retinopathy and other subtle vascular signs including arteriolar and venular calibre 
changes, might be biomarkers of underlying widespread deleterious effects of 
abnormal glucose metabolism on the systemic microcirculation and disease (Cheung 
and Wong, 2008). This section provides a brief summary of associations between 
diabetic retinopathy, changes in retinal vessel calibre and systemic factors, including 
vascular risk factors and vascular disease. Other retinal microvascular abnormalities 
such as venular tortuosity and changes in arteriolar bifurcation geometry are 
described in the next section. 
 
1.6.1. Associations with age, gender and ethnicity 
As described earlier, the relationship between diabetic retinopathy and age 
or gender in Type 2 diabetes is not clear based on available data. However, an inverse 
association between age and retinal vascular calibre has been consistently 
demonstrated across different study populations including in people with Type 2 
diabetes (Wong et al., 2003a; Leung et al., 2003a; Wong et al., 2006a; Kawasaki et 
al., 2006; Klein et al., 2006). In the Wisconsin Epidemiological Study of Diabetic 
Retinopathy (WESDR), retinal arteriolar and venular calibre decreased from 2.0-3.0 
µm for each decade increase in age, independent of sex, refractive error, arterial 
blood pressure and other risk factors (Klein et al., 2006). Moreover, after accounting 
for the correlation between retinal arteriolar and venular calibre, the inverse 
association between retinal vascular (both arteriolar and venular) calibre and age was 
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largely unchanged (Kaushik et al., 2007).  
 
Whereas many studies have examined the relationship between age and 
retinal vascular calibre, few population-based studies have evaluated the influence of 
sex or ethnicity on retinal vascular calibre, and none of them focused on diabetic 
people. Results of studies from the general population are inconsistent. In the Blue 
Mountains Eye study (Leung et al., 2003a), both mean retinal arteriolar calibre and 
AVR (a ratio between the average diameters of arterioles with respect to venules) 
were consistently higher in women than men across all age groups, in line with 
findings from the Cardiovascular Health Study and MESA (Wong et al., 2003b; 
Wong et al., 2006a) but these sex differences could not be confirmed in reports from 
other studies (Wong et al., 2005a; Leung et al., 2004). There is no adequate 
explanation for these inconsistent findings for men and women. 
  
With respect to ethnicity, both retinal arteriolar and venular calibre were 
significantly greater in black and Hispanic participants than in white and Chinese 
Americans in the general population (Wong et al., 2006a). Also as mentioned earlier, 
a higher prevalence of diabetic retinopathy was found in Hispanic and African 
Americans than Whites in people with Type 2 diabetes (Harris et al., 1998; Varma et 
al., 2004). A greater exposure to both genetic and/or environmental risk factors 
leading to obesity, diabetes, hypertension and hyperlipidaemia, may in part account 
for the observed ethnic differences in retinal vascular changes. It is also possible that 
these differences may partly reflect variations in inheritance of vascular risk factors, 
susceptibility to their effects, or other processes not examined in these studies, such 
as potential measurement error in quantifying retinal vascular calibre caused by 
ocular pigmentation (Rochtchina et al., 2008).  
 
1.6.2. Associations with duration of diabetes and glycaemic 
control 
There is clear evidence that longer duration of diabetes and poorer 
glycaemic control are the major risk factors not only for the incidence and prevalence 
of diabetic retinopathy but also progression of existing retinopathy. For example, the 
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Australian Diabetes, Obesity and Lifestyle study (Ausdiab) showed a linear trend 
between DR prevalence and diabetes duration in people with Type 2 diabetes. The 
prevalence of any DR was less than 10% in those with diabetes duration of less than 
5 years, but more than 50% in those with diabetes duration of 20 years or longer 
(Tapp et al., 2003). The importance of glycaemic control as indexed by glycosylated 
haemoglobin has been demonstrated in large-scale observational studies (Klein et al., 
1988) and in two pivotal clinical trials, including the United Kingdom Prospective 
Diabetes Study (UKPDS) in patients with Type 2 diabetes (DCCT research group, 
1993; UKPDS 33, 1998). In the UKPDS, there was a reduction in the 12-year rate of 
progression of diabetic retinopathy of 21% and reduction in need for laser 
photocoagulation of 29% in the intensive vs. the conventional treatment group 
(UKPDS 33, 1998). However, in a more recent report from the Action in Diabetes 
and Vascular Disease (ADVANCE) clinical trial with 11,140 patients with Type 2 
diabetes, further intensive glucose control (near normalisation of blood glucose 
defined as keeping HbA1c levels close to 6%) had no effect in incidence and 
progression of DR (Patel et al., 2008). Moreover, a pooled analysis of 11,000 
participants from three population cohorts showed that retinopathy lesions 
characteristic of diabetes were found in 7.4% to 13.4% of non-diabetic participants 
and were present even in individuals with normal blood glucose independent of 
blood pressure (Wong et al., 2008). These results, together with the observed limit to 
the risk reduction for DR through tighter glucose lowering, suggest that processes 
other than hyperglycaemia may also contribute to the development of DR (Nguyen 
and Wong, 2009). 
 
In general, patients with shorter duration of diabetes (<5 years) show a 
constriction of the major arteries and arterioles (Wong et al., 2002a). With more 
prolonged diabetes duration and concomitant presence of clinical retinopathy, arterial 
vessels begin to dilate accompanied or followed by venular dilatation (Curtis et al., 
2009). In the WESDR, each 10-year increase in diabetes duration was associated 
with a 0.26µm increase in arteriolar calibre in people with Type 2 diabetes (Klein et 
al., 2006). In Type 1 diabetes, wider venular calibre was associated with longer 
duration of diabetes (Klein et al., 2003). Wider retinal arterioles also have been found 
to be associated with incidence of retinopathy (Klein et al., 2007; Rogers et al., 2008; 
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Cheung et al., 2008), whereas wider venules have been associated with progression 
of retinopathy (Klein et al., 2004a) in people with diabetes. Similarly, higher 
glycosylated haemoglobin was associated with both wider retinal arteriolar and 
venular calibre in Type 1 diabetes (Klein et al., 2003) and wider venular calibre in 
Type 2 diabetes or individuals without diabetes (Klein et al., 2006; Nguyen et al., 
2008a). 
 
1.6.3. Associations with hypertension  
Raised blood pressure is another major risk factor for both the initial 
development of diabetic retinopathy and its subsequent progression. Impaired retinal 
vascular autoregulation, endothelial dysfunction and increased expression of vascular 
endothelial growth factors secondary to hypertension may play at least a partial role 
in this association in diabetes (Klein and Klein, 2002). The UKPDS trial also showed 
blood pressure control reduced the risk of DR independent of glycaemia levels in 
patients with Type 2 diabetes (UKPDS 38, 1998). However, similar to tighter glucose 
lowering, there seems to be a threshold limit to the risk reduction for DR by further 
reduction of blood pressure (Patel et al., 2008; Mitchell and Wong, 2008), which 
suggests other processes apart from elevated blood pressure and hyperglycaemia may 
also be involved.  
 
In distinct contrast to the association of hyperglycaemia with retinal 
arteriolar calibre, an inverse relationship between elevated current blood pressure and 
retinal arteriolar narrowing has been well established in general populations and in 
diabetic adults (Sharrett et al, 1999; Wong et al., 2002b; Klein et al. 1994b; Wong et 
al., 2003a; Leung et al., 2003a; Wong et al., 2006a; Klein et al., 2006). It has long 
been known that generalised retinal arteriolar narrowing is an early characteristic 
sign of hypertensive retinopathy (Wong and Mitchell, 2004). Impaired 
endothelium-dependent vasodilatation in essential hypertension caused by decreased 
nitric oxide levels may play a role in the narrowing of retinal arteriolar calibre (Sun 
et al., 2009). Moreover, lower AVR and narrowed arteriolar calibre have been found 
to be independently associated with raised past blood pressure levels, measured up to 
10 years prior to the retinal assessment, suggesting that retinal arteriolar calibre 
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changes reflect persistent damage from long-term hypertension (Sharrett et al., 1999; 
Leung et al., 2004; Sun et al., 2009). Of greater significance are prospective findings 
that retinal arteriolar narrowing is also a pre-clinical marker of hypertension risk in 
initially normotensive individuals (Ikram et al., 2006a; Smith et al., 2004; Wong et 
al., 2004a, b) which further supports the hypothesis that peripheral vascular 
resistence, reflected by retinal arteriolar narrowing, is an important contributing 
factor for hypertension (Nguyen et al., 2007). Contrary to the findings in arterioles, 
retinal venules tend to widen rather than narrow with increasing blood pressure and 
wider retinal venular calibre predicted incident hypertension (Ikram et al., 2006b; 
Liew et al., 2006).  
 
1.6.4. Associations with dyslipidaemia 
The role of higher blood lipids levels, including total cholesterol, 
low-density lipoprotein (LDL), and triglycerides, in the development of retinal hard 
exudates has been well recognised in people with diabetes (Klein et al., 1991; Chew 
et al., 1996; van Leiden et al., 2002). Recent results from the Fenofibrate 
Intervention and Event Lowering in Diabetes (FIELD) study suggest that 
lipid-lowering therapy may reduce retinopathy requiring laser treatment in people 
with Type 2 diabetes (Keech et al., 2005). 
 
Dyslipidaemia may also have an effect on retinal vascular calibre size in the 
general population. For example, larger retinal venular calibre has been reported to 
be independently related to higher triglyceride and lower HDL cholesterol levels 
(Sun et al., 2009). It has been proposed that inflammation and endothelial 
dysfunction might play a role in these relationships. As yet, no such data are 
available in people with diabetes. 
 
1.6.5. Associations with obesity 
The influence of obesity on diabetic retinopathy has been investigated in 
several studies. Although a positive relationship between higher body mass index 
and increased risk of diabetic retinopathy has been demonstrated in most studies 
(UKPDS 34, 1998; Zhang et al., 2001; Chaturvedi et al., 2001; Keen et al., 2001; 
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Henricsson et al., 2003), conflicting data were reported in the WESDR (Klein et al., 
1984; Klein et al. 1997). In older-onset diabetic patients (diagnosed as having 
diabetes at age 30 years or older), there was a 3-fold increase in risk of developing 
retinopathy for those who were underweight (BMI <20 kg/m
2
). On the other hand, 
obesity (BMI >31.0 kg/m
2
 for men and 32.1 kg/m
2
 for women) was not found to 
associate with either progression or severity of retinopathy. It has been suggested that 
underweight may be a marker of the more ‗severe‘ phase of diabetes, or an indicator 
of late-onset type 1 diabetes (Klein et al., 1997). More recently, larger waist-to-hip 
ratio but not body mass index has been reported to be independently associated with 
a number of incident individual retinopathy signs in a non-diabetic population (van 
Leiden et al., 2002). Obesity correlates with many common vascular risk factors of 
diabetic retinopathy, including hyperglycaemia, hyerlipidemia and hypertension. It 
may also have a more direct effect on the development of DR, such as inducing 
oxidative stress and increasing expression of the vascular endothelial growth factors 
(VEGFs) (Cheung and Wong, 2007).  
 
Both cross-sectional and prospective studies have shown that obesity is 
associated with larger retinal venular calibre and lower AVR in the general 
population (Wang et al., 2006) and in people with diabetes (Klein et al., 2003; Klein 
et al., 2006). Elevated markers of endothelial activation and chronic vascular 
inflammation have been observed to correlate with retinal venular dilatation. 
Furthermore, obesity is also linked with increased blood volume and leptin levels, 
which might modulate vascular calibre through local mechanisms involving nitric 
oxide release (Oren et al. 1996; Vecchione et al., 2002; Caballero et al., 2005; 
Surmacz, 2007). These factors may interact to contribute to the larger venular 
diameter in obese individuals. 
 
1.6.6. Associations with smoking  
The effect of cigarette smoking has been examined, producing contradictory 
findings. Some cross-sectional studies reported that cigarette-smoking was associated 
with an increased risk of proliferative diabetic retinopathy (Patekau et al., 1977; 
Muhlhauser et al., 1986), whereas others found no significant association with DR 
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(Moss et al., 1991). An inverse relationship of smoking status was also detected in 
relation to the incidence and progression of retinopathy in Type 2 diabetic subjects 
(Stratton et al., 2001). Possibly, a positive association of smoking with proliferative 
DR is partly due to elevated carboxyhaemoglobin levels induced by smoking, which 
may further hamper oxygen delivery to a hypoxic sensory retina and eventually lead 
to retinal neovascularization (Muhlhauser et al., 1986).  
 
In the WESDR of Type 2 diabetic population, current cigarette smoking was 
associated with both larger retinal arteriolar and venular calibre, and the number of 
pack-years smoking was linearly related to larger venular calibre (Klein et al., 2006). 
These results are in good agreement with cross-sectional findings from Type 1 
diabetic people and non-diabetic population (Klein et al. 2003; Klein et al., 2000; 
Kifley et al., 2007). While the mechanisms involved in retinal vascular dilatation in 
smokers are not yet known, venular widening has been well observed clinically in 
cigarette smokers (Stefansson et al., 1983; Rosenberg et al., 2005; Jeganathan et al., 
2005). It has been postulated that the association of smoking with venular dilatation 
may involve higher carbon monoxide levels and endothelium-dependent relaxation, 
which may result in a decrease in oxygen supply to retinal thus leading to retinal 
venular dilatation (Stefansson et al., 1983; Rahman et al., 2007).  
 
1.6.7. Associations with alcohol intake 
The role of alcohol intake in diabetic retinopathy also remains uncertain. 
For example, an English clinic-based prospective study of 296 diabetic men free of 
retinopathy at baseline examination found that heavy drinkers (>10 pints beer per 
day) were three times as likely to develop exudates or proliferative DR (Young et al., 
1984). Conversely, WESDR investigators found no association between alcohol 
intake (classified as none, light, moderate, and heavy) and the incidence or 
progression of DR (Moss et al. 1994). The discrepancy in results could have arisen 
from differences in classification or cut-off levels of the exposure variable, with less 
statistical power to detect a significant association in the WESDR due to relatively 
low exposure levels compared with the British cohort (McCarty et al., 2001). 
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So far only a few studies have examined the association of alcohol drinking 
with retinal vascular calibre in the general population and results are inconsistent. 
The AVR was low in those who drink over 20 grams per day in the Rotterdam Study, 
and lower AVR was ssociated with alcohol consumption in the ARIC study (Ikram et 
al., 2004; Klein et al., 2000). Although the former study did not find an effect of 
alcohol consumption on retinal arteriolar or venular calibre, cross-sectional data from 
the MESA indicated that current alcohol intake was related to smaller retinal 
arteriolar calibre (Wong et al., 2006a). The exact mechanism of the influence of 
alcohol on the variation of retinal vascular calibre, however, remains to be 
elucidated.  
  
1.6.8. Associations with coronary heart disease 
It is now clear that in people with Type 2 diabetes, diabetic retinopathy signs 
are associated with an increased risk of myocardial infarction (MI), coronary heart 
disease (CHD) and heart failure (Cheung and Wong, 2008). For instance, in the 
ARIC study, the presence of any DR was associated with a twofold higher risk of 
incident coronary heart disease (defined as MI, fatal CHD, and myocardial 
revascularization) and incident MI, threefold higher risk of fatal CHD, and fourfold 
higher risk of congestive heart failure (Cheung et al., 2007a; Wong et al., 2005b). 
These results were independent of diabetes duration, glycaemic control and other 
cardiovascular risk factors. There was also a graded association between increasing 
diabetic retinopathy severity and increasing risk of coronary heart disease (Cheung et 
al., 2007a). The findings are consistent with data from the World Health 
Organization Multinational Study of Vascular Disease in Diabetes (WHO-MSVDD) 
(Fuller et al., 2001), and other studies demonstrating associations of not only NDPR 
but also PDR with ischaemic heart disease (Miettinen et al., 1996; Faglia et al., 2002; 
Juutilainen et al., 2007).  
 
These associations, together with other observations such as an association 
of DR with impaired myocardial perfusion and severity of coronary artery stenosis 
on angiography, support the concept that microvascular and macrovascular 
complications of diabetes share common pathogenic mechanisms beyond the 
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traditional cardiovascular risk factors adjusted for in most studies. It has been 
suggested that retinopathy is a manifestation of generalised vascular dysfunction 
caused by endothelial dysfunction or genetically determined alterations in the 
basement membrane metabolism associated with hyperglycaemia (Cheung and 
Wong, 2008). These vascular effects may increase arterial or arteriolar wall 
permeability and leakage, which further facilitate the pathogenic cascade of 
atherosclerosis formation in large arteries (Norgaz et al., 2005; Cheung et al., 2007a). 
Alternatively, rather than being a simple indicator of a more adverse cardiovascular 
profile, microvascular disease (indicated by the presence of retinopathy) may play a 
causal role by providing the inflammatory drive in the development of 
atherosclerotic disease in people with Type 2 diabetes.  
 
Other circulatory mechanisms may also underlie a causal link between 
diabetic retinopathy and coronary heart disease. For example, diabetic retinopathy 
may represent widespread systemic microcirculatory (resistance vessel) disease, and 
places an increased impedance burden on the diabetic heart, predisposing to the 
development of diabetic cardiomyopathy and heart failure (Cheung and Wong, 
2008).  
 
There is also good evidence from prospective studies for an association 
between retinal vascular calibre and coronary heart disease. For example, prospective 
data from the Cardiovascular Health Study demonstrated that both smaller retinal 
arteriolar calibre and larger venular calibre, which contributed to a lower AVR, were 
independently associated with 5-year risk of coronary heart disease in elderly people 
(Wong et al., 2006b). In individuals with Type 1 diabetes, lower AVR was associated 
with incident myocardial infarction (Klein et al., 2004b). However, no such data are 
available to date in Type 2 diabetes, except for the findings that both smaller retinal 
arterioles and larger venules predicted 22-year cardiovascular mortality caused by 
stroke in a Type 2 diabetic cohort (Klein et al., 2006).  
 
1.6.9. Associations with stroke and sub-clinical 
cerebrovascular disease 
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In 1975, an autopsy study of patients with stroke showed a close correlation 
of retinal and cerebral arteriolar pathology (Goto et al., 1975). Since then, the 
presence of retinopathy has been shown to be associated with stroke, particularly in 
people with hypertension (Svärdsudd et al., 1978; Petitti and Bhatt, 1995; Nakayama 
et al., 1997). New population-based studies, using standardised photographic 
assessment of retinal images to ascertain retinopathy lesions, have confirmed these 
early observations in diabetes (Cheung and Wong, 2008).  
 
In the WESDR, PDR was associated with mortality from stroke in people 
with Type 2 diabetes, independent of diabetes duration, glycaemic control and other 
risk factors (Klein et al., 1992b; Klein et al., 1999). Data from the WHO-MSVDD 
demonstrated that the presence of retinopathy was also associated with incidence of 
stroke in both men and women with Type 2 diabetes (Fuller et al., 2001). More 
recently, in the ARIC study with 1, 617 middle-aged white and black Americans with 
Type 2 diabetes, retinopathy signs (the presence of individual lesions or any diabetic 
retinopathy) were associated with two to four-fold higher risk of incident ischaemic 
stroke (Wong et al., 2001a; Cheung et al., 2007b).   
 
In a sub-study of the ARIC cohort including non-diabetic people, 
participants had cranial magnetic resonance imaging (MRI) scans (Wong et al., 
2002c; Wong et al., 2003c). The presence of retinopathy was associated with 
presence and severity of cerebral white matter lesions and cerebral atrophy on MRI. 
Furthermore, there was a synergistic interaction between the presence of retinopathy 
and white matter lesions on the subsequent risk of clinical stroke (Wong et al., 
2002c). Participants with retinopathy or white matter lesions alone had about twofold 
increase in stroke risk, but participant with both retinopathy and cerebral lesions had 
higher risk than those with white lesions only and even more than 18 times higher 
than those without either phenotype. This suggests that subclinical cerebrovascular 
disease may be more severe or extensive in people with both cerebral and retinal 
markers of microvascular pathology. Findings from the ARIC study are further 
reinforced by data from other studies (Petitti and Bhatt, 1995; Wong et al., 2003b; 
Wong et al., 2003d).  
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Associations of retinopathy signs with stroke, white matter lesions and 
cerebral atrophy could reflect a contribution of small vessel disease (evident in the 
retina) to the pathophysiology of a wide spectrum of cerebrovascular conditions in 
people with Type 2 diabetes (Cheung and Wong, 2008). It is also possible that these 
cerebral conditions may be related to a break-down of the blood-brain barrier given 
that diabetic retinopathy (e.g. retinal micoraneurysms, haemorrhages and cotton wool 
spots) is usually due to a disruption in the blood retina barrier (Wardlaw et al., 2003). 
 
As mentioned, in Type 2 diabetes, both smaller retinal arterioles and larger 
venules predicted the future risk of stroke death. There is also considerable evidence 
supporting an association of altered retinal vascular calibre with both clinical and 
subclinical stroke in the general population. Prospective data from both the 
Rotterdam and Cardiovascular Health studies have consistently shown that larger 
retinal venular calibre is associated with an increased risk of clinical stroke (Ikram et 
al., 2006c; Wong et al., 2006b). A more recent meta-analysis from 6 longitudinal 
studies has further confirmed these findings (McGeechan et al., 2009). Furthermore, 
the Rotterdam study has demonstrated that wider retinal venules are also associated 
with cerebral infarction, MRI-defined whiter matter lesions and lacunar infarction 
(Ikram et al., 2006c; Ikram et al., 2006d). Conversely, no association between 
arteriolar caliber and incident stroke or progression of cerebral small vessel disease 
was observed in these studies (McGeechan et al., 2009). 
 
1.6.10. Associations with depression 
In people with Type 2 diabetes, an association between retinopathy and 
depression was reported in a meta-analysis of cross-sectional data from population 
and clinic-based studies (de Groot et al., 2001). However, given the cross-sectional 
nature of these studies the temporal relationship between diabetic retinopathy and 
depression remains unknown. This has exacerbated the argument on potentially 
underlying mechanisms linking the two conditions. For example, it has been 
speculated that depression may precede and accelerate the development of diabetic 
retinopathy either by its mediating effect on negative health behaviors such as 
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physical inactivity and lack of adherence to medications, or by a more direct 
influence of psychologically induced biochemical and physiological changes 
affecting the systemic vasculature (de Groot et al., 2001). An alternative hypothesis 
is that diabetic retinopathy may cause distress to patients resulting in symptoms of 
depression (Miyaoka et al., 1997). On the other hand, and supported by recent 
findings from brain imaging studies, it is also possible that the microvascular disease 
evident as retinopathy is also present in the brain where it plays a role in the 
development of depression in people with Type 2 diabetes. Thus, cerebral 
microvascular disease has been suggested to contribute to the development of 
late-life depression, a subtype sometimes referred to as ‗vascular depression‘ 
(Tiemeier et al., 2004). In support of such a vascular hypothesis, studies have shown 
that both silent and symptomatic brain infarcts are associated with subsequent 
depression (Chemerinski and Robinson, 2000), and that magnetic resonance imaging 
(MRI)-defined white matter lesions and deep grey-matter abnormalities are more 
frequent in depressed than in non-depressed individuals (Lyness et al., 1998).  
 
Although a vascular role in depression remains both conceptually attractive 
and biologically plausible in Type 2 diabetes, it has yet to be shown conclusively in 
clinical studies and in particular needs to be confirmed in large population-based 
studies (Baldwin, 2005; Thomas et al., 2004; Nguyen et al. 2008b). Recently, a 
clinic-based cross-sectional study in patients with Type 2 diabetes showed that wider 
retinal arteriolar calibre was associated with increasing severity of depression after 
adjusting for age, gender and duration of diabetes, but not after further adjusting for 
other vascular risk factors (Nguyen et al., 2008b). Whether the lack of association 
was mainly due to controlling for the confounding effect of poorer diabetes control 
and a high frequency of vascular risk factors or to insufficient statistical power given 
a small sample size (n=99) remains to be determined in future investigations.      
 
1.7. Measurement of retinal vascular changes in 
diabetes 
In general, clinical examination and grading of diabetic retinopathy is a 
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complex task due to variable retinal vascular characteristics of the disease. Various 
techniques have been applied to examine the retina, including direct or indirect 
ophthalmoscopy and fundus photography. Direct ophthalmoscopy is limited in this 
respect because it has a small field of view and lacks stereoscopic viewing making 
the direct observation of pre-retinal proliferation and macular oedema difficult or 
impossible. Stereoscopic slit-lamp biomicroscopy using indirect or corneal contact 
lenses is the most accurate clinical method. Retinal photography (now largely digital) 
has been preferred in large scale community programs and epidemiological studies 
because of the need for lasting documentation such as for quality assurance and 
demonstrating disease progression over time. In this context, mydriasis reduces the 
technical failure rate of ungradable photographs compared with undilated fundus 
examination.  
 
Systematic evaluation of the diabetic fundus begins with the identification 
of the number and location of individual lesions by class (e.g. haemorrhage, hard 
exudate), then summarises this information to determine the severity of retinopathy. 
Retinopathy grading is based on the concept that a hierarchy of stages can be defined, 
where the higher the grade, the higher the risk of suffering visual loss (Larsen and 
Soliman, 2007). Although the grading scale reflects the natural course of the disease 
in its unrelenting and most devastating form, in reality, diabetic retinopathy can 
regress both spontaneously and in particular, after timely therapeutic intervention 
(Larsen and Soliman, 2007). In epidemiological studies, the purpose of using a 
validated grading scale is to assess retinopathy levels and retinopathy progression 
with high sensitivity and reproducibility.  
 
With advances in digital retinal photography and new imaging technology, 
more precise assessment of the subtle changes seen in the retinal microvasculature 
has been made available, notably quantifying retinal vascular calibre in objective 
methods. Relying on an accurate measurement of retinal vessel calibre, other 
parameters of retinal vascular architecture, such as arteriolar bifurcation angles can 
also be derived and are gaining interest as potential markers of systemic disease. This 
section describes the several grading systems developed for diabetic retinopathy and 
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quantitative evaluation of retinal vascular network geometry which have been used in 
large epidemiological studies. 
 
1.7.1. Grading of diabetic retinopathy 
 
Early Treatment Diabetic Retinopathy Study Grading 
The extension of the Airlie House classification that was developed for the 
Early Treatment Diabetic Retinopathy Study (ETDRS) currently stands as the 
recognised Gold Standard system for grading DR, in terms of its outcome related 
evidence-base from randomised clinical trials (ETDRS Report No. 10, 1991). On the 
basis of a prospective evaluation of the relative risk of retinopathy progression and 
visual loss, a retinopathy severity scale was developed that divides diabetic 
retinopathy into 13 levels ranging from absence of retinopathy to severe vitreous 
haemorrhage (ETDRS Report No. 12, 1991). This scale can be used to describe 
overall retinopathy severity and change in severity over time (ETDRS Report No. 12, 
1991; ETDRS Report No. 18, 1998). 
 
ETDRS fundus photography consists of seven standard dilated stereoscopic 
photographic fields, each covering 30 degrees (Figure 14). The photographs are 
recorded on photographic film as diapositives and each stereoscopic pair of 
diapositives is inspected against light boards using stereo viewers (5×magnification). 
When needed, a comparison is performed with standard reference photographs. The 
grade for each lesion is recorded separately for each standard field based on a 
multi-step scale including absent, questionable, definitely present but less than a 
standard photograph A or a written definition, equal to or worse than the standard 
photograph A but less severe than the standard photograph B, equal to or worse than 
the standard photograph B. For some lesions a standard photograph provides the 
dividing lines between grades whereas for others a written definition is used. The 
lesion grades are summarised for each eye into an ETDRS level that defines the 





The inter-grader reliability of this scale has been assessed by comparing 
independent duplicate gradings of photographs. Complete agreement on level was 
observed in 53% eyes and agreement within 1 step was observed in 88% (ETDRS 
Report No. 12, 1991). Overall, agreement between graders was substantial with a 
weighted kappa of 0.65. When the scale was used for assessing overall retinopathy 
severity from both eyes for each patient, classifying patients by retinopathy level in 
the worse eye retained substantial reliability between independent gradings with a 
weighted kappa of 0.71 (ETDRS Report No. 12, 1991). 
 
The ETDRS scale does not cover macular oedema, which is graded 
separately. Using a grid overlaid on one photograph in Field 2 of the stereo pair, the 
grader evaluates the size and location of thickened retina, the maximum thickness of 
the thickened retina, the degree of cystoid oedema, and the location of the hard 
exudate that is often found with it (Larsen and Soliman, 2007). Diabetic macular 
oedema in the ETDRS is defined as thickening and/or hard exudate within 1 disc 
diameter of the center of the macula, given that the total amount of hard exudate 
within the Field 1 photograph exceeds that in a certain standard photograph.  
 
For individual lesions, including macular oedema, retinal haemorrhages 
and/or microaneurysms, hard exudates, new vessels and fibrous proliferations, the 
inter-grader reliability of the ETDRS system has been found to be substantial, with a 
weighted kappa varying from 0.61 to 0.80 (ETDRS Report No. 10, 1991). For other 
lesions, such as cotton wool spots, intraretinal microvascular abnormalities, and 
venous beading, the inter-grader reliability was moderate, with a weighted kappa 
 
Figure 14: Fundus photography in the Edinburgh Type 
2 Diabetes Study (ET2DS): location of the seven 
30-degree fields. Field 1 is centred on the optic disc. 
Field 2 is centred on the centre of the macula. Field 3 is 
centred just temporal to the macula. Fields 4–7 are 
tangential to horizontal lines passing through the upper 
and lower poles of the disk and to a vertical line passing 




varying from 0.41 to 0.60. 
 
Despite the reference standard in clinical trials, the ETDRS fundus 
photography places considerable demand on the patient and the resources and the 
grading is also complex and time consuming (Larsen and Soliman, 2007). As a result, 
abbreviated protocols have been developed, two of which will be described below. 
 
EURODIAB Grading 
The EURODIAB grading system is a simplified system, with reference to 
seven-field 30
o 
ETDRS classification, but adapted to facilitate large epidemiological 
studies, in which investigators may have limited experience in retinal photography 
(Aldington et al., 1995). The photographic protocol involves two 45
o
 colour 
diapositive photographs, consisting of one macular field photograph with the centre 
of the optic disc at the nasal end of the horizontal meridian of the viewing field and 
one disc/nasal field with the optic disc one disc-diameter in from the temporal edge 
of the field on its horizontal meridian (Figure 15). The diabetic retinopathy severity 
scale comprises no retinopathy (level 0), non-proliferative (level 1 to 3), and 
proliferative (level 4 to 5) retinopathy (Table 3). Non-proliferative retinopathy is 
defined as the presence of one or more microaneurysms, haemorrhages, and/or hard 
exudates. Proliferative retinopathy is defined as any new vessels, fibrous 
proliferations, preretinal haemorrhage, vitreous haemorrhage, or photocoagulation 
scars. As a consequence of not taking stereo retinal photographs, macular oedema 
(thickening) is not gradable. An overall retinopathy level is allocated from top down 
after grading of individual lesion types (Aldington et al., 1995). This means that the 
first step is to determine whether proliferative diabetic retinopathy is present. In the 
event that it is, the retinopathy level of the eye is 5, otherwise one proceeds to 
evaluate if the eye is level 4, and so on.  
 
The EURODIAB grading system has been well validated by comparing it 
with the reference standard of 7-field 30
o 
stereo photography. Within-observer 
reliability yields an unweighted kappa of 0.85 and between observer reliability a 
value of 0.83 (Aldington et al., 1995). It should be noted that the unweighted kappa 
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statistics provides an estimate of the proportion of exact agreement achieved beyond 
that expected by chance, thus compensating for the problem of agreement that looks 
better than it really is because the characteristic is rare. Weighted kappa is more 
suitable for ordinal scales as it takes the degree of disagreement into account and 





Figure 15: Example of 45
o 
retinal photograph of macular field (1) and disc/nasal 




Table 3: General comparison of gradings between ETDRS and EURODIAB system 
ETDRS Level            ETDRS severity                   EURODIAB level 
10-15 No retinopathy 0 
20-35 Mild non-proliferative 1 
43-47 Moderate non-proliferative 2 
53 Severe non-proliferative 3 




International Clinic Diabetic Retinopathy Severity Scale 
The International Clinical Diabetic Retinopathy and Diabetic Macular 
Edema Disease Severity Scale has been developed by a consensus panel of experts to 
provide a severity scale for use in clinical practice, such as retinopathy screening and 
communication among health care professionals (Wilkinson et al., 2003). With 
reference to the ETDRS grading system, the classification for diabetic retinopathy 
comprises five stages of disease severity which are further divided into three stages 
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of low risk, a fourth stage of severe non-proliferative retinopathy, and a fifth stage of 
proliferative retinopathy (Table 4). Diabetic macular oedema is classified as 
apparently present or apparently absent. If training and equipment allow the grader to 
make a valid decision, macular oedema is further categorised based on its distance 
from the central macula (fovea) (Larsen and Soliman, 2007). This simplified staging 
system may help standardise clinical retinopathy grading given that many nominally 




Table 4: Diabetic retinopathy disease severity scale (Reproduced from Wilkinson et 
al., 2003) 
Proposed Disease Severity Level Findings Observable on Dilated Ophthalmoscopy 
No apparent retinopathy No abnormalities 
Mild nonproliferative diabetic 
retinopathy 
Microaneurysms only 
Moderate nonproliferative diabetic 
retinopathy 
More than just microaneurysms but less than severe 
nonproliferative diabetic retinopathy 
Severe nonproliferative diabetic 
retinopathy 
Any of the following: more than 20 intraretinal 
haemorrhages in each of 4 quadrants; definite venous 
beading in 2+ quadrants; Prominent intraretinal 
microvascular abnormalities in 1+ quadrant. And no 
signs of  proliferative diabetic retinopathy 
Proliferative diabetic retinopathy One or more of the following: neovascularisation, 




1.7.2. Measuring retinal vessel calibre from retinal 
photography 
The apparent calibre of a normal retinal vessel is believed to be the width of 
the streaming column of reflective erythrocytes viewed perpendicularly to the flow 
direction (Figure 16). By ophthalmoscopy or fundus photography, the surrounding 
plasma zone and the vessel wall are transparent, and the former accounts for less than 
10% of the internal diameter. However, erythrocyte column width is considered to be 
a good surrogate measure of internal vessel calibre as it appears to be proportional to 
internal retinal vessel calibre in animal studies and the ratio of the width of the 
plasma layer to internal vessel calbre for both arterioles and venules stays constant 
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(Bulpitt et al., 1970). Existing techniques for measuring blood vessel width consist of 
two steps which may both affect the apparent blood vessel width. Step one is the 
acquisition of the vessel image, such as using fundus photography or fluorescein 
angiograms, and step two is the measurement of the vessel width. Photography is the 




Figure 16: A simplified diagram showing the apparent and true width of the blood 
column based on. When an image of a blood vessel is viewed from point C (the 
centre of the pupil), the apparent edge of the blood column is given by the point P, 
which is the interaction point between the incoming part of the ray and the chosen 
reference plane. (Reprinted from Brinchmann-Hansen and Heier, 1986) 
 
 
In general, retinal arterioles are often small and require high-resolution 
images to measure accurately. Also, to enhance the contrast between the retinal 
arterioles and the background, red-free images are often preferable or the green 
channel from the RGB colour image can be used. Although conventional fundus 
photography can be converted to digitalised image using a high resolution digital 
photographic scanner, direct digital capture has advantages, including immediate 
photographic evaluation and repeat capture for optimum image quality (Patton, 2006). 
Attempts at quantifying retinal arteriolar calibre were first proposed by Wagener et al 
in 1947 (Wagener et al., 1947). Later with the introduction of retinal photography, 
Parr and colleagues (Parr and Spears, 1974 a, b) developed the Central Retinal Artery 
Equivalent (CRAE) measurement by using micrometric techniques, in which 
measurements were performed in enlarged projected images with callipers.  
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Following the widespread use of digital imaging systems, more objective 
and reliable methods including those based on intensity profiles of retinal blood 
vessels (microdensitometry) have superseded previous micrometric techniques. 
Using computer-assisted programme, microdensitometry techniques are 
semi-automated, requiring some observer input to select which cross-section of blood 
vessel to measure in a grayscale image, which consists of many elements or pixels. 
The location of each pixel can be identified with spatial coordinates and each has a 
defined intensity also known as its grey value (Patton et al., 2005). Due to its 
variable grey level at each pixel point, a cross-section of a retinal blood vessel has a 
typical intensity profile, very similar to a distinct double Gaussian curve against the 
background intensity of the surrounding retina. Mathematically, this profile can be 
described by subtracting a smaller central Gaussian function (representing the central 
light reflex from retinal arterioles) from a single Gaussian model, to correct for the 
absence of the central reflex in older eyes  (Patton et al., 2005). The single Gaussian 




















Where a1 is the the amplitude of the peak of the profile, a2 is the the location of the 
peak of the curve, a3 is a specific variable indicating the width or spread of the 
Gaussian curve and a4 is the background retinal intensity (Patton et al., 2005).  
 
The double-Gaussian profile can be subjected to image analysis to estimate 
the width of the blood vessel, most commonly done by measuring the width of the 
vessel at half the height of the peak of the intensity profile (half-height method). This 
strategy minimises any effect of de-focusing at image acquisition due to medial 
opacities, such as cataracts (Patton et al., 2005). In addition to the evaluation for 
CRAE, a similar formula for venules (central retinal venule equivalent, CRVE) was 
developed by Hubbard et al. in 1999. By combining the two measures, the AVR was 
the ratio of the CRAE/CRVE. The Parr and Spear and Hubbard formulas for CRAE 
and CRVE were derived by examining numerous vascular junctions in retinal images 
and calculating the relationship between individual trunk vessels and their respective 
branch vessels using a least root mean square deviation model that best fit the 
observed data. The retinal photographs used in both groups were from a young, 
 103 
healthy, normotensive population.  
 
Recently, the Parr-Hubbard formulae have been further improved by 
Knudtson et al. to overcome some of their limitations (Knudtson et al., 2003). For 
example, the Parr-Hubbard formulae contain constants that require using 
measurements scaled only in micrometers. Thus to be able to use the formulas, a 
conversion from pixel to micrometers is required, which could be an inexact 
summarised conversation. An estimate of the pix-to-micrometre ratio is usually 
calculated based on an assumed average optic disc diameter of 1850µm (Hubbard et 
al., 1999). In addition, the formulae were dependent on the number of retinal vessels 
measured. Knudtson et al. therefore developed a set of revised formulae for 
summarising retinal vascular calibre, and showed clear superiority over the 
Parr-Hubbard formulae. In particular, Knudtson (Knudtson et al., 2003) incorporated 
the concept of ‗branching coefficient‘ which was firstly proposed by Young in 1809. 
In a young, normotensive healthy population, Knudtson arbitrarily chose to measure 
the six largest arterioles and venules in each retinal image and calculated the 
observed ‗branching coefficient‘ (e.g. 1.28 for arterioles which was against the 
theoretical value of 1.26) based on the previous formula. By placing the calculated 
empirical values into the branching coefficient formula, they calculated that (Patton 
et al., 2005):  









) [0.95=√1/1.11], where D0 is the width of trunk 
vessel and D1and D2 are the two branch vessels. 
 
More recently, Patton (Patton et al., 2006a) suggested another revised 
formula for more accurate estimation of arteriolar branching coefficient. Instead of 
adopting a constant value of 1.28, this formula used a linear regression model to 
incorporate the asymmetry index of the vessel branches being measured. However, 
whether the newer formulae are more accurate and have a better predicative value for 
outcomes compared with older ones remains to be determined by future work. 
Moreover, these estimates of retinal vessel calibre measurements have not been 
validated against entire diameters of these vessels in vivo, such as measurements 




Computerised quantification of retinal vessel calibre 
As stated earlier, digital images are formed in such a way that makes them 
accessible to simple and complex mathematical manipulation (Patton et al., 2006b). 
After a series of image processing, enhancement, restoration and segmentation, 
image quality can be improved and subjected to further analysis for quantitative 
measurements. Retinal vasculature is measured from the gray-scale image in which 
the optic disc is centred. This field provides the most detail from the retinal 
vasculature as it enters and leaves the eye, and serves as the starting point for all 
further analysis of retinal vascular network geometry. Within a circular zone defined 
as between 0.5 to 1 disc diameter from the optic disc margin, the calibre of all 
individual arterioles and venules are measured through vessel tracking technique in a 
semi-automatic fashion. For example, after manually selecting a starting and ending 
position of a vessel segment, the software commences the generation of a series of 
cross-sectional intensity profiles perpendicular to the vessel. For each intensity 
profile created, a ‗best-fit‘ Gaussian curve function is incorporated onto the data. The 
vessel calibre is calculated as the mean width of the intensity profiles at half the 
height of the intensity profile peak. These individual retinal vessel measurements are 
then summarised using formulae as described earlier reflecting the average arteriolar 
and venular calibre of that eye, taking into account branching patterns. 
 
Reliability of retinal vessel calibre measurements 
As mentioned previously, compared with observer-driven micrometric 
techniques, computer driven microdensitometry has been shown to be more accurate 
in the presence of focusing errors (Brinchmann-Hansen, 1986). The coefficient of 
variation for the computer driven microdensitometry has been calculated as 1.5-7.5% 
compared with 6-34% for the observer-driven technique (Patton et al., 2006b). Also 
there was a tendency of the latter method to underestimate the size of small vessels.  
 
Several large, population-based epidemiological studies have examined the 
reliability of computer-assisted retinal vessel measurements (Hubbard et al., 1999; 
Couper et al., 2002; Sherry et al., 2002; Wong et al., 2002c; Wong et al., 2003b; 
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Ikram et al., 2004; Wong et al., 2006a; van Hecke et al., 2006). Overall, these retinal 
vascular indices, including CRAE, CRVE and AVR, have demonstrated substantial 
reproducibility, with both intra- and inter-grader correlation coefficients ranging form 
0.67 to 0.99. For instance, in the ARIC study (Hubbard et al., 1999) correlation 
analysis (R) was used to evaluate inter-observer agreement (R=0.74, 0.77 and 0.79, 
for CRAE, CRVE and AVR, respectively, n=151 eyes). For intra-observer agreement, 
R=0.69, 0.89 and 0.84 for CRAE, CRVE and AVR respectively.  
 
In the Blue Mountains Eye Study which used a similar system and the same 
Parr-Hubbard formula, intraobserver reliability weighted kappa values ranged from 
0.8 (for trunk AVR ratios) to 0.93 (for CRVE measures) (Sherry et al., 2002). In 
addition, R
2
 correlation analysis showed agreement ranging from 0.79 to 0.92. For 
interobserver reliability, kappa ranged from 0.71 (for trunk AVR ratios) to 0.9 (for 
CRVE measures), and correlation statistics showed R
2
 ranging from 0.78 to 0.9. 
Although it is unclear as to why the kappa statistic normally applied for the analysis 
of agreement of categorical data was chosen, these values suggested a good 
agreement using computer-assisted measurements (Patton et al., 2005).  
 
Similarly, using the Knudtson‘s revised formula, the Rotterdam Study 
reported correlation coefficients for intra-observer agreement ranging from 0.67 to 
0.80 for CRAE, 0.91 to 0.94 for CRVE and 0.75 to 0.84 for AVR. For intra-observer 
agreement these were 0.69 to 0.88, 0.90 to 0.95 and 0.72 to 0.90, respectively (Ikram 
et al., 2004). Thus the findings suggest that these measurements provide a highly 
reliable research tool for objective assessment of vascular changes. 
 
Other methodological issues in measuring retinal vessel calibre  
Although measurements of retinal vascular calibre have now been used 
widely in epidemiological studies of cardiovascular and ocular disease, there are 
several methodological issues in quantification of these parameters from retinal 
photographs. First, to date, no age, sex, or blood pressure-level specific reference 
levels of retinal vascular calibre have been established (Sun et al., 2009). Existing 
retinal vascular imaging research has generally focused on the relative differences in 
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retinal vascular calibre changes in the study population (e.g. people with wider 
quartile of retinal venular calibre are more likely to have or develop cardiovascular 
disease than those with narrower quartile calibre). Normal reference ranges may 
facilitate comparison between studies and are essential for implementation of 
measurements in clinical practice. However, it may be difficult to obtain standard 
values across different populations given the various systemic and environmental 
influences on the variation of retinal arteriolar and venular calibre measurements 
(Sun et al., 2009). In particular, in adult populations, it is difficult to fully account for 
the confounding effect of vascular and ocular disease processes.  
 
Second, all images captured from the retina are subject to image 
magnification, depending on the distance from the camera to the eye as well as the 
refractive error of the eye. Magnification error could therefore be an obstacle when 
comparing retinal vascular calibre size directly between individuals, especially when 
the study population has large variation in refraction status. Therefore, several 
attempts have been made to adjust for magnification effects, such as using ocular 
biometric parameters (e.g., axial length), plain films or alternative geometric 
attributes that are dimensionless in nature, including length-diameter ratio, AVR and 
bifurcation angle. Among these, the AVR is the most commonly used measure.  
 
A smaller AVR was initially thought to reflect generalised arteriolar 
narrowing, as venular calibre was assumed to be relatively constant. However, recent 
studies suggest that the interpretation of the AVR may be overly simplistic and that it 
has significant limitations, including the inability to capture the separate information 
of individual arteriolar and venular calibre components (Liew et al., 2007). For 
example, both narrower arterioles and wider venules may contribute to a smaller 
AVR. Thus a smaller AVR cannot differentiate specific changes in arteriolar and 
venular calibre. Furthermore, narrowed retinal arterioles and widened venules may 
carry different information and use of a summary measure of AVR may lead to 
incorrect inferences on associations with different systemic diseases. Whereas 
smaller arterioles are associated with hypertension or even predict its development, 
larger venules have been associated with inflammation, smoking, obesity and 
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hyperglycaemia (Sun et al., 2009). On the other hand, the major reason for the initial 
use of AVR (to correct for magnification differences) may not be as important as 
previously thought (Liew et al., 2007). Several population-based studies found no 
relationship between refraction/axial length and retinal vascular calibre after ocular 
magnification had been controlled for, suggesting no biological link between ocular 
dimension and structural changes in the retinal vasculature (Wong et al., 2004c; 
Cheung et al., 2007 c, d). It has also been proposed that in the absence of data on 
refractive error, bias from magnification difference is not profound in most eyes 
within the refractive power range of ±3 D (Wong et al., 2004c). 
 
Third, a potential confounding effect between retinal arteriolar and venular 
calibre has been addressed. Liew et al. observed that retinal arteriolar and venular 
calibre size are highly correlated and individuals with narrower arterioles also tend to 
have narrower venules, presumably due to their shared genetic and environmental 
determinants (e.g., diet, health and growth) as well as magnification artifacts (Liew 
et al., 2007). One approach to account for this confounding effect has been to adjust 
for both fellow vessels simultaneously in the statistical analysis (e.g., controlling for 
retinal arteriolar calibre in analysis of retinal venular, and vice versa). For example, 
an association between retinal venular narrowing and incident hypertension was 
initially reported in the Rotterdam Study (Ikram et al., 2006a). However, when using 
this new analytical method by adjusting for retinal arteriolar and venular calibre all 
together, retinal venular narrowing was no longer associated with incident 
hypertension (Ikram et al., 2006b). 
 
Finally, there are other potential problems with image analysis including the 
fact that retinal vessel calibres vary according to the cardiac cycle and degree of 
fundus pigmentation. The ARIC study showed that vessel pulsation was detectable, 
mainly in the largest venules of the retina (Knudtson et al., 2004). In addition, small 
changes in retinal vessel calibre can be accurately detected by multiple frame 
electrocardiograph synchronized fundus photographs. In this context, measurement 
of vessel calibre from a single, static retinal image at a random point in the pulse 
cycle may introduce measurement error (Dumskyj et al., 1996). However, given that 
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the variation caused by cardiac pulse appears to be small and random, it may only 
contribute to the non-differential misclassification and tend to bias the associations 
found to the null (Sun et al., 2009).  
 
The effect of variation in retinal background colour on retinal vessel calibre 
was observed in the Sydney Myopia Study (Rochtchina et al., 2008). They found that 
retinal vascular calibre was significantly wider in children of East Asian ethnicity 
than those of white children, which was in accordance with the findings from another 
two population-based studies suggesting racial/ethnic differences in retinal vascular 
calibre (Cheung et al., 2007e; Wong et al., 2006a). However, when the analysis was 
limited to children with a dark brown iris as a surrogate marker of retinal pigment 
colour, there was no such difference between white and East Asian children. It was 
therefore hypothesised that the reported racial/ethnic differences may be due to 
differences in retinal pigmentation (Sun et al., 2009). Retinal pigmentation may be a 
potential source of measurement error in the variation of retinal vascular calibre 
across different ethnicities. Alternatively, given iris color itself is a complex human 
trait with very high heritability, genetic differences may also explain partly the 
observed association (Sun et al., 2009).  
 
1.7.3. Measuring retinal arteriolar bifurcation geometry from 
retinal photography  
The ultimate purpose of the arterial system is to supply sufficient blood flow 
to capillaries in all parts of the body to enable adequate exchange of substances 
through the capillary walls. It has long been known that when in a healthy state, an 
arterial structure tends to conform to an idealised optimal structure in order to 
achieve the greatest efficiency, i.e. by minimising the costs involved across the 
vascular network. These costs include the shear stress experienced by the blood 
vessels due to vascular blood flow, volume of the vascular tree, pumping power 
across the vascular network, and surface area of the lumen (Patton et al. 2005). 
Specifically, this physiological principle has a great impact on connecting large and 
small vessels at bifurcations. An optimal branching pattern of the arterial network 
would facilitate both translational intravascular blood flow and transmural diffusion, 
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with the minimisation of energy costs. Geometric features of such branching 
networks that may determine the degree to which it is optimised include the angle 
between daughter blood vessels as they bifurcate from the parent vessel, and the 
relationship between the calibre of the trunk and branch vessel (Patton et al. 2005). 
 
Arteriolar branching coefficient and bifurcation angles 
Young first proposed the concept of branching coefficient as a means of 
expressing the ratio of the area of the blood circulation before and after a vascular 







, where D1 and D2 are calibre of two branch vessels respectively, and 
D0 is the calibre of the trunk vessel. Young also derived a theoretical optimum value 
of 1.26 for the branching coefficient, which was later further explained by Murray in 
1926. In his published work, Murray (Murray, 1926 a, b) described the design of an 
optimal branching vascular system, which minimises the power required to overcome 
viscous drag in a fluid and the metabolic energy required to maintain the volume of 
blood and tissues of the vessel segments. He calculated that the most efficient 
circulation can be achieved if blood flow is proportional to the cubed power of the 
vessel‘s radius, which is known as ‗Murray‘s law‘. For example, at a vascular 
bifurcation, costs are increased when branch calibre, relative to the calibre of the 
trunk vessel, are large (viscous drag is minimised at the expense of increased 
metabolic costs) or very small (reduced metabolic costs but increased viscous drag). 
In this scenario, Murray‘s law relates the calibre of the trunk and branch vessels at a 
vascular junction in an optimal circulation, such that the cube of the calibre of the 







 (where D1 and D2 are calibre of two branch vessels respectively, and 
D0 is the calibre of the trunk vessel). The exponent of 3 is also known as optimal 
junctional exponent, predicting constant shear stress throughout the network 
(Sherman, 1981). Both human and animal studies have shown values very close to 
this ideal value for the retinal circulation as well as the coronary circulation (Patton 
et al., 2005).  
 
For a symmetrical, dichotomous junction where the two branch vessels are 
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. Thus it can be 








(≈1.26), which is in agreement with 
the theoretical value of optimal branching coefficient (BC) as given by Young.  
 
Rather than using the absolute value of the BC, it has been suggested that it 
may be important to analyse the degree of deviation of the BC from the idealised 
optimum (i.e. 1.26). Figure 17 demonstrates that a deviation in either direction would 
be associated with suboptimality, either of power losses or volume (Patton, 2006). 
The deviation of retinal arterial branching coefficients from optimal values has been 
shown to be associated with cognitive ability scores (Patton et al., 2007). Other 
similar but more complex measures of BC have also been developed. These 
optimality parameters, measuring the extent to which the measures (e.g. junctional 
exponents) deviate from the theoretical predicted optimum, are found to be 
associated with advancing age (Stanton et al., 1995a), higher body mass index 
(Hughes et al., 2009), and in association with peripheral vascular disease (Chapman 
et al., 2002) and mortality from ischemic heart mortality (Witt et al., 2006). 
 
The angle subtended between two daughter vessels at a vascular junction 
has also been found to have an optimal value (approximately 75
o
) depending on 
which costs (surface, volume, drag or power) are considered and the degree of 
asymmetry between the two daughter vessels (Patton et al., 2006). As shown in 
Figure 17, the costs are minimised as shown by the confluence of the curves, when 
branching coefficient (area ratio) approximates to 1.26 and the angle approximates 
75
o
 for power losses and volume, as predicted by Murray. Animal studies have 
further corroborated that mean bifurcation angles approximate to 75
o
 (Patton et al., 
2006). Additional work by Frame and Sarelius has shown that angles are not 
anatomically invariant or static, but change significantly with blood flow and that the 
resultant increase in vessel diameter results in changes of angles of up to 50
o
 (Frame 
and Sarelius, 1993). This change is in both directions with some angles decrease 











) and A (angle between D1 and D2), for the 
costs of power losses, drag, volume and surface area (Reproduced from Patton et al., 
2006) 
 
Several studies have demonstrated that retinal arteriolar bifurcation angles 
are reduced in hypertension (Stanton et al., 1995a), increasing age (Stanton et al., 
1995b), and in men with low birth weight (Chapman et al., 1997). Deviation of 
angles from optimality has been found to be associated with logical memory scores 
in elderly people (Patton et al., 2007). By contrast, other studies found no 
associations between the angle at vascular bifurcation and vascular risk factors, 
peripheral arterial disease or other cardiovascular disease (Chapman et al. 2002; Witt 
et al., 2006; Hughes et al., 2009). 
 
Given that the endothelium may play a significant role in optimisation of 
vascular geometry by nitric oxide and endothelin-1 release (Griffith and Edwards, 
1990; Griffith et al., 1991), it is possible that changes in retinal arterial bifurcation 
optimality may reflect endothelial dysfunction. Also altered shear stress across the 
network, which is associated with altered optimal geometry, may further compound 
the effects on the vascular endothelium and cause endothelial inflammation through 
increased expression of proinflammtory genes, increased production of free radicals 
but decreased levels of important intracellular antioxidants (Patton et al., 2007). The 
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area of greatest wall shear stress has been determined both in vivo and by 
computational fluid dynamics as occurring within one vessel diameter of a vessel 
branch (Noren et al., 2000; Patton et al., 2007). Despite these hypothesises, it 
remains unclear how angles at vascular junctions may serve as independent 
predictors of systemic disease and further studies are needed to explore these 
relationships.  
 
Computerised quantification of retinal arteriolar bifurcation 
geometry 
Image analysis has been used to calculate the branching coefficient by 
measuring the widths of the trunk and branch vessels and the angles between branch 
retinal arterioles at bifurcation. Depending on formulae, different methods have been 
applied to estimate arteriolar angles. For example, Chapman et al. measured the 
bifurcation angle by subtracting the sum of the angles measured between trunk and 
each branch arterioles from 360
o
. Patton et al. directly calculated the total bifurcation 
angle between the two branch vessels using the cosine rule (Patton, 2006).  
 
Reliability of retinal arteriolar bifurcation geometry measurements 
Given the lack of accepted formulae for quantifying branching angles or 
coefficients, the variance could be, at least in part, attributed to the variable 
measurement methods. Also, very little data is available on the reliability of these 
measurements. Chapman et al. reported an intra-observer reliability for bifurcation 
angles as a within-subject standard deviation of 2.66
o
 (mean angle 68.9
o
; coefficient 
of variation 3.86%) (Chapman et al., 2002). Patton et al. estimated both intra- and 
inter-observer reliability based on intra-class coefficient (ICC) and coefficient of 
repeatability (2SD of the differences) between the repeated measures. For 
intra-observer reliability of angle measurements, the ICC was 0.96 with a coefficient 
of repeatability of 10.4
o
. Equivalent figures for inter-observer reliability were 0.95 
and 9.2
o
. For intra-observer reliability of the arterial branching coefficient, the ICC 
was 0.55 and coefficient of repeatability 0.67. Given the small range of branching 
coefficient measurements in this cohort (1.1-2.2), the investigators pointed out that 
the intra-reliability was moderately poor and predicted that the likelihood of the 
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inter-observer reliability would be even worse. When using the alternative 
‗micrometric technique‘ to measure junctional vessel width, ICC of intra-observer 
reliability was 0.65, with a coefficient of repeatability of 0.54. For inter-observer 
reliability, ICC was 0.62 and the coefficient of repeatability was 0.61. 
 
1.7.4. Measuring other retinal quantitative parameters  
 
Retinal venular tortuosity 
Venous beading, as a feature of diabetic retinopathy, has recently been 
measured quantitatively, especially within computer-assisted screening programmes 
(Patton et al., 2006). Earlier measures assumed blood vessels as one-dimensional 
curves and applied the ‗distance metric‘ (defined as the ratio of the vessel length to 
the chord length between the end points). Recently, the perceived tortuosity of blood 
vessels has been proposed to be affected by vessel thickness as well (Azegrouz et al., 
2006). Using a thickness dependent estimation method, an excellent overall 
agreement (92.4%) for vascular tortuosity was achieved in comparison with clinical 
judgement (Azegrouz et al., 2006). Despite a promising diagnostic tool in clinics, no 
study has explored the association between venular tortuosity and systemic risk 
factors and diseasease. 
 
Fractal geometrical analysis 
In addition to individual quantitative parameters of the retinal vascular 
network, a single ‗global‘ measure combining these parameters with the branching 
pattern of the retinal vasculature has been developed. The retinal vascular tree is a 
complex branching structure that could not be adequently described by using the 
classic Euclidean geometrical terms (e.g. length, area, or volume) (Cheung et al., 
2009). Fractals represent one type of non-Euclidean geometric entity and can be 
defined as geometric patterns whose parts resemble the whole (i.e. the property of 
self-similarity). Fractal dimension is a measure of geometric complexity of a spatial 
object (e.g. retinal vascular tree), describing how thoughly the pattern fills 
two-dimensional spaces. Fractal analysis has been used to characterise the 
complexity or density of the retinal vessel branching network from digital retinal 
images. For instance, a less complex, less dense, and lower fractal dimension may 
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indicate rarefaction or loss of vessels, whereas a more complex, denser, and higher 
fractal dimension may imply a microvascular proliferation (Liew et al., 2008a) 




Recently it has been shown that fractal analysis of the retinal vasculature 
from fundus photographs can be performed reliably and efficiently using a novel 
computer-based program (Liew et al., 2008b). The variations in retinal vascular 
fractal dimension have been found to be correlated with several biological 
parameters such as age and blood pressure. They may potentially be a sensitive 
indicator of deviation from normal or optimised architecture and, thus, early 
microvascular disease possibly due to retinal hypoxia (Liew et al., 2008a). However, 
very few studies, mostly clinic-based, have examined the role of retinal vessel fractal 
analysis in diabetes and cardiovascular disease. In a cross-sectional study of 729 
patients with Type 1 diabetes aged between 12 and 20 years, higher retinal vascular 
fractal dimension was associated with an increased odds of non-proliferative diabetic 




 quartile of fractal dimension 3.9; 95%CI, 2.0, 7.6) 
(Cheung et al., 2009). However, a further follow up of these patients for three years 
failed to confirm a longitudinal association between retinal vascular fractal 
dimension and risk of developing early diabetic retinopathy (Lim et al., 2009). No 
study to date has been performed in people with Type 2 diabetes.   
 
Figure 18: Fractal pattern of retinal 
vessels. The upper series shows an eye 
with higher fractal dimension and more 
complex branching pattern, whereas the 
lower series shows one with lower fractal 
dimension and less complex branching 
pattern (vascular rarefaction) (Reprinted 
from Liew et al., 2008a) 
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‘Dynamic’ measures of retinal vascular calibre 
As well as measuring static structural features from retinal images, other 
newer techniques, such as scanning laser Doppler flowetry and Dynamic Vessel 
Analyser, have been developed to measure dynamic changes in the retinal 
microcirculation. The laser Doppler flowetry can assess retinal vascular 
hemodynamic by calculating retinal blood flow, volume and velocity (Patton et al., 
2006). However, the measurements obtained from this approach shows variable 
reproducibility (Patton et al., 2006). The Dynamic Vessel Analyser (Imedos, Jena, 
Germany) allows real-time assessment of retinal vascular diameters and has been 
previously used to measure retinal vessel dilatation in response to diffuse luminance 
flicker (Nguyen and Wong, 2009). This dynamic response may reflect instrinic 
endothelial function possibly due to the role of nitric oxide in flicker-light-induced 
retinal vasodilatation. Small clinical studies using the analyser have shown that 
impaired dilatation to this flicker is associated with systemic diseases such as 
diabetes and diabetic retinopathy (Mandecka et al., 2007). Furthermore, impaired 
flicker-induced vasodilatation has been found to be associated with wider arteriolar 
and venular diameters from retinal images in people with diabetes (Nguyen et al., 
2009).  
 
1.8. Chapter summary 
Type 2 diabetes is a chronic, complex metabolic disorder characterised by 
abnormally high blood glucose levels. Type 2 diabetes is a common condition, 
currently affecting approximately 10% of people aged over 65 years in the UK and 
this prevalence is predicted to double over the next 20 years, with a particular 
increase in elderly people. There is good evidence that Type 2 diabetes is associated 
with an increased risk of age-related cognitive impairment and an enhanced risk of 
age-related cognitive decline, in addition to higher incidences of stroke and dementia. 
Given the ageing and increasing diabetic population, the deletious effects of Type 2 
diabetes on the brain is an emerging public health concern.  
 
Current knowledge on the relationship between risk factors and the 
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development and progression of diabetes-related intellectual dysfunction has until 
now been based on relatively limited and often contradictory evidence. However, 
there is increasing evidence that several potentially modifiable diabetes-related risk 
factors may be important and have implications for strategies aimed at delaying or 
preventing cognitive deterioration in people with Type 2 diabetes.  
 
One outcome of the research effort to date has been an increase in studies 
suggesting that cerebral small vessel disease with white matter lesions and lacunar 
infarcts may be a vascular cause of cognitive impairment in the elderly population. 
However, cerebral small vessels themselves are too small to visualise in detail using 
current neuroimaging methods. Given the close anatomical and physiological 
homology between the retinal and cerebral vasculatures both in health and in disease 
states, the retinal microvasculature is considered to be a potential surrogate 
biomarker of altered cerebral vasculature and therefore may demonstrate an 
association with cognitive function. Moreover, the retinal microcirculation is the 
only vasculature that can be visualised and photographed in vivo in humans.  
 
This thesis focuses on qualitative and quantitative parameters of retinal 
vascular signs in relation to cognitive function in people with Type 2 diabetes. 
Qualitative parameters include the presence and severity of diabetic retinopathy. 
Quantitative parameters reflect more objective and subtle retinal vascular changes, 
and comprise retinal vessel calibre, arteriolar bifurcation angles and branching 
coefficient. A number of epidemiological studies have used standard photography 
and computerised image analysis to detect associations between these retinal 
vascular changes and systemic vascular risk factors and cardiovascular disease in 
both the general population and in diabetic patients. However, the epidemiological 
research on retinal vascular signs in relation to cognitive function, in particular in 
people with Type 2 diabetes is sparse. These studies are reviewed systematically in 






Retinal Microvascular Abnormalities and Cognitive 
Dysfunction: Systematic Review 
 
2.1. Introduction 
The following review provides a systematic overview of published 
epidemiological research relevant to the analysis performed in this dissertation. This 
systematic review aims to describe pertinent studies to date which have contributed 
to understanding the association between retinal microvascular abnormalities as 
proxy markers of cerebral small vessel disease and risk of cognitive impairment and 
decline in patients and in the general population. Data will be extracted including 
details on study design, sample size, methods of assessing retinal microvascular 
abnormalities, cognitive function and/or impairment, and results. The main 
methodological issues that have arisen in these studies will be discussed. By 
presenting the existing body of research, the relevance of the analysis performed in 




2.2.1. Criteria for considering studies for the review 
I aimed to include all published studies that investigated the association 
between retinal microvascular abnormalities and cognitive dysfunction or dementia 
in adult subjects (middle-aged or older), available for review by July 2007. Given the 
relative scarcity of studies in this field, criteria for the inclusion of studies were kept 
broad. Studies had to meet the following pre-determined inclusion criteria: a) 
observational epidemiological design (i.e. cross-sectional, case-control, cohort), b) 
inclusion of a cognitive function assessment tool that was either a structured 
neuropsychological test or a clinical evaluation of dementia, c) assessment of the 
retinal microvasculature (either characteristics associated with generalised 
retinopathy or changes specific to arterioles or venules, such as focal arteriolar 
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narrowing and venular tortuosity) but not other retinal conditions, which fail to offer 
a direct measure of retinal vascular signs (such as age-related maculopathy), d) 
provision of data relating retinal microvascular lesions to cognitive function. Studies 
in which participants were selected on the basis of existing infectious disease due to 
a virus or bacteria (e.g. cytomegalovirus or diphtheria) were excluded because 
cognitive dysfunction in these subjects is likely to have specific pathology peculiar to 
the infectious disease. 
 
2.2.2. Search strategy for identification of studies 
Studies were identified by computerised searches of PubMed (Medline) 
(1950-2007), EMBASE (1980-2007), PsycINFO (1950-2007), BIOSIS Previews 
(1969- 2007) and Web of Science (1945- 2007), by checking the reference lists of 
relevant original and review articles, by reference to conference proceedings, and by 
tracking articles that cited retrieved studies using Science Citation Index. A detailed 
‗topic only‘ search strategy was adopted as it proves the most sensitive but not 
specific in order to produce the maximum number of papers on this topic. The search 
string for each database was similar with the terms ―retinopath* OR (retina* AND 
(microvascu* OR arteriol* OR venul* OR vascu*)) AND (cognit* OR Alzheim* OR 
dementi* OR memor* OR neuropsycholog*)‖. Searches were limited to papers 
published in English and human studies.  
 
2.2.3. Selection of studies 
The titles and abstracts of all articles identified were screened and 
potentially relevant full-text articles were retrieved and assessed according to the 
inclusion criteria.   
 
2.2.4. Quality of studies 
The quality of studies was assessed independently by myself and a second 
reviewer, using a scoring system based on previously published guidelines (Critical 
Appraisal Skills Programme, 2004; Tooth et al., 2005). Studies were assessed for 
both internal validity (assessment of exposure, outcome status, covariates, analytical 
approach) and external validity (recruitment, sample selection, participation at 
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follow-up) (Figure 19). Studies scoring less than 6 out of a possible maximum 9 for 
case control or cross sectional studies, and less than 7 out of 11 for cohort studies 
were excluded from further analysis. Disagreements in scoring were resolved by 
discussion or arbitrated by a third reviewer. 
 
2.2.5. Data extraction 
The following information was extracted from included studies: method of 
assessment of retinal microvascular abnormalities, measurement of cognitive 
function, and all relevant results, including adjustment for potential confounding 




Owing to a high degree of heterogeneity between studies, including study 
designs, type of population, measures of retinal vascular characteristics, types of 
neuropsychological tests and covariates included in analyses, meta-analysis of study 












Participants selection and recruitment (maximum 2 points) 
 Well-defined population sample (the final study sample was likely to be representative of 
the target population) (1) 
 (Baseline) response rate 70% or more (1) 
Participation at follow-up (maximum 2 points) 
 Follow-up period more than one year (1) 
 Loss to follow-up less than 30-40% (death was excluded from the estimate) (1) 
Retinal microvascular abnormalities assessment (maximum 3 points) 
 Retinopathy status based on self-report or medical records (0) 
or 
 Ophthalmoscopic examination (1) 
or 
 Retinal photography and grading based on a standardised protocol (2) 
 Assessors blinded to cognitive status (1) 
Cognitive function and/or dementia assessment (maximum 3 points) 
 Only a global functioning test (1) 
or 
 Neuropsychological battery (2) 
or 
 Dementia based on medical records (0) 
or 
 Dementia diagnosed by active screening with specific criteria (1) 
or 
 Dementia based on world-wide recognized criteria by a central consensus committee (2) 
 Assessors blinded to ocular findings and other major clinical disease status (1) 
Adjustment for confounding (maximum 1 point) 
 Effect of main confounders not investigated (at baseline) (0) 
or 
 Main confounders reported but not adjusted in the final analysis (0) 
or 
 Main confounders reported and adequately adjusted in the analysis (1) 
Eligible studies: scoring ≥7/11 for cohort studies and ≥ 6/9 for case-control/cross-sectional 
studies 








2.3.1. Description of studies 
My PubMed search yielded 180 hits, EMBASE 262 hits, PsycINFO 46 hits, 
BIOSIS Previews 172 hits and Web of Science 198 hits. Overall I identified 474 
different citations and, following assessment of titles and abstracts, reviewed 16 
potentially relevant full text articles. The numbers of studies identified at each stage 
of the systematic review are shown in Figure 20. 
 
 




Of the full text articles reviewed, three large population-based studies were 
excluded because only age-related maculopathy was examined for an association 
with cognitive function or Alzheimer‘s disease (Klaver et al., 1999; Wong et al., 
Citations identified in at least 1 
of 5 databases (n=474) 
 
(n=603) 
 Excluded due to not relevant on  
review of  title & abstracts 
(n=458) 
 
Full text articles considered 
for inclusion (n=16)  
 
 
Excluded due to not fulfilling 
 inclusion criteria (n=8) 
 
Potential full text articles 
reviewed for quality (n=8) 
 
for quality (n=7) 
 Excluded due to not fulfilling 
quality scoring criteria (Fig. 18) 
(n=2) 
 






2002d; Clemons et al., 2006). Another three longitudinal studies which assessed the 
relationship between retinopathy of prematurity and cognitive outcome were also 
excluded because subjects were aged less than 6 years (Msall et al., 2000; Böhm et 
al., 2002; Mikkola et al., 2005). One cross sectional study was excluded because 
subjects were selected according to the presence of HIV infection in addition to 
retinal vascular abnormalities (Freeman et al., 2004). Two articles referred to the 
same study in cross sectional and longitudinal design respectively, and only the 
results of the longitudinal study were included (Ryan et al., 1993; Ryan et al., 2003). 
Of the eight studies identified as meeting our inclusion criteria (Wong et al., 2002e; 
Ryan et al., 2003; Ferguson et al., 2003; Tekin et al., 2004; Kadoi et al., 2005; 
Rotkiewicz-Piorun et al., 2006; Baker et al., 2007; Patton et al., 2007), two were 
subsequently excluded as they did not fulfill the quality criteria. In one, retinopathy 
status relied on self-reporting without any objective assessment (Rotkiewicz-Piorun 
et al., 2006). In the other, potential confounding variables were reported but not 
controlled in further analysis (Tekin et al., 2004). 
 
Included studies 
Data from 6 studies were included in the review and the key details of these 
studies are summarized in Table 5 & 6. 
  
Study design and populations 
The 6 included studies comprised 2 prospective cohort studies in which 
cognitive function was measured both at baseline (when retinal images were taken) 
and at follow-up (Ryan et al., 2003; Kadoi et al., 2005), and 4 cross sectional studies 
(Wong et al., 2002e; Ferguson et al., 2003; Baker et al., 2007; Patton et al., 2007). 
Three studies were population-based (Wong et al., 2002e; Baker et al., 2007; Patton 
et al., 2007) and 3 hospital or clinic-based (Ferguson et al., 2003; Ryan et al., 2003; 
Kadoi et al., 2005). 
 
The populations sampled came from the US, UK and Japan. The clinic and 
hospital based studies involved patients with type 1 or type 2 diabetes (Ferguson et 
al., 2003; Ryan et al., 2003) and patients with type 2 diabetes after coronary artery 
bypass graft surgery (Kadoi et al., 2005). The age range of participants (at baseline or 
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at the time of survey) was from 18-35 years (Ryan et al., 2003) to 83-84 years 
(Patton et al., 2007) and included both men and women. In the prospective studies, 
duration of follow-up was 6 months and 7 years respectively (Kadoi et al., 2005; 
Ryan et al., 2003) with losses to follow-up estimated to be 5% and 39%. 
 
In 3 of the 4 cross sectional studies, retinal examination was undertaken at 
the same time as the cognitive testing. In the other study, the cognitive function tests 
were performed either 3 years before or after retinal photography and the average test 
scores were used in the analysis (Wong et al., 2002e). One prospective study in 
which cognitive abilities were assessed both at baseline and 7 years follow-up, 
examined the presence of retinopathy biennially as well as at baseline (Ryan et al., 
2003). 
 
Two studies explicitly reported that retinopathy signs were graded without 
the examiner being aware of cognitive status and other clinical characteristics (Wong 
et al., 2002e; Kadoi et al., 2005), and two studies reported that the examiners who 
administered the cognitive tests were unaware of diabetic status and the presence of 
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women,with 















103 men & 
women,with 










































Ophthalmoscopic & photographic  
assessment for retinal 
microaneurysms  
(MA, two or more in one eye) 













Photographic grading of  
proliferative retinopathy (PDR)  










Ophthalmoscopic grading of  
retinopathy  

















DVT, DSS, GPT, 
TMTB 
A composite Z score 











MMSE, RAVLT, GPT, 
TMTA, TMTB, DSF 
Z score for MA vs. no MA 
in 
PC:  -0.13 vs. 0.07, P=0.39 
BD:  -0.55 vs.0.32, P<0.01 
OA:  -0.13 vs.0.07, P=0.44 
DSS:  -0.28 vs. 0.19, 
P=0.04 
IT:    0.29 vs. -0.15, 
P=0.03 
CRT : 0.44 vs.-0.23, 
P=0.003 
VFT:  0.07 vs. -0.04, 
P=0.72 




Z change score over 7 years  
from baseline for  
1)PDR at baseline vs. no 
PDR   
 -0.50 vs. -0.22, P<0.02 
2) incident PDR (follow-up) 
vs. no PDR 





OR for retinopathy vs. no 
retinopathy  
MA related to poorer 
cognitive measures on 2 of 
4 tests of performance IQ 
(BD, DSS), information 




retinopathy, CNS disease, 
alcohol or drug abuse 
excluded. 
Adjustment for severe hypo- 
glycaemia exposure, sex, 
premorbid IQ & duration of 
diabetes. 
     8/9 
 
PDR related to greater 
decline in cognitive 
measures of psycho-motor 
efficiency.  
Alcohol or drug abuse, head 
trauma, PD excluded. 
Adjustment for incident 
(AN, DSP, ON, CAD, 




Retinopathy related to an 










at 7 days & 6 
months  





women with  
type 2 diabetes 
scheduled   











defined as a decline 
from preoperative 
testing of more than 




at 7 days: 2.0(95%CI 1.3, 
3.0) P=0.01; 
at 6 month: 2.1(95%CI 
1.2,2.7) P<0.01; 




long term cognitive 
impairment after CABG 
surgery. 
PD, renal or active liver 
disease, type 1 diabetes 
excluded. 
Adjustment for AAA, 
hypertension, HbA1c, 
insulin therapy, Svo2 less 
than 50% time. 
8/11 
AAA, ascending aorta atherosclerosis; AN, autonomic neuropathy; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CI, confidence interval; DSP, distal 
symmetric polyneuropathy; HbA1, glycosylated haemoglobin; ON, overt nephropathy; OR: odds ratio; PD, psychiatric disorder; PVD, peripheral vascular disease; SBP, systolic 
blood pressure; SD, standard deviation; Svo2, jugular venous oxygen saturation 
a 
Boldface number indicates quality rating; 
b
 Tests of VPAL, WSTM, RCFM, SDPA ,TPT, WAIS-R (OA, BD), WCR were also administered but not used in analysis of a relationship 
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women, 
sampled 






Photographic grading of 
1) any retinopathy 
2) microaneurysm 
3) retinal haemorrhage 
4) soft exudates 
5) focal arteriolar narrowing  
(FAN) 
6) AV nicking 
Computer-assisted grading of 
7) generalised arteriolar 
narrowing, 
summarised by AVR and defined 
as lowest 20
th
 percentile of AVR 
distribution 
Classified as present vs. absent 
 
 
DWR, DSS, VFT 
Cognitive impairment  
defined as scores 
2SD or lower than 





OR for presence vs. 
absence of 
1) any retinopathy 
2.6 (95%CI 1.3 to 2.9) 
2) microaneurysms 
3.0 (95%CI 1.8 to 5.0) 
3) retinal haemorrhage  
3.4 (95%CI 2.0 to 5.8) 
4) soft exudates 
 3.1 (95%CI 1.5 to 6.2) 
5) AV nicking  
1.2 (95%CI 0.8 to 1.6) 
6) FAN  
0.6 (95%CI 0.4 to 0.9) 
7) generalized arteriolar  
narrowing 
1.0 (95%CI 0.8 to 1.5) 
Similar results for DSS 
and VFT 
 
Retinal vascular signs except 
AV nicking & arteriolar 
narrowing, related to lower 
cognitive test scores. 
Prevalent stroke, taking CNS 
relevant medication excluded. 
Adjustment for age, sex, race, 
field centre, education, 
occupation, diabetes, fasting 
glucose, hypertension, carotid 
IMT, cigarette smoking, 
alcohol intake, fasting total 
and HDL cholesterol and 
triglyceride levels. 


























Photographic grading of 
1) any retinopathy 
2) focal arteriolar narrowing  
(FAN) 
3) AV nicking 
Classified as present vs. absent 
Computer-assisted grading of 
4) CRAE 
5) CRVE 
Measured in micrometers and  
3MSE, DSS 
Clinical diagnosis of  
dementia
b
   
 
in DSS 
Adjusted mean scores 
for presence vs. absence 
of 1) any retinopathy 
39 vs. 42  P<0.02 
2) FAN 
 42 vs. 42  P=0.62 
3)  AV nicking 
 41 vs. 42  P=0.20 
1
st
  to 5
th
  quintile of  
Any retinopathy related to lower  
DSS scores; focal arteriolar  
narrowing related to an increased  
risk of dementia. Both retinal  
vascular signs related to an  
increased risk of dementia in  
hypertensive people. 
Prevalent of stroke, taking 
anti-psychotics or anti- 




persons from 4 
US 
communities 
categorised into quintiles  
 
4)CRAE or 5)CRVE  
between-group difference  
P=0.48 or P=0.64         
separately in dementia  
OR for presence vs. 
absence of  1) FAN 
1.99 (95%CI 1.11 to 
3.56); 2)FAN in 
hypertensives 3.02 
(95%CI 1.51-6.02); 
3) any retinopathy in  
hypertensives  
2.10 (95%CI 1.04-4.24) 
No statistically  
significant results  
for 3MSE 
Adjustment for age, sex, race, 
field center, education level,  
internal carotid IMT, BMI, 
hypertension, diabetes, and  
cigarette smoking. 































men & women 
born 
in 1921, 
participated in a 
mental survey of 
1932 and residing 
in the Lothian 







Computer-assisted grading of 
1)  CRAE 
2)  CRVE 
3)  AVR 
4) Suboptimal branching 
coefficient (SBC) 
5) Suboptimal bifurcation angles  
(SBA) 
CRAE & CRVE measured in 
pixels, SBA in degree; all 





General cognitive  
ability score (g) 




) of the 
variance  
in g accounted for by 
SBC: 0.034  P=0.02; 
in LMT by SBA:  
0.026  P=0.03; 
in VFT by SBC:  
0.037  P=0.01 
No statistically  
significant results for  
RPM or with CRVE,  
CRAE, and AVR.  
Suboptimal BC related to 
lower scores in g & VFT;  
suboptimal BA related to 
lower scores in LMT 
Adjustment for sex, 
diabetes, cerebrovascular 
disease, SBP, DBP, alcohol 
use, smoking,  
APOE e4 status, near visual 
acuity, social class, 
education, IQ at age 11 
7/9 
ARIC, the Atherosclerosis Risk in Communities Study; APOE, apolipoprotein E;BMI, body mass index; DBP, diastolic blood pressure; HDL, high-density lipoprotein; IMT, 
intima-media wall thickness; IQ, intelligence; SBP, systolic blood pressure; SD, standard deviation 
a 
Boldface number indicates quality rating; 
b 





Assessment of retinal microvascular abnormalities 
Both the techniques and grading methods used to evaluate retinal 
microvascular signs varied between the studies. In one study, the combination of 
ophthalmoscopic examination with digital retinal photography was adopted 
(Ferguson et al., 2003), whereas in the remaining studies, stereoscopic color fundus 
photography alone was used. Prior to retinal photography, pharmacologic dilatation 
of the pupil(s) was performed in two studies (Ryan et al., 2003; Patton et al., 2007). 
The angle used for the field of view in photography differed, ranging from 30
o
 (Ryan 
et al., 2003, Kadoi et al., 2005; Ferguson et al., 2003) to 45
o
 (Wong et al., 2002e; 
Baker et al., 2007) or 50
o
 (Patton et al., 2007). Three studies reported that only one 
eye was assessed (Wong et al., 2002e; Baker et al., 2007; Patton et al., 2007) (either 
randomly or arbitrarily based on laterality) but the other studies didn‘t provide such 
information. 
 
In the studies using a fully manual grading system, subjects were 
categorized either according to the presence of diabetic retinopathy varying with 
severity (Ryan et al., 2003, Kadoi et al., 2005; Ferguson et al., 2003), or into one of 
several defined groups, including the presence of: 1) any specific retinopathy signs 
(microaneurysms, retinal haemorrhages, cotton wool spots, soft exudates, hard 
exudates, macular edema, venous beading etc.); 2)arteriovenous nicking; 3) focal 
arterial narrowing (Wong et al., 2002e; Baker et al., 2007) (Table 7). At least three 
different classification systems for retinal vascular signs based on previous diabetic 
or hypertensive retinopathy studies were used to develop standardised grading 
protocols in five of the studies. Computer-assisted imaging techniques were applied 
in three studies to quantify retinal vessel caliber and other parameters of retinal 
vascular network geometry (Wong et al., 2002e; Baker et al., 2007; Patton et al., 
2007). One study focusing on computer-based quantitative measures alone assessed 5 
continuous variables: the central retinal arterial equivalent (CRAE), central retinal 
venular equivalent (CRVE), the arteriovenous ratio (AVR), suboptimal geometry of 






Table 7: Terminology and definitions of retinal microvascular abnormalities used in 
included studies 
Retinal microvascular signs Definitions References 
Background diabetic    
retinopathy 
The presence of two or more microaneurysms in one eye  Ferguson et al. 
Proliferative diabetic  
retinopathy (PDR) 
A grading level at 60 or higher in one eye, or less than 60 
but with panretinal photocoagulation scars consistent 
with laser therapy
a 
Ryan et al. 
 
Diabetic retinopathy A grading level greater than 10 (10=no retinopathy)
b  Kadoi et al. 
Any retinopathy The presence of any of the following lesions (not 
explicitly arteriolar in nature): microaneurysms, retinal 
haemorrhages, soft exudates, hard exudates, macular 
edema, intraretinal microvascular abnormalities (tortuous 
intraretinal vessels), venous beading, new vessels at the 
disc or elsewhere, vitreous haemorrhage, disc swelling , 
or laser photocoagulation scars
b 
Wong et al.  
Baker et al. 
Focal arteriolar narrowing 
     (FAN) 
An arteriole estimated to be 50-μm diameter or greater 
has a constricted area of 2/3 or less the width of proximal 
and distal vessel segments
c 
Wong et al.,  
Baker et al. 
Arteriovenous nicking  
(AV nicking) 
A venule is constricted on both sides of its crossing under 
an arteriole in a specified region
c 
Wong et al.,  
Baker et al. 




 percentile of the sample 
arteriole-to-venule ratio (AVR) distribution measured on 
a continuous scale via a computer-assisted technique 
Wong et al. 
Arteriovenous ratio (AVR) A ratio between the summarized caliber measurements of 
the arterioles (CRAE) with respect to the venules 
(CRVE)
d
   
Wong et al. 
Patton et al. 
Central retinal arterial 
equivalent (CRAE) 
Combined calibre measurements of individual arterioles 
coursing through a circular zone defined as between 0.5 
and 1 disc diameter from the optic disc margin
d 
Wong et al. 
Baker et al. 
Patton et al. 
Central retinal venular 
equivalent (CRVE) 
Combined calibre measurements of individual venules 
coursing through a circular zone defined as between 0.5 
and 1 disc diameter from the optic disc margin
d 
Wong et al. 
Baker et al. 
Patton et al. 
Arteriolar branching  
coefficient (BC) 
A ratio expressing the relationship between trunk vessel 
(W) and two branch vessels (w1 and w2) on vessel widths 
at arteriolar branching points:  
 BC=   22221 /Www   
Patton et al. 
Arteriolar bifurcation angles 
     (BA) 
An angle (degree) measured at arteriolar branching points 
between the two branch arterioles  
Patton et al. 
Suboptimal  
branching coefficient 
The degree of deviation of the BC from optimality (i.e., a 
theoretical value of 1.26) 
Patton et al. 
Suboptimal angles The difference of the degree of BA from optimality (i.e., 
a theoretical and empirical value of 75
o
) 
Patton et al. 
Note. a the Wisconsin Epidemiologic Study of Diabetic Retinopathy Classification and Grading 
System (ETDRS, 1980); 
b 
the Diabetic Retinopathy Study and the Early Treatment Diabetic 
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Retinopathy study grading scale (ETDRS Report No.12, 1991); 
c 
the Modified Airlie House 
Classification of Diabetic Retinopathy (ETDRS Report No. 10, 1991); 
d
 Methods for evaluation of 
retinal microvascular abnormalities associated with Hypertension/Sclerosis in the Atherosclerosis 
Risk in Communities Study (Hubbard et al., 1999) 
 
 
Assessment of cognitive function and impairment 
Cognitive function was assessed using four primary methods: (1) specific 
cognitive tests (Table 8); (2) a mean/composite score on two or more tests in the 
battery (Ryan et al., 2003); (3) general cognitive ability score (g) generated by 
extracting a component reflecting the variance shared by all tests (Patton et al., 2007); 
(4) clinical assessment alone (e.g. diagnosis of dementia) (Baker et al., 2007). 
Results were reported as either continuous or categorical outcomes. More than 17 
different psychometric tests were used among the 6 studies reviewed. To help 
organize discussion, many of these neuropsychological tests can be classified into the 
cognitive domain that they examined, including attention/concentration, information 
processing speed, manual dexterity, frontal lobe/executive function, verbal memory, 
performance IQ, and mini-mental state examination (Table 8) (Strachan et al., 1997; 
Lezak, 1995). In one study (Baker et al., 2007) with dementia as outcome, patients 
were identified by an initial screening across the whole study population, then by a 
more detailed diagnostic examination by neurologists and psychiatrists in patients 
suspected of cognitive impairment, and dementia was defined in terms of the criteria 
from the Diagnostic and Statistical Manual of Mental Disorders, 4
th
 edition 
(American Psychiatric Association, 1994). 
 
Three of the studies including one of the prospective studies divided the 
participants into two groups based on whether or not they experienced cognitive 
impairment or decline (during follow up). Cognitive impairment was defined in a 
variety of ways that included: (1) a decline by a particular amount relative to the 
baseline test scores (Kadoi et al., 2005); (2) test scores below a particular threshold 
score (Wong et al, 2002e); or (3) the presence of clinically diagnosed dementia 
(Baker et al., 2007). Three studies used variations of the Mini-Mental Examination 
(MMSE) test: two used it as a continuous variable to assess general cognitive 
functioning (Kadoi et al., 2005; Baker et al., 2007) whereas another study only 
included it to screen subjects for dementia (Patton et al., 2007).  
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Two studies assessed premorbid intellectual ability in addition to 
performance IQ, by using psychometric testing strategy. One administered the 
vocabulary-based National Adult Reading test (NART) at the time of study and 
adjusted the scores in the analysis (Ferguson et al., 2003). The other study used the 
Moray House Test scores at age 11 years as a direct estimate of premorbid IQ (Patton 
et al., 2007). 
     
Table 8: Cognitive function assessment tools used in studies evaluating the relation 
to retinal vascular signs 
Cognitive Domain
a 
Test Name References 
Attention/Concentration Paced Auditory Serial Additional Task (PASAT) 




Part A of the Trail Making test (TMTA) 
Part B of the Trail Making test
b
 (TMTB) 
Ferguson et al. 
Kadoi et al. 
Ryan et al. 
Kadoi et al. 







Inspection time & Median four-choice reaction 
time 
(IT & MRT) 
Wong et al., Ferguson  
et al., 
Ryan et al, Baker et al 
Ferguson et al. 
Manual dexterity Grooved Pegboard
b
 (GPT) Ryan et al., Kadoi et al. 
Frontal lobe/executive  
function 
Verbal Fluency Test (VFT) 
 
Wong et al., Patton et al. 





Object Assembly (OA) and Block Design 
subtests  
(BD): ( [WAIS-R]) 
Picture completion (PC)  
Raven‘s Progressive Matrices (RPM) 
Ryan et al., Ferguson et al. 
 
Ferguson et al. 
Patton et al. 
Verbal  Memory   
 
Delayed Word Recall Test (DWR) 
Rey auditory verbal learning test (RAVLT) 
Logical Memory (LMT) 
Wong et al. 
Kadoi et al. 
Patton et al. 
Mini-Mental State  
Examination (MMSE) 
MMSE 
Modified Mini-Mental State Examination 
(3MSE) 
Kadoi et al., Patton et al., 
Baker et al. 
 
Note. WAIS-R= Wechsler Adult Intelligence Scale-Revised; 
a Classification of cognitive domain 
based on descriptions by Lezak (1995) and widely used definitions; 
b 
Tests used as part of 
Psychomotor Efficiency domain in Ryan et al.; 
c
 Test used as part of  performance IQ domain in 
Ferguson et al.  
 
 
2.3.2. Findings from studies on diabetic patients 
The results of the studies on subjects with Type 1 or Type 2 diabetes are 
shown in Table 5.  
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In 74 patients with Type 1 diabetes (Ferguson et al., 2003), the presence of 
retinal microaneurysms was associated with poorer performance on some tests of 
performance IQ (Block Design, Digital Symbol Test), information processing speed 
and attention /concentration but not on other tests of performance IQ (Picture 
Completion, Object Assembly) or frontal/executive functions. In a second study of 
103 patients with Type 1 diabetes (Ryan et al., 2003), the presence of proliferative 
diabetic retinopathy (PDR) at baseline or development of the condition during 
follow-up was associated with poorer performance on measures of ‗psychomotor 
efficiency‘ (a composite score based on the results of 4 tests: Digit Vigilance, Digital 
Symbol Test, Grooved Pegboard and Part B of the Trail Making). Compared with 
diabetic people without retinopathy at either assessment, there was a decline in 
subjects with PDR (change in test score -0.50 or -0.56 vs. -0.22, both P<0.02) over 7 
years. In both studies, the association remained significant after adjusting for a 
variety of demographic and several important diabetes-related variables. The 
magnitude of the cognitive deficits observed in these young adult subjects was 
moderate to large, with effect sizes for the group difference ranging from about 0.3 to 
0.7 SD (according to Cohen‘s [1988] terminology).  
 
In 180 patients with Type 2 diabetes (Kadoi et al., 2005), after adjustment 
for a number of biomedical and demographic variables, the presence of diabetic 
retinopathy assessed prior to coronary artery bypass grafting surgery was associated 
with an increased risk of cognitive decline (compared with pre-operative cognitive 
performance) after 7 days (OR 2.0, 95%CI 1.3, 3.0) and 6 months (OR 2.1, 95%CI 
1.2, 2.7) following surgery.  
 
2.3.3. Findings from studies on population-based samples 
The results from population-based studies are shown in Table 6. 
 
In the Atherosclerosis Risk in Communities Study of 8,734 middle-aged 
men and women free of stroke (Wong et al., 2002e), the presence of any retinopathy, 
microaneurysms, retinal haemorrhages or soft exudates was associated with an 
increased risk of impaired performance on tests of verbal memory (Delayed Word 
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Recall), information processing speed (Digital Symbol Test) and frontal 
lobe/executive function (Verbal Fluency Test). The presence of arteriolar narrowing 
or AV nicking was not associated with these tests. Subjects with any of these retinal 
vascular lesions were 2.6 (OR, 95%CI 1.3, 2.9) to 3.4 (OR, 95%CI 2.0, 5.8) times 
more likely to have cognitive impairment than people without these lesions 
independent of other biomedical, psychosocial and demographic covariates. 
 
In the Cardiovascular Health Study (Baker et al., 2007) of 2,211 men and 
women, the presence of any retinopathy was associated with poorer performance on 
information processing speed (Digital Symbol Test, adjusted mean test scores 39 vs. 
42, P=0.02), but not on the MMSE. No association was found with the presence of 
focal arteriolar narrowing, AV nicking or quintiles of retinal caliber. In a hypertensive 
subgroup, the presence of any retinopathy (multivariable-adjusted OR, 2.10 95%CI 
1.04, 4.24) or focal arteriolar narrowing (OR, 3.02 95%CI 1.51, 6.02) was associated 
with an increased risk of dementia, but no association was found with the presence of 
other retinal vascular signs.  
 
In the Lothian Birth Cohort 1921 (LBC1921) study of 321 elderly men and 
women (Patton et al, 2007), deviation from optimality of the retinal vascular network 
geometry was associated with lower cognitive ability scores, but no association was 
found for retinal arteriolar or venular calibers. After controlling for mental ability at 
age 11, APOE e4 status and a variety of other demographic, behavioral and 
biomedical covariates, sub-optimality of angles at arteriolar bifurcations (from 
theoretically derived-optimum values) was associated with poorer verbal memory 
(Logical Memory) but not other cognitive modalities including general cognitive 
ability (g), frontal lobe/executive function (Verbal Fluency Test) or performance IQ 
(Raven‘s Matrices), and suboptimal branching coefficient (from theoretically 
derived-optimum values) was associated with poorer general cognitive ability and 
verbal fluency but not verbal memory or performance IQ. The effect size of the 
variance in cognitive test scores explained by the retinal vascular abnormalities was 




The preceding systematic review aimed to describe and examine relevant, 
published research that has investigated the association between retinal vascular 
signs and cognitive dysfunction. To date, research in this area is very limited. 
Findings are consistent with the hypothesis that retinal microvascular abnormalities 
are associated with cognitive impairment and dementia in diabetic patients and in the 
general population, although findings are not conclusive due to varied and sometimes 
poor methodology in the included studies. The presence of retinal vascular signs was 
mostly associated with poorer verbal memory, information processing speed (Digit 
Symbol Test) and frontal lobe function (Verbal Fluency Test) in the general 
population, and with poorer information processing speed in patients with Type 1 
diabetes. Cognitive dysfunction among diabetic patients with retinal vascular signs 
was also suggested on measures of attention and concentration. However, these 
findings were inconsistent, possibly due in part to a lack of precision in linking 
cognitive tests to function (e.g. using only a composite test score rather than 
individual ones). 
 
A number of important methodological issues need to be considered when 
interpreting the findings of this review and understanding inconsistencies in the 
findings from different studies. These issues are also important for planning future 
research in this area. 
   
2.4.1. Study design 
Half of the studies were clinic-based on diabetic patients, using variable 
inclusion criteria that limited generalization of the results. Diabetes-related cognitive 
impairment may have different underlying mechanisms from cognitive dysfunction 
in the general population and may differ in patients with Type 1 diabetes, Type 2 
diabetes and postoperatively. However, population-based studies are scarce so far 
restricted to a cross-sectional design, which makes it impossible to determine the 
temporal relationship between retinal vascular disease and cognitive dysfunction 




Although longitudinal studies are superior to cross sectional studies when 
investigating ageing or cohort effects (Allen et al., 2004), the longitudinal studies in 
this review may have underestimated the impact of retinal vascular abnormalities on 
cognitive function in patients with diabetes because of survival bias or learning 
effects. Diabetic patients with retinopathy at baseline were more likely not to attend 
for follow-up (including deaths), when follow-up success itself could well be linked 
to good cognitive function. However, the two studies did not track retinopathy 
information among patients lost to follow-up, as the cognitive effects of retinopathy 
were not their primary focus (Ryan et al., 2003; Kadoi et al. 2005). This could 
introduce bias given one study had a proportion of losses to follow-up as high as 
39% (Ryan et al., 2003). Learning effects (Morris et al., 1999) may also obscure any 
true underlying cognitive decline particularly when intervals between test sessions 
are short and tests are administered multiple times, even if parallel versions are 
applied (Rasmussen et al., 2001). 
 
2.4.2. Measuring retinal microvascular abnormalities 
Compared with ophthalmoscopic examination, the assessment of retinal 
photographs has been suggested as a more reliable method for measuring a number 
of retinal vascular signs, including generalized and focal arteriolar narrowing, 
arteriovenous (AV) nicking, isolated retinal haemorrhages, microaneurysms and 
cotton wool spots  (Couper et al., 2002; Wong et al., 2001b; Wong, 2004; Porta et 
al., 2005). Computer-assisted measures of retinal vascular widths (to define 
generalized arteriolar narrowing, venular dilatation and other measures of retinal 
vascular network geometry), have been found to detect subtle microvascular changes 
with low intra and inter-observer variability (Couper et al., 2002; Sherry et al., 2002; 
Wong et al., 2003b,c). Grading of other abnormalities (such as focal arteriolar 
attenuation and retinal haemorrhages) is still largely done manually and therefore 
highly operator dependent, though automated techniques are being developed. The 
reliability of grading of focal retinal abnormalities has also been shown to be 
dependent on the classification system used (Boehm et al., 2002). Despite the use of 
standardised protocols, differing methods and grading systems for measuring retinal 
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microvascular abnormalities could explain at least in part some of the inconsistent 
findings between studies in this review.  
 
2.4.3. Measuring cognitive function 
Many observed changes in cognitive function of interest in studies are 
generally small in comparison with the entire range of function (Morris et al., 1999). 
However, mild cognitive impairment is an established risk factor for the subsequent 
development of dementia (Petersen et al., 2001) and may therefore be considered to 
be clinically relevant (Allen et al., 2004). This requires measurement of cognitive 
function that use validated (sensitive to small increments of change) and reliable 
psychometric tests, covering the range of different domains of interest including 
memory, reasoning and language (Areosa et al., 2003). In two of the studies, less 
than 3 neuropsychological tests were used and only a narrow range of cognitive 
domains could be assessed (Wong et al., 2002e; Baker et al., 2007). In one of the 
studies, MMSE scores were used to examine the relationship with retinal vascular 
signs (Baker et al., 2007). However, the MMSE is not designed to measure subtle 
changes in cognitive decline, but to screen for dementia (Folstein et al., 1975; 
Tombaugh and McIntyre, 1992). This simple test is likely to produce a ceiling effect 
in measurement and has reduced sensitivity to detect a mild change in cognitive 
performance in people with high educational achievement (Allen et al., 2004) 
 
The majority of cross-sectional studies of cognitive function relied on 
cognitive performance at a single time point, which does not capture the pathological 
process under study--cognitive decline or change in cognitive function over time. 
Pre-morbid cognitive ability represents the highest level of ability attained prior to 
any cognitive decrements taking place and is also known to account for a substantial 
proportion of the variance in cognitive function scores in old age (Strachan et al., 
1997; Deary 2000; Deary et al., 2003). However, such prior cognitive data are rarely 
available for most people, especially from a previous period of good health (Deary et 
al., 2004a). Some studies estimated prior ability by a patient‘s education and 
occupation history, but this is limited in that these features may be influenced by lack 
of opportunity rather than lack of ability (Nelson and Willison, 1991). The National 
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Adult Reading Test (NART) could be a more useful measure as word reading ability 
is preserved even in generalized cognitive decline (Nelson and Willison, 1991). 
Adjusting scores on a fluid mental test for NART has also been shown to be a valid, 
instantaneous measure of lifetime cognitive change or cognitive decline (Deary et al., 
2004a; McGurn et al., 2004). Only one study adjusted for pre-morbid IQ using 
cognitive data from youth of early life for aging cohort in an attempt to get a direct 
measure of lifetime cognitive decline (Patton et al., 2007). 
 
2.4.4. Confounding and effect modification 
Most studies assessed important potential confounders such as age, gender, 
lifestyle factors and medical conditions, including diabetes, diabetes-specific 
variables (such as duration of diabetes and HbA1c levels), hypertension, 
dyslipidemia and other cerebrovascular or cardiovascular disease. Patients with 
neurological conditions (including a history of stroke) that might interfere with 
cognitive abilities were also excluded from the majority of studies. However, 
subjects with a history of chronic alcohol or drug abuse were only variably excluded. 
In addition, inadequate adjustment was generally made for visual acuity and 
depression. Some of the cognitive tasks may require at least moderate visual function 
to complete and if diabetic people with severe retinopathy have greatly impaired 
vision, their scores on the relevant cognitive testing could be affected. Two of the 
studies collected data on visual acuity (Ryan et al., 2003; Patton et al., 2007) and one 
study controlled for this in assessing the relationship between retinal vascular 
abnormalities and cognitive function (Patton et al., 2007). Depression may confound 
the association between retinal microvascular disease and cognitive dysfunction 
because depression can be mistaken for dementia (and vice versa), and is associated 
with deficits of memory and learning, and occurs more frequently in those with 
diabetes-related complications including retinopathy (Reding et al. 1985; Austin and 
Mitchell, 1997; Visser et al., 2000; Anderson et al., 2001; Roy et al., 2007). Two 
studies assessed the potential effects of low mood (Ryan et al., 2003; Ferguson et al., 
2003).  
 
Studies which attempted to evaluate effect modification looked at 
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interaction with diabetes and hypertension and found that retinal microvascular 
disease may be linked to an increased risk of cognitive impairment in those with high 
blood pressure or diabetes (Wong et al., 2002b; Baker et al, 2007). Such analyses 
may provide insights into etiologic mechanisms. However, the relationship between 
retinal vascular disease and cognitive dysfunction in other different sub-groups of the 
population (e.g. younger and older, males and females) has not been well examined, 
as most studies lacked sufficient statistical power for analysis. 
 
2.4.5. Limitations of review 
It should be noted that I reviewed only published studies and it is possible 
that studies which did not show an association between retinal vascular disease and 
cognitive dysfunction may not have been published as often as studies that did. It 
was not possible to test for this formally (e.g. by use of a funnel plot) because studies 
were too few and too methodologically heterogeneous.   
 
2.5. Chapter summary  
There is some epidemiologic evidence from six published studies suggesting 
that the presence of retinal microvascular abnormalities may be associated with an 
increased risk of cognitive impairment or dementia in both diabetic patients and in 
the general population. However, findings are still inconclusive regarding the true 
nature and importance of this association, as previous findings are limited by 
substantial differences in methodology between studies, small size of some of the 
studies, limited controlling for potential confounding factors and variability in the 
range of cognitive domains and retinal microvascular abnormalities measured. In 
particular, no study to date has explored such an association in a large group of 
patients with Type 2 diabetes.  
 
Therefore, the epidemiological study and the analysis which are presented in 
Chapters 3 to 5, appear to be well suited to contribute to the body of knowledge in 
this field as the ongoing study is based on a uniquely large sample size of 1,066 older 
people with Type 2 diabetes designed to investigate the association between 
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microvascular disease and cognitive decreaments, using a battery of 
neuropsychological tests, standardised retinal vascular assessment, and measurement 



































Aims and Objectives  
 
3.1. Introduction 
Chapter 1 highlighted the fact that Type 2 diabetes is associated with poor 
cognitive ability especially in late adulthood. However, few data are available on the 
risk factors associated with the development of cognitive impairment in Type 2 
diabetes. Although cerebral microvascular disease has been hypothesised to 
contribute to the deleterious effect of diabetes on cognition, very little 
epidemiological data has been reported to support such an association, particularly in 
large numbers of people with Type 2 diabetes. The systematic review in Chapter 2 
demonstrated that retinal microvascular abnormalities, which are prevalent in Type 2 
diabetes, have been proposed as markers of cerebral microvascular disease. Such 
abnormalities have therefore been hypothesised as potential risk factors for cognitive 
dysfunction in a general population and in people with diabetes. However, their 
relationship with cognitive impairment in people with Type 2 diabetes has not been 
well-established due to scarce data from relatively small clinical samples. 
 
3.2. Aim 
The principal aim of this thesis was to determine whether several parameters 
of retinal microvascular abnormality were related to cognitive ability, to estimated 
lifetime cognitive decline, and to cognitive impairment (based solely upon cognitive 
test performance) in people with Type 2 diabetes in order to explore possible 
mechanisms involved in the aetiology of diabetes-related cognitive impairment. Data 
from the cross-sectional phase of the Edinburgh Type 2 Diabetes Study, an ongoing 
population cohort with plans to undertake repeat cognitive testing at four years 
follow-up, were used (the ET2DS is described in detail in the following chapter). The 
following parameters of retinal microvascular abnormality were assessed: diabetic 
retinopathy, retinal vessel calibres summarised as the central retinal arterial and 
venular equivalents (CRAE and CRVE, respectively), arterio-venous ratio (AVR), 
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and retinal arteriolar bifurcation geometry expressed as absolute and deviation of the 
median branching coefficient (BC) and median angle (BA). The main outcomes 
examined were cognitive ability (scores on neuropsychological tests), lifetime 
cognitive decline estimated by adjusting scores on a fluid mental test for pre-morbid 
ability (the Mill-Hill Vocabulary Scale) and the presence of cognitive impairment 
defined as scores 1.5 SD or lower than the mean score of the group. 
 
3.3. Objectives 
1. To estimate the total prevalence of diabetic retinopathy and the prevalences of 
diabetic retinopathy according to severity level in older people with Type 2 diabetes. 
 
2. To examine the distribution of the following quantitative parameters of retinal 
vascular network geometry in elderly people with type 2 diabetes: 
(a) CRAE, CRVE, and AVR 
(b) absolute value of arteriolar branching coefficient (BC) and angle (BA) 
(c) deviation of the BC from optimality (sub-optimal BC) 
(d) deviation of the BA from optimality (sub-optimal BA)  
 
3. To determine the association of the presence and severity of diabetic retinopathy 
and other retinal vascular abnormalities as described above with 
(i) sociodemographic characteristics (age, sex, educational level, occupational 
social class) 
(ii) conventional cardiovascular risk factors (alcohol consumption, smoking habit, 
obesity, brachial arterial blood pressure and blood lipids) 
(iii) cardiovascular disease (myocardial infarction or angina pectoris, stroke or 
transient ischaemic attack, and peripheral arterial disease) 
(iv) diabetes history and control (duration of diabetes, HbA1c level and treatment 
modality) 




4. To determine the association between current cognitive ability and 
(i) sociodemographic characteristics (age, sex, educational level, occupational 
social class) 
(ii) conventional cardiovascular risk factors (alcohol consumption, smoking habits, 
obesity, brachial arterial blood pressure and blood lipids) 
(iii) cardiovascular disease (myocardial infarction or angina pectoris, stroke or 
transient ischaemic attack, and peripheral arterial disease) 
(iv) diabetes history and control (duration of diabetes, HbA1c level and treatment 
modality) 
(v) mood and prior cognitive ability level (depression and peak prior cognitive 
ability) 
 
5. To determine the association of the presence of diabetic retinopathy and severity 
of diabetic retinopathy with cognitive ability, estimated lifetime cognitive decline 
and cognitive impairment 
 
6. To determine the association of quantitative parameters of retinal vascular 
network geometry (CRAE, CRVE, AVR, absolute and suboptimal BA and BC) 
with cognitive ability, estimated lifetime cognitive decline and cognitive 
impairment 
 
7. To determine the independence of associations between the retinal microvascular 
  abnormalities as above and cognitive function after adjusting for psychosocial   












This chapter describes the baseline methodology of the Edinburgh Type 2 
Diabetes Study, which is the first population-based epidemiological study in the 
United Kingdom to focus principally on cognitive dysfunction in people with Type 2 
diabetes. Specifically, the chapter provides information on recruitment of the study 
population as well as the baseline clinical examinations. In addition, the grading 
protocols used for diabetic retinopathy and the assessment of other retinal vascular 
abnormalities are described. Finally the chapter presents the methods used to define 
cardiovascular variables which were used in subsequent analyses, and the statistical 
analysis plan. The Edinburgh Type 2 Diabetes study was originally designed by other 
investigators and Section 4.2.1 and 4.2.2 were mainly taken from the ET2DS 
Methods paper (Price et al., 2008). 
 
4.2. The Edinburgh Type 2 Diabetes Study 
 
4.2.1. Study design and subject recruitment 
The principal aim of the Edinburgh Type 2 Diabetes Study (ET2DS) was to 
investigate potentially modifiable risk factors for cognitive dysfunction in people 
with Type 2 diabetes. The ET2DS commenced as a cross-sectional survey in 2006 
and continues as a 4-year longitudinal study. The study population of the ET2DS 
comprised 60 to 74 year-old inhabitants of Lothian, Scotland with established Type 2 
diabetes. A random sample of participants stratified by sex and 5-year age bands was 
selected from the Lothian Diabetes Register (LDR), which is a computerised 
database containing clinical details on over 20,000 patients with known Type 2 
diabetes. Comparison of age-sex specific prevalences of diabetes recorded on the 
LDR with those from other data sources in Scotland suggests that the LDR captures 
almost everyone with diagnosed diabetes in Lothian (Price et al., 2008). The sample 
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size of 1,000 was estimated on the basis of the number required to conduct a baseline 
and a subsequent follow-up study with sufficient statistical power to detect any risk 
factor that contributed 1% or more to the variance in continuous outcome measures 
(i.e. cognitive test scores).  
 
All eligible subjects were approached about attending a research clinic for 
medical examination (n=5,454). Following publicity in the local media, letters of 
invitation to participate in the study were sent by the custodians of the Lothian 
Diabetes Register. Subjects not replying to the invitation letter, with letters returned 
by the Post Office, or refusing to participate were replaced by another randomly 
selected subject from the same sex and 5-year age band. To preserve patient 
confidentiality, only the names and addresses of subjects who expressed interest in 
participating were forwarded to the ET2DS team. On receipt of an affirmative reply, 
an appointment was booked for the research clinic, and a map, along with a 
questionnaire to be completed and returned was sent. Transport to and from the clinic 
was provided for those having difficulty in attending the clinic. Travelling expenses 
were paid if required. Respondents who did not attend the clinic were offered a 
second appointment both by telephone and mail, and reminder calls on the day 
preceding clinic appointments were made (Price et al., 2008). The overall subject 
recruitment is summarised in Figure 21. 
 
Of the 1,077 subjects attending the baseline clinic, four were subsequently 
excluded because they were unable for physical or emotional reasons to complete the 
cognitive or clinical examination. In addition, seven subjects were excluded as they 
did not meet the criteria for Type 2 diabetes after detailed review of medical notes, 
searching of electronic databases and, where necessary, discussion with the general 
practitioner (Price et al., 2008). Of these seven subjects, two diet-treated patients 
with HbA1c <6.5% at the research clinic could not be confirmed as having diabetes, 
four were felt to have Type 1 diabetes due to starting on insulin within 1 year of 
diagnosis or being treated with insulin and diagnosed under the age of 35 years, and 
one subject had a previous pancreatic neuroendocrine tumour. This left 1,066 
subjects who were both willing and eligible to take part in the study and who formed 
the total study population of the ET2DS. The study was approved by Lothian 
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n = 5454 
Replied 
n = 3286 (60.2%) 
 
Not Interested in Participation  
(n = 2034) 
Interested in Participation 
n = 1252 (23.0%) 
Attended Baseline Clinic 
 n=1077 (19.7%) 
 
ET2DS Participants 
n = 1066 
Didn’t Attend Baseline Clinic 
(i) unable/unwilling to attend (n=111) 
(ii) could not be contacted (n=56) 
(iii)repeatedly failed to keep appointment 
(n=5) 
(iv) deceased (n=3) 
Sampling Frame 
 Patients aged 60-75 on 01/08/2006, 
retrieved from LDR on 20/06/2006  
n = 9464  
Selected from randomised lists to 
receive invitation 
n = 5561 
No Longer on LDR, Invitation Not Sent 
(n = 107) 
No Response (n=2104) 
Moved Address (n = 64) 
Failed to Meet Inclusion Criteria 
(i) unable to complete physical/cognitive  
examination (n= 4) 
(ii) not Type 2 diabetes (n=7) 
Eye Clinic Participants 
n = 1044 
(i) withdrew or did not attend eye clinic after 
baseline clinic (n=20) 
(ii) ungradable for diabetic retinopathy (n=2) 
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4.2.2. Clinical examination 
Physical examinations were conducted each weekday morning from August 
2006 to September 2007 at a research clinic. All subjects were asked to fast from 
11pm the previous evening and a venous blood sample was taken for subsequent 
measurements of biochemical, inflammatory and genetic factors. Before the clinical 
procedures were performed, a self-administered questionnaire was filled in by each 
participant and read over for completeness by one of research nurses. 
 
Questionnaire 
The self-administered questionnaire contained validated questions enquiring 
about personal characteristics (age, sex, and marital status), highest education level 
completed, occupational social class, smoking history, alcohol consumption, diabetes 
history and control (age at onset of diabetes, current treatment by insulin injections 
or tablets), other medication use and recall of a doctor‘s diagnosis of cardiovascular 
disease (myocardial infarction, angina pectoris, stroke, transient ischaemic attack, 
and peripheral arterial disease) (Appendix D). The WHO Chest Pain (Rose, 1962) 




Standing height (without shoes) was measured to the nearest 5mm using a 
wall-mounted vertical metal ruler. Weight without outdoor clothing and shoes was 
measured to the nearest 0.1kg on mechanical scales (SECA 761). Waist 
circumference was measured during exhalation at the level midway between the 
lower rib margin and the iliac crest (pre-marked at the mid-axillary line on each side 
of the subject), with the subject standing with their feet 30cm apart. Hip 
circumference was taken with the subject in the same standing position, by wrapping 
the tape measure around the buttocks and lowering or raising the tape until the 
maximum circumference was located and the tape fitted comfortably. Both 
measurements were taken using a non-expandable tape measure and the average of 
two readings taken to the nearest 0.5cm was used as the final measurement. Systolic 
and diastolic brachial blood pressure (phase V) were measured in the right arm only 
to the nearest 2mmHg with subjects in the supine position, using a standard 
 148 
stethoscope and an aneroid, 6 inch dial desk standing sphygmomanometer (Acceson 
TM
, AC Crossor &Son (Surgical) Ltd, Harlow, UK).  
 
A resting 12-lead electrocardiogram (ECG) was recorded according to 
standard procedures (Marquette MAC1200 machine) and independently coded by 
three clinical members of the research team using the Minnesota coding system 
(http://www.epi.umn.edu/ecg/; Prineas et al, 1982).   
 
Blood sampling and laboratory assays 
A 40ml sample of venous blood was taken. All samples were obtained 
between 09:00am and 10.00am to minimise diurnal variation. HbA1c was measured 
by ion exchange high performance liquid chromatography (HPLC) on a fully 
automated analyser (HA 8160) manufactured by Arkray, Japan and distributed by 
Menarini Diagnostics. Cholesterol and HDL cholesterol were measured 
enzymatically using dry slide technology on the Vitros 5.1 FS analyser manufactured 
by Johnson and Johnson. 
 
4.2.3. Cognitive testing  
Research nurses were trained in cognitive testing and then observed for 
validation by one ET2DS investigator who is an expert in psychological testing. A 
battery of psychometric tests was administered at the research clinic in a standardised 
order during one clinical session in a mildly warm, quiet and well-lit room. The test 
running time was about one hour. Prior to testing, distance visual acuity was 
examined by using the Snellen Chart as well as near vision by applying Sussex 
test-types for both eyes. Corrected visual acuity worse than 6/36 for distance vision 
or inability to read large print text were used as exclusion criteria as at least moderate 
visual function was required to complete some of the cognitive tasks. Capillary blood 
glucose was also measured to exclude prevailing hypoglycaemia. The 
neuropsychological session was rescheduled if antecedent hypoglycaemia (blood 
glucose < 4.0 mmol/l) occurred. The cognitive function test battery used in the 
ET2DS was chosen to be sensitive to small-to-moderate difference in ability, 
comprising eight neuropsychological tests, a test assessing subjects‘ pre-morbid 
 149 
ability and a scale aimed at measuring mood states. The individual parts of the test 
battery are described below. Copies of each of these are supplied in secions 1 to 10 of 
Appendix E. 
 
The Hospital Anxiety and Depression Scale 
The Hospital Anxiety and Depression Scale (HADS) is a short, well 
accepted questionnaire consisting of two sub-scales, used for evaluating current 
anxiety and depression levels in non-psychiatric patients (Zigmond & Snaith, 1983). 
Each sub-scale is comprised of 7 items on the basis of the psychic symptoms of 
anxiety or depression, and each item is rated on a four-point scale (0-3). The range of 
total scores for either anxiety or depression is between 0 and 21 with non-cases and 
possible cases falling into the range 0-7 and 8-10, and ‗probable cases‘ having a total 
score of 11 or more. The HADS has been found to be a valid measure in identifying 
a probable case of anxiety or depression with good sensitivity and specificity 
although it does not allow a definite diagnose, and only gives a dimensional rather 
than a categorical representation of mood (Herrmann, 1997; Snaith, 2003). 
 
The Mini-Mental State Examination 
The Mini-Mental State Examination (MMSE) is a brief and general 
cognitive measure with components for orientation, concentration, language, praxis 
and immediate and delayed memory with a maximum (best) score of 30. It is widely 
used for assessing cognitive status among older people and particularly as a 
screening test for dementia. An MMSE score of <24 is often used to indicate 
significant cognitive impairment. 
 
The Mill Hill Vocabulary Scale 
The Mill Hill Vocabulary Scale (MHVS) is a brief self-administered reading 
test used as a measure of acquired verbal knowledge. The MHVS, in common with 
other vocabulary tests, is primarily an indicator of previous (―best ever‖ or premorbid) 
cognitive ability, which changes little with age (Salthouse, 2004; Schaie, 2005). A 
combined version of the Junior and Senior Form A synonyms of the Mill Hill 
vocabulary scale was used (Raven et al., 1998). Subjects are presented with a word 
and asked to identify the closest synonym by choosing one of six given words. The 
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number of correctly sorted words comprises the score (the maximum score was 44). 
It has been used to compare the characteristics of the population and to enable 
assessment of the impact of any difference in previous cognitive ability on changes 
in cognitive performance over time. The test has been shown previously to correlate 
highly with other tests of previous cognitive ability that are used in a similar manner 
(Crawford et al., 2001) 
 
The Wechsler Memory Scale-III: Logical Memory Test (Immediate & 
Delayed Recall) 
The Wechsler Memory Scale-Revised 3rd Edition is a revised version of the 
Wechsler Memory Scale which is a widely used clinical instrument for evaluation of 
major dimensions of memory functions in adolescents and adults (Wechsler, 1987). 
The Logical Memory (LMT) test, a sub-test from the WMS-III, is a test of verbal 
declarative memory. It measures immediate (short-term) free recall after auditory 
presentation and delayed (long-term) recall. With high interrater reliability, this test 
has been demonstrated to be a valid and sensitive measure (Spreen & Strauss, 1998).  
 
One brief story (story A) with 25 elements is read aloud to the subject, and 
after reading, the subject is asked to recall as much as possible (Logical Memory Part 
I). Delayed Recall (Logical Memory Part II) is tested and recorded in the same way 
after approximately 40 minutes, when the participant is asked to recall the story from 
memory without hearing the story again. Participants are not informed in advance 
that they will be re-tested on the recall of the story. Prose recall is rarely word for 
word in adults, which normally is divided into ‗gist‘ recall and ‗verbatim‘ exact word 
recall (Haaland et al., 1983). In the ET2DS population for scoring, both of gist and 
verbatim recall words were counted. Participants are scored based on the number of 
story elements recalled correctly (one point for each correct element) and the points 
are summed for the immediate and delayed recall, respectively.  
 
The Trail Making Test-Part B 
The Trail Making-Part B Test from the Halstead Reitan battery (Reita, 1958) 
assesses mental flexibility, including complex visual scanning and a motor 
component that measures visual conceptual and visual motor tracking. Subjects are 
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required to draw a line between numbers and letters in an alternating order and in as 
short a time as possible. Scores are calculated by recording the time (in seconds) it 
takes to complete Part B (errors are not counted). In the ET2DS, before undertaking 
the test, subjects were given a simple sample to enable a short practice trial and to 
ensure they had fully understood the test directions. 
 
The Wechsler Memory Scale-III: Faces & Family Pictures Test 
(Immediate & Delayed Recall) 
The Faces and Family Pictures task is a sub-test of the WMS-III designed 
for assessing non-verbal memory using facial recognition format. Subjects are shown 
a series of 24 pictures of human faces and then, in subsequent immediate and delayed 
(following an approximately 30 minutes delay) tests, they are asked to select these 
faces from a larger series of 48 pictures, including both target and distractor faces. 
The total number of correct responses comprises the immediate and delayed scores 
respectively (the overall maximum score on each test is 48).  
 
The Wechsler Adult Intelligence Scale-III: Matrix Reasoning Test 
The Matrix Reasoning is a sub-test from the Wechsler Adult Intelligence 
Scale 3rd Edition (WAIS-III) (Wechsler, 1981) and constitutes a measure of 
non-verbal reasoning designed to measure a person‘s ability to reason by induction 
(Raven et al., 1977). It requires the subject to make sense of complex situations and 
identify spatial, design and numerical relationships between apparently unrelated 
structures, ranging from the very obvious and concrete to the very complex and 
abstract (Lezak, 1995).  In each item of the test, participants examine a pattern 
arrayed in matrix with a portion missing. The participant has to work out the rules on 
the array of the elements in matrix, apply them to find out what the missing portion 
should look like, and select the correct piece from the five answer options. The 
number of correctly completed items comprises the total score (the maximum score 
is 26). 
 
The Wechsler Adult Intelligence Scale-III: Digit Symbol-Coding 
Test 
The Digit Symbol-Coding Test (DST), a subtest from the WAIS-III is a test 
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of coding performed at speed (information processing speed). This is a 
paper-and-pencil task requiring timed translation of numbers (1-9) to symbols using 
an information key that pairs each number with a unique symbol printed at the top of 
the page. Participants are asked to fill in empty boxes with the respective code, with 
empty boxes below a given selection of random numbers. After an initial 7 boxes 
which are used for practice only, and are not counted towards the overall score, the 
participants are then asked to complete the remaining boxes. In total, there are a 
maximum of 133 boxes to fill in. The test is scored as the number of symbols the 
participant correctly matches to their corresponding numbers in 120 seconds.  
 
The Borkowski Verbal Fluency Test 
The Borkowski Verbal Fluency Test (BVFT) is a phonemic test used as a 
brief cognitive assessment of executive function (the speed and flexibility of verbal 
thought processes or language ability related to executive function such as formation 
of appropriate strategies for words retrieval; lexical fluency tasks involving specific 
regions of right and left frontal lobes). This phonemic fluency is opposed to semantic 
fluency where the test taker generates words according to categories. The test has 
established reliability and validity (Spreen & Strauss, 1998), and age, level of 
education and gender play a role in verbal fluency task performance (Loonstra et al., 
2001). Participants are asked to vocally generate as many words as possible in one 
minute that begin with a particular letter of the alphabet. The test is repeated for three 
different letters (C, F and L), which are chosen on the basis of the frequency of 
English words beginning with these letters (Rafnsson, 2007). The score is the 
number of appropriate words named, excluding proper nouns (names of persons and 
places), numbers, repeats, and the same words with different suffixes (e.g. play, 
player and playing). The total test score is the sum of all words produced in each of 
the three letters. 
 
The Wechsler Adult Intelligence Scale-III: Letter-Number 
Sequencing Test 
The Letter-Number Sequencing test is another subtest of WAIS-III used for 
assessing working memory, temporary storage, active maintenance and information 
organization. The participant is read mixed strings of numbers and letters (in 
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alternating order) with increasing lengths (from 2 to 8 digits). The participant is  
asked to repeat the numbers first, in numerical order, and then the letters in 
alphabetical order. For example, T-9-A-3 will be reported as 3-9-A-T. The test is 
divided into 7 groups and each group composes of three different strings. Group 1 
consists of one letter / one number string (x 3), which is used only as a trial to ensure 
the participants understand the instructions of the task. Following this, group 2 
consists of either 1 letter / two numbers, or two letters / one number. The process will 
continue and become progressively more difficult, until the seventh group, which 
consists of 8 constituent for each of the three strings (Patton, 2006). For each group, 
if the participant fails on all three strings, the test will be discontinued. The total 
score is calculated by adding up the correct response of each string and the maximum 
is 21. 
 
4.2.4. Retinal photography 
Approximately two or three weeks after their initial visit to the research 
clinic, subjects returned to a separate research clinic based within the major 
ophthalmology department for NHS Lothian for digital retinal photography. If 
subjects cancelled or did not attend they were contacted to arrange another 
appointment. Photography was conducted between 9.30 am and 3.00 pm each 
weekday by a single specially trained medical photographer. Subjects had 1% 
tropocamide drops instilled into both eyes if possible to allow pupillary dilatation 
before image capture unless ocular opacities (eg. cataract) or false eye existed. Pupils 
were inspected after approximately 20 minutes and if dilatation was insufficient, a 
further 1% tropocamide dose was given. Subsequent to this, standard 7-field 
non-stereoscopic retinal colour photographs of both eyes were taken at 35
o
 using a 
high resolution digital retinal camera (TOPCON TRC-50FX, Topcon Optical 
Company, Tokyo, Japan). The seven standard photographic fields are shown in 
Figure 22. All images were stored as JPEG or TIFF format files (both are high 
resolution digital images) on the study computer attached to the retinal camera, 
backed up onto an external drive and subsequently transferred to a dedicated server 
at the University of Edinburgh for long term back up and storage. 
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Figure 22: Diagrams (a and b) showing 7-field definition in right eye. Field 1 is 
centred on the optic disc, field 2 on the macular. Field 3 is temporal to the macula. 
Fields 4 to 7 are tangential to horizontal lines passing through the upper and lower 
poles of the disc and to a vertical line passing through its centre (Sources: 
www.bt-asia.com/visdr_medicalprof.htm; Diabetic retinopathy grading protocol for 
ET2DS, 2007) 
 
4.3. Grading for diabetic retinopathy 
Prior to grading, two sets of grading equipment (including computers with 
large colour monitors for viewing photographs and laptops for entering data) were set 
up. Electronic data entry forms were created for each batch of 50 subjects at the 




(Diabetic retinopathy grading protocol for ET2DS, 2007). All photographs were 
graded by two trained optometrists, working independently and according to the 
scale described by the Early Treatment Diabetic Retinopathy Study (ETDRS) 
(ETDRS Report No. 10, 1991) research group, which was an adaption of the 
modified Airlie House classification of diabetic retinopathy. All fields were graded 
regardless of their deviation from the field definition. Throughout the grading 
process, graders checked photos for quality, and a paper/acetate record of the 
position and nature of artefacts (e.g. due to dust on the camera) was maintained to 
minimise the chances of artefacts being mistakenly graded as features. Characteristic 
lesions of diabetic retinopathy were recorded for seven fields in each eye. The final 
level retinopathy score for each eye was generated automatically through a series of 
calculations embedded in the data entry form. Discrepancies in the final level score 
at subject level between the graders were resolved in the first instance by discussion 
between the graders. Unresolved discrepancies were further reviewed and arbitrated 
by a consultant ophthalmologist.  
 
Diabetic retinopathy was considered to be present if microaneurysms alone, or with 
any of the following characteristic lesions (as defined by ETDRS scale) were present: 
haemorrhages, cotton wool spots, intraretinal microvascular abnormalities, hard 
exudates, venous beading, venous loops and/ or reduplication, fibrous proliferations, 
pre retinal haemorrhage, vitreous haemorrhage and new vessels. Standard retinal 
colour photographs (No.1-14) of the Modified Airlie House Classification of 
Diabetic Retinopathy (The Diabetic Retinopathy Study Research Group, 1981) were 
used as references to define grades of lesions. Lesions were graded using the 
following descriptive terms:  
a. Grade 0= None /Absent (A), when the lesion was absent or the grader was less 
than 50% certain that it was present; 
b. Grade 1=Questionable, (i) when the grader was 50% to 90% certain that the lesion 
was present, or (ii) an abnormality was definitely present but its nature was uncertain 
(in this case the grader assigned the grade ‗questionable‘ for the characteristic 
considered to be most likely and ‗absent‘ for the ones least likely); 
c. Grade 2 to 5= Definite, when the grader was greater than 90% certain that the 
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lesion was present. In addition, the following grading codes were used to express the 
severities of the lesion, which were defined in terms of the number or retinal area 
present, or the photographic standards related: grade 2= definitely present; grade 3= 
moderate; grade 4=severe; grade 5= very severe; 
d. Cannot grade, when no lesion was seen and 100% of the field was missing (e.g. 
due to obscuration from vitreous haemorrhage).  
- e.g. Hard exudates grading – Standard Photographs (SP) 3 4 5 (2-7 fields 
were graded ) 
CODE CODE DEFINITION 
0 No hard exudates 
1 Questionable hard exudates 
2 Definite hard exudates < SP 3 
3 Definite hard exudates > SP 3 but <5 
4 Definite hard exudates >SP 5 but < 4 
5 Definite hard exudates >SP 4 
x Cannot grade 
 
Each abnormality was graded separately for each of the seven fields in each 
eye. Features graded in the seven fields included: 
 fields 2-7: haemorrhages and/or microaneurysms, hard exudates, cotton wool 
spots, venous calibre abnormalities, intra retinal microvascular abnormalities, 
new vessels elsewhere, fibrous proliferations elsewhere, preretinal haemorrhages, 
and vitreous haemorrhage 
 field 1 only: new vessels at the disc, fibrous proliferations at the disc 
 
For lesions graded only in field 1, the grading code as described above was 
used directly to indicate the severity of that lesion for the eye. For lesions graded in 
multiple fields, a summary scale of the grades was assigned which combined the 
maximum severity in any field with the number of non overlapping fields (i.e. fields 
3-7) in which that maximum was present (Table 9). Any field in which a lesion was 
graded could establish the maximum grade, but for two or more fields to be recorded 
as having the maximum, both or all had to be in non overlapping fields 3 to 7. On the 
basis of summary grade of each lesion in 7 fields, the final diabetic retinopathy level 
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was defined for each eye, varying from level 10 (no diabetic retinopathy) to level 81 
(advanced proliferative diabetic retinopathy). For the purpose of this study a score of 
81 was added for panretinal photocoagulation scars only if the laser treatment was 
for diabetic retinopathy (e.g. photocoagulation scars for other conditions such as 
retinal vein occlusion were not graded as 81). Table 10 presents the final diabetic 
retinopathy severity scale, which was originally from ETDRS report No. 12 (ETDRS 
Report No. 12, 1991) and modified for use in ET2DS. 
 
Table 9: Scale for characteristics graded in multiple fields (Adapted from the 
ETDRS report No.10, 1991) 










































1 to 5 fields 
 
1 field 
2 or 3 fields from fields 3 to 7 
4 or 5 fields from fields 3 to 7 
 
1 field 
2 or 3 fields from fields 3 to 7 
4 or 5 fields from fields 3 to 7 
 
1 field 
2 or 3 fields from fields 3 to 7 
4 or 5 fields from fields 3 to 7 
 
1 field 
2 or 3 fields from fields 3 to 7 
4 or 5 fields from fields 3 to 7 
 
1 field 
2 or 3 fields from fields 3 to 7 
















Table 10: Modified final diabetic retinopathy severity scale for each eye in ET2DS 
(Replicated from Diabetic retinopathy grading protocol for ET2DS, 2007) 


































































High Risk PDR(2) 
Microaneurysms and other characteristics absent/questionable
#
 
HE, CWS or IRMA definite: MA absent/questionable
#
 
Haemorrhage(s) definite: MA absent/questionable
#
 
MA definite, other characteristics absent 
One of more of the following: 
a. Venous loops ≥ D/1 
b. CWS, VB or IRMA = Q 
c. Retinal haemorrhage present 
d. HE ≥ D/1 
f. CWS ≥ D/1 
One (only) of the following: 
a. H/MA = M/4-5 – S/1 or 
b. IRMA = D/1-3 
Both Level 43 characteristics and/or one (only) of the following: 
a. IRMA = D/4-5 
b. HMA = S/2-3 
c. VB = D/1       
One or more of the following: 
a. At least 2 of the last 3 Level 47 definitions 
b. HMA ≥ S/4-5 
c. IRMA ≥ M/1 
d. VB ≥ D/2-3 
a. FPD or FPE present (with NVD and NVE absent) 
b. NVE = D 
Either of the following: 
a. NVE ≥ M/1 or NVD = D; and VH and PRH = A or Q 
b. VH or PRH = D and NVE < M/1 and NVD absent 
Any of the following: 
a. VH or PRH ≥ M/1 
b. NVE ≥ M/1 and VH or PRH ≥ D/1 
c. NVD = 2 and VH or PRH ≥ D/1 
d. NVD ≥ M 













a. Retina obscured due to VH 
b. Photocoagulation scars in any field in the absence of any evidence  
of vein occlusion or other non-diabetic retinopathy reason for such  
treatment. Subject considered to have received laser treatment for  
diabetic retinopathy, hence classification as advanced PDR 
No characteristics graded for eye concerned 
 
* NPDR Levels 35 and above require presence of micro-aneurysms; 
#
 for Levels 10,14 and 15, 
wherever absence of a characteristic forms part of a set of criteria; questionable is interpreted as absent; 
DR, diabetic retinopathy; HE, hard exudates; CWS, cotton wool spots; IRMA, intraretinal microvascular 
abnormalities; MA, microaneurysms ; NPDR, nonproliferative DR; VB, venous beading; HMA, 
haemorrhages/microaneurysms; PDR, proliferative DR; NVE, new vessels elsewhere; NVD, new vessels  
at the disc; FPE, fibrous proliferations elsewhere; FPD, fibrous proliferations at the disc; VH,vitreous 




4.4. Assessing parameters of retinal vascular network 
geometry 
Retinal photographs containing the optic disc in the centre field were 
chosen and used to assess parameters of retinal vascular network geometry. 
Measurement was performed on one randomly selected eye or the eye with the best 
photographic quality. All parameters of retinal vascular network geometry were 
measured by myself using operator-directed image analysis and a custom-written (by 
TM) software package within the MATLAB environment on a personal computer 
with a high-resolution 17 inch monitor (MathWorks Inc., Natick, Massachusetts). 
The red, green, and blue (RGB) colour image was converted to a grayscale image 
prior to analysis, and image contrast was enhanced by contrast-limited adaptive 
histogram equalization. The original colour image was used as a reference to identify 
an arteriole or a venule on the grayscale image.  
 
Retinal vessel width was recorded for each individual. In addition, the 
retinal arteriolar bifurcation angles and branching coefficients were measured.  
 
4.4.1. Measurements of retinal vessel width 
In accordance with the Atherosclerosis Risk in Communities (ARIC) study 
(Hubbard et al., 1999), after defining the boundary of the optic disc manually, a 
concentric circular grid centered on the optic disc was overlaid each retinal 
photograph to define the measurement area (Figure 23). The six largest arterioles and 
venules were then selected in the area between 0.5 and 1 disc diameter from the optic 
disc margin. For each vessel, a portion of vessel segment which was uniform in 
thickness and not obscured by any crossing or fairly close vessels was selected by 
means of a mouse-driven cursor to mark edges. A series of lines perpendicular to the 
vessel were created automatically at regular intervals using an imaging analysis 
programme (Figure 24). The intensity profile of each created line was fitted to a 
double-Gaussian curve with microdensitomety and the width of the vessel was taken 
at half the height of the fitted curve (Figure 25). The overall width of the vessel was 
derived from the mean width value of these profile cross-sections. The measurement 
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was rejected and repeated if less than 3 of the fitted curves were, on inspection, 
deemed to be a good fit (the majority of poor fits related to background ‗noise‘ 
producing artifact of vessel profiles) or accurate, or if the standard deviation of the 
calculated widths was greater than 10% (an arbitrarily chosen cut-off based on 
previous studies) of the mean widths measured. 
 
Computer-assisted measurements of individual arterioles and venules were 
each summarized according to formulas developed by Hubbard et al (1999), 
Knudtson et al (2003) and Patton et al (2007) to provide the average calibre of retinal 
arterioles (central retinal arteriolar equivalent [CRAE]) and venules (central retinal 
venular equivalent [CRVE]) in that eye. These summary indices were also expressed 
as the retinal arteriole-to-venule ratio, which is a measure of relative caliber of retinal 





Figure 23: Retinal vessel diameter measurements were performed in Zone B, which 






Figure 24: Automatic tracking of a segment of blood vessel. Red dots correspond to 
vessel centre points and blue dots to vessel edges determined at regular intervals 






Figure 25: A typical intensity profile of a cross-section of a retinal vessel. A curve of 
best fit has been placed over the actual intensity data, showing a double-Gaussian 
configuration. The height of the intensity profile was calculated by subtracting the  
nadir intensity from the background intensity measured across the vessel. Vessel 





Width at  
‘half  the height’ 
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4.4.2. Measurements of retinal arteriolar bifurcation geometry 
Other parameters of retinal vascular network geometry measured and 
quantified were the angle subtended between two retinal arterioles and the branching 
coefficient based on vessel widths between the parent vessel and the two daughter 
vessels across the arteriolar bifurcation (Figure 26a).   
 
As stated in Chapter 1, vascular topographical geometry tends to conform to 
optimal principals to minimise physical properties such as shear stress and volume 
across vascular network (Murray, 1926a, b; Patton et al., 2005). According to 
Murray‘s law, the most efficient circulation across a vascular network can be 
achieved if blood flow is proportional to the cubed power of the vessel‘s radius (i.e., 






 where x is the junction 
exponent, D0 is the diameter of parent vessel, and D1 & D2 are the diameters of the 
two daughter vessels). An empirically derived method to express Murray‘s law is to 






 (Figure 26b).  
 
At least 3 arteriolar junctions that were of good photographic image quality 
were assessed. To calculate the BC, the area that contained the arteriolar junction to 
be measured was selected, which then opened in a new window. By means of a 
mouse-driven cursor, the two edges of the parent vessel were marked by locating one 
point at the midpoint of the junction and the other at some distance beyond the 
junction. Another two points were defined in each of two daughter vessels, with the 
point at the junction fixed. The diameters of the parent and daughter vessels were 
then calculated by deriving the mean value of several (mostly 5) parallel lines 
perpendicular to the vessel, each line being 5-10 pixels away from its neighbor 
(Figure 27). The intensity profile of each created line was fitted to a double-Gaussian 
curve and the width of the vessel was taken at half the height of the fitted curve. 
Having measured the vessel widths, the middle points of the daughter vessels (red 
points in Figure 27) were identified and marked simultaneously by a vessel tracking 
technique in the above process. A line fixed in the selected bifurcation was drawn 
through the accepted middle points of each daughter vessel and the angle between 
the two lines was measured by using the cosine rule and presented in degrees (Figure 
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28). The median BC and the median bifurcation angle of the 3 arteriolar junctions 
were taken as the final measurements respectively.  
 
To standardise procedures and to overcome the difficulty of drawing a line in 
the daughter vessel when either of the daughter vessel segments curved immediately 
after the bifurcation point, width measurements were arbitrarily defined after taking 
into account the influence of the bifurcation on the shear stress in the daughter 
vessels. Widths were measured in daughter vessels along a distance of 2 times of the 
parent width, and the vessel tracking started at a distance of 0.75 to 1.5 times of the 
parent width from the bifurcation point. 
 
The measurements were rejected and the bifurcation was remeasured or 
declared unevaluable if  
(i) less than 3 of the fitted curves were on inspection deemed to be good fit or 
accurate  
or 
(ii) the standard deviation of the calculated widths was greater than 10% of the 
mean widths measured in either of branch vessels (parent and daughter 
vessels) 
 
Although images with the best quality (from either eye) were chosen, the 
number of measurable arteriolar bifurcations did not reach the required minimum of 
3 in 60% of the images. Using multiple branching point measurement from 
individual image has been shown to provide a more reliable estimate (compared with 
one measurement) and to minimise a great deal of variation between different images 
(Patton et al., 2006b). In one previous study, the average of measurements (median 
value) from 5 bifurcations was used (Patton et al., 2007). However, scrutiny of the 
ET2DS retinal photographs in the first instance showed that it was difficult to 
identify or measure the five most proximal bifurcations from the optic disc margin, 
largely caused by the more strict semi-automatic method (instead of manual 
estimation) applied in our study (comparison of the two methods is discussed in 
Chapter 6). Thus the measurement was restricted to at least the three arteriolar angles. 
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More specifically, the failure to get a measure on arteriolar bifurcation could be due 
to: 
(1) Arteriolar bifurcations were obscured by other vessels which were crossing or 
fairly close 
(2) Branch vessel segments (parent and daughter vessels) were too thin (<10 pixels) 
to be accurately measured (i.e. their vessel edges were often not sufficiently resolved 
to be able to measure with good accuracy) 
(3) Branch vessel segments were not uniform in thickness (focal narrowing or 
distension) 
(4) Background ‗noise‘ weakened the contrast at some points in vessel segments such 
that vessel edges could not be identified correctly 
(5) Too little contrast between vessel segment and the background intensity of the 
surrounding retina (retinal pigment epithelium) disabled the measures 
(6) Either the daughter or parent vessel segments were too short to measure 
(7) Bifurcation was beyond the 35 degree image field  
 
 
















         (a)                                          (b) 
Figure 26: A schematic representation (b) of an arterial bifurcation in digitized 
retinal image (a). D0=parent diameter, D1=1
st
 daughter diameter, D2=2
nd
 daughter 











Figure 27: An example of an arteriolar bifurcation: having selected 4 points in the 









Figure 28: An example of an arteriolar bifurcation demonstrating the Cosine Rule 
used to calculate the angle subtended by the two arteriolar daughter vessels 
 
4.4.3. Reliability of retinal vascular parameter measurements 
A quality control session with a random subsample of 20 digital retinal 
images was designed with repeat measurment performed after a 10-week interval to 
assess intraobserver reliability of retinal vessel width parameters (i.e. CRVE, CRAE, 
AVR, BC and BA). Inter-observer variability of measurements on these parameters 
was assessed at a later date by another trained grader measuring a separate set of 30 
images. The intraclass correlation coefficient (ICC) (ratio of between-groups 
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intra- and inter-observer reliability.  
 
4.5. Derivation of variables used in analysis 
Data obtained from the baseline questionnaire and data collection forms 
were coded and entered onto a master Microsoft Access database by members of the 
ET2DS research team. The results of plasma assays were entered onto the same 
master database either from paper records (biochemistry and haematology) or from 
electronic files provided by the laboratories. For retinopathy grading, data on 
individual retinal characteristics for each relevant photographic field were entered 
directly onto a specially designed spreadsheet (Microsoft Excel). The overall 
retinopathy grade for the right and left eyes for each subject was calculated 
automatically and these results were transferred to a separate master database. Data 
on retinal quantitative parameters were entered onto a second Microsoft Excel file at 
the time of assessment.  
 
The majority of data from paper records were double entered and 
discrepancies resolved by reference to the original paper documentation. For the 
retinopathy grading data, a random sample of 50 records were double-checked by 
myself. Data from assessment of retinal vascular parameters were checked by 
reviewing the saved ‗measurement log‘ or retinal images. All data from Access 
Database or Excel spreadsheets were exported into SPSS version 14.0 which was 
used for statistical description and analysis (SPSS, 2005). Study ID numbers (a 
unique five digit number assigned to each patient) were used to match the retinal data 
set with cognitive and other clinical data collected from the baseline examination. 
The complete data set was inspected for errors (e.g. values outside the possible range 
for a given variable) and missing values. 
 
4.5.1. Diabetic retinopathy and retinal vascular parameters 
The final level of diabetic retinopathy of the more severely affected eye 
(higher score) was used for assigning a grade to a participant. This ‗worse eye‘ 
method provided the overall measurement representing the presence and extent of 
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diabetic retinopathy. When the severity of diabetic retinopathy could not be graded in 
an eye, it was considered to have a score equivalent to that in the opposite eye. Any 
diabetic retinopathy was defined as level 20 and above. This was further divided into 
mild nonproliferative diabetic retinopathy (NPDR) (levels 20 to 35), moderate-severe 
NPDR (levels 43 to 53) and proliferative retinopathy (levels 61 to 81). The latter two 
were combined into moderate-severe DR due to small numbers in the proliferative 
retinopathy category (n=15, levels 61 to 81).  
 
In order to achieve the most efficient circulation across a vascular 
network, the theoretical and optimal BC (assuming a symmetrical dichotomous 
vessel branching where branch D1 = branch D2) should approximate 1.26. Similarly, 
both theoretical and empiric studies have shown an optimized arteriolar bifurcation 
(BA) geometry of approximately 75
o
 to minimise shear stress and work across the 
vascular network (Patton et al., 2007). To express the degree of deviation of the 
actual measurements (i.e. absolute BC or BA) from optimality, two ‗sub-optimal‘ 
variables, measuring the magnitude of varying quantity, were derived. The 
sub-optimal branching coefficient was calculated by using the root mean square of 
the difference of the median BC from 1.26 (i.e. √(1.26-branching coefficient)
2
) and 
sub-optimal branching angle was calculated by using the root mean square of the 
difference of the median BA from 75
o
 (i.e. √(75-branching angle)
2
. The root mean 
square was used to remove the negative sign of the deviation as ‗quantity‘ was the 
interest of the study.  
 
In order to enable a comparison with other published studies, the dimensions 
measured on the image (pixels) for retinal vascular width were converted into actual 
measurements (micrometers) by using a reference value of the average optic disc 
(OD) diameters (1850µm) derived from the ARIC study. Thus, the mean optic disc 
diameter using microdensitometry in the series of images (mean OD=327 pixels) in 
the ET2DS was transformed by multiplying the value in pixel by 5.7 (1850/327), to 




4.5.2. Cognitive variables 
Given the moderate to high correlation between the immediate and delayed 
sub-components of the Faces task (r=0.55), these were combined to form a total 
score, pertaining to ‗immediate and delayed non-verbal memory‘. A similar approach 
was taken for the immediate and delayed recall sub-components of the Logical 
Memory Test (r=0.87), giving an overall score for Logical Memory. All of the other 
cognitive test scores were retained as individual measures. Each of the cognitive test 
scores was normally distributed except for the Trail-Making Test which was 
normalised through a natural logarithm transformation. 
 
Scores on the individual tests were used to calculate a general intelligence 
factor score (g) representing the amount of shared variance between all of the 
cognitive tests. This was generated by Principal Components Analysis (PCA) from 
the scores of the 7 correlated cognitive tests (Logical memory, Verbal Fluency, Faces, 
Digit Symbol, Matrix Reasoning, Letter Number Sequencing and Trail-Making) 
(Table 11). Scores were saved on the first unrotated principal component. Each 
cognitive test loaded strongly on this component which accounted for 44.03% of the 
total variance among the 7 test scores, further validating the use of the general factor. 
It should be noted that memory test scores as indexed by Faces and Logical Memory 
contributed relatively lower to ‗g‘ than other cognitive test scores, which may reflect 
possible distinction between memory and fluid intelligence (Deary et al., 1998). A 
scree plot was examined to confirm the results from the PCA factor extraction. Table 
12 shows how much each cognitive test contributed to calculation of ‗g‘. Prior to 
PCA, the data were checked and adequately met the criteria for PCA with respect to 
the large sample size, factorability of the correlation matrix measure of sampling 
adequacy, Bartlett‘s test of sphericity on the adequacy of the intercorrelations among 
the cognitive test scores (Rafnsson, 2006). Scatter plots of all cognitive outcome 








Table 11: Pearson‘s correlations of cognitive test scores  
Mill Hill   Verbal   Faces   Trail      Logical      Matrix      Digit   Letter-Number       
Vocabulary   Fluency        Making (ln)  Memory    Reasoning    Symbol   Sequencing          





Trail Making (ln) 
Logical Memory 
Matrix Reasoning  




































































Table 12: Contributions of each cognitive test to ‗g‘ 










Cognitive impairment was defined as scores 1.5SD or lower than the mean 
scores of the total sample on individual cognitive tests. The cut-off of 1.5 standard 
deviations was selected as it was consistent with one of the recommendations for the 
diagnostic criteria for mild cognitive impairment (MCI) (Petersen et al., 1999). The 
full diagnostic criteria for MCI could not be used as other standardised information 
on functional ability or activities of daily living were not collected in the ET2DS.  
 
4.5.3. Demographic, diabetic and vascular variables 
 
Education, social class and deprivation 
Level of education (highest level completed) was categorised as a 
three-level variable with secondary and primary school combined (university, other 
professional or technical qualification, secondary & primary school). Social class 
 Adjusted R
2
  P-value 
Verbal Fluency  
  0.448 <0.001 
Faces 0.206 <0.001 
Trail Making Test(loge) 0.630 <0.001 
Logical Memory 0.279 <0.001 
Matrix Reasoning  0.443 <0.001 
Digit Symbol Test  0.569 <0.001 
Letter-Number Sequencing  0.503 <0.001 
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was coded according to the Registrar General‘s classification with female married 
subjects classified by their husband‘s occupation (OPCS, 1980). Retired and 
currently unemployed participants were coded according to their last held job. Thus 
level of occupational social class was grouped as a five-level variable with social 
class IIIN and IIIM combined (I, II, IIIN &IIIM, IV and V). In addition, a Scottish 
Index of Multiple Deprivation (SIMD, 2006) quintile score was calculated by a 
research statistician and allocated to each subject from 1 (most deprived) to 5 (least 
deprived), based on the link of postcode with 37 indicators of deprivation across 
seven domains.         
 
Smoking  
Smoking habits were self-reported and included information on both current 
and lifetime smoking status. Smoking status was coded as a three-level variable 
(current, ex and never smoker). Subjects were classified as smokers if they smoked 
any of cigarettes, cigars or pipes and as current smokers if they answered that they 
were currently smoking or had given up in the past 6 months. For purpose of analysis, 
a dichotomous variable was also created (smoker and never smoker). Pack-years of 
smoking was derived as an index of life time smoking, by calculating the number of 
20-cigarette packs per day smoked, multiplied by the number of years being a 
smoker at current or former levels. A zero value was entered for life-long 
non-smokers. The above measure on pack-years smoking has been used in previous 
epidemiological studies in which it was judged to be sufficiently valid because the 




Alcohol intake was also self-reported and included information on both 
beverage-specific and global questions. The number of drinks consumed over the 
past week was recorded in three categories: beer, spirits and wine. One unit of 
alcohol was defined as a half a pint of beer, one glass of wine or a single measure of 
spirits. Subjects were also asked whether this represented a typical week‘s 
consumption, and if not, whether they usually drank more or less. A typical week‘s 




In addition, the alcohol intake over the past year was recorded using an 
‗expanded quantity frequency‘ (QF) (Dawson, 2003) approach with respect to:  
(a) the frequency of drinking alcohol (never, monthly or less, 2 to 4 times a month, 2 
to 3 times a week, 4 to 5 times a week, and 6 or more times a week) 
(b) the quantity of standard drinks, as defined by a can or bottle of beer, a glass of 
wine, one cocktail or a measure of spirits (like scotch, gin or vodka), on a typical 
drinking day (0, 1-2 drinks, 3-4 drinks, 5-6 drinks, 7-9 drinks and 10 or more drinks) 
(c) the frequency of atypical or high-risk drinking (≥ 6 drinks) (never, less than 
monthly, monthly, weekly, daily or almost daily).  
Frequency of drinking at each quantity level was converted into the number of 
drinking days per year by using midpoints for each frequency category (e.g. 2 -3 
times a week =2.5×52=130 days per year) (Goddard 2007).  
 
Two components of annual alcohol intake were derived:  
(1) the typical quantity using the midpoint of the quantity category times the 
frequency of drinking that typical quantity (i.e. the overall frequency drinking minus 
the frequency of atypical or high-risk drinking) 
(2) the high-risk drinking quantity (6 drinks) times the frequency of high-risk 
drinking. The annual volume of alcohol an individual consumed (standards drinks 
per year) was the sum of these two components ((Dawson, 2003). To enable a 
comparison with published studies, the average weekly alcohol intake was calculated 
by dividing the annual volume by 52.  
 
Diabetes treatment 
Based on self-reported mode of diabetes treatment and listed medications, 
diabetes treatment was classified into three groups, (i) diet control only, (ii) 
hypoglycaemic oral agents without insulin and (iii) insulin injection with or without 
oral agents. A dichotomous variable was also created to compare subjects who were 




Obesity, hypercholesterolaemia and hypertension 
Two indicators were derived to assess obesity. Body Mass Index (BMI) was 
defined as the weight in kilograms divided by square of the height in meters. Waist 
to hip ratio (WHR) was calculated as the waist circumference divided by the hip 
circumference. Hypercholesterolaemia was defined as plasma total cholesterol ≥ 5 
mmol/L or when subject self-reported medication prescribed by a doctor to lower 
blood lipids level. Hypertension was defined as systolic blood pressure ≥140mmHg 
or diastolic blood pressure ≥85mmHg or when subject self-reported medication 
prescribed by a doctor to lower blood pressure.  
 
Cardiovascular disease categories 
Information about the following cardiovascular events was obtained: 
myocardial infarction (MI), angina, stroke, transient ischaemic attacks (TIA) and 
intermittent claudication (IC). The data used to define a cardiovascular event were 
collected from three sources: 
(a) Baseline questionnaire and 12-lead ECG 
(b) Hospital discharge data from Information and Statistics Division (ISD) of NHS 
Scotland  
(c) Clinical notes 
 
(a) Baseline questionnaire and ECG 
Medical history items in the self-administered questionnaire addressed 
subject‘s recall of diagnoses by a doctor and/or treatment for angina, coronary heart 
disease/MI, stroke, TIA, and peripheral arterial disease. In addition, the WHO‘s 
Chest Pain and Edinburgh Claudication Questionnaires were completed by subjects 
to assess the symptoms of pain in the chest and legs (Rose, 1962) (Appendix B). The 
ECG was coded as coronary artery ischaemia if Minnesota codes were 1.1 to 1.3; 4.1 
to 4.2; 5.1 to 5.3; 7.1, and coded as diagnostic Q-waves (indicating a definite MI) if 
Minnesota codes were 1.1.1 to 1.2.5; 1.2.7; or 9.2 plus 5.1 or 5.2 (Prineas et al., 
1982). 
 
(b) Hospital discharge data 
ISD provided information on medical and surgical discharges from Scottish 
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hospitals since 1981 for all study participants. All discharges with ICD-10 
(International Classification of Diseases, 10
th
 revisions) codes for cardiovascular 
disease (I20-I25, I61, I63-I66, I252, I679, I694, G45 and G659) were extracted 
manually by research staff.  
 
(c) Clinical notes 
When necessary to confirm the diagnosis, participants who had a 
cardiovascular event identified from either the baseline questionnaire or the ISD 
computer print-out were further investigated by reviewing case notes from hospital 
records or clinical details from the Lothian Diabetes Register. 
 
Myocardial infarction was recorded if two out of the first 3 of the following 
criteria were met, or if both the first and last criteria were met:  
(i) Self-report (subject‘s recall of a doctor‘s diagnosis) of heart attack 
(ii) myocardial infarction indicated by WHO chest pain questionnaire 
(iii) ECG evidence of ischaemia  
(iv) prior hospital discharge code for MI (ICD10 codes I21-I23, I252)  
 
Angina was recorded if two out of the first three of the following criteria 
were met, or if both the first and last criteria were met:  
(i) self report of doctor-diagnosed angina or taking regular anti-anginal medication 
(ii) angina indicated on WHO Chest Pain Questionnaire 
(iii) Ischaemic ECG codes 
(iv) prior hospital discharge code for ischemic heart disease (ICD10 codes I20-I25).  
 
Stroke was recorded if two out of three following criteria were present:  
(i) subject recall of a doctor‘s diagnosis of stroke  
(ii) prior hospital discharge code consistent with stroke (ICD10 codes I61, I63-I66, 
I679, I694)  
(iii) confirmation by clinical notes review that event not due to transient ischemic 
attack (TIA).   
 
Transient ischaemic attack was recorded if two out of three of the following 
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criteria were present: 
(i) subject recall of a doctor‘s diagnosis of stroke  
(ii) prior hospital discharge code consistent with TIA (eg. ICD10 codes G45, G659)  
(iii) confirmation by clinical notes review that event due to TIA.   
TIA was also recorded if subjects volunteered a self-reported history of 
‗TIA‘, ‗mini-stroke‘ or ‗slight stroke‘ on the questionnaire. 
 
Intermittent claudication was recorded if a positive response (i.e. definite 
and atypical) to the Edinburgh Claudication Questionnaire was present. 
 
Five major cardiovascular disease (CVD) categories were further identified: 
(i) coronary artery disease (myocardial infarction and/or angina); or (ii) 
cerebrovascular disease (stroke and/or transient ischaemic attacks); or (iii) peripheral 
arterial disease (intermittent claudication); or (iv) any CVD (MI, angina, stroke, TIA, 
or IC); and (v) ‗healthy‘ group without CVD (no coronary artery disease, or 
cerebrovascular disease, or intermittent claudication). Assignment to any of the CVD 
groups was based on the presence of the disease noted for each case, yet 
acknowledging there was a considerable overlap between some CVD exposure 
groups given that multiple events co-existed in a substantial number of subjects ever 
reporting symptomatic CVD (Rafnsson, 2006).  
 
4.6. Data analysis 
Variables used in the statistical analyses were examined and described. In 
addition to descriptive statistics, multivariate analysis was performed to assess the 
relationship between retinal parameters and cognitive outcomes after controlling for 
potential confounding variables.  
 
4.6.1. Data description  
Prior to undertaking any statistical analysis, the dataset was examined for 
extreme values/outliers and missing data. Categorical variables were described with 
respect to the frequency (percentage/number). The distribution of continuous 
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variables was explored by inspecting histograms first. Any outliers were corrected if 
necessary or omitted from subsequent analysis. Continuous variables showing a 
positively skewed distribution on histogram plots were normalised using square root 
or logarithm transformation. The transformed variables were used in all subsequent 
analyses. For descriptive purposes, the median and the interquartile range (IQR) were 
quoted for the skewed variables and the mean and standard deviation (SD) were used 
for other continuous variables. 
 
4.6.2. Bivariate statistical analysis 
Pearson‘s r correlation coefficients were used to examine the direction and 
strength of the relationship between continuous variables (e.g. between quantitative 
retinal vascular parameters and continuous cardiovascular risk factors). The 
Chi-square test (or Chi-square test for trend in the case of ordinal variables) was used 
to test the statistical significance of differences in categorical risk factors. The 
Mann-Whitney U Test or Kruskal-Walli test was applied to assess the differences in 
median levels of risk factors by diabetic retinopathy status (presence or severity). 
The independent t-test or ANOVA was used to compare the mean levels of each 
cognitive function test variable and other normally distributed risk factors. 
 
4.6.3. Multivariate statistical analysis 
Analysis of covariance (ANCOVA) was used to examine the statistical 
significance of mean differences in both general and specific cognitive functions 
between subjects (i) with and without diabetic retinopathy and (ii) with different 
severity levels of diabetic retinopathy while adjusting for potential confounding 
factors. Multiple linear regression analysis was used to assess the independent 
contribution of (i) diabetic retinopathy and (ii) quantitative retinal vascular 
parameters to estimated change in both general and specific cognitive abilities while 
adjusting for possible confounders. In a further set of examinations, the multiple 
linear regression-based analyses above were repeated using the general cognitive 
factor-adjusted standardised residuals of each cognitive test as dependent variable. 
 
In the modeling process (in both the ANCOVA and multiple linear 
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regression analyses), potential confounding variables were introduced into the 
models generally in three cumulative steps. In the first model, age and sex were 
adjusted for. Further, adjustment for the Mill-Hill Vocabulary Scale was used to 
control for the effects of pre-morbid cognitive ability. By controlling for a 
well-validated estimate of peak prior ability, it was possible to assess the impact of 
retinal vascular disease on the imputed lifetime decline from best-ever level of 
cognitive function to that actually measured here in old age (Deary et al., 2004a). 
Finally, adjustment was made for potential confounding by education level, vascular 
risk factors (alcohol intake, smoking, waist to hip ratio, systolic blood pressure and 
HDL cholesterol), the presence of cardiovascular disease (MI and/or angina, stroke 
and/or TIA), mood level (depression), and diabetes-related variables (duration of 
diabetes and HbA1c).  
 
Variables were selected as possible confounders if univariate association 
with retinal variables (between group differences or correlation) was significant or if 
from previous literature a variable was known to be associated with both retinal 
variables and cognitive test performance. They were incorporated into the age, sex, 
and Mill-Hill adjusted model cumulatively in a predetermined sequence, with the 
most distal factors on the hypothesized causal pathway added first and then all other 
factors except for glycaemic control and duration of diabetes (Victoria et al., 1997).  
 
In people with diabetes, cognitive ability is associated with hyperglycaemia 
and longer duration of diabetes. Longer duration of diabetes reflects many biological 
changes and pathologic processes, including hyperglycaemia and development of 
diabetic retinopathy. Hyperglycaemia may cause diabetic retinopathy. Thus analyses 
adjusted for HbA1c level and duration of diabetes may lead to an over-adjustment of 
the association between diabetic retinopathy and cognition to some extent. As a result, 
these two diabetes-related variables were added to the model in the final step to 
examine their impact on the association of diabetic retinopathy with cognitive ability 
over and above the effect of other variables. B values (unstandardised and 
standardised regression coefficients) were reported, as was the proportion of variance 
explained by each model.  
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Logistic regression was performed in order to further examine the clinical 
relevance of the relationship between cognitive impairment and diabetic retinopathy 
adjusted for age, sex and the Mill-Hill Vocabulary Scale. This analysis was not 
anticipated a priori, but was done as a descriptive exercise, mainly driven by 
significant results of the previous multiple linear regression analysis which seemed to 
indicate the presence of diabetic retinopathy was associated with poorer cognitive 
ability scores. Although this was a less efficient use of the available data than using 
all test scores as continuous scores, this step allowed the increased risk of cognitive 
impairment for diabetic retinopathy to be quantified (Price et al., 2006). Variables 
were then entered into the multivariate model using the ‗ENTER‘ procedure and odds 
ratios (95%CI) for cognitive impairment were calculated.  
 
With all covariates in the model, the interaction between all main effects was 
tested. The interaction term was not significant in all analyses except for sex and 
diabetic retinopathy in relation to performance on the general cognitive ability factor 
(g) and Verbal Fluency test. These data were analysed separately for men and women. 
A two sided p value <0.05 was taken to denote statistical significance throughout all 
analyses. However, given that many statistical tests were performed (e.g. there were 
7 retinal vascular parameters and each correlated with 8 cognitive variables), the 
prudent approach here was to acknowledge that very low p values were more likely 
to indicate replicable associations (Deary et al., 2006). 
 
4.6.4. Model assumptions  
Prior to the above analyses, model assumptions were assessed and found to 
be met. 
 
For independent t-test and the analysis of variance, normality of 
distributions was examined by plotting histogram or box-whisker plot. The 
homogeneity of variance was tested by visualising the standard deviations of mean 
scores or using the Levene‘s test. 
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For multiple linear regressions, standardised residual scatter plots were 
visually inspected for violations of normality, linearity, and homoscedasticity. 
Collinearity was checked by scanning the correlation matrix between independent 
variables (r >0.9) or by looking at the variance inflation factor (VF<10) and none of 
the variables constituted a combination of other independent variables. The data were 
visually inspected for outliers as a part of the univariate description of the data. 
 
Prior to logistic modeling, variables were checked for any ‗zero cells‘ which 
would result in spurious coefficients (Hosmer & Lemeshow, 1989). The assumption 
that predicator variables are linearly related to the log odds (B) of the outcome was 
tested by looking at separate log odds plots of outcome by covariates for all ordered 
categorical and continuous variables. The model‘s goodness-of-fit (Hosmer & 










This chapter presents results on the relationship between retinal 
microvascular abnormalities, vascular risk factors and CVD, and cognitive outcomes 
in elderly participants with Type 2 diabetes in the ET2DS. Descriptive data on the 
ET2DS population are presented first. Correlations between all parameters of retinal 
microvascular abnormality and the association of these parameters with 
socio-demographic, vascular risk factors and CVD are presented next. This is 
followed by the association of cognitive parameters with the sociodemographic and 
vascular variables. Finally, univariate and multivariate analyses of the association 
between retinal microvascular abnormalities and cognitive function are presented.   
 
5.2. Study population 
 
5.2.1. Representativeness 
Crude levels of sociodemographic and diabetes-related factors in those who 
had been invited to take part in the study but had not participated (n=4,385) 
compared with those subjects who participated in the ET2DS (n=1,066) are shown in 
Table 13. Age, median duration of diabetes, total cholesterol, HbA1c and treatment 
status (% on insulin) did not differ greatly between participants and non-participants. 
The mean age of the study population was 67.4 years and approximately 51% of 
subjects were men. Table 14 shows that there was a slight under representation of 
females aged 70-74 years. The proportion of men in the study participant group was 
greater than in the non-participant group (51.3% vs. 41.9%) due to the stratified 
sampling process (response rates were higher for men than for women). Subjects 
from the most deprived SIMD categories (SIMD 2006 quintiles, 1&2) made up 
31.4% of participants, which was lower than the proportion of non-participants in 
these quintiles (42.7%). The difference in deprivation profile between participants 
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and non-participants could be explained by the replacement of subjects who refused 
to participate in the study being age and sex stratified, but not socio-economic 
position such as the same postcode area. Mean systolic blood pressure of participants 
(133.3mmHg) was also slightly lower than that of non-participants (137.2 mmHg).  
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Male sex, % (n) 
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Less than 5 years duration of DM, % (n) 
Insulin treatment, % (n) 
Mean cholesterol, mmol/L 
Mean Systolic blood pressure, mmHg 









































 Maximum n=1066, minimum n=1028 for participants 
b





Table 14: Age by sex distribution of the study participants 
Age (years)             Males (%)                Females (%) 
60-64                  175 (32.0)                187 (36.0) 
65-69                  183 (33.5)                177 (34.1) 
70-74                  189 (34.6)                155 (29.9) 




Assessment of missing data 
Complete data were available for the following variables: age, sex, 
education level, treatment of diabetes, smoking status (current, former, never), 
hypertension and hypercholesterolaemia. Very small amounts of data (less than 3%) 
were missing for social class, duration of diabetes, BMI, WHR, annual volume of 
alcohol consumption, brachial blood pressure, total and HDL cholesterol. HbA1c 
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was not assessed in 38 (3.6%) subjects, and pack-years smoking was missing for 65 
(6.1%) subjects. This was mostly due to an insufficient volume of plasma sent for 
HbA1c measurement or questions left blank in the smoking questionnaire. Typical 
week‘s alcohol consumption had a relatively high level of missing data (n=189, 
17.7%) due to subjects in whom the previous week was not reported as ‗typical‘ in 
terms of drinking (subjects were excluded from variable calculation). Given that 
typical week‘s alcohol intake correlated highly with average weekly alcohol intake in 
the past year (r=0.92, p<0.001), but the former had high degree of missing data, the 
variable of average weekly alcohol intake alone was used in subsequent statistical 
analysis. 
 
The proportion of subjects with missing cognitive function test data ranged 
from 0.3% to 1.7%. The Letter-Number Sequencing test was most frequently missing, 
due to participant refusal or inability to attempt or complete the test. The LNS was 
used as a measure of auditory working memory which requires the concurrent 
retention and manipulation of information (Baddeley, 1986). In the LNS testing, the 
subject must recall the inter-mixed numbers and letters (verbally presented), stating 
the numbers in ascending numerical order followed by the letters in alphabetical 
order. The test was discontinued when the subject failed 3 consecutive trials of the 
same length. Thus, a number of factors could particularly contribute to the highest 
refusal/discontinuation rate in the LNS, including task difficulty, illiteracy, hearing 
impairment, cognitive impairment, fatigue, and anxiety or mood disturbance. Further 
analysis showed no relationship between missing values for the cognitive tests and 
demographic or vascular risk profile or retinal microvascular abnormalities (see 
Appendix G, Table g1).  
 
Twenty-two subjects (2%) had missing diabetic retinopathy status, due to 
ungradable or unavailable retinal photographs. Characteristics of participants with 
and without gradable retinal photographs are described in Table 15. Subjects with 
gradable photographs (n=1044) performed better on Faces, Logical Memory and 
general cognitive ability tests, but did not differ from subjects (n=22) without 
gradable photographs with respect to any of the cardiovascular risk factors or other 
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cognitive test scores.  
 
Missing data for the quantitative retinal vascular parameters was highest for 
arteriolar bifurcation angle and branching coefficient (58%), due to poor image 
quality or technical and practical difficulties in measurement (See Section 4.4.2). A 
comparison was made between subjects with and without missing individual retinal 
quantitative parameter with respect to characteristics of the cohort (Table 16 and 17). 
Subjects with retinal width or arteriolar bifurcation measurements had a lower 
prevalence of cardiovascular disease (e.g. stroke and/or TIA) and significantly better 
scores on most cognitive tests, but no major difference in other cardiovascular risk 
factors was detected. However, the magnitude of the differences on these cognitive 
































Table 15: Characteristics for subjects with and without retinal photographs which 
were gradable for diabetic retinopathy 
                                    Subjects with                Subjects with missing  
                                 retinal grading (n=1044)
a
         retinal grading  (n=22)
b 
Age (years),mean (SD) 
Sex, (% (n) men) 
BMI (kg/m
2
), mean (SD) 
WHR, mean (SD) 
HbA1c, median (IQR) 
Total cholesterol (mmol/L), mean (SD) 




Cardiovascular disease, %(n) 
MI and/or Angina
 
Stroke and/or TIA 
Cognitive tests, mean (SD) 
Mill-Hill Vocabulary Scale 
Verbal Fluency 
Faces 
Trail Making Test (ln) 
Logical Memory 
Matrix Reasoning  
Digit Symbol  
Letter-Number Sequencing 


















































Smoker=current or former smoker; * P <0.05; 
a
 Maximum n=1044, minimum n=1000 for subjects 
with retinal grading; 
b

















Table 16: Characteristics of subjects with and without retinal width measurements 
                                   Subjects with retinal             Subjects with missing retinal 
                              width measurement (n=980)
a
        width measurement (n=86)
b 
Age (years),mean (SD) 
Sex, (% (n) men) 
BMI (kg/m
2
), mean (SD) 
WHR, mean (SD) 
Duration of DM (yrs), median (IQR) 
HbA1c, mean (SD) 
Total cholesterol (mmol/L), mean (SD) 
HDL cholesterol (mmol/L), mean (SD) 
Smoker, %(n) 
Hypertension, %(n) 
Cardiovascular disease, %(n) 
MI and/or Angina
 
Stroke and/or TIA 
Cognitive tests, mean (SD) 
Mill-Hill Vocabulary Scale 
Verbal Fluency 
Faces 
Trail Making Test (ln) 
Logical Memory 
Matrix Reasoning  
Digit Symbol  
Letter-Number Sequencing 

























































Smoker=current or former smoker; * P <0.05; 
a
 Maximum n=980, minimum n=938 for subjects with 
retinal width measurement; 
b
















Table 17: Characteristics of subjects with and without retinal bifurcation 
measurement 
                                   Subjects with retinal              Subjects with missing retinal 
                                 BA measurement (n=444)
a
           BA measurement (n=622)
b 
Age (years),mean (SD) 
Sex, (% (n) men) 
BMI (kg/m
2
), mean (SD) 
WHR, mean (SD) 
HbA1c, mean (SD) 
Total cholesterol (mmol/L), mean (SD) 




Cardiovascular disease, %(n) 
MI and/or Angina
 
Stroke and/or TIA 
Cognitive tests, mean (SD) 
Mill-Hill Vocabulary Scale 
Verbal Fluency 
Faces 
Trail Making Test (ln) 
Logical Memory 
Matrix Reasoning  
Digit Symbol  
Letter-Number Sequencing 





































33.4 (208) * 
















Smoker=current or former smoker; * P <0.05; 
a
 Maximum n=444, minimum n=431 for subjects with 
retinal arteriolar bifurcation measurement; 
b
 Maximum n=622, minimum n=590 for subjects without 
retinal arteriolar bifurcation measurement 
 
 
5.2.2. Characteristics of study population 
Full characteristics of the study population are shown in Table 18. The 
median duration of diabetes was 6.7 years (IQR 3.9-11.3). Glycaemic control was 
assessed by HbA1c levels and diabetes treatment modality. The mean HbA1c level 
was 7.4% and 63.7% of the participants were treated with oral hypoglycaemic agents 
without insulin. A further 17.4% were receiving insulin injection with or without oral 
hypoglycaemic agents. Approximately 18.9% were diet controlled.  
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Regarding the highest level of education completed, 16 % of subjects had 
completed university and 28.8% had finished post school training of some profession. 
About 55.2% had completed secondary (54.5%) and primary school (0.7%) (these 
were combined due to the small number in primary school). Most social classes were 
well represented in the sample and 23.3% of the population was classified in social 
class I, 22.5% in class II, 28.8% in class III, 11.0% in class IV and 14.0% in class V. 
 
Cardiovascular risk factors measured included smoking habit, alcohol 
consumption, obesity (assessed with body mass index and waist-to-hip ratio), 
cholesterol levels, and blood pressure. About 14.3% of the population were 
self-reported current smokers and 46.6% were former smokers, whereas 39.1% had 
never smoked. Alcohol intake referred to average weekly alcohol intake in the past 
year and 28.5% of subjects reported not having consumed any alcohol in the year 
prior to examination. A further 45.6% had consumed less than 7 drinks per week, 
13.4% had had 7-15 drinks, and 9.9% had consumed more than 15 drinks of alcohol. 
Also, around 90% of the population had hypercholesterolaemia and 84.8% were 
suffering from hypertension. 93 subjects (8.7 %) had suffered a stroke or TIA, 150 
(14.1 %) had met study criteria for diagnosis of myocardial infarction and 298 
(28.0 %) had angina prior to the examination. In addition, 63 (5.9 %) subjects were 
suffering from intermittent claudication as identified by the Edinburgh Intermittent 
Claudication questionnaire. 
 
Approximately 11.8% of the population had depression scores ≥8 indicating 
possible or probable clinical depression. The MMSE was used to screen for dementia 
and most individuals had close to the upper-limits of the scale (median 29, IQR 28 to 
30), with only a very small proportion having an MMSE score below 24 (n=30), 









Table 18: ET2DS population characteristics 
                                                 Mean (SD)/Percent (n) 
Age (years) 
Males (%) 
Duration of diabetes 
HbA1c (% of haemoglobin) 
Treatment of diabetes 
Diet only 
Hypoglycaemic oral agents 
Insulin ± hypoglycaemic oral agent 
Education Level 
               University 
               Other professional/technical qualification              
               Secondary & Primary school 
Social Class 
               I 
               II 
               III 
               IV 
               V 
Obesity Indices   Body Mass Index (kg/m
2
) 
Waist to hip ratio 
Plasma Lipids    Total cholesterol (mmol/L) 
HDL cholesterol (mmol/L) 
Hypercholesterolaemia (%) 
Smoking        Smoker (current or former) 
Pack-yrs smoking (among smokers) 
Alcohol intake 
Average weekly alcohol intake  
(standard drinks/week) 
Average weekly alcohol intake category (%) 
Never  
Light drinker  (≤7 drinks ) 
Moderate drinker (7-15 drinks) 
Heavy drinker (>15 drinks) 
Blood pressure    Systolic blood pressure (mmHg) 














































Cardiovascular disease  Stroke and/or TIA 
Myocardial infarction and/or Angina
 
Intermittent caludication (IC) 
Any CVD (MI, angina, stroke, TIA, and IC) 
Mood and cognitive status  Depression score 
Depressive symptoms (≥8) 
















The median (IQR) was quoted for skewed variables 
b
 Duration of diabetes= (age at examination-age at diagnosis); zero indicated duration was less than 
one year 
c 
Cerebrovascular disease (n=93) included subjects with cerebrovascular disease (stroke and/or TIA) 
only (n=40), coronary artery disease and cerebrovascular disease (MI and/or angina, stroke and/or 
TIA) (n=38), cerebrovascular disease and peripheral arterial disease (stroke and/or TIA, and IC) (n=4), 
MI and/or angina, stroke and/or TIA and IC (n=11);  
d
 Coronary artery disease (n=330) included subjects with coronary artery disease (MI and/or angina) 
only (n=251), coronary artery disease and cerebrovascular disease (MI and/or angina, stroke and/or 
TIA) (n=38), coronary artery disease and peripheral arterial disease (MI and/or angina, and IC) (n=30), 
MI or angina, stroke or TIA and IC (n=11);  
e 
Peripheral arterial disease (n=63) included subjects with IC only (n=18), IC and coronary artery 
disease (IC, MI and/or angina) (n=30), IC and cerebrovascular disease (IC, stroke and/or TIA) (n=4), 
MI and/or angina, stroke and/ or TIA, and IC (n=11). 
 
 
5.3. Retinal microvascular abnormalities 
This section focuses on the prevalence of diabetic retinopathy, the 
distribution of parameters of retinal vascular network geometry, and the 
interrelationships between the various retinal microvascular abnormalities. It also 
describes the associations between retinal microvascular abnormalities and 
sociodemographic characteristics, vascular risk factors and cardiovascular disease.  
 
5.3.1. The prevalence and severity of diabetic retinopathy 
Of the 1,066 participants in the ET2DS, 20 did not undergo digital retinal 
photography, and 2 had no gradable photographs for diabetic retinopathy in either 
eye, leaving 1,044 participants who provided data for the analysis. 
 
The crude prevalence of diabetic retinopathy (DR) at baseline was 32.5% 
(95%CI: 29.7, 35.3). Men were more likely to have diabetic retinopathy than women 
(35.1% vs. 29.7%) but the difference was of borderline statistical significance 
(P=0.058). There was no age-related trend in the prevalence of diabetic retinopathy 
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between 5-year age groups (P=0.86) (Figure 29). Mild NPDR was found in 28% of 
the population, moderate-severe NPDR in 3.1%, and proliferative diabetic 
retinopathy in 1.4% (Table 19). 
 







60-64 65-69 70-74 Total


















Figure 29: Diabetic retinopathy (DR) in ET2DS by age and gender 
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Table 19: Age- and gender-specific prevalence (95% Confidence Interval) of diabetic retinopathy in ET2DS 
 
Severity of 
diabetic retinopathy (DR) 











60-64            65-69              70-74 
(n=356)          (n=351)            (n=337) 
 
Female           Male 







31.7 (26.9, 36.5) 
26.4(21.8, 31.0) 
3.4 (1.5, 5.3) 
2.0(0.6, 3.4) 
 
33.3 (28.4, 38.2) 
















































5.3.2. Reliability of retinal quantitative parameters 
measurement 
The Bland-Altman plot of the difference between the two repeats or raters 
measurements against their means was drawn and the range of the mean difference 
±2 standard deviations (SDs) was examined for measuring agreement (Appendix H). 
The repeatability coefficient was also used to indicate that the difference between 
two measurements by the same rater or two raters was within 2SD for 95% of 
subjects. 
 
Table 20 presents information on the reliability of retinal quantitative 
parameters as determined by replicate grading exercises. Results are divided into 
intra-observer (i.e., the same grader in our study at different time) and inter-observer 
(i.e., two graders) comparisons. In summary, there were both high intra- and 
inter-rater reliability in retinal width measurement compared with previous studies. 
The intra-rater reliability in branching angle and coefficient was lower than the 
values in a published study (Patton et al., 2007) which however used a different 
measuring method from the study here (0.53 vs. 0.65 in BC, 0.72 vs. 0.96 in BA). 
The inter-rater reliability for BC that ranged between 1.6 and 2.3 was also low given 
the two ratings by different raters fell within ±0.7 for 95% of subjects, and even 
poorer for branching angle, in which the two raters‘ measurements were not 
correlated at all.  
 
Table 20: Intra- and Inter-observer reliability of quantitative measurements, 
described by intra-class correlation coefficient and coefficient of repeatability 
between two measures  
 
Measurements 




Repeatability Coefficient (±2SDs) 
Intra-observer    Inter-observer Intra-observer    Inter-observer      
CRAE (pixels) 0.72 0.74  2.7 pixels 3.6 pixels 
CRVE (pixels) 0.95 0.67  2.6 pixels 5.6 pixels 
Arteriole-to-venule ratio 0.92 0.79  0.07 0.14 






Arteriolar branching coefficient 0.53 0.69  0.36 0.7 
CRAE: central retinal arteriolar equivalent; CRVE: central retinal venular equivalent; 
a
All ICCs 
were significant at 0.05 level except for inter-observer reliability of arteriolar branching angle; 
b
The ICC was non-significant (P=0.76) thus the Bland-Altman plot was not drawn.  
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5.3.3. Distribution of retinal quantitative parameters  
Of the 1,044 participants who had gradable photographs for diabetic 
retinopathy severity, 64 did not have gradable retinal vessels for analysis of any of 
the retinal vascular parameters in either eye. In all of the remaining 980 individuals, 
the retinal width parameters of CRVE, CRAE, and AVR were measured. However, of 
980 images that were gradable for CRVE, CRAE and AVR, 536 were either of too 
poor quality to analyse 3 arteriolar junctions, or less than 3 arteriolar junctions were 
evaluable within the 35
o 
field. Thus for arterial branching angle and coefficient (BA 
& BC), only 444 subjects provided data for the analysis. The frequency of 
measurements was approximately equal for the right and left eyes (51% vs. 49% for 
left and right eye on retinal width measures, and 49.5 % vs. 50.5% on retinal angles). 
 
Frequency histograms for retinal parameters are shown in Figure 30. All 
parameters followed a normal distribution except for suboptimal branching angles 
(BA). The absolute values of deviations of the median angles from optimality were 
positively skewed and underwent natural log (n+1) transformation in subsequent 
analyses that assume approximate normality.  
 
The mean (SD) or median (IQR) of each retinal vascular network parameter 
for all subjects and for males and females separately are shown in Table 21. For the 
vessel width measurements, the values in pixels translated into the following values 
in micrometers, (undertaken to aid comparison with other studies, based on an 
assumption of the average optic disc diameter (approximately 327 pixels) being 
equal to 1850µm): CRAE= 167.5µm and CRVE=227.8µm. There were no significant 
























Table 21: Parameters of retinal vascular network geometry in males and females 
                               N   All subjects         N     Males        N     Females     P-value
* 
CRAE, pixels, Mean (SD) 
CRVE, pixels, Mean (SD) 
AVR, Mean (SD) 
Median angle BA, degrees,  
Mean (SD) 
Median BC, Mean (SD) 
Suboptimal BA, degrees,  
Median(IQR) 
































































*P-value for difference between males and females was calculated with independent t-test; transformed 
suboptimal BA was used 
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5.3.4. Correlations between parameters of retinal 
microvascular abnormalities 
Overall, most quantitative retinal vascular parameters showed significant 
inter-correlation (Table 22). There was a perfect correlation for suboptimal BC and 
median BC (r=1.00, P<0.01). Suboptimal BC measured the degree of deviation of the 
BC from optimality (i.e.1.26). All the values of median BC were greater than 1.26, 
suggesting they were all abnormal relative to 1.26. Thus suboptimal BC and the 
absolute BC were not two separate sources of information and median BC alone was 
used in subsequent analysis. For other parameters, the strongest associations were 
between CRAE and CRVE (r=0.61, P<0.01), AVR and CRVE (r=-0.51, P<0.01) and 
suboptimal BA and median BA (r = 0.50, P<0.01). Suboptimal BA and median BA 
did not show strong associations with other parameters. 
 
There were no significant differences in mean CRAE, CRVE, AVR, median 
BA or median BC between subjects with and without diabetic retinopathy. 
Suboptimal BA was significantly higher in those with diabetic retinopathy based on 
grading level either from the matched eye (P=0.007) or from the worse eye (P=0.019) 
(Table 23). 
 
When the presence of diabetic retinopathy was further categorized into mild 
and moderate-severe diabetic retinopathy, none of the parameters except for 
suboptimal BA showed a clear trend across the worsening categories of diabetic 
retinopathy. Based on gradings from the worse eye, the mean suboptimal BA 
increased from 0.82 (95%CI 0.78, 0.86) to 0.94 (95%CI 0.79, 1.08) between the 
absent and moderate-severe groups, with an intermediate value for mild diabetic 
retinopathy (mean 0.89, 95%CI 0.83, 0.95), indicating that increased abnormality in 
arteriolar branching angles was associated with more severe diabetic retinopathy 
(Table 24). Although the trend was also significant based on the gradings from the 
single matched eye, the group means were not apparently in a correct order but with 
the mild diabetic retinopathy group having the highest and non-diabetic retinopathy 
group the lowest. This was possibly due to the small number of subjects having 
moderate-severe diabetic retinopathy (n=14). Further tests for reversals (Page et al., 
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2003) by testing each adjacent pair of means (e.g. no vs. mild, mild vs. 
moderate-severe) were all non-significant supporting a monotonic trend. However, 
increasing severity of diabetic retinopathy was not associated with changes in mean 
CRAE or CRVE (Figure 31). For both CRAE and CRVE, the standard deviation was 
nearly constant across levels of severity except for level 53, which had a very small 
number of subjects (n=3 based on grading from the single matched eye and n=4 




Table 22: Pearson correlation coefficients between retinal vascular parameters 
CRAE      CRVE      AVR        Median BA      Median BC    Suboptimal BA
a
   Suboptimal BC  
(pixels)     (pixels)                   (degrees)                       (degrees) 
 




Median arteriolar branching angle 
 
Median arteriolar branching coefficient 
 
Suboptimal branching angle 
 












































































































CRAE: Central Retinal Arteriolar Equivalent; CRVE: Central Retinal Venular Equivalent; AVR: Arteriovenous ratio; BA: arteriolar branching angle; BC: 
arteriolar branching coefficient; 
a
 transformed suboptimal BA was used; 
†
 significant at 0.01 level; 
*
















Table 23: Retinal width and arteriolar bifurcation parameters according to presence of diabetic retinopathy  
                                   Retinopathy of the matched single eye                 Retinopathy of the worse eye 




CRAE, µm, Mean (SD) 
 
CRVE, µm, Mean (SD) 
 




Median BA, degrees, Mean (SD) 
 
Median BC, Mean (SD) 
 


















 227 (34) 
 



































 168 (25) 
 
 227 (34) 
 






















N=980 for subjects with retinal width measurements, of which 233 subjects had diabetic retinopathy based on the grading from the matched single eye 
whereas 323 subjects had diabetic retinopathy from the worse eye; 
b
N=444 for subjects with retinal arteriolar bifurcation measurements, of which 109 
subjects had diabetic retinopathy based on the grading from the matched single eye whereas 155 subjects had diabetic retinopathy from the worse eye; 
c
 















Table 24: Retinal width and arteriolar bifurcation parameters according to diabetic retinopathy severity 
                                     Retinopathy severity of the matched single eye              Retinopathy severity of the worse eye 
                                None         Mild       Moderate-severe    P         None         Mild         Moderate-severe     P  
                                              DR           DR       for trend                     DR            DR         for trend 
Retinal width parameters
a 
CRAE, µm, Mean (SD) 
 
CRVE, µm, Mean (SD) 
 




Median BA, degrees, Mean (SD) 
 
Median BC, Mean (SD) 
 

















 227 (34) 
 









 171 (19) 
 
 235 (30) 
 





 1.84 (0.2) 
 


























0.82 (0.3)  
 
 168 (26) 
 
 226 (34) 
 









  170 (21) 
 
  232 (31) 
  





   1.84 (0.1) 
 















N=980 for subjects with retinal width measurements, of which 233 subjects had diabetic retinopathy based on the grading from the matched single eye 
whereas 323 subjects had diabetic retinopathy from the worse eye; 
b
N=444 for subjects with retinal arteriolar bifurcation measurements, of which 109 
subjects had diabetic retinopathy based on the grading from the matched single eye whereas 155 subjects had diabetic retinopathy from the worse eye; 
c
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Figure 31: Mean central arteriolar equivalent (CRVE) and central retinal venular 
equivalent (CRVE) and standard deviations (SDs) by retinopathy severity level. Error 















5.3.5. Associations of diabetic retinopathy with 
sociodemographic variables, vascular risk factors and 
cardiovascular disease  
Table 25 presents levels of sociodemographic variables, vascular risk factors 
and cardiovascular disease in subjects with and without diabetic retinopathy. 
Subjects with diabetic retinopathy were slightly more likely to be male (55.5%) 
compared to those without diabetic retinopathy (49.2%, P=0.06). A higher proportion 
of subjects with diabetic retinopathy were on insulin treatment (31.9% vs. 10.5%, 
P<0.001) and they had a longer duration of diabetes (median 10.3 vs. 5.5, P<0.001) 
and higher mean HbA1c levels (mean 7.6 vs. 7.3, P<0.001). Mean waist-to-hip ratio 
was higher in subjects with diabetic retinopathy (mean 0.98 vs. 0.96, P=0.001), 
whereas mean diastolic blood pressure was significantly lower (mean 67.8 vs. 69.7, 
P=0.002). Of those subjects with diabetic retinopathy, 13.6% had suffered a stroke or 
TIA compared with 6.2% in the group without diabetic retinopathy (P<0.001). No 
statistically significant differences were found for other variables, including 
education, social class, smoking habits, alcohol intake, BMI, systolic blood pressure, 
hypertension, plasma cholesterol, coronary artery disease or peripheral arterial 
disease.  
 
Subjects with diabetic retinopathy were further divided into those who had 
mild non-proliferative diabetic retinopathy (NPDR), and those who had moderate to 
severe NPDR or PDR. Levels of variables were calculated across retinopathy 
severity categories (Table 26). A significant trend across worsening retinopathy 
categories was found for diabetes-related variables, including the median duration of 
diabetes and mean HbA1c, with longer duration of diabetes and worse glycaemic 
control in the mild diabetic retinopathy group and even longer duration and worse 
glycaemic control in the moderate-severe NPDR or PDR group. The percentage of 
subjects on insulin treatment and mean waist to hip ratio were significantly higher in 
the mild retinopathy group and even higher in the group with moderate to severe 
retinopathy. Conversely, mean diastolic blood pressure was significantly lower in the 
mild retinopathy group and even lower in the moderate to severe group, possibly 
because of the higher percentage of subjects in the diabetic retinopathy groups who 
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were on treatment for hypertension. There was no significant relationship across 
diabetic retinopathy severity categories for BMI, alcohol intake, pack-years smoking, 
systolic blood pressure, and plasma cholesterol. The prevalence of any 
cardiovascular disease, in particular cerebrovascular disease, was significantly higher 
in the diabetic retinopathy group, with the moderate to severe diabetic retinopathy 









































Table 25: Levels of socio-demographic variables, vascular risk factors and 
cardiovascular disease by presence of diabetic retinopathy  
                                              No Diabetic          Diabetic 
                                              Retinopathy         Retinopathy    P-value for 
                                               (N=705)            (N=339)       difference† 
Sociodemographic Variables 
Age, yrs, mean (SD) 
Sex, male, n (%) 
Education level, n (%) 
University 
Other profession/technical qualification 
Secondary& Primary school 







Diabetes duration, yrs, median (IQR) 
Treatment, n (%) 
Diets  
Oral hypoglycaemics only  
Insulin ± oral hypoglycaemics 
HbA1c (% of haemoglobin), mean (SD) 
Vascular Risk Factors 
Body Mass Index, kg/m
2
, mean (SD) 
Waist-hip ratio, mean (SD) 




Pack-years smoking, median (IQR) 
Average alcohol intake, drinks/week, median (IQR) 
Alcohol (drinks consumed per week), n (%) 
   Never 
   ≤7 
   7-15 
   >15 
Systolic blood pressure, mmHg, mean (SD) 
Diastolic blood pressure, mmHg, mean (SD) 
Hypertension, n (%) 
Total cholesterol, mmol/L, mean (SD) 
HDL cholesterol, mmol/L, mean (SD) 
Total/HDL cholesterol ratio, mean (SD)  
Hypercholesterolaemia, n (%) 
Cardiovascular Disease  
Myocardial infarction and/or Angina, n (%)  
Stroke and/or TIA, n (%) 
Intermittent caludication, n (%) 











































































































































median (IQR= interquartile range); †For categorical variables P values were calculated with the 
chi-square test, for quantitative and normally distributed variables, with t-test and for skewed 
variables with Mann-Whitney U test
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Table 26: Levels of socio-demographic & diabetes-related variables, vascular risk factors and cardiovascular disease by severity of 
diabetic retinopathy  
No diabetic              Mild diabetic             Moderate-severe  
retinopathy              retinopathy               NPDR-PDR          P value for 
                                                      (N=705)                  (N=292)                    (N=47)            trend† 
Sociodemographic Variables 
Age, yrs, mean (SD) 
Gender, male, n (%) 
Education level, n (%) 
University 
Other profession/technical qualification 
   Secondary& Primary school 








Diabetes duration, yrs, median (IQR) 
Treatment, n (%) 
Diets  
Oral hypoglycaemics only  
Insulin ± oral hypoglycaemics 
HbA1c (% of haemoglobin), mean (SD) 
 
Vascular Risk Factors 
Body Mass Index, kg/m
2
, mean (SD) 
Waist-hip ratio, mean (SD) 





















































































































Pack-years smoking, median (IQR) 
Average alcohol intake, drinks/week, median (IQR) 
Alcohol (drinks consumed per week), n (%) 
   Never 
   ≤7 
   7-15 
   >15 
Systolic blood pressure, mmHg, mean (SD) 
Diastolic blood pressure, mmHg, mean (SD) 
Hypertension, n (%) 
Total cholesterol, mmol/L, mean (SD) 
HDL cholesterol, mmol/L, mean (SD) 
Total/HDL cholesterol ratio, mean (SD)  
Hypercholesterolaemia, n (%) 
   
Cardiovascular Disease Variables 
Myocardial infarction and/or Angina, n (%)  
Stroke and/or TIA, n (%) 
Intermittent caludication, n (%) 





















































































† For categorical variables P values were calculated with the chi-square test, for quantitative and normally distributed variables, with ANOVA test and for 







5.3.6. Associations of retinal quantitative parameters with 
sociodemographic variables, vascular risk factors and 
cardiovascular disease  
Tables 27 to 30 present the association of parameters of retinal vascular 
network geometry with sociodemographic and vascular variables, both before and 
after adjustment for age and sex.  
 
Higher mean arteriolar diameter (CRAE) was significantly associated with 
lower social class (P for trend=0.003), insulin treatment use (P for trend=0.008), 
former or current smoking (highest in current smokers, P for trend=0.01) and 
prevalent coronary heart disease (MI and/or angina, P=0.002). Conversely, lower 
mean CRAE level was associated with the presence of hypertension (P=0.002).   
 
Increased mean venular diameter (CRVE) was associated with higher 
HbA1c levels, waist-hip ratio, body mass index, and lifetime smoking (r ranged from 
0.08 to 0.11, P<0.05), as well as with prevalent coronary artery disease (P=0.001). 
Mean CRVE was highest in current smokers (P for trend<0.001). Conversely, 
decreased CRVE was associated with increasing age (r=-0.09, P<0.01).  
 
Trends towards higher mean CRAE and CRVE in subjects with 
cerebrovascular disease and peripheral arterial disease did not reach statistical 
significance, possibly because of a small number of these events.  
 
Lower mean AVR (as a relative measure that combined information from 
both CRAE and CRVE) was associated with increased waist-hip ratio, lifetime 
smoking and average alcohol intake (r ranged from -0.07 to -0.10, p<0.05) as well as 
with the presence of hypertension (P=0.001). Mean AVR was lowest in current 
smokers (P for trend=0.006). Higher AVR was associated with increasing age 
(r=0.07, P<0.05) and higher education level (P for trend=0.03). 
 
Decreased mean arteriolar branching coefficient was associated with higher 
plasma total cholesterol (r=-0.1, P<0.05). Raised mean of deviation level from 
 207 
optimality of the arteriolar angle was associated with lower education level (P for 
trend=0.002), lower social class (P for trend=0.01), and prevalent peripheral arterial 
disease (P=0.01). 
 
All the above associations remained largely unaffected by adjustment for 
age and sex, except for the associations between AVR, alcohol intake and education 
level, which both became attenuated and no longer statistically significant. There 
were no other significant associations between retinal width, arteriolar bifurcation 










































Table 27: Pearson correlation coefficients between retinal vascular parameters and 
continuous vascular risk factors 
CRAE      CRVE      AVR   median BA     median BC    Suboptimal  















Pack-years smoking √ 
 
Average alcohol intake 
  (drinks/week)√ 
Total cholesterol (mmol/L) 
 
HDL cholesterol (mmol/L) 
 
Total/HDL cholesterol ratio 
 
Systolic blood pressure (mmHg) 
 
























































































































































 Transformed variable was used; CRAE: Central Retinal Arterial Equivalent; CRVE: Central 
Retinal Venular Equivalent; AVR: Arteriovenous ratio; BA: arteriolar branching angle; BC: 




P≤0.01, *P<0.05.  
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Table 28: Age-sex adjusted partial correlation coefficients between retinal vascular 
parameters and continuous vascular risk factors 
CRAE      CRVE      AVR  median BA     median BC   Suboptimal  
















Pack-years smoking √ 
 
Average alcohol intake 
  (drinks/week)√ 
Total cholesterol (mmol/L) 
 
HDL cholesterol (mmol/L) 
 
Total/HDL cholesterol ratio 
 
Systolic blood pressure (mmHg) 
 


















































































































































 Transformed variable was used; 
b 
For the age category, adjustments were made for gender only; 
CRAE: Central Retinal Arterial Equivalent; CRVE: Central Retinal Venular Equivalent; AVR: 
Arteriovenous ratio; BA: arteriolar branching angle; BC: arteriolar branching coefficient; 
























































   
Mean (SD)    P value Mean (SD)  P value Mean (SD)  P value Mean (SD)  P value Mean(SD) P value Mean (SD) P value 
Education level 
University 
Other profession qualification 









Oral hypoglycaemics only  






Alcohol intake (drinks/week) 
   Never 
   ≤7 
   7-15 
























































































































































































0.74 (0.1)     0.87 
0.74 (0.1) 
 







































































































1.85(0.14)   0.51 













1.84 (0.16)  0.18 
1.87 (0.14) 
 















































































































































0.74 (0.1)     0.51 
0.74 (0.1) 
 
0.74 (0.1)     0.94 
0.74 (0.1) 
 
0.75 (0.1)     0.56 
0.74 (0.1) 
 











































1.83(0.16)   0.40 
1.85(0.15)   
 
1.85(0.18)   0.86 
1.84 (0.15)     
 
1.85(0.14)   0.82 
1.84 (0.16)     
 


































































































Arteriolar Angles   
Mean     P value Mean     P value Mean     P value Mean    P value Mean    P value Mean    P value 
Education level 
University 
Other profession qualification 









Oral hypoglycaemics only  






Alcohol intake (drinks/week) 
   Never 
   ≤7 
   7-15 
























































































































































































0.74          0.87 
0.74  
 







































































































1.85         0.5 













1.84        0.18 
1.87  
 
















































































































































0.74          0.51 
0.74  
 
0.74          0.94 
0.74  
 
0.75          0.56 
0.74  
 











































1.83        0.40 
1.85   
 
1.85        0.86 
1.84      
 
1.85        0.82 
1.84     
 













































5.4. Cognitive outcomes 
This section describes the distribution and the interrelationships of the 
cognitive test results. Also, it presents their associations with sociodemographic 
characteristics, vascular risk factors and cardiovascular disease. 
 
5.4.1. Distribution of cognitive test scores and correlations 
between different tests and depression 
As an early step in the statistical analysis of the ET2DS data, the central 
tendency and distribution of each of the cognitive test scores was determined in the 
1,044 subjects who had retinal data. Results from each of the cognitive tests and g 
were normally distributed, except for TMT which was normalised through a natural 
log (ln) transformation. As defined, the mean general cognitive factor score for the 
sample was 0.00 (SD±1.00) and valid data were available for 1,000 subjects. Mean 
scores for each of the individual tests are given in Table 31.  
 
All of the cognitive tests demonstrated statistically significant and at least 
moderate, positive correlations between each other apart from TMT, for which the 
correlations were negative. TMT was measured as time spent to complete the task 
and therefore a lower score or shorter time indicated better performance. The 
depression score showed generally weaker correlations with the cognitive test 





Table 31: Mean (SD), cognitive test scores and Pearson correlation coefficients between cognitive test and depression (N=1,044) 
 
 
Test                     Mean (SD)      N                        
      
                                 Correlation Coefficient 
                                                                                     
Mill-Hill  Verbal    Faces    Trail-Making   Logical    Matrix     Digit    Letter-Number  Depression 
Fluency            Test B (ln)   Memory   Reasoning  Symbol    Sequencing     Score
a 
 












































































































































































































































 The Hospital Depression Scale was logarithmically transformed on the n+1 scores (to avoid a logarithmic transformation of a score of zero)  










5.4.2. Associations of cognitive function with 
sociodemographic variables, vascular risk factors and 
cardiovascular disease  
Tables 32-35 show the associations of cognitive test scores and depression 
with sociodemographic characteristics, vascular risk factors and cardiovascular 
disease, both before and after adjustment for age and sex (for categorical variables, 
only age- and sex-adjusted associations are shown). All the cognitive tests and the 
general intelligence factor (g) were significantly associated with age, with increasing 
age associated with poorer performance. Neither the Mill-Hill Vocabulary Scale 
(MHVS) nor the depression scale was correlated with age. Mean scores for the 
MHVS and MR were significantly higher in men than in women whereas for Faces, 
LMT, DST and depression, mean scores were higher in women than in men. 
 
After adjustment for age and sex, lower mean ‗g‘ scores were significantly 
associated with longer duration of diabetes, higher waist to hip ratio, body mass 
index, and lifetime smoking (r ranged from -0.17 to -0.09, P<0.05), as well as with 
insulin treatment use (P=0.002), prevalent coronary heart disease (P<0.001) and 
cerebrovascular disease (P<0.001) (Tables 36-38). Higher mean ‗g‘ scores were 
associated with higher alcohol intake (r=0.15, P<0.001), HDL cholesterol level 
(r=0.10, P<0.01), higher education level (P<0.001) and higher social class (P<0.001). 
The individual tests contributing to the association between ‗g‘ and these risk factors 
differed for each factor. For example, the inverse association of ‗g‘ with duration of 
diabetes was mainly due to poorer individual test scores on VFT, Faces, DST, LNS (r 
ranged from -0.15 to -0.08, P<0.001) and TMTB (r=0.12, P<0.001); with waist to hip 
ratio, tests for VFT, Faces, MR, DST, LNS (r ranged from -0.15 to -0.09, P<0.01) 
and TMTB (r=0.16, P<0.001); and with cerebrovascular disease, tests for VFT, 
TMTB, MR, DST and LNS (all significant at P<0.05) (Table 33-35).  
 
In addition to individual tests contributing to the associations between ‗g‘ 
and risk factors, significant negative associations were found between VFT and 
HbA1c (r=-0.07, P<0.05), and MR and total/HDL cholesterol level (r=-0.06, P<0.05). 
Poorer individual test scores on TMTB (P=0.01), MR (P=0.003) and DST (P<0.001) 
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were associated with current smoking. Conversely, higher mean MR scores were 
associated with the presence of hypertension (P=0.005), possibly because of a high 
percentage of subjects on treatment for increased blood pressure.  
 
Lower mean MHVS was associated with higher waist to hip ratio, body 
mass index and lifetime smoking (r ranged from -0.15 to -0.08, P<0.01), as well as 
with prevalent coronary heart disease (P<0.001). Higher scores on MHVS were 
associated with higher alcohol intake (r=0.14, P<0.001) and HDL cholesterol (r=0.08, 
P<0.001), and with higher education and social class levels (P<0.001 for both). 
Higher depression levels were associated with longer duration of diabetes, higher 
HbA1c, waist to hip ratio, body mass index, lifetime smoking and total/HDL 
cholesterol ratio (r ranged from 0.09 to 0.20, P<0.01), as well as with current 
smoking (P<0.001) and all prevalent cardiovascular diseases (i.e. coronary artery 
disease, cerebrovascular disease and peripheral arterial disease) (P<0.001). Lower 
depression levels were associated with higher HDL cholesterol (r=-0.13, P<0.001) 
and higher education and social class levels (P<0.001).  
 
Neither systolic nor diastolic blood pressure was correlated with any of the 
cognitive measures or depression. There were no other significant associations 











Table 32: Pearson correlation coefficients between vascular risk factors, cognitive tests and depression 











                                  Verbal         Faces        Trail         Logical      Matrix        Digit      Letter-Number    g      Mill-Hill  Depression
a
   
Fluency                   Making (㏑)    Memory    Reasoning     Symbol      Sequencing                                       
Age (years) 
 










Pack-years smoking √ 
 
Average alcohol intake√ 
  (drinks/week) 
 
Total cholesterol (mmol/L) 
 
HDL cholesterol (mmol/L) 
 
Total/HDL cholesterol ratio 
 
Systolic blood pressure (mmHg) 
 































































































































































































































































0.002    -0.01 
 































0.03      0.002 
 
0.07*    -0.10 
 




-0.02     -0.03 
 
0.03      -0.05  
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Table 33: Age-sex adjusted partial correlation coefficients between vascular risk factors, cognitive tests and depression 






 Transformed variable was used; 
b 
For the age category, adjustments were 




                                  Verbal         Faces        Trail         Logical      Matrix        Digit      Letter-Number    g      Mill-Hill  Depression
a
   














Pack-years smoking √ 
 
Average alcohol intake√ 
  (drinks/week) 
 
Total cholesterol (mmol/L) 
 
HDL cholesterol (mmol/L) 
 
Total/HDL cholesterol ratio 
 
Systolic blood pressure (mmHg) 
 











































































































































































































































































-0.001    -0.005 
 











































-0.02     -0.03 
 
0.01      -0.03  
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Table 34: Age- and sex- adjusted mean (Standard Error) differences in cognitive test scores by sociodemographic characteristics and vascular risk factors  
 
                                   Mill-Hill                                                   Logical    Matrix                    Letter-Number    General 
                               Vocabulary Scale    Verbal Fluency   Faces     Trail Making (ln)   Memory   Reasoning   Digit Symbol     Sequencing      Factor (g)   Depression (log)  
                                                                                                                                  
                               n    Mean(SE)   P   Mean(SE)  P  Mean(SE)  P   Mean(SE)   P  Mean(SE)  P  Mean(SE)  P   Mean(SE)  P  Mean(SE)  P   Mean(SE)  P   Mean(SE)  P 
Gender 
  Male 




Other profession qualification 











Oral hypoglycaemics only  


























































































































































































































































































































































































Table 35: Age- and sex- adjusted mean (Standard Error) differences in cognitive test scores according to cardiovascular disease status 
 
                                   Mill-Hill                                                   Logical     Matrix                     Letter-Number  General 
                               Vocabulary Scale    Verbal Fluency   Faces     Trail Making (ln)   Memory    Reasoning    Digit Symbol    Sequencing    Factor (g)   Depression (log)  
                                                                                                                                  
                           n       Mean(SE)          Mean(SE)     Mean(SE)     Mean(SE)        Mean(SE)    Mean(SE)    Mean(SE)       Mean(SE)      Mean(SE)     Mean(SE)   
 
Coronary artery disease 



















































































































































































































































































































































MI: myocardial infarction; IC: intermittent claudication; CVD: cardiovascular disease; TIA: Transient Ischaemic Attack  
a
 No CVD: No MI, Angina, stroke, TIA or IC;  P 
values for difference between individual CVD group with the group free of any CVD (no CVD) or with the group free of specific CVD, which were significant at 
‡
≤ 0.001 level, 
†
≤ 0.01 level, and * < 0.05 level 
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5.5. Diabetic retinopathy and cognitive function 
This section describes the associations between diabetic retinopathy and 
cognitive function, measured as current cognitive ability and estimated lifetime 
cognitive decline. Univariate analysis for the cognitive ability and diabetic 
retinopathy associations is presented first, followed by the multivariate analysis for 
associations between estimated cognitive decline and diabetic retinopathy. Further, 
associations between any non-general factor cognitive elements (using the general 
factor-adjusted standardised residuals as outcome) and diabetic retinopathy are 
shown. Finally, sensitivity analyses by excluding subjects with cerebrovascular 
disease or severe cognitive impairment are performed to examine further the 
associations between cognitive decline and diabetic retinopathy. 
 
5.5.1. Associations of diabetic retinopathy with current 
cognitive ability 
Figure 32 presents crude mean cognitive test scores and depression scores in 
subjects with and without diabetic retinopathy. Subjects with diabetic retinopathy had 
significantly lower mean scores on ‗g‘ (P=0.03) and the Digit Symbol Test (P=0.001). 
Subjects with diabetic retinopathy also had poorer test scores for VFT, Faces and 
TMTB, but differences were not statistically significant. There was no significant 
difference in mean MHVS, LM, MR LNS or depression scores. When evaluated 
separately by sex (Table 36), the differences in g, DST and VFT scores were each 
found to be significant only in males (P=0.036, 0.005, and 0.02 respectively). In each 
case, men with diabetic retinopathy had decreased ability. 
 
When diabetic retinopathy was categorised into mild retinopathy and moderate to 
severe diabetic retinopathy, there was a significant trend across worsening severity of 
diabetic retinopathy for ‗g‘ (P=0.005), Faces (P=0.02), TMTB (P=0.005) and DST 
(P<0.001), with the moderate to severe diabetic retinopathy group having poorest 
cognitive test performance (Figure 33). The trend also approached statistical 
significance for the VFT (P=0.05). When evaluated separately by sex (Table 36), a 
significant trend was found only in men for ‗g‘ (P=0.008), VFT (P=0.008) and 
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TMTB (P=0.02) scores, whereas the trend for DST remained significant in both men 
and women. A trend in mean Faces in males also approached statistical significance 
(P=0.08). 
 
After adjustment for age and sex, the associations of diabetic retinopathy 
with current cognitive ability were essentially unchanged except for the VFT, in 
which a trend with increasing severity of diabetic retinopathy became significant 
(P=0.04) (Table 37).
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Figure 32: Crude mean (±2SE) of cognitive test performances according to presence of diabetic retinopathy 
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Figure 33: Crude Mean (±2SE) Cognitive Test performances by severity of diabetic retinopathy. 
        
              P for trend=0.005                                    P for trend=0.05                           P for trend=0.02     
     











Table 36: Crude mean (95%CI) of cognitive test scores by diabetic retinopathy for men and women separately 
 
 
      Presence of Diabetic Retinopathy (DR)                   Severity  of  Diabetic Retinopathy (DR) 
 
DR Absent       DR Present    P value                  
                                                             P value 




























































































































































































                
30.3(29.4, 31.2) 
 












































































































-0.12(-0.28, 0.04)  
 
0.04(-0.15, 0.23) 
-0.53(-0.87, -0.18)  
 












           Presence of Diabetic Retinopathy (DR) 
          
                Severity of Diabetic Retinopathy (DR) 
DR Absent          DR Present           P 
(N=705)              (N=339)           value 
                                  Moderate-Severe           
No DR            Mild DR              DR           P value 
(N=705)            (N=292)              (N=47)        for trend 
Mill-Hill Test 
 




Trail Making Test (ln) 
 
Logical Memory  
 
Matrix Reasoning  
 
Digit Symbol  
 
Letter-Number Sequencing  
 
General factor score 
 




































































































































































P≤0.01, *P<0.05 ANCOVA test of pair-wise difference in a given mean from the mean of the group without diabetic retinopathy  
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5.5.2. Associations of diabetic retinopathy with estimated 
lifetime cognitive decline 
In a regression model containing age and sex, further adjustment for peak 
prior cognitive ability as estimated by performance on the Mill-Hill Vocabulary Scale 
(MHVS) allowed for the investigation of the relationship between diabetic 
retinopathy and the imputed decline from best-ever level of cognitive function, not 
just cognitive function at one time point (i.e. estimated lifetime cognitive decline). 
Table 38 shows the association between severity of diabetic retinopathy and 
estimated lifetime cognitive decline after adjustment for age, sex and the MHVS.  
 
For five of the cognitive measures, including ‗g‘, there was a statistically 
significant trend across diabetic retinopathy severity categories, with poorer 
performance in subjects with diabetic retinopathy, suggesting that severity of diabetic 
retinopathy was associated with estimated lifetime cognitive decline. The general 
intelligence score was significantly lower in the group with moderate-severe diabetic 
retinopathy (mean -0.36, 95%CI -0.60, -0.13) compared with the group without 
diabetic retinopathy (mean 0.05, 95%CI -0.01, 0.10, P≤0.01), with an intermediate 
score for the mild diabetic retinopathy group (mean -0.05, 95%CI -0.14, 0.04) 
(one-way ANOVA, P for linear trend=0.001).This trend in g across worsening 
diabetic retinopathy severity was mainly due to similar trends in the individual 
Verbal Fluency (P=0.022), Faces (P=0.024), Trail Making Test B (P=0.002) and 
Digit Symbol (P<0.001) tests. In particular, subjects with moderate-severe diabetic 
retinopathy had an adjusted mean score on the Digit Symbol test which was 9.2 
points (0.7 SD)(P<0.01) (Cohen, 1988) lower than in subjects without retinopathy 
(Table 38) (mean scores 41.3, 95%CI 37.5, 45.0 and 50.5, 95%CI 49.5, 51.4 
respectively).  
 
There was no statistically significant trend with increasing severity of 
diabetic retinopathy on adjusted mean scores for the Logical Memory, Matrix 
Reasoning and Letter-Number Sequencing tests. Nor was there any evidence of 
gender by diabetic retinopathy interaction for these three individual cognitive tests. 
Therefore, no further analyses were carried out on these data. 
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Multivariate associations in the total sample 
In addition to age, sex and peak prior cognitive ability, a series of multiple 
linear regression analyses were carried out to determine the importance of severity of 
diabetic retinopathy as an independent explanatory factor of cognitive test 
performance (Table 38-39). Education level was entered first into the model since it 
is considered as an additional marker of prior cognitive ability (together with 
vocabulary tasks, such as the MHVS). Cardiovascular risk factors and the presence 
of cardiovascular disease were then added in the second and third steps, since these 
vascular variables were either associated with retinal parameters in univariate 
associations or with both retinal variables and cognitive test performance in previous 
literature. Depression scores were entered in the fourth step since this mood variable 
was associated with both cognitive dysfunction and cerebral microvascular disease. 
In the final step, diabetes-related factors including HbA1c and duration of diabetes 
were added to determine whether the retinopathy-cognition association was 
independent of hyperglycaemia, which is considered as a causal factor in the 
development of diabetic retinopathy.  
 
For all five cognitive measures, adjustment for education level in addition to 
age, sex and the MHVS, did not greatly alter the associations between diabetic 
retinopathy and estimated cognitive change. The addition of the five cardiovascular 
risk factors (smoking status, alcohol intake, waist to hip ratio, systolic blood pressure 
and total cholesterol level) in the second step led to a general attenuation in the 
associations, with the regression coefficients for the Verbal Fluency and Faces tests 
becoming non-significant. Additional adjustment for the presence of cardiovascular 
disease (coronary heart disease and cerebrovascular disease) resulted in further 
attenuation of the associations, but the associations of diabetic retinopathy with ‗g‘, 
Trail Making and Digit Symbol Test remained statistically significant. Including the 
depression scores made very little difference to the associations. Finally, following 
the addition of HbA1c and duration of diabetes to the models, only the Digit Symbol 




When the presence of diabetic retinopathy (absent vs. present) was fitted in 
the models instead of severity of diabetic retinopathy, the results were almost the 
same (Table 40). The Digit Symbol Test remained statistically associated with 
diabetic retinopathy but the association was less significant (P changed from <0.001 
to <0.05). 
 
Table 41 presents a summary of the final regression models. In the 
aforementioned final models, the significance of interaction terms between all main 
effects (explanatory variables) was tested. There was no evidence of an interaction 
between these factors in relation to cognitive performance on the Digit Symbol, 
Faces, and Trail-Making tests, and therefore none of them were included in the final 
models. However, both ‗g‘ and the Verbal Fluency test had a significant interaction 
between sex and severity of diabetic retinopathy (P=0.006 for g, P=0.004 for VFT), 
which accounted for 0.8% to 0.9% of variation in the mean scores. This indicated 
that the association (magnitude or direction) between diabetic retinopathy and 
estimated lifetime cognitive decline in g and the VFT may differ for males and 
females in the population sample. Therefore the results for g and the VFT were 
shown separately for men and women. The final linear regression models are 
presented in a complete form in the attached Appendix I (Tables i1 to i5). 
 
For the Digit Symbol test, the following contributed independently to the 
variance in the outcome in the final model: severity of diabetic retinopathy 
(B=-2.44/standardised beta=-0.09, P<0.01), age (B=-0.72/standardised beta=-0.21, 
P<0.001), male sex  (B=-4.22/standardised beta=-0.14, P<0.001), MHVS 
(B=0.94/standardised beta=0.32, P<0.001), smoking status (B=-2.62/standardised 
beta=-0.09, P<0.01), waist to hip ratio (B=-1.31/standardised beta=-0.07, P<0.05), 
presence of stroke and/or TIA (B=-3.19/standardised beta=-0.06, P<0.05), depression 
(B=-6.19/standardised beta=-0.11, P<0.001) and duration of diabetes 
(B=-0.92/standardised beta=-0.06, P<0.05) (Table 41). Severity of diabetic 
retinopathy explained close to 1% of the variance in DST scores over and above the 
effect of all other factors and this final model accounted for over 26% of the total 
variance. When lifetime smoking was fitted in the model instead of smoking status, 
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the results were almost the same and the association between diabetic retinopathy 
and the DST remained significant (B decreased from -2.44 to -2.58, P<0.05). The 
adjusted mean (95%CI) DST scores in the final model according to severity of 












































Table 38: Mean differences (95%CI) in cognitive test scores by severity of diabetic 
retinopathy, adjusted for age, gender and peak prior cognitive ability (MHVS) 
Cognitive Measure                No Diabetic          Mild Diabetic        Moderate-severe      P for trend 
                                Retinopathy           Retinopathy        Diabetic Retinopathy 
(n=705)              (n=339)              (n=47) 
 




Trail Making Test (ln) 
 
Logical Memory test 
 
Matrix Reasoning test 
 
Digit Symbol Test 
 
Letter-Number Sequencing test 
 











































































P≤0.01, *P<0.05 ANCOVA test of pair-wise difference in a given mean from the 














































Figure 34: Multivariate adjusted mean (95%CI) Digit Symbol test scores according 
to severity of diabetic retinopathy 
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Table 39: Multivariate associations between severity of diabetic retinopathy and late-life cognition, and estimated lifetime cognitive decline 
 
   
Severity of Diabetic retinopathy 
 
General Factor (g)     Verbal Fluency         Faces          Trail Making Test B      Digit Symbol 
                      Unstandardised  Beta Coefficient (Standard Error) (95%CI) 
 
Model I 

































-1.45 (0.63) * 
(-2.69, -0.22) 
 













Age, sex, MHVS and all other variables adjusted 
Step 1 







































(-2.51, 0.04)  
 
-0.70 (0.42) 












   + Cardiovascular disease 
 

















   + Depression 
 













































Table 40: Multivariate associations between presence of diabetic retinopathy and late-life cognition, and estimated lifetime cognitive decline 
 
   
Severity of Diabetic retinopathy 
 
General Factor (g)     Verbal Fluency         Faces          Trail Making Test B      Digit Symbol 
                          Unstandardised  Beta Coefficient (Standard Error) 
 
Model I 

















































Age, sex, MHVS and all other variables adjusted 
Step 1 






















































   + Cardiovascular disease 
 
















   + Depression 
 















































Table 41: Summary of multiple linear regression analysis for severity of diabetic retinopathy with the general intelligence factor and individual 
cognitive function tests as the dependent variables (Standardised Beta regression coefficients and standard errors) 
    
Variables in final model 
‘g’  
 
Verbal Fluency   Faces   
 
Trail Making Test B  
 
Digit Symbol Test  
B (SE)           η
2 
B (SE)        η
2 
B(SE)         η
2
 B(SE)       η
2
 B (SE)        η
2
                                                     
Diabetic retinopathy  









































































































































   
0.05 (0.36) 
   
0.003 (0.02) 































    
0.002 (0.52) 
   
0.03 (0.03) 







Waist to hip ratio  
  




























   
0.02 (0.02) 
   
0.02 (0.001) 






























    
-0.01 (0.55) 
   
-0.01 (0.03) 













    
0.001 (0.86) 
   

















    
-0.05 (0.93) 


















    
0.02 (0.23) 









√ Duration of diabetes 
 




-0.07 (0.41) * 
 
0.004 




















P≤0.01, *P<0.05; Partial eta-squared (η
2
) for diabetic retinopathy and variables significantly associated with cognitive outcome.
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Multivariate associations for General Factor Scores and Verbal 
Fluency in men and women 
Tables 42 to 45 show the association between severity of diabetic 
retinopathy and scores for ‗g‘ and the VFT in men and women separately. A 
comparison of age adjusted mean ‗g‘ scores in men revealed a significant trend 
across worsening severity of diabetic retinopathy (one-way ANOVA, P=0.003). 
Further adjustment for peak prior ability (MHVS) led to a slight increase in the 
observed difference. ‗g‘ was significantly lower in the group with moderate-severe 
diabetic retinopathy (mean -0.61, 95%CI -0.91, -0.32; P<0.001) compared with the 
group without diabetic retinopathy (mean 0.04, 95%CI -0.05, 0.12), with an 
intermediate score for mild diabetic retinopathy group (mean -0.15, 95%CI 0.26, 
-0.03). Also in men, subjects with moderate-severe diabetic retinopathy had an age- 
adjusted mean verbal fluency score which, on average, was 6.5 points (P<0.05) lower 
than in subjects without diabetic retinopathy (Table 42). Following adjustment for 
peak prior ability, difference in test scores across worsening diabetic retinopathy 
severity categories became more obvious and P changed from 0.006 to <0.001. Mean 
VFT scores fell from 38.4 (95%CI 37.1, 39.6) to 31.7 (95%CI 27.2, 36.1) between 
the absent and moderate-severe diabetic retinopathy groups, with an intermediate 
score for the mild diabetic retinopathy group (mean 35.5, 95%CI 33.7, 37.3).  
 
No statistical significant difference was found in age adjusted mean scores 
for ‗g‘ and VFT between retinopathy absent and present subjects for women. Neither 
was there a linear trend with increasing severity of diabetic retinopathy. The 
difference was more attenuated and even reversed (subjects with mild or 
moderate-severe diabetic retinopathy had increasingly higher mean VFT scores) after 
further adjustment for the MHVS, and remained non-significant. Further multivariate 
analyses did not show any significant associations between retinopathy and ‗g‘ and 
VFT in women and data were not shown in tables. 
 
For the general intelligence factor and the Verbal Fluency test in men, 
adjustment for education level in addition to age and MHVS did not greatly alter the 
diabetic retinopathy-estimated cognitive change associations (Table 43). 
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Cumulatively, the inclusion of the five cardiovascular risk factors, the presence of 
coronary heart disease and cerebrovascular disease and depression in the subsequent 
steps led to a gradual and slight attenuation of the associations which, however, 
remained statistically significant. Finally, the addition of HbA1c and duration of 
diabetes to the models led to a further decrease in the associations with a 
considerable decline in the strength of the association for the Verbal Fluency Test (B 
increased from -3.10 to -1.99). However, both associations remained significant.  
  
When the presence of diabetic retinopathy (absent vs. present) was fitted in 
the models instead of severity of diabetic retinopathy, the results became 
non-significant after further adjustment for HbA1c and duration of diabetes (Table 
44). 
 
Table 45 presents a summary of the final regression models. Further models 
were fitted including interactions between all main effects (explanatory variables), 
but none of them reached significance levels for inclusion in the final models. 
Severity of diabetic retinopathy remained independently associated with the outcome 
variable (B=-0.17/standardised beta=-0.10, P<0.05), accounting for about 1% of the 
variance in general cognitive factor over and above the effect of other factors, along 
with age (B=-0.06/standardised beta=-0.24, P<0.001), the MHVS 
(B=0.09/standardised B=0.46, P<0.001), education (B=0.14/standardised beta=0.11, 
P<0.01), alcohol intake (B=0.05/standardised beta=0.08, P<0.05), the presence of 
stroke and/or TIA (B=-0.31/standardised beta=-0.10, P<0.01) and depression 
(B=-0.36/standardised beta=-0.10, P<0.01). Taken together, approximately 43% 
(based on adjusted R
2
) of the variance in general cognitive factor score was 
explained by the final regression model. Similarly in the final model, the following 
factors independently contributed to the variance in VFT scores: diabetic retinopathy 
(B=-1.99/standardised beta=-0.09, P<0.05), MHVS (B=0.88/standardised beta=0.36, 
P<0.001), alcohol intake (B=0.71/standardised beta=0.10, P<0.05) and systolic blood 
pressure (B=-0.09/standardised beta=-0.11, P<0.01). Diabetic retinopathy explained 
approximately 1% of variance in VFT over and above the effect of other factors 
whereas just over 20% of the variance was explained by the model as a whole.  
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The adjusted mean (95%CI) general factor and VFT scores of men and 
women (calculated for women) in the final models by severity of diabetic retinopathy 
are shown graphically on Figures 35 and 36. The final linear regression models in 







Table 42: Mean differences (95%CI) in ‗g‘ and the Verbal Fluency test (VFT) scores 
by severity of diabetic retinopathy for men and women separately, adjusted for age 
and peak prior cognitive ability 
             No Diabetic          Mild Diabetic        Moderate-severe      P for trend 
                             Retinopathy           Retinopathy        Diabetic Retinopathy        
Men 
General factor score 
Age Adjusted 
 
Age & MHVS Adjusted 
 




Age & MHVS Adjusted  
 
Women 
General factor score 
Age Adjusted 
 
Age & MHVS Adjusted 
 





























































                     
 
31.5(26.6, 36.4) * 
 







































P≤0.01, *P<0.05 ANCOVA test of pair-wise difference in a given mean from the 











Table 43: Multivariate associations between severity of diabetic retinopathy and 
late-life cognition, and estimated lifetime cognitive decline for ‗g‘ and Verbal 
Fluency test in men 
 
Severity of Diabetic retinopathy 
   General Factor (g)             Verbal Fluency  
Unstandardised  Beta Coefficient (Standard Error) (95%CI) 

























Age, MHVS and all other variables adjusted 
Step 1 





















































































Table 44: Multivariate associations between presence of diabetic retinopathy and 
late-life cognition, and estimated lifetime cognitive decline for ‗g‘ and Verbal 
Fluency test (VFT) in men 
 
 Presence of Diabetic retinopathy 
   General Factor (g)             Verbal Fluency  
Unstandardised  Beta Coefficient (Standard Error) 
Model I    
Age adjusted 
 
-0.19 (0.09) * 
(-0.36, -0.02)  
 
-2.65 (1.16) * 
(-4.94, -0.37)  
Model II 











Age, MHVS and all other variables adjusted 
Step 1 














   + Vascular risk factors 
 
-0.22 (0.07) †  
 (-0.36, -0.08) 
 
-3.42 (1.08)
 †  
(-5.54, -1.30)  
Step 3 







(-5.33, -1.08)  
Step 4 














































Table 45: Summary of multiple linear regression analysis for severity of diabetic 
retinopathy with the general intelligence factor and Verbal Fluency test (VFT) as the 
dependent variables in men (Standardised Beta regression coefficients and standard 
errors) 
         ‘g’       Verbal Fluency 
B (SE)          η
2






























































Smoking status (smoker vs. non-smoker) 
 
0.02 (0.08) 




Waist to hip ratio 
 
-0.04 (0.06) 




Systolic blood pressure 
 
-0.03 (0.002) 














MI and/or Angina 
 
-0.01 (0.08) 

































√ Duration of diabetes 
 
-0.06 (0.04) 














P≤0.01, *P<0.05; Partial eta-squared (η
2
) for diabetic retinopathy and variables 























































Figure 35: Multivariate adjusted mean (95%CI) general factor scores of men and 



















































Figure 36: Multivariate adjusted mean (95%CI) Verbal Fluency test scores of men 
and women according to severity of diabetic retinopathy  
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5.5.3. General-factor adjusted residuals of individual cognitive 
tests by diabetic retinopathy status  
Given the high loading of each of the tests on the general factor, further 
outcome variables were computed in order to examine any non-general factor 
cognitive elements associated with diabetic retinopathy. This was carried out by 
using multiple linear regressions whereby each of the cognitive tests (VFT, Faces, 
TMTB and DST) were regressed on the general cognitive ability factor each at a time. 
The new outcome variables in the current analysis comprised the general 
factor-adjusted standardised residuals for each cognitive test. 
 
As shown in Table 46, in age and sex adjusted models, severity of diabetic 
retinopathy was significantly associated with the Digit Symbol test residual scores 
only but not with others. Further adjustment for peak prior ability did not have any 
impact on the relationships between diabetic retinopathy and the outcome variables. 
Addtional adjustment for other potential confounding factors changed the 
associations only very slightly. In none of the models did diabetic retinopathy exert 
independent effects on the outcomes except the DST residuals. In the final model 
(Table 47), diabetic retinopathy (standardised beta=-0.11, P<0.01) remained a 
significant independent predictor of the DST residual scores, explaining about 1% of 
variance in the dependent variable over and above the effect of other factors. The 
model as a whole accounted for approximately 6% of the total variance in the DST 
residuals. The final linear regression models are presented in a complete form in the 














Table 46: Multivariate associations between severity of diabetic retinopathy and residuals of individual cognitive test scores regressed on ‗g‘  
 
   
Severity of Diabetic retinopathy 
 
Verbal Fluency (men)        Faces          Trail Making Test B        Digit Symbol 
                         Standardised  Beta Coefficient (Standard Error) 
 
Model I 
Age and sex adjusted 
 
 













Age, sex and MHVS adjusted 
 










Age, sex, MHVS and all other variables adjusted 
Step 1 




















   + Vascular risk factors 
 










   + Cardiovascular disease 
 










   + Depression 
 





































Table 47: Summary of multiple linear regression analysis for severity of diabetic retinopathy with residuals of individual cognitive test scores 
regressed on ‗g‘ as the dependent variables (Standardised Beta regression coefficients and standard errors) 
    
Variables in final model 
 
 
Verbal Fluency (men)  Faces   
 
Trail Making Test B  
 
Digit Symbol Test  
B (SE)          η
2 
B(SE)           η
2
 B(SE)       η
2
 B (SE)         η
2
                                                   
Diabetic retinopathy  

































































































Education (increasing level) 
 
-0.001 (0.07) 
    
0.01 (0.05) 

































(smoker vs. non-smoker) 
 
0.06 (0.11) 
    
0.01 (0.07) 
   
0.03 (0.07) 

































   
0.03 (0.002) 
   
-0.001 
(0.002) 





















MI and/or Angina  
 
0.11 (0.10) * 
 
0.012 
   
-0.02 (0.08) 
   
-0.01 (0.07) 




Stroke and/or TIA  
 
-0.01 (0.15) 
    
0.04 (0.12) 
   
0.03 (0.12)  
   
-0.02 (0.12)  
 
 
㏒ Depression  
 
0.03 (0.19) 
    
0.01 (0.13) 













    
0.01 (0.13) 









√ Duration of diabetes 
 
-0.04 (0.05)  
 
 





0.01 (0.04)  
   








P≤0.01, *P<0.05; Partial eta-squared (η
2
) for diabetic retinopathy and variables significantly associated with cognitive outcome. 
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5.5.4. Diabetic retinopathy and cognitive impairment 
A binary variable indicating an impaired score on each of the four cognitive 
tests as well as the general intelligence factor was created. The proportions of 
impaired test scores are presented in Table 48.  
 
 
Table 48: Proportions of impaired test scores on four cognitive tests and the general 
intelligence factor (N=1,044) 
                                                      Proportion of Individuals 
Cognitive Test                Cutoff value     n           with impaired score 
 
Verbal Fluency  
Faces  
Trail Making (ln) 
Digit Symbol 




























 In men, n=40 (7.5%); 
b
 In men, n=34 (6.7%) 
 
 
In univariate analyses to determine the association between the presence of 
diabetic retinopathy and an impaired score on the four cognitive tests and the general 
cognitive ability factor (Table 49), odds ratios above the value of 1 were found for all 
cognitive measures. However, only for the Trail Making and the Digit Symbol tests, 
confidence intervals did not include the null value of one and were thus significant. 
Further adjustment for age and sex did not greatly alter the calculated odds ratios. 
The addition of the Mill-Hill Vocabulary Scale into the logistic regression models led 
to a slight increase in the odds ratios, with the associations for Trail Making and 
Digit Symbol tests becoming more significant (P values from 0.002 to 0.001 or from 
0.001 to <0.001). The adjusted odds ratios for other cognitive tests remained 
non-significant. Results in the final models indicated that the odds of an ‗impaired‘ 
score on the Trail Making test for individuals with diabetic retinopathy was 2.32 
(95%CI 1.39, 3.90) times that of individuals without diabetic retinopathy. Similarly, 
diabetic retinopathy was also associated with an increased risk of impairment on the 
Digit Symbol test (odds ratio 2.71, 95%CI
 
1.57, 4.70) (Table 49). The odds ratios 






Table 49: Unadjusted and adjusted odds ratios (95%CI) for cognitive impairment in 




Age & Sex            Age, sex & Mill-Hill       








































































































Figure 37: Odds ratios and 95%CIs for cognitive impairment in participants with 






5.5.5. Sensitivity analyses  
Given that retinal capillary microaneurysm is usually the first visible sign of 
diabetic retinopathy, the presence of other characteristics (e.g. hard exudates, cotton 
wool spots) in the absence of microaneurysms was graded as ‗possible diabetic 
retinopathy‘ (grading level 14 or 15). These isolated lesions could be principally 
caused by other pathphysiological process rather than diabetes itself, such as 
hypertension. When the analyses were repeated on a subgroup of 983 subjects 
(excluding subjects having possible diabetic retinopathy), the associations between 
severity of diabetic retinopathy and estimated cognitive decline were essentially 
unchanged after adjustment for age, sex and the MHVS (Table 50). After further 
adjustment for education level, vascular risk factors, cardiovascular disease and 
depression, diabetic retinopathy remained significantly associated with poorer 
performance on the Digit Symbol test (P<0.001) and in males, poorer scores for g 
(P<0.01) and Verbal Fluency test (P<0.001) (Table 50). However, the observed 
association between diabetic retinopathy and Trail Making Test became borderline 
non-significant (P for trend=0.054), indicating that this association was affected by 
subjects with ‗possible diabetic retinopathy‘ to some extent. The associations for g, 
VFT and DST were also independent of glycaemic control (HbA1c) and duration of 
diabetes.  
 
In diabetic individuals, a history of ischemic stroke is commonly associated 
cerebral microvascular disease (Cheung et al., 2007c). When the ET2DS population 
was limited to 954 subjects without stroke or TIA, the associations between diabetic 
retinopathy and cognitive decline were little changed (results adjusted for age, sex, 
the MHVS and other risk factors shown in Table 51). Diabetic retinopathy severity 
was significantly associated with worse performance on the Digit Symbol (P<0.001) 
and Trail Making (P<0.01) tests and in males, poorer scores for the general cognitive 
factor (P<0.001) and Verbal Fluency test (p<0.001). These associations for g, VFT 
and DST were independent of glycaemic control (HbA1c) and duration of diabetes. 
 
When the analysis was limited to the 1,015 subjects with an MMSE 
scores≥24 (to reduce the probability that subjects with dementia were included), 
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similar results were found and the effect of diabetic retinopathy on estimated lifetime 
cognitive decline was little changed in multivariate adjusted analyses (Table 52).
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Table 50: Multivariate associations between severity of diabetic retinopathy and late-life cognition, and estimated lifetime cognitive decline 
(subjects with possible diabetic retinopathy were excluded) (N=983) 
 
   
Severity of Diabetic retinopathy 
 
General Factor (g)     Verbal Fluency       Faces          Trail Making Test B      Digit Symbol 
   (males)               (males) 
                          Unstandardised  Beta Coefficient (Standard Error) 
 
Model I 













































Age, sex, MHVS and all other variables adjusted 
Step 1 























































































   + HbA1c and duration of diabetes  
 


























Table 51: Multivariate associations between severity of diabetic retinopathy and late-life cognition, and estimated lifetime cognitive decline in 
subjects free of stroke or TIA (N=954) 
 
   
Severity of Diabetic retinopathy 
 
General Factor (g)     Verbal Fluency       Faces          Trail Making Test B      Digit Symbol 
   (males)               (males) 
                          Unstandardised  Beta Coefficient (Standard Error) 
 
Model I 













































Age, sex, MHVS and all other variables adjusted 
Step 1 



























































































































Table 52: Multivariate associations between severity of diabetic retinopathy and late-life cognition, and estimated lifetime cognitive decline 
(N=1,015, subjects with MMSE <24 were excluded) 
 
   
Severity of Diabetic retinopathy 
 
General Factor (g)     Verbal Fluency       Faces          Trail Making Test B      Digit Symbol 
   (males)               (males) 
                          Unstandardised  Beta Coefficient (Standard Error) 
 
Model I 













































Age, sex, MHVS and all other variables adjusted 
Step 1 

























































































   + HbA1c and duration of diabetes  
 
























5.6. Retinal vascular network geometry and cognitive 
function 
This section describes the associations between the parameters of retinal 
vascular network geometry and cognitive function, measured as current cognitive 
ability and estimated lifetime cognitive decline. Univariate relationships between the 
quantitative retinal vascular parameters and cognitive ability are presented first, 
followed by the multivariate analyses for associations between these parameters and 
estimated cognitive decline. Finally, sensitivity analyses excluding subjects with 
severe proliferative diabetic retinopathy or severe cognitive impairment are 
performed to explore further associations between estimated cognitive decline and 
retinal parameters. 
 
5.6.1. Associations of quantitative retinal vascular parameters 
with current cognitive ability 
Pearson correlation coefficients were calculated for retinal vascular 
parameters and cognitive function variables (Table 53 and 54).  
 
Higher arteriolar diameters (CRAE) were significantly associated with 
lower MHVS (r=-0.09, P<0.01) and Logical Memory (r=-0.11, P<0.001) scores and 
with higher depression scores (r=0.07, P<0.05). Increased venular diameters (CRVE) 
were only associated with lower scores for Logical Memory (r=-0.07, P<0.05). This 
implied that the wider retinal vessel width (an increase either in CRVE or CRAE) 
was significantly related to a worse performance on logical memory test. Raised 
deviation levels on suboptimal BA were associated with lower scores for MHVS 
(r=-0.11, P<0.05) and increased arteriolar angles were associated with lower scores 
for the Verbal Fluency Test (r=-0.09, P<0.05).  
 
When the correlations were adjusted for both age and sex, the partial 
correlation coefficients (rs) remained significant between the CRAE, CRVE and 
logical memory test, and arteriolar angle and VFT. There were no other significant 




5.6.2 Associations of quantitative retinal vascular parameters 
with estimated lifetime cognitive decline 
After further adjustment for MHVS, the partial correlation coefficients 
declined and only the higher CRAE remained significantly associated with lower 
scores on logical memory (r=-0.09, P<0.01) (Table 53 and 54). When evaluated 
separately by sex (Table 55 and 56), significant negative correlations were found 
between Logical Memory and CRAE (r=-0.17, P<0.001) and CRVE (r=-0.13, P<0.01) 
in men after adjusting for age and MHVS score. Conversely, significant positive 
correlations emerged between the Faces test and CRAE (r=0.09, P<0.05) and CRVE 
(r=0.13, P<0.01) in women after adjustment for both age and MHVS. No other 
significant associations in either men or women were demonstrated. As a 
consequence, further multivariate analyses (a series of multiple linear regression 
analyses) were only carried out on the associations of CRAE and CRVE with Logical 
Memory test in men and Faces test in women but not on other data. 
 
When further adjusted for education, vascular risk factors, cardiovascular 
disease and depression, both increased retinal arteriolar and venular diameters 
(CRAE and CRVE) remained significantly associated with poorer performance on 
the Logical Memory in men (P<0.01) (Table 57 and 58). In women, increased CRVE 
continued to be associated with better performance on Faces (P<0.01) whereas the 
association between CRAE and Faces became non-significant (Table 59 and 60). The 
addition of duration of diabetes and HbA1c did not change the associations greatly. 
 
Lastly, whether CRAE and CRVE contributed separately to variance in 
performance on Logical Memory in men or Faces in women, was examined by 
adding the fellow vessel calibre in the multivariate models as a covariable. This was 
done because the retinal arteriolar and venular width were highly correlated (r=0.61, 
P<0.01) and had a similar profile of associations with cognitive test scores. Also 
findings from previous studies have demonstrated the main determinant of retinal 
arteriolar width is in fact venular width, presumably due to their shared genetic and 
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environmental factors as well as magnification artifacts (Hubbard et al., 1999; Liew 
et al. 2007). As shown in Tables 57 to 60, Model IV adjusted for variables in model 
III as well as the fellow vessel calibre (i.e. addition of CRAE in models for CRVE, 
and CRVE in models for CRAE). In this model, increased CRAE was independently 
associated with poorer Logical Memory scores (P<0.05) in men but increased CRVE 
was no long associated with LM. Similarly, only increased CRVE contributed 
significantly to higher Faces scores in women whereas the positive association with 
CRAE became reversed in direction and non-significant. The change in association 
between CRVE and LM was unlikely to be due to collinearity between these two 
correlated variables as the variance inflation factors for both terms were low 
(approximately 1.7).  
 
As shown in Table 61, for the Logical Memory test, in this final model 
where both vessel calibres were simultaneously entered, CRAE 
(B=-0.04/standardised beta=-0.12, P<0.05) explained about 1% of the variance in 
LM scores in men over and above the effect of all other factors, along with the 
MHVS (B=0.44/standardised beta=0.29, P<0.001) which also exerted independent 
effects on LM scores. The model as a whole accounted for 14.1% of the variance in 
the outcome. For the Faces test (Table 62), CRVE (B=0.03/standardised beta=0.12, 
P<0.05) explained about 1% of the variance in Faces scores in women over and 
above the effect of all other factors and as a whole, the model accounted for 15.3% of 
the total variance. 
 
Table 61 and 62 present a summary of the final regression models. Using the final 
models, the significance of interaction terms between all explanatory variables were 
tested. None of these reached significance levels for inclusion in the models. The 
final linear regression models in men and women are presented in a complete form in 




Table 53: Pearson correlation coefficients of retinal width parameters with cognitive test variables and depression (N=980) 
 
Depression    MHVS    Verbal       Faces       Trail         Logical      Matrix        Digit  Letter-Number   g         
Fluency                 Making (㏑)   Memory    Reasoning      Symbol  Sequencing         
CRAE 
  Unadjusted 
  Adjusted for age and sex 
  Adjusted for age, sex and MHVS 
 
CRVE 
  Unadjusted 
  Adjusted for age and sex 
  Adjusted for age, sex and MHVS 
 
AVR 
  Unadjusted 
  Adjusted for age and sex 




















































































































































































Table 54: Pearson correlation coefficients of retinal bifurcation parameters with cognitive test variables and depression (N=444) 
Depression   MHVS      Verbal     Faces       Trail      Logical      Matrix        Digit      Letter-Number   g         
Fluency             Making (㏑)  Memory    Reasoning     Symbol      Sequencing          
Arteriolar bifurcation angle 
  Unadjusted 
  Adjusted for age and sex 
  Adjusted for age, sex and MHVS 
 
Arteriolar branching coefficient 
  Unadjusted 
  Adjusted for age and sex 
  Adjusted for age, sex and MHVS 
 
Suboptimal bifurcation angle (Ln) 
  Unadjusted 
  Adjusted for age and sex 









































































































































































Table 55: Pearson correlation coefficients of retinal width parameters with cognitive test variables and depression in men and women separately 
Depression    MHVS    Verbal       Faces        Trail         Logical      Matrix      Digit    Letter-Number   g         
Fluency                 Making (㏑)   Memory    Reasoning    Symbol    Sequencing         
Men 
CRAE 
  Unadjusted 
  Adjusted for age  
  Adjusted for age and MHVS 
CRVE 
  Unadjusted 
  Adjusted for age  
  Adjusted for age and MHVS 
AVR 
  Unadjusted 
  Adjusted for age  




  Unadjusted                          
  Adjusted for age 
  Adjusted for age and MHVS 
CRVE 
  Unadjusted 
  Adjusted for age  
  Adjusted for age and MHVS 
AVR 
  Unadjusted 
  Adjusted for age  






















































































































































































































































































































Table 56: Pearson correlation coefficients of retinal bifurcation parameters with cognitive test variables and depression in men and women 
separately 
Depression   MHVS      Verbal     Faces       Trail      Logical      Matrix        Digit      Letter-Number   g         
Fluency             Making (㏑)  Memory    Reasoning     Symbol      Sequencing          
Men 
Arteriolar bifurcation angle 
  Unadjusted 
  Adjusted for age and sex 
  Adjusted for age, sex and MHVS 
Arteriolar branching coefficient 
  Unadjusted 
  Adjusted for age and sex 
  Adjusted for age, sex and MHVS 
Suboptimal bifurcation angle (Ln) 
  Unadjusted 
  Adjusted for age and sex 
  Adjusted for age, sex and MHVS 
 
Women 
Arteriolar bifurcation angle 
  Unadjusted 
  Adjusted for age and sex 
  Adjusted for age, sex and MHVS 
Arteriolar branching coefficient 
  Unadjusted 
  Adjusted for age and sex 
  Adjusted for age, sex and MHVS 
Suboptimal bifurcation angle (Ln) 
  Unadjusted 
  Adjusted for age and sex 
































































































































































































































































































Table 57: Multivariate associations between retinal arteriolar width (CRAE) and 




             Logical Memory 
Unstandardised  Beta Coefficient (Standard Error) 




 ‡  
  
Model II 







Age, MHVS and all other variables adjusted 
Step 1 






























   + HbA1c and duration of diabetes 
 
-0.05 (0.01) †  
  
Model IV  
    All variables in Model III 











Table 58. Multivariate associations between retinal venular width (CRVE) and 




             Logical Memory 
Unstandardised  Beta Coefficient (Standard Error) 
Model I    
Age adjusted 
 
-0.03 (0.01) *  
  
Model II 
Age and MHVS adjusted 
 
-0.03 (0.01) † 
  
Model III 
Age, MHVS and all other variables adjusted 
Step 1 




-0.03 (0.01) † 
  
Step 2 
   + Vascular risk factors 
 
-0.03 (0.01) † 
  
Step 3 










   + HbA1c and duration of diabetes 
 
-0.03(0.01) †  
  
Model IV  
    All variables in Model III 










Table 59: Multivariate associations between retinal arteriolar width (CRAE) and 
late-life cognition, and estimated lifetime cognitive decline for Faces test in women 
 
CRAE 
              
Faces 
Unstandardised  Beta Coefficient (Standard Error) 








Age and MHVS adjusted 
 
0.03 (0.01) *  
  
Model III 
Age, MHVS and all other variables adjusted 
Step 1 






















   + HbA1c and duration of diabetes 
 
-0.02 (0.02)  
  
Model IV  
    All variables in Model III 












Table 60: Multivariate associations between retinal venular width (CRVE) and 
late-life cognition, and estimated lifetime cognitive decline for Faces test in women 
 
CRAE 
              
Faces 
Unstandardised  Beta Coefficient (Standard Error) 
Model I    
Age adjusted 
 
0.02 (0.01)  
  
Model II 
Age and MHVS adjusted 
 
0.03 (0.01) †  
  
Model III 
Age, MHVS and all other variables adjusted 
Step 1 




0.03 (0.01) †  
  
Step 2 
   + Vascular risk factors 
 
0.03 (0.01) † 
  
Step 3 
   + Cardiovascular disease 
 
0.03 (0.01) † 
  
Step 4 
   + Depression 
 
0.03 (0.01) † 
  
Step 5 
   + HbA1c and duration of diabetes 
 
0.03 (0.01) *  
  
Model IV  
    All variables in Model III 
   + Retinal arteriolar width (CRAE)  
 
 







Table 61: Summary of multiple linear regression analysis for retinal width (CRAE and CRVE) with the Logical Memory Test as the dependent 
variables in men (Standardised Beta regression coefficients and standard errors) 
         Logical Memory
1 









































































   
0.07 (0.52) 









0.06 (0.21)  
   








Smoking status (smoker vs. non-smoker) 
 
0.06 (0.81) 
   
0.06 (0.82) 





Waist to hip ratio 
 
0.004 (0.06) 
   
0.02 (0.06) 





Systolic blood pressure 
 
-0.01 (0.002) 














   
0.01 (0.43) 





MI and/or Angina 
 
0.06 (0.77) 
   
0.06 (0.77) 










   
-0.06 (1.14) 












   
-0.08 (1.39) 










   
-0.07 (0.34) 





√ Duration of diabetes 
 
0.03 (0.36) 
   
0.03 (0.36) 











P≤0.01, *P<0.05; Partial eta-squared (η
2
) for CRAE, CRVE and variables significantly associated with cognitive outcomes. 
1
Model adjusted for all the variables in 
the table except for CRVE; 
2
Model adjusted for all the variables in the table except for CRAE; 
3

































Table 62: Summary of multiple linear regression analysis for retinal width (CRAE and CRVE) with the Faces Test as the dependent variables in 
women (Standardised Beta regression coefficients and standard errors) 
         Faces




B (SE)         η
2
 B (SE)          η
2






0.05 (0.02)  0.003   
 


















   
-0.05 (0.09) 


































   
0.09 (0.54) 























Smoking status (smoker vs. non-smoker) 
 
0.00 (0.75) 
   
-0.01 (0.75) 





Waist to hip ratio 
 
-0.04 (0.5) 
   
-0.04 (0.52) 





Systolic blood pressure 
 
0.03 (0.02) 














   
-0.03 (0.39) 





MI and/or Angina 
 
0.04(0.9) 
   
0.03 (0.86) 










   
-0.02 (1.66) 


























   
0.06 (0.4) 































P≤0.01, *P<0.05; Partial eta-squared (η
2
) for CRAE, CRVE and variables significantly associated with cognitive outcomes. 
1
Model adjusted for all the variables in 
the table except for CRVE; 
2
Model adjusted for all the variables in the table except for CRAE; 
3
Model adjusted for all the variables in the table including CRAE and CRVE.
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5.6.3. General-factor adjusted residuals of individual cognitive 
tests   
The new outcome variables in the current analysis comprised the general 
factor-adjusted standardised residuals for the two individual cognitive tests: Logical 
Memory and Faces. 
 
As shown in Tables 63 and 64, in age and sex adjusted models, increased 
CRAE was significantly associated with lower Logical Memory test residual scores 
in men, whereas increased CRVE was associated with higher Faces test residual 
scores in women. Further adjustment for peak prior ability did not greatly alter the 
associations although the association between CRVE and Faces residuals was a little 
strengthened. The cumulative adjustment for other potential confounding factors 
after control for age, sex and MHVS changed the associations only slightly. Finally, 
the addition of the fellow vessel width led to an attenuation of the associations which, 
however, remained statistically significant. In the final model (Table 65), CRAE 
(standardised beta=-0.13, p<0.05) continued to exert independent effects on the DST 
residual scores, explaining about 1% of variance in the dependent variable over and 
above the effect of other factors. The model as a whole accounted for approximately 
2.6% of the total variance in the DST residuals. Similarly, CRVE (standardised 
beta=0.13, p<0.05) remained independently associated with Faces residuals, 
accounting for 1.1% of variance and the whole model explained about 3.1% of the 












Table 63: Multivariate associations between retinal arteriolar width (CRAE) and 
residuals of Logical Memory test scores regressed on ‗g‘ in men 
 
CRAE 
              
Logical Memory 
Standardised  Beta Coefficient (Standard Error) 








Age and MHVS adjusted 
 
-0.15 (0.002) † 
  
Model III 
Age, MHVS and all other variables adjusted 
Step 1 




 -0.15 (0.002) † 
  
Step 2 
   + Vascular risk factors 
 
-0.15 (0.002) † 
  
Step 3 
   + Cardiovascular disease 
 
-0.16 (0.002) † 
  
Step 4 
   + Depression 
 
 -0.15 (0.002) † 
  
Step 5 
   + HbA1c and duration of diabetes 
 
  -0.15 (0.002) † 
  
Model IV  
    All variables in Model III 













Table 64: Multivariate associations between retinal venular width (CRVE) and 
residuals of Faces test scores regressed on ‗g‘ in women 
 
CRVE 
              
Faces 
Standardised  Beta Coefficient (Standard Error) 
Model I    
Age adjusted 
 
0.12 (0.001) *  
  
Model II 
Age and MHVS adjusted 
 
0.13 (0.001) † 
  
Model III 
Age, MHVS and all other variables adjusted 
Step 1 




0.14 (0.001) † 
  
Step 2 
   + Vascular risk factors 
 
0.14 (0.001) † 
  
Step 3 
   + Cardiovascular disease 
 
0.14 (0.001) † 
  
Step 4 
   + Depression 
 
0.14 (0.001) † 
  
Step 5 
   + HbA1c and duration of diabetes 
 
0.13 (0.001) †  
  
Model IV  
    All variables in Model III 











Table 65: Summary of multiple linear regression analyses for retinal arteriolar and 
venular width with residuals of individual cognitive test scores regressed on ‗g‘ as 
the dependent variables (Standardised Beta regression coefficients and standard 
errors) 
Variables in Final Model    Logical Memory (men)        Faces (women) 
B (SE)         η
2
 B (SE)         η
2
 
CRAE -0.13 (0.002) * 0.010 
 
0.004 (0.003) 0.000 
CRVE -0.04 (0.002) 0.001 
 
0.13 (0.002) * 0.01 
Age 0.11 (0.01) * 0.012 
 
0.06 (0.012)  
MHVS 0.04 (0.01)  
 
0.06 (0.01)  
Education (increasing level) -0.01 (0.07)  
 
0.06 (0.07)  
√Alcohol intake 0.03 (0.03)  
 
0.11 (0.04) * 0.012 
Smoking status (smoker vs. 
non-smoker) 
0.06 (0.11)  
 
0.02 (0.10)  
Waist to hip ratio 0.03 (0.09)  
 
-0.01 (0.71)  
Systolic blood pressure 0.01 (0.003)  
 
0.06 (0.003)  
Total cholesterol 0.01 (0.06)  
 
-0.02 (0.05)  
MI and/or Angina 0.09 (0.11)  
 
0.02 (0.12)  




-0.003 (0.22)  
㏒Depression -0.03 (0.19)  
 





0.03 (0.05)  















P≤0.01, *P<0.05; Partial eta-squared (η
2
) for CRAE, CRVE for diabetic retinopathy and 
variables significantly associated with cognitive outcome
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5.6.4. Sensitivity analyses 
When the analysis was limited to 954 subjects with an MMSE scores ≥24, 
CRAE was independently associated with Logical Memory in men (P<0.05), 
whereas CRVE was no longer associated with Faces in women (Table 66), 
suggesting that the latter association could at least in part be attributed to subjects 
with severe cognitive impairment.  
 
In addition, for a few participants (n=14) who had advanced proliferative 
diabetic retinopathy with a grade of 81, arteriolar diameters can be narrowed mostly 
due to laser therapy. When the analysis was limted to 966 subjects not receiving laser 
treatment, the results were essentitally unchanged. The wider CRAE was 
independently associated with poorer Logicl Memory in men (P<0.05), whereas the 
wider CRVE was associated with better Faces test scores in women (P<0.05). Data 
were not shown in here. 
 
 
Table 66: Multivariate associations between retinal vessel width and late-life 
cognition, and estimated lifetime cognitive decline (N=954, subjects with MMSE 
<24 were excluded) 
 
 
Logical Memory-CRAE        Faces-CRVE 
(Male)                    (Female) 
Standardised  Beta Coefficient (Standard Error) 














0.12 (0.01) † 
Model III 
Age, MHVS and all other variables adjusted 
Step 1 










0.12 (0.01) † 
Step 2 






0.13 (0.01) † 
Step 3 






0.13 (0.01) † 
Step 4 






0.13 (0.01) †  
Step 5 
   + HbA1c and duration of diabetes 
 
-0.16 (0.01) †  
 
0.11 (0.01) * 
Model IV  
    All variables in Model III 












5.7. Chapter summary 
The main aim of this chapter was to present data from the sample of 1,044 
Edinburgh Type 2 Diabetes Study subjects who underwent both cognitive function 
assessment and diabetic retinopathy grading. A comparison of socio-demographic 
and biomedical characteristics showed that subjects with diabetic retinopathy were 
slightly more likely to be male, had a longer duration of diabetes and a corresponding 
worse vascular risk factor profile compared with those without diabetic retinopathy. 
After age and sex adjustment, subjects with diabetic retinopathy had poorer mean 
scores on ‗g‘ and on most of the individual cognitive tests. When analysed by 
severity of diabetic retinopathy (none, mild, and moderate-severe), these cognitive 
measures showed a significant relationship with increasing severity of diabetic 
retinopathy. Those with moderate-severe diabetic retinopathy had poorest 
performances on general cognitive ability factor ‗g‘, which was mainly due to poorer 
scores on the individual Verbal Fluency, Faces, Trail Making and Digit Symbol tests.  
 
In the total sample, after adjustment for MHVS to estimate lifetime 
cognitive decline, a trend toward worse performance across diabetic retinopathy 
severity categories remained significant for ‗g‘ and the four individual cognitive tests. 
In multivariate analyses adjusting for other possible confounding factors (including 
vascular risk factors and prevalence of macrovascular disease), there was a 
significant interaction between diabetic retinopathy and sex for both the general 
factor score and the Verbal Fluency Test but not for other tests. Severity of diabetic 
retinopathy remained significantly associated with MHVS-adjusted scores for the 
Trail Making, Faces and Digit Symbol tests and, in males, for ‗g‘ and the Verbal 
Fluency test. The multivariate associations of diabetic retinopathy with DST 
persisted after additional adjustment for HbA1c and duration of diabetes. In males, 
the associations of diabetic retinopathy with g and VFT remained. When a sensitivity 
analysis was performed excluding subjects with a history of cerebrovascular disease, 
the associations of diabetic retinopathy with ‗estimated‘ lifetime cognitive decline 
were essentially the same.   
 
Further analyses showed that, the associations with estimated cognitive 
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decline in all specific cognitive measures except for Digit Symbol test, principally 
attributed to the relationship between diabetic retinopathy and general cognitive 
ability. It was likely that the diabetic retinopathy-DST association resulted from this 
individual function per se.  
 
For quantitative parameters of retinal vascular network geometry, both 
increased arteriolar and venular width were significantly associated with lower 
scores on Logical Memory in men, whereas they were associated with higher scores 
on Faces in women after adjustment for age and prior cognitive ability. When further 
adjusted for education, vascular risk factors, cardiovascular disease, depression and 
hyperglycaemia, the association of CRAE with Faces became non-significant 
whereas others remained statistically significant. After additional adjustment for the 
fellow vessel, increased CRAE was independently associated with poorer 
performance on Logical Memory in men and increased CRVE continued to exert 
independent and positive effects on Faces scores in women. When a sensitivity 
analysis was performed excluding subjects with an MMSE<24, the association of 
CRAE with Logical Memory was not altered, whereas the association of CRVE with 
Faces was attenuated beyond statistical significance, suggesting the latter association 
could at least in part be attributed to subjects with severe cognitive impairment. 
These associations could also attribute to the associations of retinal vascular width 
with non-general cognitive ability component. Other parameters did not show any 





















In this chapter the main findings from the study are discussed. Findings are 
considered in relation to results from other published studies. General issues on the 
methodology and the analysis are addressed, and potential neuropathological 
mechanisms underlying the association between cognitive dysfunction and cerebral 
microvascular disease in diabetes are proposed. 
 
6.2. Summary of main findings 
 
6.2.1. Diabetic retinopathy and cognition 
Diabetic retinopathy is the most common and specific microvascular 
complication of diabetes. Over and above its adverse impact on vision, the present 
study demonstrated that retinopathy signs were associated with greater estimated 
age-related decline in neuropsychological functioning in people with Type 2 diabetes. 
Subjects with diabetic retinopathy performed worse on the majority of cognitive tests 
undertaken compared with those without. These cognitive measures also showed a 
statistically significant relationship with increasing severity of diabetic retinopathy 
(none, mild, and moderate-severe). In multiple linear regression analyses, there was a 
statistically significant trend in cognitive function across severity of diabetic 
retinopathy for information processing speed and, in men, for general cognitive 
function and word fluency, independent of prior cognitive ability and 
socio-demographic factors, cardiovascular risk factors, macrovascular disease and 
hyperglycaemia. Diabetic retinopathy explained 1 to 2 % of the variation in these 
cognitive measures. As there were a limited number of subjects with proliferative 
diabetic retinopathy in the ET2DS, it is likely that the findings were heavily 
influenced by the cognitive experience of subjects with mild to moderate diabetic 
retinopathy. Further analyses examining the association between retinal 
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microvascular abnormalities and estimated cognitive change after controlling for 
performance on the general cognitive factor revealed that the association of diabetic 
retinopathy with cognition was principally explained by an association with general 
mental ability. 
 
6.2.2. Retinal vascular network geometry and cognition 
Larger retinal arteriolar and venular calibres were statistically significantly 
associated with lower scores on a test of verbal memory but not with the results of 
other tests in men. Multiple linear regression analyses demonstrated that larger 
retinal arteriolar calibre was statistically significantly associated with verbal memory 
(accounting for 1% of the total variance) even after adjustment for pre-morbid 
cognitive ability and once possible confounding by retinal venular calibre, vascular 
risk factors and vascular disease was taken into account. In contrast, findings did not 
support an independent association between retinal venular calibre and estimated 
cognitive change. The association of retinal arteriolar calibre with decline in verbal 
memory was not related to an association with general mental ability but was 
attributable to an association with this specific cognitive function itself. Parameters 
of retinal arteriolar bifurcation geometry were not associated with cognitive outcome.  
 
6.2.3. Gender-specific findings 
A striking finding was the significant interaction of diabetic retinopathy with 
gender. The negative associations of diabetic retinopathy with verbal fluency and 
general cognitive ability were statistically significant only in men. A non-significant 
trend towards a positive association between severity of diabetic retinopathy and 
verbal fluency was observed in women. This sex difference was not anticipated a 
priori and previous research has not examined whether gender modifies the 
relationship of diabetic retinopathy with cognition. There are also limited previous 
data comparing diabetes as a risk factor for cognitive dysfunction in men versus 
women. Despite a prior hypothesis that Type 2 diabetes may be a more potent risk 
factor for cognitive dysfunction in women than in men, given their higher risk of 
diabetes-related cardiovascular disease complications (Okereke et al., 2008), the 
existing literature generally supports the findings of similar relationships between 
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diabetes and cognitive function in men and women.  
 
The sex-specific effect of diabetic retinopathy on cognitive functioning 
may be related to the fact that in the ET2DS, women were less likely to have diabetic 
retinopathy (29.7% vs. 35.1%, P=0.058), prevalent coronary heart disease (24.4% vs. 
37.8%, P<0.001) and stroke and/or TIA (5.5 vs. 11.6, P<0.001) relative to men. 
However, adjusting for these macrovascular disease variables in the statistical 
models did not alter the sex-specific effects. It is also possible that other unknown 
risk factors or disease which were not examined in this analysis (e.g. carotid 
intima-medial thickness, estrogen use, physical activity), might have differed in male 
and female participants and could play a mediating role in such an association. Given 
the possible protective effects of estrogen on cognitive functioning in older women 
with Type 2 diabetes, it is also possible that use of hormone replacement therapy 
(HRT) by women in the ET2DS may be important. Estrogen may stimulate multiple 
neurotransmitters, enhance cerebral blood flow, act as an antioxidant and induce a 
highly significant increase in the morphological complexity of neurons associated 
with learning and memory (Coker and Shumaker, 2003). The degree to which these 
and other variables may help to explain sex-specific associations of diabetic 
retinopathy with cognitive function needs to be further explored. However, since 
there was no specific a priori reason for assuming that the association of diabetic 
retinopathy with cognitive function would be different between males and females, 
and given that there is no evidence from other studies suggesting such a gender 
difference in the general populations or in people with diabetes, caution is needed in 
interpreting the gender-diabetic retinopathy interaction until this finding is replicated 
in other large studies. 
 
Another unexpected finding was the significant interaction of retinal vessel 
calibre with gender. The associations of both the increased retinal arteriolar and 
venular calibres with lower verbal memory scores were significant in men but not in 
women. On the other hand, larger retinal venular calibre was significantly associated 
with higher Faces test scores in women but not in men. This aspect has not been 




6.3. Comparison with previous studies, 
methodological issues and possible mechanisms 
 
6.3.1. Diabetic retinopathy and cognition 
 
Comparison with findings from previous studies 
This is the first study to date that specifically addresses the association 
between retinal microvascular abnormalities and cognitive functioning in a large 
group of people with Type 2 diabetes. The consistency of the results with previous 
studies, including those on people with Type 1 diabetes and in the general 
populations is considered in detail below. However, comparison of results across 
studies is challenging given the methodological heterogeneity between studies 
including differences in the selection of population, the comparison group ‗free‘ of 
disease used, the assessment and definition of diabetic retinopathy, the choice of 
cognitive measures and the approach to controlling for potential confounding factors. 
In addition, very few previous studies have used multi-field retinal photography and 
a detailed, validated grading system to evaluate diabetic retinopathy, or have 
comprehensively assessed cognitive change in a full range of major domains in 
relation to diabetic retinopathy in people with Type 2 diabetes.  
 
Association with general cognitive ability  
The present study used an approach for assessing general cognitive ability 
which is in line with current theoretical concepts of the hierarchical construct of 
human cognitive abilities (Rafnsson, 2006; Deary and Batty, 2007). General 
cognitive ability, as indexed by a general factor, was computed by subjecting 
individual mental tests to a principal component analysis and represented the 
variance common to the specific tests the ET2DS used. By contrast, of the limited 
number of previous studies on this topic, several have administered only the MMSE 
for assessing general mental ability. Such a global measure may not be well-suited 
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for this purpose (Morris et al., 1999). In particular, as a brief and summary measure 
of general cognitive function, the MMSE is likely to exhibit a ceiling effect (e.g. 
where the majority of values lie close to the maximum score of 30) when used in 
non-demented study populations. The MMSE is also relatively insensitive for the 
detection of subtle changes in cognitive function, such as those which might be 
expected in studies of cognitively-intact older people. In this context, the use of the 
MMSE may underestimate the true extent of cognitive impairment and decline. 
 
Present findings of an inverse association between retinopathy severity and 
general ability scores are consistent with results from some but not all previous 
studies. In a sub-group of subjects with hypertension aged 49 years and older 
participating in the Blue Mountains Eye Study, Liew et al. (2009) reported that 
people with signs of retinopathy were significantly more likely to score below 23 on 
the MMSE. Retinopathy was defined as an ETDRS level of 15 or greater (presence 
of any, microaneurysms, haemorrhages, hard exudates, cotton wool spots or evidence 
of laser treatment for retinopathy). The analysis was cross sectional and change in 
MMSE performance over time was not assessed in relation to retinopathy status. The 
findings were based on a hypertensive sub-group and the associations were not found 
in people with diabetes or in the total study population. In cross-sectional analysis of 
the Cardiovascular Health Study, retinopathy was associated with lower mean score 
on the modified MMSE scale in people without stroke aged 69 to 97 years at 
recruitment. However, this crude association did not hold after adjustment for factors 
such as age, hypertension, diabetes and internal carotid intima-media thickness 
(Baker et al., 2007).  
 
Studies whose results deviate from the present findings include a study by 
Umegaki et al. (2008), which reported no association between prevalent diabetic 
retinopathy and global cognitive dysfunction (MMSE<24) in elderly Japanese adults 
with diabetes. Also, in the Utrecht Diabetic Encephalopathy study, Manschot et al. 
(2007) found no significant difference in average performance on a composite 
cognitive score from five domains in a cross-sectional comparison of 122 older 
people with Type 2 diabetes with and without retinopathy. In addition to the 
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discrepancy between these studies and the ET2DS in measures of general cognitive 
ability, other differences between the studies may have contributed to the different 
findings. For example, the diagnosis of diabetic retinopathy was either based solely 
on a direct clinical ophthalmoscopic examination (Umegaki et al., 2008) or a 
single-field retinal photograph (Manschot et al., 2007), methods which are imprecise 
and less reliable compared with 7-field retinal photography (only imaging a small 
portion of the retina when compared with multiple field retinal photographs). Both 
previous studies may have underestimated the prevalence of retinopathy signs in 
older people with diabetes. The imprecision of retinopathy gradings may also have 
resulted in non-differential misclassification, which is likely to attenuate associations 
between retinal vascular abnormalities and cognition.  
 
Association with specific cognitive ability 
With respect to tests of specific cognitive domains, age and sex adjusted 
comparisons showed a significant trend with increasing severity of diabetic 
retinopathy for tests of non-verbal memory, mental flexibility, verbal fluency and 
information processing speed, with moderate to severe diabetic retinopathy groups 
having worst cognitive performance. Furthermore, severity of diabetic retinopathy 
was independently associated with greater estimated decline in information 
processing speed, and in men, for verbal fluency.  
 
Findings were consistent with reports from five other studies, including 
those in people with Type 1 diabetes. Ferguson et al. (2003) reported an overall 
downward shift in the distribution of several test scores in relation to background 
diabetic retinopathy (presence of microaneurysms) in a cross-sectional analysis of 71 
young people with Type 1 diabetes. The magnitude of the influence of diabetic 
retinopathy on cognitive performance was moderate to large (e.g. diabetic 
retinopathy explained about 7% of the total variance in information processing speed 
as measured by Digit Symbol test). By contrast, the effect sizes from the ET2DS did 
not exceed 2%. The smaller effect sizes in the ET2DS may reflect higher variability 
in cognitive performance among older patients with Type 2 diabetes. It is also 
possible that larger effect sizes observed by Ferguson et al. (2003) were caused by 
stringent selection of the ‗no retinopathy‘ comparison group in which subjects had 
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less co-morbidity and, specifically, were free of other microvascular disease (e.g. 
neuropathy and nephropathy). The ‗no retinopathy‘ group in the ET2DS was not 
necessarily ‗microvascular disease-free‘. For example, the comparison group 
included those who had ‗possible diabetic retinopathy‘ (n=61) (i.e. the presence of 
other retinal vascular lesions including haemorrhages, hard exudates and cotton wool 
spots but in the absence of microaneurysms). Indeed, when the analyses were 
repeated after excluding those subjects, the associations of diabetic retinopathy with 
verbal fluency and information processing speed were slightly stronger. In addition, 
even those who did not have characteristics of diabetic retinopathy may have had 
other manifestations of systemic microvascular disease and this ‗dilution‘ would 
have made differences between the groups less extreme, biasing the results toward 
the null and leading to possible underestimation of effect sizes. 
 
In another set of analyses based on 103 young and middle-aged patients 
(mean age 40 yrs) with Type 1 diabetes, Ryan et al. (2003) demonstrated that the 
presence of proliferative diabetic retinopathy at baseline was associated with 
significantly greater decline in psychomotor efficiency over a follow-up of seven 
years. The cognitive domain of psychomotor efficiency was measured through the 
administration of multiple tests including the Digit Symbol test assessing information 
processing speed.  
 
Although in the population-based Cardiovascular Health Study, Baker et al. 
(2007) did not find statistically significant multivariate-adjusted differences in mean 
global cognitive test scores between people with and without any retinopathy signs, 
the retinopathy groups did perform significantly worse on Digit Symbol test. 
 
In the Atherosclerosis Risk in Communities (ARIC) Study based on a 
considerably larger sample than the ET2DS, Wong et al. (2002e) reported that 
retinopathy was independently associated with worse cognitive function on several 
tests in middle-aged people without stroke. Subjects with retinopathy had 
significantly lower scores on delayed verbal memory, executive function and 
information processing speed compared with retinopathy-free controls. These 
 282 
associations were similar in people with and without diabetes and hypertension. 
Although differences in the measurement of verbal memory between the ARIC and 
the ET2DS need to be considered, these may not fully account for the discrepancy in 
findings (i.e. no such association was found in the ET2DS). In the ET2DS, verbal 
memory was assessed using immediate and delayed recall of one story (WMS-R 
Logical Memory Test) whereas Wong et al. (2002) administered the Delayed Word 
Recall Test, which is based on recalling a list of 10 words. It could be argued that 
recalling a list of random words (free recall) might pose different challenges for 
memory functioning than memorising a story which may have some cues in 
facilitating a recall (Rafnsson, 2006). Also, in the relatively healthier and younger 
cohort of the ARIC study, performance on cognitive tests is heavily influenced by 
prior mental ability level. Adjustment for differences regarding level of education in 
this study (Wong et al., 2002e) might not have provided adequate control for prior 
ability differences between subjects with and without retinopathy, given the potential 
wide variation of cognitive ability levels within the same education category. As a 
result, some residual confounding by prior ability level cannot be ruled out in the 
data by Wong et al. (2002e). Finally, of the associations found in a subgroup of 
subjects with diabetes in the ARIC study, lack of specific data regarding 
characteristics of diabetes (e.g. Type 1 or 2, duration of diabetes and glycaemic 
control) hinders further interpretation of the results in diabetic patients.  
 
Subsequent findings from the 14-year follow-up of the ARIC study found 
that people with retinopathy showed a greater 10-year decline in verbal fluency and 
information processing speed compared with those without retinal microvascular 
abnormalities (Lesage et al., 2009). In contrast to the earlier cross-sectional 
associations (Wong et al., 2002e), there was no association of retinopathy with 
decline in delayed verbal memory. This may reflect different measures of cognitive 
change over time (actual measured change versus estimated change using a single 
time point). Longitudinal analysis of cognitive change tends to reduce the influence 
of extrinsic potential confounding factors (e.g. education) that cannot be completely 
accounted for with multivariate modeling in cross sectional studies. It is also 
suspected that the Delayed Word Recall applied in the ARIC study is a test of 
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episodic memory (a form of memory in which information is stored with ‗mental 
tags‘) which is more typically affected in Alzheimer‘s disease rather than in 
cognitive impairment of vascular origin (Fleisher et al., 2007). Indeed, no significant 
association with verbal memory was found in the ET2DS and the pattern of cognitive 
decline associated with diabetic retinopathy was, in general, more indicative of 
vascular dementia. 
 
In the ET2DS the associations of diabetic retinopathy with decline in 
specific cognitive abilities were largely attributed to the relationship of diabetic 
retinopathy with general cognitive ability rather than with the individual component 
tests per se. An exception was the DST (measuring information processing speed), 
with which diabetic retinopathy remained associated after controlling for the 
influence of the general factor. This implies that the DST might have variance in 
common with the general ability factor, but it could still have a different 
developmental trajectory such as a unique retinopathy-related influence, which is 
similar to that sometimes found with ageing (Salthouse, 1994). Given that DST is not 
only a measure of psychomotor speed, but also working memory (Joy et al., 2004), it 
is also possible that the assumption of non-overlap between component/factors in 
using principal component analysis without orthogonal rotations could be violated. In 
this case, non-orthogonal rotations may provide a better or informative model.  
 
DST is a paper-pencil based test in which subjects are asked to translate 
numbers into symbols using a key in 120 seconds. Preliminary analysis in the 
ET2DS demonstrated that diabetic people with retinopathy were more likely to have 
peripheral neuropathy as measured by an increased vibration perception threshold at 
the great toe compared with those without retinopathy (55.2% vs. 45.8%, P<0.05). It 
is possible that people with diabetic retinopathy also had some sensorimotor 
difficulties related to neuropathy, which could have affected their performance on the 
DST. Specific information on functional impairment or disabilities, such as limited 
joint mobility or the presence of arthritis in the hands was not collected in the ET2DS. 
However, adjustment for neuropathy in a post hoc analysis did not alter the observed 
associations between DST and retinopathy. Whether unrecognised sensorimotor 
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dysfunctions mediated the association to some extent remains unclear. 
 
Severe diabetic retinopathy, including maculopathy and proliferative 
retinopathy, can produce visual impairment, in particular affecting near visual acuity 
and resulting in reading difficulties. This could have influenced performance on the 
DST. However, this was unlikely to account for the associations reported here given 
that participants who had corrected visual acuity worse than 6/36 for distance vision 
or inability to read large print text were excluded. Subjects with poor visual acuity 
performed the DST with glasses and there was no significant difference in corrected 
near visual acuity between people with and without diabetic retinopathy. The 
DST-specific effects remain difficult to interpret until the DST can be grouped with 
other processing speed tests (e.g. inspection time and reaction time) to probe this 





A number of factors may confound the association between diabetic 
retinopathy and cognitive dysfunction in people with Type 2 diabetes. If not 
adequately controlled for, these confounding factors may give rise to spurious results. 
In particular, possible confounding by prior cognitive ability has been sufficiently 
taken into account in very few previous studies. Where attempted, adjustment has 
often been made for education or social class status, variables which may be 
influenced by factors such as lack of opportunity rather than lack of ability and 
which exhibit wide variation of ability levels within the same category. Statistical 
adjustment for differences in these characteristics may not adequately control for 
subject‘s prior level of mental ability. In contrast, findings in the ET2DS were 
unlikely to be explained solely by differences in prior cognitive ability between 
subjects with and without diabetic retinopathy because vocabulary ability assessed 
by using MHVS is preserved even in generalised cognitive decline.  
 
The measurement of a wide range of diabetes-specific characteristics, 
conventional vascular risk factors and macrovascular diseases further allowed the 
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examination of the independence of association between severity of diabetic 
retinopathy and cognitive function in relation to these parameters. In particular, 
subjects with diabetic retinopathy had significantly longer duration of diabetes, 
higher mean HbA1c level, and greater waist-to-hip ratio and were more likely to 
suffer from cardiovascular disease, especially cerebrovascular disease, compared 
with those without diabetic retinopathy. The findings that retinopathy remained 
significantly associated with estimated cognitive decline after adjustment for these 
factors suggests that the association may depend on mechanisms resulting in cerebral 
small vessel disease eventually leading to insidious ischaemia and injuries in brain 
parenchyma rather than on any other concomitant influences such as hyperglycaemia 
and macrovascular disease.  
 
The transient deleterious effects of acute hypoglycaemia are also unlikely to 
account for the associations between diabetic retinopathy and cognitive function, 
because blood glucose was measured before cognitive testing to ensure that subjects 
were not suffering from unrecognised hypoglycaemia.  
 
Bias 
There were twenty-two subjects who had cognitive testing but did not 
provide diabetic retinopathy status data mostly due to unavailable retinal 
photographs (non-participation). When comparing the characteristics of participants 
who had gradable retinal photographs to those not graded, those not graded were 
more likely to have prevalent stroke and/or TIA, and performed significantly worse 
on non-verbal memory, verbal memory and general cognitive ability. Given that the 
differences between the graded and ungraded groups in these cognitive abilities were 
moderate to large, this raises the possibility of selection bias. If those who did not 
have gradable retinal photographs had severe diabetic retinopathy, then the results 
presented here will have been biased towards the null or underestimating effect sizes. 
Because subjects with missing retinal data had a relatively higher proportion of 
cerebrovascular disease (13.6% vs. 8.6%) and neuropathy (72.7% vs. 51.2%), these 
subjects may well have had more severe diabetic retinopathy. Nonetheless, it is 
unlikely that this selection bias had a large impact on the results given that only 2% 
of subjects had missing data on diabetic retinopathy status.  
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Grading of diabetic retinopathy was performed independently by two 
optometrists according to a validated standardised classification system. It should be 
noted that graders assessed retinal vascular lesions with overlapping fields, not 
following the stringent field definitions (although the deviation from the field 
definition was noted for each field and was measured in terms of disc diameters). 
This may have led to the over-grading of images given that lesions could be counted 
in more than one field. This is more of a problem in the higher grades, only 
accounting for a very small proportion of subjects (Preston, 2008). However, to the 
extent that the diabetic retinopathy severity category included ‗false severe‘ cases, 
any misclassification of cases would have reduced the observed associations towards 
the null value and have underestimated the effect sizes.  
 
Possible mechanisms 
In the early stages of diabetic retinopathy, a spectrum of retinal vascular 
signs such as microaneurysms, haemorrhages, cotton wool spots and hard exudates, 
result from microvascular closure and loss of vascular integrity. With increasing 
severity, retinal venous beading and intra-retinal microvascular abnormalities may 
develop, which usually precede frank new vessel formation and the onset of 
proliferative diabetic retinopathy. In addition to a break-down of the blood-retinal 
barrier, these ischaemic processes are likely in turn to damage the neural retinal 
tissues supplied. 
 
As the retinal and cerebral microvasculature share common anatomy, 
embryology and physiology, these retinal vacular changes may provide an indirect 
marker of similar or concomitant changes in the brain microvasculature. As 
discussed in detail later, it is possible that instead of circumscribed vascular lesions, a 
disruption of the blood brain-barrier, and/or ischaemia from more generalised and 
widespread cerebral microvascular disease may lead to disruption of complex, 
intricate neural networks underlying general cognition by affecting the functional 
connectivity of different cerebral regions. More specifically, ischaemic changes 
disrupt the structural integrity of white matter tracts and subcortical gray matter, 
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which are essential for intact inter-regional communication of cortical and 
subcortical grey matter areas. As a result, they may affect not only the functional 
capacity of the white matter but also the processing ability of neuro-cognitive 
networks such as frontal-subcortical circuits, most notably leading to deficits in 
executive function and processing speed (Jokinen et al., 2006; Rafnsson, 2006; 
Verdelho et al. 2007).  
 
As the findings were not attenuated after excluding subjects with 
recognised clinical stroke and/or TIA, perivascular brain damage and/or ischaemic 
injuries from unrecognised or asymptomatic cerebral small vessel disease (SVD) 
would appear to be a plausible explanation for the cognitive associations presented 
here. 
 
The association between diabetic retinopathy and estimated decline in 
specific cognitive tests was largely mediated by the effects of diabetic retinopathy on 
the general cognitive factor. This suggests that those neurocognitive processes 
represented by general ability may be more susceptible to cerebral mcirovascular 
pathology. The additional effect on processing speed may be at least partially 
attributable to demyelination of neurons in relation to cerebral microvascular disease 
associated with Type 2 diabetes (Deary, 2000). 
 
6.3.2. Retinal vessel calibre and cognition 
Changes in retinal vessel calibre have been relatively understudied in 
cognitive ageing epidemiological investigations, in particular in diabetic patients. 
Three quantifiable parameters of retinal vessel calibre were examined in the ET2DS 
including the central retinal arteriolar equivalent (CRAE), central retinal venular 
equivalent (CRVE), and the arteriovenous ratio (AVR). 
 
Comparison with findings from previous studies 
The finding of an association between retinal arteriolar dilatation and lower 
scores for verbal memory has not been previously reported, although one larger 
population-based study found that retinal venular dilatation was associated with 
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lower MMSE scores (Liew et al., 2009). Findings in the ET2DS contrast with the 
majority of published evidence which did not find a significant association between 
any parameters of retinal vessel calibre and cognitive test performance (Wong et al., 
2002e; Baker et al., 2007; Patton et al., 2007; Lesage et al., 2009). For example, in 
the ARIC study with a considerably larger sample than the ET2DS, no association 
was found between the AVR and risk of cognitive impairment in delayed 
components of verbal memory, information processing and verbal fluency (Wong et 
al., 2002e). However, as a ratio, the AVR is a crude summary measure. If both the 
CRAE and CRVE associate with cognition in the same direction as shown in the 
ET2DS, no relationship would be detected. Another possible reason for the lack of 
association seen in population-based studies is that retinal arteriolar dilatation might 
be a specific indicator of diabetes-related microvascular dysfunction, but not a 





The association between retinal arteriolar dilatation and worse verbal 
memory is unlikely to be explained by confounding by differences in levels of mood, 
vascular risk factors or cardiovascular disease. Higher retinal arteriolar calibre was 
significantly associated with higher depression scores and the presence of coronary 
heart disease. Mean CRAE was raised in current smoker and lower mean CRAE was 
associated with the presence of hypertension. However, the finding of an 
independent relationship between increased CRAE and lower verbal memory scores 
suggests that, at least to a degree, the association may be due to underlying cerebral 
microvascular pathology rather than the concomitant influences of vascular risk 
factors and disease.  
 
When excluding subjects with an MMSE scores<24, retinal venular calibre 
was no longer associated with Faces test scores in women. It is possible that the 
association could be mediated by subjects with severe cognitive impairment. After 
the exclusion of participants with prevalent stroke and/or TIA, the association 
between the CRAE and verbal memory became attenuated and lost statistical 
 289 
significance. However, whether this was due to lack of statistical power or indicates 
that stroke plays an intermediate role remains uncertain.  
 
In contrast to the associations of diabetic retinopathy with several of the 
cognitive tests, an association was found between retinal vessel calibre and memory 
function alone. However, no association between diabetic retinopathy and verbal 
memory was found. It is possible that before the onset of retinopathy, retinal 
arteriolar dilatation in diabetic subjects may contribute to variation in cognitive 
abilities. Although the data were not presented in this thesis, additional adjustment 
for diabetic retinopathy in analyses did not alter the significant association between 
CRAE and verbal memory. On the other hand, the ET2DS population comprised 
older diabetic patients without dementia. Memory is often the first domain of 
cognition that is affected in subjects with mild cognitive impairment, with otherwise 
relatively preserved cognitive and functional abilities (Nordahl et al., 2005; Patton, 
2006). Furthermore, there may have been a relatively greater degree of variation of 
logical memory scores, compared with other cognitive domains tested in the present 
study, which may have increased the sensitivity to detect an association (Patton, 
2006). After examining the coefficients of variation for each of the tests, this is 
possible but could not account fully for the observed association. 
 
An important concern in controlling for anatomy and measurement error 
using the fellow vessel calibre is the potential for overadjustment when both are 
associated with cognition in the same direction. As there is a large proportion of 
shared variance between the CRAE and CRVE, and both are related to verbal 
memory, they may each cancel out the effect of the other, and both would have 
dropped out of the equation. Furthermore, there are other factors that were not 
controlled for that may influence retinal vessel calibre such as genetic, ocular (e.g. 
axial length) and other cardiovascular risk factors (e.g. inflammation markers). By 
adjusting for the fellow vessel, effects of other ‗non-measurable‘ factors are negated.  
 
Bias 
Of the 1,044 subjects who had gradable retinal photographs for diabetic 
retinopathy status, 64 subjects had retinal images of insufficient quality in either eye 
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to make retinal vessel calibre measurements. This was mostly due to the high 
prevalence of medial opacities in this older group as well as technical reasons for 
failure to obtain the 6 measurable largest retinal arterioles or venules. When 
comparing the characteristics of participants included in this analysis with those 
excluded (no retinal photographs or ungradable retinal vessels), those excluded were 
more likely to have prevalent stroke and/or TIA, and performed significantly worse 
on non-verbal memory, information processing speed and general cognitive ability. 
The magnitude of the differences in these cognitive abilities between the analysed 
and un-analysed individuals (for retinal vessel calibre) was small to moderate. 
However, if people with greater variation in retinal vessel calibre (very high or low 
values) were excluded, and also had lower cognitive test scores on these domains, 
then the results presented here will have been biased towards the null or 
underestimating effect sizes, or possibly even shown associations in the opposite 
direction.  
 
Before retinal photography, pharmacologic pupillary dilatation of both eyes 
was performed and a very low percentage of photographs (6.1%) were ungradable in 
the study. A semi-automated computer assisted method was used to measure retinal 
vessel diameters from digital retinal images with high resolution. Reliability of these 
retinal vessel measurements in the study was substantial, with intra- and inter-grader 
intra-class correlation coefficient ranged from 0.67 to 0.95. 
 
In all ET2DS participants, retinal images from one randomly selected eye or 
the eye with the best image quality were measured. Findings from population-based 
epidemiological studies have demonstrated substantial correlation between right and 
left eyes for retinal arteriolar (Pearson correlation coefficients ranged from 0.70-0.72) 
and venular calibre (0.74-0.77), and moderate correlation for the AVR (0.49-0.64) 
(Leung et al., 2003b; Couper et al., 2002; Wong et al., 2004a). Slightly lower 
correlations for arteriolar calibre than for venular calibre are likely to reflect a greater 
precision when measuring venular calibre given the better and more distinct contrast 
between the retinal background and the venular blood column than the arteriolar 
blood column. As expected, lower correlation was found for the AVR as a ratio 
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exaggerates the errors of its components (Wong et al., 2004a). Although a high 
correlation between eyes would indicate that measurement of retinal vessel calibre in 
one eye might be adequate for studies evaluating the systemic associations of retinal 
vascular calibre, there is a potential for loss of statistical power to detect such 
associations due to lower precision in vessel calibre data compared with averaged 
measurements in two eyes. When measurements from both eyes are taken into 
account, there would be less of the total variation caused by measurement error (e.g. 
R
2
 increased in the regression models that used the mean calibre of two eyes) (Wong 
et al., 2004a). Thus measuring one eye may have diminished the chances of finding 
significant associations, particularly if they are small. 
 
Wong et al. (2004a) found that women had poorer correlations in retinal 
vessel calibre measurements between eyes than men. These differences may reflect 
greater variability of measurement in women, as a result of variations in biological 
and physiological factors, such as blood pressure, the cardiac cycle and other ocular 
disease. It is possible that measurements from one eye in women are more influenced 
by measurement error and such non-differential error would have tended to dilute 
associations toward the null. This may, at least in part, explain why an interaction 
was observed between retinal vessel calibre and gender and a significant association 
with cognition was found only in men in the ET2DS. 
 
Retinal vascular calibre may change in an individual, even over a short 
period-for example, with the pulse cycle. Thus, taking photographs at untimed points 
in the dynamic pulse cycle may result in further random variation in the 
measurement of retinal vessel calibre. Such non-differential misclassification may 
also have masked or attenuated the associations towards null.  
 
Possible mechanisms 
Arteriolar dilatation is considered to be a sign of impaired arteriolar 
autoregulation in diabetes, which has been suggested to play an important role in the 
initiation and progression of diabetic retinopathy (Gardiner et al., 2007). 
Experimental studies indicate that arteriolar dilatation and the associated increase in 
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retinal blood flow are frequently found in the retinas of people with diabetes, which 
may reflect underlying arteriolar autoregulation dysfunction (Gardiner et al., 2007). 
This could be due to hyperglycaemia and hypoxia mediated endothelin-1 resistance 
and calcium-influx channel inhibition in smooth muscle cells. These processes could 
impair retinal arteriolar constriction. In turn, hyperperfusion could exacerbate retinal 
arteriolar dilatory response by a drop in retinal oxygen tension from capillary 
non-perfusion (Gardiner et al., 2007). On the other hand, retinal venular dilatation 
may represent a later sign of such haemodynamic abnormalities which possibly 
reflect a direct consequence of arteriolar dysfunction (Gardiner et al., 2007). Another 
possibility is that hypercapnia or elevated partial pressure of carbon dioxide in 
systemic arterial blood, may increase retinal blood flow as a result of retinal 
vasodilatation (Schmetterer and Polak, 2001). Because there is no reason to assume 
that participants were retaining carbon dioxide, this is unlikely to have a major effect 
on retinal arteriolar dilatory response. Based on these observations, retinal arteriolar 
dilatation could be a general marker of retinal ischaemia and by proxy cerebral 
ischaemia. It is also possible that retinal arteriolar dilatation in some way reflects 
cerebral arteriolar abnormalities in diabetes. 
  
In this context, cerebral microvascular disease associated with diabetes may 
play a role in the episodic memory impairment characteristics of mild cognitive 
impairment (Nordahl et al., 2005). Findings from a number of epidemiological 
studies have demonstrated that memory is not solely dependent on the hippocampus 
and medial temporal lobe region in the brain, but that multiple cortical-subcortical 
circuits may be involved (Ungerleider, 1995; Nyberg et al., 1996; Tulving and 
Markowitsch, 1997; Nordahl et al., 2005; Buffon et al., 2006). It is possible that 
ischaemic injuries from cerebral small vessel disease may compromise frontal-lobe 
executive control processes that are critical for working memory (the ability to hold 
and manipulate information mentally as a component of executive function), which 
may in turn result in episodic memory (information encoding) deficits (Nordahl et al., 
2005). 
 
Recently, the cognitive profile in patients with CADASIL (the archetypal 
model of pure cerebral microangiopathy) showed that memory was affected in 
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approximately 70% of subjects, illustrating the role that cerebral small vessel disease 
may have on changes in memory (Buffon et al., 2006; Patton, 2006). CADASIL is a 
rare autosomal dominant microangiopathy, resulting from defects in the Notch3 gene. 
Notch3 encodes a cell surface receptor that is exclusively expressed in vascular 
smooth muscle cells and pericytes (Patton et al., 2005). Histopathological 
examinations have shown loss of vascular smooth muscle cells with perivascular 
fibrosis but with no evidence of vascular occlusion in both cerebral and retinal 
arterioles (Patton et al., 2005). Interestingly, the pathological changes of retinal 
arterioles in CADASIL are similar to the observations in diabetes, which lends 
further support to the relatively unappreciated role of arteriolar dysfunction in 
cerebral microvascular disease associated with diabetes. 
 
6.3.3. Retinal arteriolar bifurcation geometry and cognition 
Retinal arteriolar bifurcation geometry including median bifurcation angle 
(BA), median branching coefficient (BC) and suboptimal angles has not been 
explored in people with diabetes. In the ET2DS, none of the three parameters of 
arteriolar bifurcation were related to any measures of cognitive function. 
 
Comparison with findings from previous studies 
Null results in the present study are in conflict with cross-sectional 
findings from the Lothian Birth Cohort (LBC) 1921 study (Patton et al., 2007), the 
only other available investigation in non-demented elderly population. Patton et al. 
demonstrated that deviation of the median BC from optimality was significantly 
negatively associated with general cognitive ability and verbal fluency, whereas 
deviation of the angle at arteriolar bifurcation from optimality was significantly 
associated with verbal memory (Logical memory), with effect sizes ranging from 2% 
to 3%. Apart from differences in sample structure and disease profile, the 
discrepancy between the ET2DS and the LBC may also be partly attributed to the 
different methods in quantifying these retinal bifurcation parameters. 
 
The ET2DS used a 35
o 
retinal image with optic disc in the centre to evaluate 
the parameters on at least 3 measurable arteriolar bifurcation angles. Using multiple 
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numbers of branching point measurements from one individual image has been 
shown to provide a more reliable estimate (compared with one single angle 
measurement) and to minimise a great deal of variation between different images 
(Patton et al., 2006). However, Patton et al. (2007) measured the median value from 
the five most proximal arteriolar bifurcations, which represented the first bifurcation 
of the arterioles from the optic disc margin. In the ET2DS, measurements were not 
restricted to the most proximal bifurcations but often extended to those which could 
most easily be evaluated given that on many occasions it was difficult to detect at 
least three arteriolar angles in the whole field of a retinal image. Although it has been 
shown in a healthy normotensive population that the calculated branching coefficient 
from peripheral arteriolar junctions was not different from more central arteriolar 
junctions (Patton et al., 2006), the relationship between bifurcation angles and degree 
of eccentricity remains uncertain. Using an animal model (isolated arterioles 
examined in vivo from cremasteric muscle) to evaluate actual measured angles, 
Frame and Sarelius (1993) found that arteriolar bifurcation angles vary 
systematically with position for sequential branches and that angles change with flow. 
It is possible that the three angle measures in the present study are subject to greater 
variability due to the random position of arteriolar bifurcations and their limited 
number. 
 
Despite choosing the images with the best quality from either eye, in about 
55% of the images, the number of measurable arteriolar bifurcations did not reach 
the required minimum of 3. The narrower field of view prohibited the observation of 
more arteriolar angles than were seen in the larger field (e.g. 45
o
) of Patton‘s study. 
In addition, a semi-automatic method of measurement was applied, which was 
technically more demanding compared with the manual estimation used by Patton et 
al. (2007). However, this could be more accurate than the manual estimation given 
that identification of the three midlines in trunk and branch vessels is heavily 





Intra-grader reliability for arteriolar bifurcation angles and branching 
coefficient was moderate to high (intra-class correlation coefficient of 0.72 and 0.53). 
For inter-grader reliability, the intraclass correlation coefficient for branching 
coefficient was 0.69 and the Bland-Altman plot demonstrated a large degree of 
variability with a coefficient of repeatability of 0.7. This was considered moderately 
poor, in view of the small range of scale of the branching coefficient in this cohort. 
There was no correlation for angle measurements between the two graders. Although 
it should be noted that each median angle measurement reflects the three arteriolar 
junctions, and therefore will not solely reflect individual angle measurement 
difference but also the differing choice between individuals as to which are the three 
measurable junctions, this finding seriously questions the usefulness of this 
semi-automatic measure in epidemiological studies.  
 
Within one junction measurement, the manual selection of the central 
bifurcation position as starting point is subjective and also variable between 
individual graders. It has been noted that the precise location of the centre of the 
bifurcation is important for angle calculation. One pixel of difference in angle vertex 
position can result in two to three degrees of difference in the calculated angle (Gao 
et al., 2000). More recently, Hughes et al. (2009) has developed a new method, in 
which the initial estimate provided by the grader acts only as a first step in the 
determination of the centre of the bifurcation and will be further refined by a 
computer programme in the subsequent steps. It could be more objective and 
efficient using such an automatic process compared with the semi-automatic method 
used in the ET2DS. 
 
In all of the remaining 980 subjects who had gradable images for retinal 
vessel calibre measurements, 536 subjects had retinal images either of too poor 
quality to analyse all three arteriolar junctions or less than three arteriolar junctions 
were evaluable within the 35
o 
field. The high proportion of missing data for arteriolar 
bifurcation angle and branching coefficient raises concerns about selection bias. 
When comparing the characteristics of participants included in this analysis with 
those excluded (no retinal photographs or ungradable retinal arteriolar bifurcations), 
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those excluded were more likely to have prevalent coronary heart disease, stroke or 
TIA, and performed worse on all cognitive tests. However, differences between the 
graded and ungraded groups in these cognitive abilities were small. 
 
6.4. General limitations 
Several general study limitations deserve mentioning in relation to the 
findings presented above. Analyses were cross-sectional, limiting the ability to 
determine the temporal sequence of the associations reported. Lifetime imputed 
cognitive decline was estimated by including the MHVS as a covariable in analyses. 
However, to date only the difference between the NART and scores on the Raven‘s 
Standard Progressive Matrices (non-verbal general fluid reasoning) has been 
validated as a measure of lifetime change in cognitive function (Deary et al., 2004a). 
It is likely that the MHVS might not have adequately reflected the test components 
represented by other neuropsychological measures that were used in the study. The 
ET2DS is an ongoing four-year follow-up study and the actual cognitve change or 
decline from the baseline performance may provide a more objective outcome 
measure.  
 
Associations may have been attenuated by potential survival bias. Diabetic 
retinopathy and severe cognitive impairment have been shown to be related to 
mortality in the diabetic population (McGuire et al., 2006). If people with more 
severe retinal microvascular abnormalities died, and also had worse cognitive test 
scores, those still living would have represented neither the most severe retinal 
vascular disease nor the most extreme cognitive ability scores. The original study 
cohort was recruited from the pool of surviving diabetic patients on the Lothian 
Diabetes Register. Participants in the ET2DS were less likely to be socially deprived 
and had slightly lower mean systolic blood pressure compared with non-participants. 
Other characteristics, including age, median duration of diabetes, total cholesterol, 
HbA1c and treatment status (percentage on insulin) were similar in the two groups. 




The cognitive test battery used in the present study included widely-used, 
validated measures of major components of human cognitive function which are 
known to be sensitive to the effects of biological ageing or neurological insults by 
diabetes. However, only one single test was used for assessing any particular 
cognitive domain. As a result, it is possible that only some or limited aspects of what 
may be considered complex mental functions were actually determined (Lezak, 
1995). For example, executive functioning was assessed only by a single brief task of 
word fluency. It is possible that this measure itself did not sufficiently reflect the 
complexity and importance of this particular cognitive domain (Rafnsson, 2006). In 
addition, as a measure of high level of cognitive ability, digit symbol test is an 
obscure ‗package of information processing speed‘ with a number of different 
fundamental components, such as nerve conduction velocity, inspection and reaction 
time. It may be more helpful for understanding age or diabetes-related variances in 
cognitive function if these specific processing parameters of the brain are assessed 
individually. For example, simpler reaction time indices have been shown to play an 
intermediate role in the association between white matter abnormalities (i.e. water 
diffusion tensor parameters) and higher level cognitive test scores associated with 
ageing (Deary et al., 2006). 
 
Some potential confounders of the retinopathy-cognition associations 
presented were not taken into account in the multivariate analyses, including 
medication history and other ocular factors (e.g. intraocular pressure). As a 
consequence, the possible confounding of the associations reported herein by 
medication use, where diabetic patients with retinal microvascular abnormalities 
were more likely to be taking medication with an effect on interfering with cognitive 
performance, cannot be ruled out.  
 
As many statistical tests were performed, it is possible that a type I error 
(incorrect rejection of a true null hypothesis) may have occurred i.e. some of the 
findings may be due to chance despite being statistical significant. Use of the 
commonly applied Bonferroni corrections to reduce the p-value taken as statistically 
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significant would have been inappropriate because the cognitive test variables were 
not independent (Deary et al., 2006). In addition, use of Bonferroni corrections may 
lead to additional problems, including increased likelihood of a type II error 
(incorrect acceptance of a null hypothesis when the alternative is true) (Rafnsson, 
2006). The aim of the study was to investigate both overall cognitive ability and 
specific cognitive domains individually and so consider the role of individual 
associations in their own right (e.g. biological plausibility), rather than addressing a 
universal null hypothesis, i.e. where the null hypothesis states that there is no 
difference between groups for any of the variables under study. The relationships 
examined were specified as a priori thus minimising the number of possible analyses. 
The possibility of a type I error was further decreased by data reduction in generating 
a general cognitive factor.  
 
In some instances, associations became stronger after controlling for 
potential confounding variables. While this may have occurred by chance, in some 
instances it may reflect the complexity of the associations between small vessel 
disease and cognitive outcomes in Type 2 diabetes. Findings from the stratified 
analyses should be interpreted with caution, as they were not specified a priori and 
there may be statistical power concerns following stratification. 
 
Despite the exclusion of patients with overt dementia or AD, it is possible 
that some clinically cognitively impaired patients might have been included in the 
study. Only about 2.8% of the 1066 subjects scored less than 24 on the MMSE, a 
widely used cut-point for severe cognitive impairment. Impaired performance on the 
MMSE was not related to diabetic retinopathy status or to quantitative retinal 
vascular parameters. In sensitivity analyses, after excluding these patients, the 
significant associations highlighted and discussed were essentially unaltered. 
 
6.5. Possible neuropathological mechanisms of 
cerebral microvascular disease in cognitive 
dysfunction in diabetes 
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To date, information on the microvascular contributions to cognitive 
dysfunction has arisen primarily from pathologic and brain imaging studies. The lack 
of structural neuroimaging in the ET2DS hindered the further interpretation of the 
potential neuropathological substrates underlying the relationships which were found. 
On the other hand, there are still no accepted standards for the lesion load on imaging 
that can explicitly characterise a person‘s cognitive dysfunction as vascular origin 
(Jellinger, 2007). However, it is likely that cerebral microvascular disease associated 
with diabetes, can induce diverse changes affecting fibres and tracts connecting 
eloquent cortical and subcortical grey matter areas, either visible or invisible on 
standard MRI (e.g. microinfarcts detectable only by direct microscopic examination 
of the brain), eventually leading to disruption of normal neurocognitive processes. 
Furthermore, a disintegration of the cerebral microcirculation‘s blood-brain barrier 
may be an important pathophysiological mechanism in the occurrence of cognitive 
dysfunction in Type 2 diabetes. 
 
6.5.1. Neuropathological substrates  
Cerebral microvascular disease accounts for about a third of acute cerebral 
ischaemic events (i.e. transient ischaemic attack or stroke) and contributes to the 
development of asymptomatic ischaemic injuries of the brain (Grau-Olivares and 
Arboix, 2009). These clinically overt or ‗silent‘ lesions and their manifestations 
predominantly involve subcortical gray matter and white matter structures. The 
spectrum of the lesion loads seen on brain imaging includes lacunar infarcts, white 
matter lesions and microbleeds. 
 
Lacunar infarcts 
In general, people with Type 2 diabetes are 1.3 times more likely to have 
small subcortical infarcts (lacunar infarcts) than those without diabetes (van Harten 
et al., 2006). Lacunar infarcts may cause acute symptoms when they occur at 
strategic sites where descending and ascending long tracts are concentrated 
(Norrving, 2008). However, substantial evidence has clearly shown that direct 
ischaemic injuries to deep central gray matter mostly involving the basal ganglia and 
thalamus, occur most commonly without any apparent neurological symptoms 
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(clinically ‗silent‘) (Vermeer et al., 2007; Norrving, 2008). On MRI scanning, 
subcortical infarcts are characterised by areas of focal hypertensities on T2 weighted 
images with corresponding hypointense lesions on T1 or FLAIR imaging, that are 
usually less than 15 mm in diameter. These anatomic regions are served by deep, 
small and non-branching end arteries, arising directly from large cerebral arteries. 
 
Although emboli (from the heart or extracranial arteries) can cause lacunar 
inarcts, the vast majority of infarcts are attributable to cerebral microvascular disease 
(Wardlaw et al., 2009). It has been suggested that both arteriolosclerosis and 
lipohyalinosis may contribute directly to subcortical gray matter infarctions. For 
example, microatheromatous vessel pathology (atheromatous plaques) may produce 
lumen stenosis or occlusion of small penetrating arterioles which are lack of 
collateral supply. Lipohyalinosis pathology may lead either to thrombotic occlusion 
of the lumen or to mural destruction with formation of microaneurysms and 
haemorrhages. A popular hypothesis is that these cerebral microvascular 
abnormalities may cause an inability of the blood vessels to maintain and 
autoregulate cerebral blood flow and therefore predispose small regions of the brain 
parenchyma served by each vessel to ischaemia and necrosis (Thompson and Hakim, 
2009). More recently, it has been proposed that vascular leakage is associated with 
small vessel disease in the brain, and damage to the blood-brain barrier could be an 
important mechanism in the initiation or worsening of cerebral microvascular disease 
(Farrall and Wardlaw, 2008). This is discussed below. 
 
Lacunar infarcts and retinal microvascular abnormalities 
There are limited data on the presence of symptomatic or silent small brain 
infarcts in relation to retinal microvascular abnormalities. In a recent small-scale 
analysis of older patients with lacunar and cortical ischaemic stroke, Doubal et al. 
(2009a) found no significant differences in proportions with retinopathy features 
(defined as the presence of haemorrhages, microaneurysms, and hard or soft exudates) 
between stroke subtypes. However, relative to large artery cortical ischaemic stroke, 
wider retinal venular diameter was significantly associated with lacunar stroke 
subtype (Doubal et al., 2009b). In another cross-sectional study with relatively larger 
sample size, the patients with lacunar stroke were more likely than those with other 
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stroke subtypes to have smaller AVRs, retinal arteriovenous crossing abnormalities 
and enhanced light reflex of the arteriolar wall (indicates arteriolar wall thickening) 
(Lindley et al., 2009). 
 
With respect to asymptomatic infarcts, Kwa et al. (2002) reported that the 
prevalence of retinal exudates was significantly higher in patients with lacunar 
infarctions than those without any MRI-defined cerebral small vessel disease. In a 
large population-based cross-sectional study of middle-aged people free of stroke, 
the presence of retinal microvascular abnormalities (presence of arteriovenous 
nicking, focal arteriolar narrowing, blot haemorrhages and microaneurysms) was 
independently associated with higher prevalence of cerebral infarcts (most of which 
were lacunar)(Cooper et al., 2006). In the Cardiovascular Health Study, the smaller 
AVRs and the presence of arteriovenous nicking were independently associated with 
the presence of lacunar infarcts in elderly people (Longstreth et al., 2007). In 
longitudinal analyses from the Rotterdam Study, Ikram et al., (2006d) found wider 
retinal venular diameters were associated with a higher risk of 3.3-year progression 
of lacunar infarcts between two MRI scans. However, the association was attenuated 
beyond statistical significance after controlling for other cardiovascular risk factors.  
 
Lacunar infarcts and cognitive dysfunction 
There is epidemiological evidence that deep subcortical infarcts could induce 
measurable changes in higher cortical functioning as indexed by cognitive tests. In 
particular, deep gray matter (basal ganglia and thalamus) infarcts may be an 
important predicator (Gold et al., 2005). In a modest sample size (n=164) of healthy 
elderly people, the presence of subcortical brain infarctions (defined by pathological 
examination) has been associated (but non-significantly) with worse domain-specific 
cognitive test performance including working and semantic memory, perceptual 
speed and visual-spatial abilities. Conversely, no association was found with reduced 
global cognitive function based on a summary score of all tests (Schneider et al., 
2003).  
 
In other cross-sectional analyses, silent infarcts in the basal ganglia 
determined by MRI were associated with slower verbal memory retrieval speed and 
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worse executive functioning (O‘Brien et al., 2002). Thalamic infarcts were related to 
worse focused attention in addition to impaired performance in verbal memory 
retrieval speed and executive functioning. In the Rotterdam Scan study, silent 
thalamic infarcts at baseline predicated a greater four-year decline in verbal memory 
performance, whereas the presence of silent infarcts that were not located in the 
thalamus (mostly located in the basal ganglia) were associated with a decline in 
psychomotor speed tasks (Vermeer et al., 2003). In addition to location, multiple 
silent infarcts compared with a single lesion were more strongly associated with 
cognitive decline. The effects were limited to those with incident silent infarcts, 
irrespective of whether they had silent lesion at baseline, suggesting a stepwise 
worsening in higher cortical functioning following silent subcortical infarction 
(Rafnsson, 2006). Manschot et al. (2006) demonstrated that in modestly-sized 
samples of subjects with Type 2 diabetes, the presence of infarcts was negatively and 
significantly associated with information processing. Negative associations were also 
shown in attention/executive function, abstract reasoning and memory albeit 
non-significant.  
 
Given the complex cortico-subcortical circuitry networks connecting the 
superficial and deep structures, these subcortical infarcts may lead to wider-ranging 
effects on cortical functioning (Mori, 2002; Tekin and Cummings, 2002; Rafnsson, 
2006). Specifically, Baron et al. (1986) observed that up to 20% reduction in 
metabolism in cortical areas both ipsi- and contralateral to unilateral thalamic infarcts. 
This pattern may reflect the fact that the thalamocortical connections comprise 
specific systems connecting relay nuclei with specific cortical areas as well as 
non-specific systems projecting diffusely into the cerebral cortex (Rafnsson, 2006). 
However, it remains unclear how exactly wide-ranging cortical inactivity might 
come about secondary to a focal thalamic infarction. As a result, several pathways 
have been proposed by Baron et al. (1986) which include: a) anterograde 
degeneration of thalamocortical terminals, b) retrograde degeneration of the 
corticothalamic neurons following damage to their thalamic terminals, c) 
transsynaptic degeneration of the cortical neurons, following damage to the 
thalamocortical system, or d) decreased activity of cortical neurons without structural 
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damage secondary to the loss of activating afferences from the thalamus (Rafnsson, 
2006). 
 
White matter lesions  
Changes in the subcortical white matter, visualised as bright, hypertensive 
deep or periventricular white matter regions on T2-weighted MRI scans, are 
frequently observed in neurologically intact older people. White matter changes are 
not specific to infarcts, and frank infarction might be rare changes seen with 
neuroimaging than white matter lesions (WMLs) (Moorhouse and Rockwood, 2008).  
 
Although diverse pathogenic processes may cause changes in the cerebral 
white matter, most lesions in the elderly are thought to be of vascular origin (Malloy 
et al., 2007) and the primary vascular mechanism is small vessel disease. For 
example, arteriolosclerosis with thickening (hyalinisation) of deep perforating (e.g. 
medullary) arterioles may induce complete or incomplete ischaemic infarctions 
and/or hypoperfusion-hypoxic injury such as diffuse rarefaction. These may then 
induce loss of axons, demyelination, inflammation (gliosis) and necrotic changes 
which are characteristic neuropathological correlates of vascular-related white matter 
abnormalities (Englund, 2002). Recently, it has been proposed that different from 
deep WMLs specifically due to small vessel disease, periventricular WMLs could be 
more likely determined by chronic hemodynamic insufficiency (e.g. focal or 
systematic hypoperfusion due to carotid atherosclerosis) or inability of blood brain 
barrier to absorb excessive interstitial fluid resulting from disruption of the 
ependymal lining (the blood-cerebrospinal fluid barrier) (Kim et al., 2008).   
 
White matter lesions and retinal microvascular abnormalities 
There have been a few studies looking at the association of diabetic 
retinopathy with WML, although some earlier studies may have been affected by 
confounding factors, such as the presence of hypertension and other co-morbidity. 
For example, in a small clinic-based study based on people with Type 1 diabetes who 
had had laser treatment for proliferative diabetic retinopathy, no association was 
found between retinopathy and cerebral MRI whiter matter abnormalities (Yousem et 
al., 1991). More recently, Ferguson et al. (2003) reported on a cross-sectional study 
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of young people with type 1 diabetes and found an association between the presence 
of microaneurysms and small focal white-matter hyperintensities in the basal ganglia. 
 
In population-based studies, Kwa et al. (2002) found that the presence of 
retinal arteriolar abnormalities, including narrowing and arteriolosclerosis was 
significantly more frequent in patients with MRI signs of cerebral white matter 
lesions than those without any cerebral small vessel disease. In the ARIC study, 
people with retinopathy and other arteriolar abnormalities were 2.1 to 4.0 times more 
likely to have MRI-defined WMLs than people without these retinal signs, 
independent of age and vascular risk factors. In particular, the more severe signs of 
microvascular damage (microaneurysms, haemorrhages and exudates) were most 
strongly associated with WMLs (Wong et al., 2002c). In another cross-sectional 
analyses based on elderly people in the Cardiovascular Health Study, the smaller 
AVRs were independently associated with the more severe white matter grade 
(Longstreth et al., 2007). In longitudinal analyses from the Rotterdam Study, Ikram 
et al. (2006d) found wider retinal venular diameters were significantly associated 
with a higher risk of 3.3-year progression of both periventricular and subcortical 
WML between two MRI scans.  
 
White matter lesions and cognitive dysfunction 
There is well-established evidence on the significance of the cerebral white 
matter integrity for higher cortical functioning (Malloy et al., 2007). In a recent 
quantitative review of 23 empirical studies, the burden of white matter 
hyperintensities was also found to be associated with poorer cognitive performance 
on tasks of global cognitive function, processing speed, delayed memory and 
executive functioning (Dixon and Raz, 2000). Other studies have associated the 
presence or progression of white matter lesions with a greater decline in mental 
processing speed (van den Heuvel et al., 2006; van Dijk et al., 2008), memory 
(Silbert et al., 2008), conceptualisation and visuopractical skills (Schmidt et al., 2005) 
and executive functioning (Kramer et al., 2007). White matter abnormalities also 
contributed independently of childhood mental ability to lifetime decline in general 
cognitive ability but not individual mental functions per se (Deary et al., 2003).  
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Additional evidence comes from recent studies using diffusion tensor MRI 
(DTI) where markers sensitive to the detection of white matter microstructural 
integrity have been associated with cognitive outcomes (Rafnsson, 2006). As a result, 
Vernooij et al. (2009) reported white matter water diffusion parameters were 
significantly associated worse performance on tasks assessing global cognition, 
information processing speed and memory. While in normal-appearing white matter, 
diffusivity was related to executive function. Interestingly, Shenkin et al. (2005) 
showed a strong, consistent and negative relationship between diffusion indices and 
performance on executive functioning, which was not restricted to any of the 
anatomical regions examined, including the frontal lobe area.  
 
In the light of these reports, white matter hyperintensities have an impact on 
higher cortical functions, particularly these may rely on either processing speed or 
the intact diffuse neural networks (e.g. executive functions) (Rafnsson, 2006). These 
findings further lend support to the neurobiological hypothesis that the loss of white 
matter integrity may lead to impaired information transfer between different cortical 
areas, from a loss of transfer speed in the case of demyelination to complete 
disconnection when axonal disruptions occur (Deary et al., 2009). Interactions 
between distant cortical areas are considered as crucial for the appearance of higher 
cognitive functions (Sullivan and Prefferbaum, 2006). 
 
Importantly, there is very limited evidence regarding the importance of 
white matter lesion as a substrate of cognitive deficits in diabetic patients. In a small 
sample (n=92) older people with Type 2 diabetes, periventricular hypertintensities 
correlated significantly and negatively with motor speed tasks (van Harten et al., 
2007). In another sample (n=113) of people with Type 2 diabetes, both the 
periventricular and deep white matter hypertintensities were significantly and 
inversely related to measures of information processing speed (Manschot et al., 
2006). In addition, periventricular hypertintensities were associated with worse 
attention and executive function. Despite the paucity of data, both studies may 
emphasize the importance of white matter integrity for processing speed or executive 
function, implying that deficits in other cortical functions may be secondary to 
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suboptimal functioning of either of them in Type 2 diabetes.  
 
Cerebral microbleeds 
Another group of lesions that has received increasing attention is cerebral 
microbleeds (CMBs), which are recognised by small round homogenous low signal 
appearance on gradient-echo T2* MRI scans but are difficult to detect on standard 
T2-weighted MRI sequences. Demonstrated MRI-based microbleeds have been 
found in more than half of patients with lacunar strokes and are associated with 
increasing age, hypertension, diabetes, the presence of lacunar infarcts and white 
matter hyperintensities (Cordonnier et al., 2007). CMBs apparent on gradent echo 
MRI are characterised histopathologically by haemosiderin deposits due to frank 
microvascular haemorrhages or blood leakage from arterioles, with necrosis or 
infarction of the surrounding tissue (Cordonnier et al., 2007). Lipohyalinosis, 
ruptured arteriosclerotic mcirovessels and occasional amyloid deposits have been 
observed in the deep perforating arterioles feeding the areas of the brain surrounding 
CMBs. 
 
Cerebral microbleeds and retinal microvascular abnormalities 
To date, there is only one epidemiological study examining the relation of 
retinal microvascular signs to CMBs. In this large population-based study, Qiu et al. 
(2008) described multiple CMBs in one third of people (mean age 78.1 years) with 
retinal microaneurysms/haemorrhage and half of those with arteriovenous nicking. 
More specifically, those with diabetes, in combination with the presence of either 
retinal arteriovenous nicking (odds ratio, 2.47; 95%CI: 1.42, 4.31) or retinal 
microaneurysms/haemorrhage (odds ratio, 2.28; 95%CI: 1.24, 4.18) were 
significantly more likely to have multiple cerebral microbleeds. 
 
Cerebral microbleeds and cognitive dysfunction 
The existence and quantitative burden of microbleeds on cortical 
functioning have remained relatively unexplored. In a small case-control study 
(Werring et al., 2004), the presence of microbleeds was significantly associated with 
an increased risk of executive impairment, independent of the prevalent ischaemic 
stroke and white matter lesions. In addition, patients with executive dysfunction had 
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more microbleeds in the frontal region and in the basal ganglia. There was also a 
modest correlation between the number of microbleeds and the number of cognitive 
domains impaired. Although the confounding by lacunar infarcts cannot be excluded 
given that no T1-weighted imaging was performed to make a definitive count of 
lacunar infarcts, the authors proposed that microbleeds may influence cortical 
functioning by the effects of small focal destructive lesions accumulating in strategic 
subcortical and cortical structures, or important connection fibres (Werring et al., 
2004). Whether such radiological abnormality is also associated with cognitive 
dysfunction in diabetic patients remains to be investigated. 
 
6.5.2. Increased blood-brain barrier permeability 
Fisher originally observed in his pathological work that a substantial 
proportion of lacunar infarcts were attributable to an intrinsic cerebral small 
arteriolar abnormality, characterised by vessel wall thicknening, focal arteriolar 
dilatation, striking loss of normal vessel wall architecture, and extravasation of blood 
components into and through the wall (Fisher, 1968). This is also described as 
‗segmental arteriolar disorganization‘, ‗lipohyalinosis‘, or ‗fibrinoid necrosis‘ (Fisher, 
1968; Lammie, 2000). Recently, the intrinsic small vessel disease is recognised as a 
generalised rather than focal small vessel condition given that these changes are also 
associated with white-matter lesions (WMLs) and microbleeds (Wardlaw et al., 
2008). 
 
The main theories on what causes the cerebral micvascular abnormality 
include microatheroma, endothelial dysfunction or inflammation (Davis and Donnan, 
2004). On the other hand, while ischaemia may be the primary mechanism whereby 
the microvascular disease damages the brain parenchyma, evidence for reduced 
blood flow is conflicting, and low cerebral blood flow could be consequence upon 
reduced tissue supply (Farrall and Wardlaw, 2008). Accumulating observations from 
pathological and imaging studies as well as animal models have suggested the 
primary event could be alteration of cerebral microvascular endothelial (i.e., 
blood-brain barrier [BBB]) dysfunction. The small-vessel endothelium becomes 
more permeable, allowing substance that should remain intravascular to enter and 
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damage the vessel wall (causing thickening, inflammation and eventual 
disintegration) and then into the perivascular parenchyma to cause the tissue lesions 
(Wardlaw et al., 2009). The BBB is crucial for the regulation of the normal neuronal 
and glial cell environment and is a key component of the ‗neurovascular unit‘ 
(Farrall and Wardlaw, 2008). Elevated BBB permeability with normal ageing, 
vascular cognitive impairment, white matter lesions and AD has been increasingly 
recognised (Wardlaw et al., 2009). In particular, using magnetic resonance imaging 
on patients with Type 2 diabetes, Starr et al. (2003) demonstrated increased BBB 
permeability to gadolinium-diethylenetriamine penataacetic acid (DPTA) and 
concluded that although the openings in the BBB were to a small molecule 
(gadolinium-DTPA), clinical significance was substantial given their potential effects 
in the increased progressive cognitive impairment often seen in diabetic patients. 
 
Several endogenous agents have been implicated in altered BBB 
permeability, possibly leading to cerebral microvascular disease. These include 
abnormally elevated inflammatory and endothelial activation markers, which have 
been found to be associated with established and progressive white-matter lesions 
(Abbott, 2000; Hassan et al., 2003; van Dijk et al., 2005).  
 
Hyperglycaemia has been shown to damage endothelial cells in the BBB 
through activation of protein kinase C (PKC) and increased oxidative stress. 
Activation of PKC may enhance nuclear translocation of NF-κB which is a central 
transcription factor involved in the inflammatory response processes (Taguchi, 2009). 
Hyperglycaemis also induces excess production of reactive oxygen species (ROS), 
chemically reacting with and damaging DNA, proteins and lipids (Taguchi, 2009). 
Overproduction of ROS causes pathological changes in the endothelium of the BBB, 
promotes nuclear translocation of NF-κB, and activates microglia (Taguchi, 2009). 
Advanced glycation endproducts (AGEs) may also induce chronic inflammation 
involving NF-κB and further cause chronic pathological changes in both endothelium 




6.6. Chapter summary 
Analysis in the ET2DS has shown that both diabetic retinopathy and retinal 
vessel calibres are associated with a modest but significant estimated decline in a 
range of diverse cognitive functions in older people with Type 2 diabetes. In 
particular, these cognitive measures showed a significant relationship with increasing 
severity of diabetic retinopathy. Severity of diabetic retinopathy was related to a 
greater decline in information processing speed and, in men for general cognitive 
function and word fluency. Larger retinal arteriolar calibre was also associated with 
an increased decline in verbal memory in men. Retinal microvascular abnormalities 
explained about 1 to 2 % of the total variance in these cognitive measures. 
 
Previous studies in people with Type 1 diabetes and in the general 
population that examined retinal microvascular abnormalities and cognitive function 
show results that are comparable with the ET2DS. The robust control for a large 
number of potential confounding factors suggest these associations may in fact rely 
on the underlying pathophysiological processes. Although structural neuroimaging 
was not conducted in the present study and prevented further interpretation of the 
results, the effects of cerebral microvascular disease as indicated by retinal vascular 
signs were mainly mediated through the relationship of these with general cognitive 
function. Given that general intelligence is thought to reflect neurocognitive 
processes depending on intact deep white and matter integrity, it is possible that 
cerebral microvascular disease associated with diabetes may affect subcortical 
structures and the disruption of the blood-brain barrier may be an important 
pathophysiological feature in the occurrence of cognitive dysfunction in people with 








Conclusions and Recommendations 
 
    In this chapter, the principal conclusions are summarised and the 
recommendations for future research are presented. 
 
7.1. Conclusions 
In the ageing population, Type 2 diabetes is an established risk factor for 
age-related cognitive impairment and decline, in addition to stroke and dementia. In 
people with diabetes, retinal microvascular disease is associated with reduced 
cognitive ability and with estimated cognitive decline, especially in men, and 
independent of a range of potential confounding factors. Given the homology 
between the retinal and cerebral microcirculations, this supports the hypothesis that 
cerebral microvascular disease is involved in the aetiology of diabetes-related 
cognitive decline during aging. Cerebral microvascular disease may induce 
neuropathological changes in white matter and deep subcortical gray matter 
structures which lead to deficits in higher cortical functioning. However, further 
investigation is required to confirm the direction and potential causal nature of the 
association between retinal microvascular disease and cognitive decline. 
 
In people with Type 2 diabetes, larger retinal arteriolar calibre, but not other 
quantitative retinal abnormalities, may also be associated with a greater decline in 
cognitive ability. This is especially the case for verbal memory in men. However, the 
mechanisms underlying this association are unclear. 
 
7.2. Recommendations for further research 
 
1. The direction of the association between diabetic retinopathy and cognitive 
impairment, and whether the associations of diabetic retinopathy and retinal vessel 
calibre with estimated cognitive decline may be causal in nature, remain uncertain. 
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Cerebral microvascular disease, as indexed by retinopathy, may lead to cognitive 
decline, or cognitive decline may make diabetes management more difficult, in turn 
promoting the development of cerebral microvascular disease. It is also possible that 
a third unidentified factor is causing both diabetic retinopathy and the cognitive 
decline. Prospective studies would help to clarify the temporal sequence of these 
associations and the clinical significance of these small, early cognitive function 
changes. Such a follow-up project involving the present study population for actual 
cognitive change is underway.  
 
From a clinical perspective, if the above findings are substantiated, 
diabetes-associated cognitive dysfunction may be amenable to treatment and 
preventive strategies targeted at small vessel disease and its risk factors in an ageing 
diabetic population. Such management strategies would need to be tested in 
randomised controlled trials of diabetic retinopathy risk reduction. 
 
2. Computer-assisted retinal vessel calibre measurements have proven to be accurate 
and reproducible and may provide additional clues to understanding the pathology 
and consequences of cerebral microvascular disease. However, quantification of 
arteriolar bifurcation angles is imprecise and time-consuming. More objective and 
efficient methods need to be developed.  
 
3. In the Edinburgh Type 2 diabetes study, retinal microvascular abnormalities were 
measured only at the baseline examination. Further studies are needed to investigate 
the progression and incidence of diabetic retinopathy and their associations with 
cognitive function. 
 
4. The sex-specific effect of diabetic retinopathy and retinal vessel calibre on 
cognitive function merits further examination in order to understand the complex 
association between microvascular disease and cognitive function in people with 
diabetes. Large studies in both men and women with Type 2 diabetes should be 
continued. 
 
5. The current findings are based on a primarily white sample representative of a 
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North European diabetic population. Replication of these findings in other 
racial/ethnic diabetic populations is required. 
 
6. In further studies, the administration of a number of tests for each major cognitive 
domain, particularly executive function and information processing, should be 
considered as opposed to the use in the present study of only a single marker of each 
principal domain. Moreover, the impact of subtle cognitive deficits on activities of 
daily living needs to be assessed given the importance of self-management behaviors 
in diabetes and the high complexity of diabetes treatment regimens (e.g., blood 
glucose testing, meal planning and medication compliance) (Munshi et al., 2006). 
This may also provide insights into the extent to which decline in specific cognitive 
abilities may be predictive of further cognitive decrements in the diabetic population. 
 
7. Few available previous studies have highlighted the importance of MRI-detected 
subcortical white matter and grey matter changes in patients with Type 2 diabetes 
(Manschot et al., 2006; van Harten et al., 2007). MRI studies need to be performed in 
older people with Type 2 diabetes recruited from different populations. They will 
provide complementary information to retinal vascular signs by using a different 
modality to fill gaps in knowledge on the relation between structural neuroimaging 
and neuropsychological outcomes in people with diabetes. When possible, future 
studies should adopt more sensitive neuroimaging techniques, such as diffusion 
tensor MRI, for the measurement of the integrate connectivity of cerebral white 
matter to determine the potential impact of early or very small changes in the white 
matter on cognitive function. Studies are also needed to relate established 
neuro-imaging markers of cerebral microvasuclar disease (such as cerebral white 
matter lesions and lacunar infarcts) with retinal microvascular abnormalities in 
diabetes. 
 
8. Further animal/experimental studies are required to elucidate the pathophysiology 
of diabetic retinopathy as well as changes in retinal vessel calibre. Histo-pathological 
studies are also needed on the association between changes in cerebral and retinal 
microvasculature. A better understanding of both may shed light onto the complex 
pathogenesis of the consequences of cerebral microvascular disease. 
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9. Further genetic association studies may be informative. For example, genetic 
variants can serve as unconfounded markers of exposures (instrumental variables) for 
determining the causal effect of non-genetic risk factors on disease traits and clinical 
outcome. However, current genome-wide association studies on retinal vascular 
calibre genotypes are inconclusive (Sun et al., 2009). Whether retinal vascular 
calibres are intermediate phenotypes of diabetic retinopathy and cerebral 
microvascular disease needs to be further investigated. 
 
10. Retinal microvascular abnormalities could serve as a useful biomarker of cerebral 
microvascular disease to improve risk stratification in people with diabetes. However, 
the utility of retinal vascular imaging for risk stratification should be judged by a 
demonstration of independent predicative value that would substantially add to 
conventional methods (Nguyen and Wong, 2009). Application of common analytical 
methods in different studies would facilitate data pooling to generate more valid risk 
estimates (Nguyen and Wong, 2009). Until the additional value of these potential 
retinal vascular parameters is examined, the cost-effectiveness of retinal photography 
in screening for cognitive impairment in diabetes and identifying people with 
unexplained cognitive impairment who might benefit from risk reduction 
modification cannot be determined. 
 
11. Other systemic microvascular disease may be important but is not as specific as 
retinal microvascular abnormalities which serve a proxy of cerebral microvascular 
disease. Peripheral neuropathy (Perlmuter et al., 1984; Zaslavsky et al., 1995) and 
microalbuminuria (albumin-to-creatinine ratio, ACR) (Bruce et al., 2008) have also 
been found to predict the degree of cognitive slowing in people with Type 2 diabetes. 
A relationship between the number of microvascular complications and the 
magnitude of cognitive decline has been shown in patients with Type 1 diabetes. 
Evaluation of the additive or synergistic effects of these microvascular complications 
on cognitive decline is needed in order to promote risk prediction and stratification in 





Aartsen MJ, Martin M, Zimprich D. Gender differences in level and change in 
cognitive function: results from the Longitudinal Aging Study Amsterdam. 
Gerontology 2004; 50: 35-38. 
 
Abbott NJ. Inflammatory mediators and modulation of blood-brain barrier 
permeability. Cellular and molecular neurobiology 2000; 20: 131-147. 
 
Ahto M, Isoaho R, Puolijoki H, Laippala P, Sulkava R, Kivelä SL. Cognitive 
impairment among elderly coronary heart disease patients. Gerontology 1999; 45:  
87-95. 
 
Alberti KG, Zimmet PZ. Definition, diagnosis and classifi cation of diabetes mellitus 
and its complications. Part 1: Diagnosis and classifi cation of diabetes mellitus. 
Provisional report of a WHO consultation. Diabetic Medicine 1998; 15: 539-553. 
 
Aldington SJ, Kohner EM,Meuer S, Klein R, Sjolie AK. Methodology for retinal 
photography and assessment of diabetic retinopathy: the EURODIAB IDDM 
Complications Study. Diabetologia 1995; 38: 437-444. 
 
Allen KV, Frier BM, Strachan MWJ. The relationship between type 2 diabetes and 
cognitive dysfunction: longitudinal studies and their methodological limitations. 
European Journal of Pharmacology 2004; 490: 169-175. 
 
Alley D, Suthers K, Crimmins E. Education and cognitive decline in older Americans: 
results from the AHEAD sample. Research on Aging 2007; 29: 73–94. 
 
Almdal T, Scharling H, Jensen JS, Vestergaard H.The independent effect of type 2 
diabetes mellitus on ischaemic heart disease, stroke, and death: a population-based 
study of 13,000 men and women with 20 years of follow-up. Archives of internal 
medicine 2004; 164: 1422-1426. 
 
 315 
American Psychiatric Association. Diagnostic and Statistical Manual of Mental 
Disorders, Fourth edition (DSM-IV). Washington DC: American Psychiatric 
Association 1994. 
 
American Psychiatric Association. Diagnostic and statistical manual of mental 
disorders. 4
th
 edition test version (DSM-IV-R). Washington DC: American 
Psychiatric Association. 2000. 
 
American Diabetes Association. Report of the expert committee on the diagnosis and 
classification of diabetes mellitus. Diabetes Care 2002; 25 (Suppl.1): S5-S20. 
 
Anderson RJ, Freedl KE, Clouse RE, Lustman PJ. The prevalence of comorbid 
depression in adults with diabetes. Diabetes Care 2001; 24: 1069-1078. 
Anderson JV, Gale EAM. Diabetes mellitus and other disorders of metabolism. In: 
Kumar P, Clark M (Eds) Clinical Medicine, 5th edition. London: Elsevier Saunders 
Limited, 2002. pp.1069-1112. 
Anstey K, Christensen H. Education, activity, health, blood pressure and 
apolipoprotein E as predictors of cognitive change in old age: a review. Gerontology 
2000; 46: 163-177. 
 
Anstey KJ, Hofer SM, Luszcz MA. A latent growth curve analysis of late-life 
sensory and cognitive function over 8 years: evidence for specific and common 
factors underlying change. Psychology and Aging 2003; 18: 714–726. 
 
Anstey KJ, Lipnicki DM, Low LF. Cholesterol as a risk factor for dementia and 
cognitive decline: a systematic review of prospective studies with meta-analysis. The 
American journal of geriatric psychiatry 2008; 16: 343-354. 
 
Archer DB, Gardiner TA, Stitt AW. Functional anatomy, fine structure and basic 
pathology of the retinal vasculature. In Joussen AM, Gardner TW, Bernd K, Stephen 
R(eds). Retinal vascular disease Berlin Heidelberg: Springer-Verlag 2007. pp. 3-22. 
 316 
 
Areosa SA, Grimley EJ. Effect of the treatment of Type II diabetes mellitus on the 
development of cognitive impairment and dementia. Cochrane database of 
systematic reviews 2002; (4):CD003804. 
 
Arvanitakis Z, Wilson RS, Li Y, Aggarwal NT, Bennett DA.Diabetes and function in 
different cognitive systems in older individuals without dementia. Diabetes Care 
2006; 29: 560-565. 
 
Au R, Massaro J, Wolf P, Young M, Beiser A, Seshadri S, D‘Agostino R, DeCarli C. 
Association of white matter hyperintensity volume with decreased cognitive 
functioning: The Framingham Heart Study. Archives of Neurology 2006; 63: 246 
–250. 
 
Austin MP, Mitchell P. The anatomy of melancholia: does frontocortical 
pathophysiology underpin its psychomotor and cognitive manifestations? 
Psychological Medicine 1997; 25: 665-672. 
 
Awad N, Gagnon M, Messier C. The relationship between impaired glucose 
tolerance, type 2 diabetes, and cognitive function. Journal of clinical and 
experimental neuropsychology 2004; 26: 1044-1080. 
 
Azegrouz H, Trucco E, Dhillon B, MacGillivray T, MacCormick. Thickness 
dependent tortuosity estimation for retinal blood vessels. Conference proceedings  
28th IEEE Engineering in Medicine and Biology Society 2006; 4675-4678. 
 
Baddeley AD. Working Memory. Oxford, UK: Clarendon Press, 1986.  
 
Bain GH, Lemmon H, Teunisse S, Starr JM, Fox HC, Deary IJ, Whalley LJ. Quality 
of Life in healthy old age: relationships with childhood IQ, minor psychological 




Baker ML, Marino Larsen EK, Kuller LH, Klein R, Klein BE, Siscovick DS, Bernick 
C, Manolio TA, Wong TY. Retinal microvascular signs, cognitive function, and 
dementia in older persons. Stroke 2007; 38: 2041-2047. 
 
Baldwin RC. Is vascular depression a distinct sub-type of depressive disorder? A 
review of causal evidence. International journal of geriatric psychiatry 2005; 20: 
1–11. 
 
Baron JC, D‘Antona R, Pantano P, Serdaru M, Samson Y, Bousser MG. Effects of 
thalamic stroke on energy metabolism of the cerebral cortex. A positron tomography 
study in man. Brain 1986; 109: 1243-1259. 
 
Baron AD, Hemodynamic actions of insulin. American Journal of Physiology 1994; 
267: 187–202. 
 
Barrett-Connor E, Kritz-Silverstein D. Gender differences in cognitive function with 
age: The Rancho Bernardo Study. Journal of the American Geriatrics Society 1999; 
47: 159-164. 
 
Batty GD, Mortensen EL, Nybo-Andersen AM, Osler M. Childhood intelligence in 
relation to adult coronary heart disease and stroke risk: evidence from a Danish birth 
cohort study. Paediatric and Perinatal Epidemiology 2005; 19: 452-459. 
 
Batty GD, Deary IJ, Gottfredson LS. Premorbid (early life) IQ and later mortality 
risk: systematic review. Annals of Epidemiology 2007; 17: 278-288. 
 
Baune BT, Suslow T, Engelien A, Arolt V, Berger K. The association between 
depressive mood and cognitive performance in an elderly general population — The 
MEMO study. Dementia and Geriatric Cognitive Disorders 2006; 22: 142–149. 
 
Bell DS. Stroke in the diabetic patient. Diabetes Care 1994; 17:213-219. 
 318 
 
Bender R, Lange S. Multiple test procedures other than Bonferroni's deserve wider 
use. British Medical Journal 1999; 318: 600-601. 
 
Biessels GJ, van der Heide LP, Kamal A, Bleys RL, Gispen WH. Ageing and 
diabetes: implications for brain function. European journal of pharmacology 2002; 
441: 1–14. 
 
Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P Risk of dementia in 
diabetes mellitus: a systematic review. Lancet neurology 2006; 5: 64-74. 
 
Biessels GJ, Kerssen A, de Haan EH, Kappelle LJCognitive dysfunction and diabetes: 
implications for primary care. Primary care diabetes 2007: 187-193. 
 
Bischkopf J, Busse A, Angermeyer MC. Mild cognitive impairment-a review of 
prevalence, incidence and outcome according to current approaches. Acta 
Psychiatrica Scandinavica 2002; 106: 403-414. 
 
Boehm AG, Bowd C, Vasile C, El-Beltagi TA, Booth M, Zangwill LM, Weinreb RN. 
Comparison of two grading methods to evaluate focal narrowing of retinal arterioles 
in glaucoma. Graefe's archive for clinical and experimental ophthalmology 2002; 
240: 810-815. 
 
Bohannon AD, Fillenbaum GG, Pieper CF, Hanlon JT, Blazer DG.Relationship of 
race/ethnicity and blood pressure to change in cognitive function. Journal of the 
American Geriatrics Society 2002; 50: 424-429. 
 
Böhm B, Katz-Salamon M, Institute K, Smedler AC, Lagercrantz H, Forssberg H. 
Developmental risks and protective factors for influencing cognitive outcome at 5 
1/2 years of age in very-low-birth weight children. Developmental medicine and 
child neurology 2002; 44: 508-516. 
 
 319 
Bond GE, Burr R, McCurry SM, Rice MM, Borenstein AR, Kukull WA, Teri L, 
Bowen JD, McCormick WC, Larson EB. Alcohol, gender, and cognitive performance. 
Journal of Aging and Health 2004; 16: 615-640. 
 
Bourne VJ, Fox HC, Deary IJ, Whalley LJ. Does childhood intelligence predict 
variation in cognitive change in later life? Personality and Individual Differences 
2007; 42: 1551-1559. 
 
Brancati FL, Kao WH, Folsom AR, Watson RL, Szklo MIncident type 2 diabetes 
mellitus in African American and White adults: The Atherosclerosis Risk in 
Communities Study. Journal of American Medeical Association 2000;283: 
2253-2259. 
 
Brands AM, Van den Berg E, Manschot SM, Biessels GJ, Kappelle LJ, De Haan EH, 
Kessels RPA detailed profile of cognitive dysfunction and its relation to 
psychological distress in patients with type 2 diabetes mellitus. Journal of the 
International Neuropsychological Society 2007; 13: 288-297. 
 
Brayne C, Nickson J, McCracken C, Gill C, Johnson AL and the Analysis Group of 
the MRC CFA Study. Cognitive function and dementia in six areas of England and 
Wales: the distribution of MMSE and prevalence of GMS organicity level in the 
MRC CFA Study. Psychological Medicine 1998; 28: 319-335. 
 
Brinchmann-Hansen O, Heier H. The apparent and true width of the blood column in 
retinal vessels. Acta Ophthalmologica 1986; (Suppl.179): 29-32. 
 
Breteler MM, van Swieten JC, Bots ML, Grobbee DE, Claus JJ, van den Hout JH, 
van Harskamp F, Tanghe HL, de Jong PT, van Gijn J. Cerebral white matter lesions, 
vascular risk factors, and cognitive function in a population-based study: the 
Rotterdam Study. Neurology 1994; 44: 1246-1252. 
 
Brownlee M. Biochemistry and molecular cell biology of diabetic complications, 
 320 
Nature 2001; 414: 813–820. 
 
Bruce DG ,Davis WA, Casey GP, Starkstein SE, Clarnette RM, Almeida OP, Davis 
TME. Predictors of Cognitive Decline in Older Individuals With Diabetes Diabetes 
Care 2008; 31: 2103-2107. 
 
Buffon F, Porcher R, Hernandez K, Kurtz A, Pointeau S, Vahedi K, Bousser MG, 
Chabriat H.Cognitive profile in CADASIL. Journal of neurology, neurosurgery, and 
psychiatry 2006; 77: 175-180. 
 
Bulpitt CJ, Dollery CT, Kohner EM. The marginal plasma zone in the retinal 
microcirculation. Cardiovascular Research 1970; 4: 207-212. 
 
Butters MA, Becker JT, Nebes RD, Zmuda MD, Mulsant BH, Pollock BG, Reynolds 
CF. Changes in cognitive function following treatment of late-life depression. 
American Journal of Psychiatry 2000; 157: 1949-1954. 
 
Butters MA, Whyte EM, Nebes RD, Begley AE, Dew MA, Mulsant BH, Zmuda MD, 
Bhalla R, Meltzer CC, Pollock BG, Reynolds CF 3rd, Becker JT. The nature and 
determinants of neuropsychological functioning in late-life depression. Archives of 
General Psychiatry 2004; 61: 587–595. 
 
Caballero AE. Metabolic and vascular abnormalities in subjects at risk for type 2 
diabetes: the early start of a dangerous situation. Archives of Medical Research 2005; 
36: 241-249. 
 
Carroll JB. Human cognitive abilities: a survey of factor analytic studies. Cambridge, 
UK: Cambridge University Press, 1993. 
 
Chapman N, Mohamudally A, Cerutti A, Stanton A, Sayer AA, Cooper C, Barker D, 
Rauf A, Evans J, Wormald R, Sever P, Hughes A, Thom S. Retinal vascular network 




Chapman N, Dell'omo G, Sartini MS, Witt N, Hughes A, Thom S, Pedrinelli R. 
Peripheral vascular disease is associated with abnormal arteriolar diameter 
relationships at bifurcations in the human retina. Clinical Science 2002; 103: 
111-116. 
 
Chaturvedi N, Sjoelie AK, Porta M, Aldington SJ, Fuller JH, Songini M, Kohner EM; 
EURODIAB Prospective Complications Study. Markers of insulin resistance are 
strong risk factors for retinopathy incidence in type 1 diabetes. Diabetes Care 2001; 
24: 284–289. 
 
Chemerinski E, Robinson RG. The neuropsychiatry of stroke. Psychosomatics 2000; 
41: 5–14. 
 
Chen MS, Kao CS, Fu C, Chen C, Tai T. Incidence and Progression of Diabetic 
Retinopathy among Non-Insulin-Dependent Diabetic Subjects: A 4-Year Follow-Up 
International Journal of Epidemiology 1995; 24: 787-795. 
 
Cheung N, Wong TY. Obesity and eye disease Survey of Ophthalmology 2007; 52: 
180–195 
 
Cheung N., Wang JJ, Klein R, Couper DJ, Sharrett AR, Wong TY. Diabetic 
retinopathy and the risk of coronary heart disease: the Atherosclerosis Risk in 
Communities Study. Diabetes Care 2007a; 30: 1742–1746. 
 
Cheung N, Rogers S, Couper DJ, Klein R., Sharrett AR, Wong TY. Is diabetic 
retinopathy an independent risk factor for ischemic stroke? Stroke 2007b; 38: 398–
401. 
 
Cheung N, Tikellis G, Saw SM, Amirul Islam FM, Mitchell P, Wang JJ, Wong TY. 
Relationship of axial length and retinal vascular caliber in children. American 
 322 
Journal of Ophthalmology 2007c; 144: 658-662. 
 
Cheung N, Tong L, Tikellis G, Saw SM, Mitchell P, Wang JJ, Wong TY. 
Relationship of reitnal vascular caliber with optic disc diameter in children. 
Investigative ophthalmology & visual science 2007d; 48: 4945-4948. 
 
Cheung N, Islam FM, Saw SM, Shankar A, de Haseth K, Mitchell P, Wong TY. 
Distribution and associations of retinal vascular caliber with ethnicity, gender, and 
birth parameters in young children. Investigative ophthalmology & visual science 
2007e; 48: 1018-1024. 
 
Cheung N, Wong TY. Diabetic retinopathy and systemic vascular complications. 
Progress in Retinal and Eye Research 2008; 27: 161-176. 
 
Cheung N, Rogers SL, Donaghue KC, Jenkins AJ, Tikellis G, Wong TY. Retinal 
arteriolar dilation predicts retinopathy in adolescents with type 1 diabetes. Diabetes 
Care 2008; 31(9): 1842-1846. 
 
Cheung N, Donaghue KC, Lie G, Rogers SL, Wang JJ, Lim SW, Jekins AJ, Hsu W, 
Lee ML, Wong TY. Quantitative assessment of early diabetic retinopathy using 
fractal analysis. Diabetes Care 2009; 32: 106-110. 
 
Chew EY, Klein ML, Ferris FL 3rd, Remaley NA, Murphy RP, Chantry K, Hoogwerf 
BJ, Miller D. Association of elevated serum lipid levels with retinal hard exudate in 
diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 
22. Archives of Ophthalmology 1996; 114: 1079-1084. 
 
Christensen H, Henderson AS. Is age kinder to the initially more able? A study of 
eminent scientists and academics. Psychological Medicine1991; 21: 935-946. 
 
Christensen H, Hofer SM, Mackinnon AJ et al. Age is no kinder to the better 
educated: Absence of an association investigated using latent growth techniques in a 
 323 
community sample. Psychological Medicine 2001; 31: 15-28. 
 
Chui H Subcortical ischaemic vascular dementia. (SIVD). Neurologic Clinics 2007; 
25: 717-740. 
 
Cichowska A. Diabetes mellitus prevalence, obesity and deprivation in adults in 
Lothian, Scotland. Unpublished Master Dissertation, University of Edinburgh, UK. 
2004. 
 
Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema. 
Pathophysiology, screening and novel therapies. Diabetes Care 2003; 26: 
2653–2664. 
 
Clemons TE, Rankin MW, McBee WL. Cognitive impairment in the age-related eye 
disease study: AREDS Report No.16. Archives of Ophthalmology 2006; 124: 
537-543. 
 
Cohen J. Statistical power analysis for the behavioral sciences, 2nd edition. Hillsdale, 
NJ: Lawrence Earlbaum Associates.1988. 
 
Coker LH, Shumaker SA. Type 2 diabetes mellitus and cognition. An understudied 
issue in women‘s health. Journal of Psychosomatic Research 2003; 54: 129-139. 
 
Comijs HC, Dik MG, Deeg DJH, Jonker C. The course of cognitive decline in older 
persons: results from the Longitudinal Aging Study Amsterdam. Dementia and 
Geriatric Cognitive Disorders 2004; 17: 136-142. 
 
Cooper LS, Wong TY, Klein R, Sharrett AR, Bryan RN, Hubbard LD, Couper DJ, 
Heiss G, Sorlie PD. Retinal microvasuclar abnormalities and MRI-defined subclinical 




Cordonnier C, Al-Shahi Salman R, Wardlaw J. Spontaneous brain microbleeds: 
systematic review, subgroup analyses and standards for study design and reporting 
Brain 2007; 130: 1988-2003. 
 
Cosway R, Strachan MW, Dougall A, Frier BM, Deary IJ. Cognitive function and 
information processing in type 2 diabetes. Diabetic Medicine 2001; 18: 803-810. 
 
Couper DJ, Klein R, Hubbard LD, Wong TY, Sorlie PD, Cooper LS, Brothers RJ, 
Nieto FJ. Reliability of retinal photography in the assessment of retinal 
microvascular characteristics: the Atherosclerosis Risk in Communities Study. 
American Journal of Ophthalmology 2002; 133: 78-88. 
 
Cogan DG, Kuwabara T. Comparison of retinal and cerebral vasculature in trypsin 
digest preparation. British Journal of Ophthalmology 1984; 68: 10-12. 
 
Cowie CC, Rust KF, Byrd-Holt DD, Eberhardt MS, Flegal KM, Engelgau MM, 
Saydah SH, Williams DE, Geiss LS, Gregg EW. Prevalence of diabetes and impaired 
fasting glucose in adults in the U.S. population. Diabetes Care 2006; 29: 1263-1268. 
 
Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific 
mechanisms. Lancet Neurology 2004; 2: 169–178. 
 
Crawford JR. Current and premorbid intelligence measures in neuropsychological 
assessment. In JR Crawford, Parker DM, WW McKinlay (Eds.) A handbook of 
neuropsychological assessment. London: Erlbaum. 1992. pp.21-49. 
 
Crawford JR, Deary IJ, Starr J, Whalley LJ. The NART as an index of prior 
intellectual functioning: a retrospective validity study covering a 66 year interval. 
Psychological Medicine 2001; 31: 451-458. 
 
Crawford JR. Psychometric foundations of neuropsychological assessment. In LH 
Goldstein and J McNeil (Eds) Clinical Neuropsychology: a practical guide to 
 325 
assessment and management for clinicans. Chichester:Wiley. 2003. 
 
Critical Appraisal Skills Programme. 2004. http://www.chsrf. ca/kte_docs/casp_case. 
control_tool.pdf, http://www.chsrf.ca/kte_ docs/casp_cohort_tool.pdf  
 
Cukierman T, Gerstein HAC, Williamson JD. Cognitive decline and dementia in 
diabetes-systematic overview of prospective observational studies. Diabetologia 
2005; 48: 2460-2469. 
 
Cullum S, Huppert FA, McGee M, Dening T, Ahmed A, Paykel ES, Brayne C. 
Decline across different domains of cognitive function in normal ageing: results of a 
longitudinal population-based study using CAMCOG. International Journal of 
Geriatric Psychiatry 2000; 15: 853-862. 
 
Curtis TM, Major EH, Trimble ER, Scholfied CN. Diabetes-induced activation of 
protein kinase c inhibits store-operated Ca
2+
 uptake in rat retinal microvascular 
smooth muscle. Diabetologia 2003; 46: 1252-1259. 
 
Curtis TM, Scholfield CN. The role of lipids and protein kinase cs in the 
pathogenesis of diabetic retinopathy. Diabetes/metabolism research and reviews 
2004; 20: 28-43. 
 
Curtis TM, Gardiner TA, and Stitt AW. Microvascular lesions of diabetic retinopathy: 
clues towards understanding pathogenesis? Eye 2009; 23: 1496-1508. 
 
Davis SM, Donnan GA. Why lacunar syndromes are different and important. Stroke 
2004; 35: 1779-1780. 
 
Davis HS, Rockwood K. Conceptualisation of mild cognitive impairment: a review. 
International Journal of Geriatric Psychiatry 2004; 19: 313-319. 
 
Dawson D. Methodological issues in measuring alcohol use. Alcohol Research and 
 326 
Health 2003; 27:18-29. 
 
Deary IJ, Starr JM, Maclennan WJ. Fluid intelligence, memory and blood pressure in 
cognitive aging. Personality and Individual Differences 1998; 25: 605-619. 
  
Deary IJ. Looking down on human intelligence. New York: Oxford University Press, 
2000. 
 
Deary IJ, Leaper SA, Murray AD, Staff RT, Whalley LJ. Cerebral white matter 
abnormalities and lifetime cognitive change: a 67-year follow-up of the Scottish 
Mental Survey of 1932. Psychology and Aging 2003; 18: 140-148. 
 
Deary IJ, Whalley LJ, Crawford JR. An ‗instantaneous‘ estimate of a lifetime‘s 
cognitive change. Intelligence 2004a; 32:113-119. 
 
Deary IJ, Whiteman MC, Starr JM, Whalley LJ, Fox HC. The impact of childhood 
intelligence on later life: following up the Scottish mental surveys of 1932 and 1947. 
Journal of Personality and Social Psychology 2004b; 86: 130-147. 
 
Deary IJ, Bastin ME, Pattie A, Clayden JD, Whalley LJ, Starr JM, Wardlaw JM. 
White matter integrity and cognition in childhood and old age. Neurology 2006; 66: 
505-512. 
 
Deary IJ, Batty GD. Cognitive epidemiology: a glossary. Journal of Epidemiology 
Community and Health 2007; 61: 378-384.  
 
Deary IJ, Corlety J, Gow AJ, Harris SE , Houlihan LM, Marioni RE, Penke L, Snorri 
B. Rafnsson SB, Starr JM. Age-associated cognitive decline. British Medical Bulletin 
2009; 92: 135-152. 
 
Deary IJ, Penke L, Johnson W. The neuroscience of human intelligence differences. 
Nature reviews. Neuroscience 2010; 11: 201-211.  
 327 
 
DECODA Study Group. Age- and sex specific prevalence of diabetes and impaired 
glucose regulation in 11 Asian cohorts. Diabetes Care 2003; 26: 1770-1780. 
 
DECODE Study Group on behalf of the European Diabetes Epidemiology Group. Is 
fasting glucose sufficient to define diabetes? Epidemiological data from 20 European 
studies. Diabetologia 1999; 42: 647-654. 
 
DECODE Study Group. Age- and sex-specific prevalences of diabetes and impaired 
glucose regulation in 13 European cohorts. Diabetes Care 2003; 26; 1: 61-69. 
 
de Fine Olivarius N, Nielsen NV, Andreasen AH. Diabetic retinopathy in newly 
diagnosed middle-aged and elderly diabetic patients. Prevalence and interrelationship 
with microalbuminuria and triglycerides. Graefe's archive for clinical and 
experimental ophthalmology 2001; 239: 664-672. 
 
de Groot J, de Leeuw F, Oudkerk M, van Gijn J, Hofman A, Jolles J, Breteler M. 
Cerebral white matter lesions and cognitive function: The Rotterdam Scan Study. 
Annals of Neurology 2000; 47: 145–151. 
 
de Groot M, Anderson R, Freedland KE, Clouse RE, Lustman PJ. Association of 
Depression and Diabetes Complications: A Meta-Analysis Psychosomatic Medicine 
2001; 63: 619–630. 
 
de Pantoni L, Garcia JH, Gutierrez JA. Cerebral white matter is highly vulnerable to 
ischemia. Stroke 1996; 27: 1641-1647. 
 
der G, Deary IJ. Reaction time age changes and sex differences in adulthood. 
Resultsfrom a large, population based study: the UK Health and Lifestyle Survey. 
Psychology and aging 2006; 21: 62–73. 
 
de Vegt F, Dekker JM, Jager A, Hienkens E, Kostense PJ, Stehouwer CD, Nijpels G, 
 328 
Bouter LM, Heine RJ. Relation of impaired fasting and postload glucose with 
incident Type 2 diabetes in a Dutch population. The Hoorn Study. Journal of the 
American Medical Association 2001; 285: 2109-2113. 
 
Detterman DK. Spearman‘s g: past, present, and future. In: Peel RA, Zeki M (Eds.) 
Human ability. Genetic and environmental influences. London: The Galton Institute, 
2006. pp. 19-45. 
 
Diabetes Control and Complications Research Group. The effect of intensive 
treatment of diabetes on the development and progression of long-term 
complications in insulin-dependent diabetes mellitus. New England Journal of 
Medicine 1993; 329: 977-986. 
 
Diabetic Retinopathy Study Research Group. Report Number 7: a modification of the 
Airlie House classification of diabetic retinopathy. Investigative ophthalmology & 
visual science 1981; 21: 210-226. 
 
Dik MG, Deeg DJH, Bouter LM, Corder EH, Kok A, Jonker C. Stroke and 
apolipoprotein E ε 4 are independent risk factors for cognitive decline. A 
populationbased study. Stroke 2000; 31: 2431-2436. 
 
Dik MG, Jonker C, Comijs HC, Deeg DJ, Kok A, Yaffe K, Penninx BW. 
Contribution of metabolic syndrome components to cognition in older individuals. 
Diabetes Care 2007; 30: 2655-2660. 
 
Doubal F, Dhillon B, Dennis MS, Wardlaw JM. Retinopathy in ischaemic stroke 
subtypes. Stroke 2009a; 40: 389-393. 
 
Doubal F, MacGillivray TJ, Hokke PE, Dhillon B, Dennis MS, Wardlaw JM. 
Differences in retinal vessels support a distinct vasculopathy causing lacunar stroke. 
Neurology 2009b; 72: 1773-1778. 
 
 329 
Drevets WC. Functional anatomical abnormalities in limbic and prefrontal cortical 
structures in major depression. Progress in brain research 2000; 126:413-431. 
 
Dufouil C, Ducimetière, Alpérovitch A. Sex differences in the association between 
alcohol consumption and cognitive performance. American Journal of Epidemiology 
1997; 146: 405-412. 
 
Dumskyj MJ, Aldington SJ, Dore CJ, Kohner EM. The accurate assessment of 
changes in retinal vessel diameter using multiple frame electrocardiograph 
synchronized fundus photography. Current Eye Research 1996; 15: 625-632. 
 
Dunstan DW, Zimmet PZ, Welborn TA, De Courten MP, Cameron AJ, Sicree RA, 
Dwyer T, Colagiuri S, Jolley D, Knuiman M, Atkins R, Shaw JE. The rising 
prevalence of diabetes and impaired glucose tolerance. The Australian Diabetes, 
Obesity and Lifestyle Study. Diabetes Care 2002; 25: 829–834. 
 
Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic 
retinopathy fromstereoscopic color fundus photographs- an extension of the modified 
Airlie House classification. ETDRS Report Number 10. Ophthalmology 1991; 98 (5 
Suppl): 786–806. 
 
Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic 
risk factors for progression of diabetic retinopathy. ETDRS Report Number 12. 
Ophthalmology 1991; 98 (5 Suppl): 823–833. 
 
Early Treatment Diabetic Retinopathy Study Research Group. Risk factors for 
high-risk proliferative diabetic retinopathy and severe visual loss. ETDRS Report 
No.18. Investigative ophthalmology & visual science 1998; 39: 233-252. 
 
Ekoe JM, Zimmet P, Williams R. The epidemiology of diabetes mellitus. An 
International perspective. West Sussex: WileyBlackwell, 2001.  
 
 330 
El-Assaad W, Buteau J, Peyot ML, Nolan C, Roduit R, Hardy S, Joly E, Dbaibo G, 
Rosenberg L, Prentki M. Saturated fatty acids synergize with elevated glucose to 
cause pancreatic β-cell death. Endocrinology 2003; 144 :4154-4163. 
 
Elias MF, Wolf PA, D‘Agostino RB, Cobb J, White LR. Untreated blood pressure 
level is inversely related to cognitive function: The Framingham Study. American 
Journal of Epidemiology 1993; 138: 353-364. 
 
Elias PK, Elias MF, D'Agostino RB, Cupples LA, Wilson PW, Silbershatz H, Wolf 
PA. NIDDM and blood pressure as risk factors for poor cognitive performance. The 
Framingham Study. Diabetes Care 1997; 20: 1388-1395. 
 
Elias PK, Elias MF, D‘Agostino RB, Silbershatz H, Wolf PA. Alcohol consumption 
and cognitive performance in the Framingham Heart Study. American Journal of 
Epidemiology 1999; 150: 580-589. 
 
Elias MF, Elias PK, Sullivan LM, Wolf PA, D'Agostino RB Obesity, diabetes and 
cognitive deficit: the Framingham Heart Study. Neurobiology of Aging 2005; 26S:  
S11-S16. 
 
Elkind MS, Sciacca R, Boden-Albala B, Rundek T, Paik MC, Sacco RL.Moderate 
alcohol consumption reduces risk of ischemic stroke: the Northern Manhattan Study. 
Stroke 2006; 37: 13-19. 
 
Elwood PC, Pickering J, Bayer A, Gallacher JE. Vascular disease and cognitive 
function in older men in the Caerphilly cohort. Age and Ageing 2002; 31: 43-48. 
 
Engelgau MM, Thompson TJ, Herman WH, Boyle JP, Aubert RE, Kenny SJ, Badran 
A, Sous ES, Ali MA.Comparsion of fasting and 2-hour glucose and HbA1c levels for 
diagnosing diabetes. Diagnostic criteria and performance revisited. Diabetes Care 
1997; 20: 785-791. 
 
 331 
Englund E. Neuropathology of white matter lesions in vascular cognitive impairment. 
Cerebrovascular Diseases 2002; 13 (suppl. 2): 11-15. 
 
Eslinger PJ, Swan GE, Carmelli D. Changes in Mini-Mental State Exam in 
community-dwelling older persons over 6 years: relationship to health and 
neuropsychological measures. Neuroepidemiology 2003; 22: 23-30. 
 
Everson-Rose SA, de Leon CFM, Bienias JL, Wilson RS, Evans DA. Early life 
conditions and cognitive function in later life. American Journal of Epidemiology 
2003; 158: 1083-1089. 
 
Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report 
of the expert committee on the diagnosis and classification of diabetes mellitus. 
Diabetes Care 1997; 20: 1183-1197 
 
Faglia E, Favales F, Calia P, Paleari F, Segalini G, Gamba PL, Rocca A, Musacchio 
N, Mastropasqua A, Testori G, Rampini P, Moratti F, Braga A, Morabito A. Cardiac 
events in 735 type 2 diabetic patients who underwent screening for unknown 
asymptomatic coronary heart disease: 5-year follow-up report from the Milan Study 
on Atherosclerosis and Diabetes (MiSAD). Diabetes Care 2002; 25: 2032-2036. 
 
Fan XD, O‘Donnel A, Singh SP, Pungan R. Light to moderate alcohol drinking is 
associated with higher cognitive function in males with type 2 diabetes. 
Experimental Aging Research 2008; 34: 126-137. 
 
Farias ST, Mungas D, Reed BR, Harvey D, DeCarli C.Progression of Mild Cognitive 
Impairment to Dementia in Clinic- vs Community-Based Cohorts. Archives of 
Neurology 2009; 66: 1151-1157. 
 
Farkas E, Luiten PG. Cerebral microvascular pathology in aging and Alzheimer‘s 
disease. Progress in neurobiology 2001; 64: 575-611. 
 
 332 
Farrall AJ, Wardlaw JM. Blood-brain barrier: ageing and microvascular 
disease-systematic review and meta-analysis. Neurobiology of Aging 2009; 30: 
337-352. 
 
Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, Eckman CB, 
Tanzi RE, Selkoe DJ, Guenette S. Insulin-degrading enzyme regulates the levels of 
insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular 
domain in vivo. Proceedings of the National Academy of Sciences of the United 
States of America 2003; 100: 4162–4167. 
 
Ferguson SC, Blane A, Perros P, McCrimmon RJ, Best JJ, Wardlaw J, Deary IJ, Frier 
BM. Cognitive ability and brain structure in Type 1 diabetes: Relation to 
microangiopathy and preceding severe hypoglycemia. Diabetes 2003; 52: 149-156. 
 
Fisher CM. Lacunes: small, deep cerebral infarcts. Neurology 1965; 15: 774-784. 
 
Fisher CM. The arterial lesions underlying lacunes. Acta neuropathologica 1968; 12: 
1-15. 
 
Fisher CM. Lacunar strokes and infarcts: a review. Neurology 1982; 32: 871-876. 
 
Fisher P, Jungwirth S, Zehetmayer S, Weissgram S, Hoenigschnabl S, Gelpi E, 
Krampla W, Tragl KH. Conversion from subtypes of mild cognitive impairment to 
Alzheimer dementia. Neurology 2007; 68: 288-291. 
 
Fisk JD, Merry H, Rockwood K. Variations in case definition affect prevalence but 
not outcomes of mild cognitive impairment. Neurology 2003; 61: 1179-1184. 
 
Fisk JD, Rockwood K. Outcomes of incident mild cognitive impairment in relation 




Fitzpatrick AL, Kuller LH, Ives DG, Lopez OL, Jagust W, Breitner JC, Jones B, 
Lyketsos C, Dulberg C. Incidence and prevalence of dementia in the Cardiovascular 
Health Study. Journal of the American Geriatrics Society 2004; 52: 195-204. 
 
Fleisher AS, Sowell BB, Taylor C, Gamst AC, Petersen RC, Thal LJ. Clinical 
predictors of progression to Alzheimer disease in amnestic mild cognitive 
impairment. Neurology 2007; 68: 1588-1595. 
 
Fonda SJ, Rosanna B, O‘Donnell A, Longcope C, McKinley JB. Age, hormones, and 
cognitive function among middle-aged and elderly men: cross-sectional evidence 
from the Massachusetts Male Aging Study. Journal of Gerontology 2005; 60A:  
385-390. 
 
Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for 
grading the cognitive state of patients for the clinician. Journal of psychiatric 
research 1975; 12: 189 –198. 
 
Fontbonne A, Ducimetiere PD, Alperovitch A. Changes in cognitive abilities over a 4 
year period are unfavourably affected in elderly diabetic subjects. Diabetes Care 
2001; 24: 366-370.  
 
Fowkes FGR, Housley E, Riemersma RA, Macintyre CC, Cawood EH, Prescott RJ, 
Ruckley CV. Smoking, lipids, glucose tolerance, and blood pressure as risk factors 
for peripheral atherosclerosis compared with ischaemic heart disease in the 
Edinburgh Artery Study. American Journal of Epidemiology 1992; 135: 331-340. 
 
Frame M, Sarelius I. Arteriolar bifurcation angles vary with position and when flow 
is changed. Microvascular Research 1993; 46: 190-205. 
 
Freeman WR, McCutchan JA, Arevalo JF, Wolfson T, Marcotte TD, Heaton RK, 
Grant I; HNRC Group. The relationship between AIDS retinal cotton wool spots and 
neuropsychological impairment in HIV-positive individuals in the pre-highly active 
 334 
antiretroviral therapy era. Ocular immunology and inflammation 2004; 12: 25-33. 
 
Freiberg MS, Cabral HJ, Heeren TC, Vasan RS, Curtis Ellison R;  Alcohol 
consumption and the prevalence of the metabolic syndrome in the US: a 
cross-sectional analysis of data from the Third National Health and Nutrition 
Examination Survey. Diabetes Care 2004; 27: 2954-2959. 
 
Frisoni GB, Galluzzi S, Pantoni L, Filippi M. The effect of white matter lesions on 
cognition in the elderly: small but detectable. Nature clinical practice. Neurology 
2007; 3: 620–627. 
 
Frölich L, Blum-Degen D, Bernstein HG, Engelsberger S, Humrich J, Laufer S, 
Muschner D, Thalheimer A, Türk A, Hoyer S, Zöchling R, Boissl KW, Jellinger K, 
Riederer P. Brain insulin and insulin receptors in aging and sporadic Alzheimer's 
disease. Journal of neural transmission 1998; 105: 423–438. 
 
Fuhrer R, Antonucci TC, Gagnon M, Dartigues JF, Barberger-Gateau P, Alperovitch 
A. Depressive symptomatology and cognitive function: an epidemiological survey in 
an elderly community sample in France. Psychological Medicine 1992; 22: 159-172. 
 
Fuller JH, Stevens LK, Wang SL. Risk factors for cardiovascular mortality and 
morbidity: the WHO Multinational Study of Vascular Disease in Diabetes. 
Diabetologia 2001; 44 (Suppl.2): 54-64. 
 
Galanis DJ, Petrovitch H, Launer LJ, Harris TB, Foley DJ, White LR. Smoking 
history in middle age and subsequent cognitive performance in elderly Japanese- 
American men: the Honolulu-Asia Aging Study. American Journal of Epidemiology 
1997; 145: 507-515. 
 
Gao XW, Bharath A, Stanton A, Hughes A, Chapman N, Thom S. Quantification and 
characterization of arteries in retinal images. Computer Methods and Programs in 
Biomedicine. 2000; 63: 133-146. 
 335 
 
Garde E, Mortensen L, Krabbe K, Rostrup E, Larsson HBW. Relation between 
age-related decline in intelligence and cerebral white-matter hyperintensities in 
healthy octagenarians: a longitudinal study. Lancet 2000;356: 628-634. 
 
Garde E, Lykke Mortensen E, Rostrup E, Paulson OB. Decline in intelligence is 
associated with progression in white matter hyperintensity volume. Journal of 
neurology, neurosurgery, and psychiatry 2005; 76: 1289-1291. 
 
Gardiner TA, Archer DB, Curtis TM, Stitt AW. Arteriolar involvement in the 
microvascular lesions of diabetic retinopathy: implications for pathogenesis. 
Microcirculation 2007; 14: 25-38. 
 
Gardner TW, Aiello LP. Pathogenesis of diabetic retinopathy. In Flynn HF, Smiddy 
W (Eds) Diabetes and Ocular Disease: Past, Present, and Future Therapies. San 
Francisco, CA: American Academy of Ophthalmology 2000, pp.1-17. 
 
Gasparini L, Xu H. Potential roles of insulin and IGF-1 in Alzheimer's disease. 
Trends in Neurosciences 2003; 26: 404–406. 
 
Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, Belleville S, 
Brodaty H, Bennett D, Chertkow H, Cummings JL, de Leon M, Feldman H, Ganguli 
M, Hampel H, Scheltens P, Tierney MC, Whitehouse P, Winblad B; International 
Psychogeriatric Association Expert Conference on mild cognitive impairment. Mild 
cognitive impairment. Lancet 2006; 367: 1262-1270. 
 
Gerstorf D, Herlitz A, Smith J. Stability of sex differences in cognition in advanced 
old age: the role of education and attrition. Journals of Gerontology Series B: 
Psychological Sciences and Social Sciences 2006; 61: 245-249. 
 
Gispen WH, GJ Biessels. Cognition and synaptic plasticity in diabetes mellitus, 
Trends in Neurosciences 2000; 23: 542–549. 
 336 
 
Glynn RJ, Beckett LA, Hebert LE, Morris MC, Scherr PA, Evans DA.Current and 
remote blood pressure and cognitive decline. Journal of the American Medical 
Association 1999; 281: 423-445. 
 
Goddard E. Estimating alcohol consumption from survey data: updated method of 
converting volumes to units. National Statistics Methodological Series 37. 2007 
[Electronic source] 
 
Gold G, Kövari E, Herrmann FR, Canuto A, Hof PR, Michel JP, Bouras C, 
Giannakopoulos P. Cognitive consequences of thalamic, basal ganglia, and deep 
white matter lacunes in brain imaging and dementia. Stroke 2005; 36: 1184-1188. 
 
Goto I., Katsuki S., Ikui H., Kimoto K, Mimatsu T. Pathological studies on the 
intracerebral and retinal arteries in cerebrovascular and noncerebrovascular diseases. 
Stroke 1975; 6: 263-269. 
 
Gradman TJ, Laws A, Thompson LW, Reaven GM. Verbal learning and/or memory 
improve with glycemic control in older adults with non-insulin-dependent diabetes 
mellitus. Journal of the American Geriatrics Society 1993; 41: 1305-1312. 
 
Grau-Olivares M, Arboix A. Mild cognitive impairment in stroke patients with 
ischemic cerebral small-vessel disease: a forerunner of vascular dementia? Expert 
review of neurotherapeutics 2009; 9: 1201-1217. 
 
Graves AB. Alzheimer‘s disease and vascular dementia. In: Nelson LM, Tanner CM, 
Van Den Eeden SK, McGuire VM (Eds). Neuroepidemiology. New York: Oxford 
University Press, 2004. pp. 102-130. 
 
Gregg EW, Yaffe K, Cauley JA, Rolka DB, Blackwell TL, Narayan KM, Cummings 
SR. Is diabetes associated with cognitive impairment and cognitive decline among 
older women? Archives of Internal Medicine 2000; 160: 174-180. 
 337 
 
Greenberg SM. Small vessels, big problems. The New England Journal of Medicine 
2006; 354: 1451-1453. 
 
Griffith T, Edwards D. Basal EDRF. activity helps to keep the geometrical 
configuration of arterial bifurcations close to the Murray optimum. Journal of 
theoretical biology 1990; 146: 545-573. 
 
Griffith T, Edwards D, Randall M. Blood flow and optimal vascular topography: role 
of the endothelium. Basic research in cardiology 1991; 86 (suppl 2):89-96. 
 
Gunning-Dixon FM, Raz N. The cognitive correlates of white matter abnormalities 
in normal aging: a quantitative review. Neuropsychology. 2000; 14: 224-32. 
 
Guo Z, Fratiglioni L, Winblad B, Viitanen M.Blood pressure and performance on the 
mini-mental state examination in the very old: cross-sectional and longitudinal data 
from the Kungsholmen Project. American Journal of Epidemiology 1997; 145: 
1106-1113. 
 
Haaland K, Linn R, Hunt W, Goodwin J. A normative study of Russell's variant of 
the Wechsler Memory Scale in a healthy elderly population. Journal of Consulting 
and Clinical Psychology 1983; 51: 878-881. 
 
Haan MN, Shemanski L, Jagust WJ, Manolio TA, Kuller L. The role of APOE ε4 
in modulating effects of other risk factors for cognitive decline in elderly persons. 
Journal of the American Medical Association 1999; 282: 40-46. 
 
Hanninen T, Koivisto K, Reinikainen KJ, Helkala EL, Soininen H, Mykkänen L, 
Laakso M, Riekkinen PJ. Prevalence of ageing-associated cognitive decline in an 
elderly population. Age and Ageing 1996; 25: 201-205. 
 
Harris MI, Klein R, Cowie CC, Rowland M, Byrd-Holt DD. Is the risk of diabetic 
 338 
retinopathy greater in non-Hispanic whites with type 2 diabetes? A U.S. population 
study. Diabetes Care 1998; 21: 1230-1235. 
 
Hart CL, Taylor MD, Smith GD, Whalley LJ, Starr JM, Hole DJ, Wilson V, Deary IJ. 
Childhood IQ and cardiovascular disease in adulthood: prospective observational 
study linking the Scottish Mental Survey 1932 and the Midspan studies. Social 
Science and Medicine 2004; 59: 2131-2138. 
 
Hassan A, Hunt BJ, O‘Sullivan M, Parmar K, Bamford JM, Briley D, Brown MM, 
Thomas DJ, Markus HS. Markers of endothelial dysfunction in lacunar infarction 
and ischaemic leukoaraiosis. Brain 2003; 126: 424-432. 
 
Hassing LB, Hofer SM, Nilsson SE, Berg S, Pedersen NL, McClearn G, Johansson B. 
Comorbid type 2 diabetes mellitus and hypertension exacerbates cognitive decline: 
evidence from a longitudinal study. Age and Ageing 2004; 33: 355-361. 
 
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of 
cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised 
placebo-controlled trial. Lancet 2002a; 360: 7-22. 
 
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of 
antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised 
placebo-controlled trial. Lancet 2002b; 360: 23-33. 
 
Hedden T, Gabrieli JD. Insights into the ageing mind: a view from cognitive 
neuroscience. Nature reviews. Neuroscience 2004; 5: 87–96. 
 
Helkala EL, Niskanen L, Viinamaki H, Partanen J, Uusitupa M. Short-term and 
long-term memory in elderly patients with NIDDM. Diabetes Care 1995; 18: 
681-685. 
  
Henricsson M, Nyström L, Blohmé G, Ostman J, Kullberg C, Svensson M, Schölin 
 339 
A, Arnqvist HJ, Björk E, Bolinder J, Eriksson JW, Sundkvist G. The incidence of 
retinopathy 10 years after diagnosis in young adult people with diabetes: results from 
the nationwide population-based Diabetes Incidence Study in Sweden (DISS). 
Diabetes Care 2003; 26: 349–354. 
 
Herbert LE, Scherr PA, Bennett AD, Bienias JL, Wilson RS, Morris MC, Evans DA. 
Blood pressure and late-life cognitive function change: a biracial longitudinal 
population study. Neurology 2004; 62: 2021-2024. 
 
Herrmann C. International experiences with the Hospital Anxiety and Depression 
Scale-a review of validation data and clinical results. Journal of Psychosomatic 
Research 1997; 42: 17-41. 
 
Herrmann LL, Goodwin GM, Ebmeier KP. The cognitive neuropsychology of 
depression in the elderly. Psychological Medicine 2007; 37: 1693–1702. 
 
Hiller R, Sperduto RD, Podgor MJ, Ferris 3
rd
, FL, Wilson PW. Diabetic retinopathy 
and cardiovascular disease in type II diabetics. The Framingham Heart Study and the 
Framingham Eye Study. American Journal of Epidemiology 1988; 128: 402-409. 
 
Horn JL. Theory of fluid and crystallised intelligence. In Sternberg RJ (ed). 
Encyclopedia of human intelligence. New York: Macmillan, 1994. pp. 443-451. 
 
Hosmer D, Lemeshow S. Applied Logistic Regression. New York: Wiley & Sons 
1989. 
 
Hosmer D, Lemeshow S. Applied Logistic Regression. New York: Wiley & Sons 
2000. 
 
Hove MN, Kristensen JK, Lauritzen T, Bek T. The prevalence of retinopathy in an 
unselected population of type 2 diabetes patients from Arhus County, Demark. Acta 
ophthalmologica Scandinavica 2004; 82: 443-448. 
 340 
 
Howard AA, Arnsten JH, Gourevitch MN. Effect of alcohol consumption on diabetes 
mellitus: a systematic review. Annals of Internal Medicine 2004; 140: 211-219. 
 
Hubbard LD, Brothers RJ, King WN, Clegg LX, Klein R, Cooper LS, Sharrett AR, 
Davis MD, Cai J. Methods for evaluation of retinal microvascular abnormalities 
associated with hypertension/sclerosis in the Atherosclerosis Risk in Communities 
Study. Ophthalmology 1999; 106: 2269-2280. 
 
Hudson C. A clinical perspective of diabetic retinopathy. Geriatrics and Aging 2008; 
11: 333-341. 
 
Hughes AD, Wong TY, Witt N, Evans R, Thom SA, Klein BE, Chaturvedi N, Klein 
R. Determinants of retinal microvascular architecture in normal subjects. 
Microcirculation 2009; 16: 159-166. 
 
Hultsch DF, Hertzog C, Dixon RA, Small BJ. Memory change in the aged. New 
York: Cambridge University Press.1998. 
 
Hyman BT, Gomez-Isla T, Briggs M, Chung H, Nichols S, Kohout F, Wallace R. 
Apolipoprotein E and cognitive change in an elderly population. Annals of neurology 
1996; 40: 55–66. 
 
Ikram MK, de Jong FJ, Vingerling JR, Witteman JC, Hofman A, Breteler MM, de 
Jong PT. Are retinal arteriolar or venular diameters associated with markers for 
cardiovascular disorders? The Rotterdam Study. Investigative ophthalmology & 
visual science 2004; 45: 2129-2134. 
 
Ikram MK, Witteman JC, Vingerling JR, Breteler MM, Hofman A, de Jong PT. 




Ikram MK, Witteman JC, Vingerling JR, Breteler MM, Hofman A, de Jong PT. 
Response to Are Narrower or Wider Retinal Venules Associated With Incident 
Hypertension? Hypertension. 2006b; 48(e11). 
 
Ikram MK, de Jong FJ, Bos MJ, Vingerling JR, Hofman A, Koudstaal PJ, de Jong PT, 
Breteler MM Retinal vessel diameters and risk of stroke: the Rotterdam Study. 
Neurology 2006c;66: 1339-1343. 
 
Ikram MK, De Jong FJ, Van Dijk EJ, Prins ND, Hofman A, Breteler MM, De Jong 
PT. Retinal vessel diameters and cerebral small vessel disease: the Rotterdam Scan 
Study. Brain 2006d; 129: 182-188. 
 
Isomaa B. A major health hazard: the metabolic syndrome. Life Sciences 2003; 73: 
2395-2411. 
 
Jagust W, Harvey D, Mungas D, Haan M. Central obesity and the aging brain. 
Archives of Neurology 2005; 62: 1545-1548. 
 
Jeganathan VS. Smokers‘ veins: a useful clinical sign--comment. Clinical & 
experimental ophthalmology 2005; 33: 675-676. 
 
Jellinger KA. The enigma of vascular cognitive disorder and vascular dementia. Acta 
neuropathologica 2007; 113: 349-388. 
 
Jeong SK, Nam HS, Son MH, Son EJ, Cho KH. Interactive effects of obesity indexes 
on cognition. Dementia and Geriatric Cognitive Disorders 2005; 19: 91-96. 
 
Johnson W, te Nijenhuis J, Bouchard TJ, Jr. Still just 1 g : consistent results from five 
test batteries. Intelligence 2008; 36: 81-95. 
 
Jokinen H, Kalska H, R Mäntylä, Pohjasvaara T, Ylikoski R, Hietanen M, Salonen O, 
Kaste M, Erkinjuntti T. Cognitive profile of subcortical ischaemic vascular disease. 
 342 
Journal of Neurology, Neurosurgery, and Psychiatry 2006;77: 28-33. 
 
Joussen AM, Murata T, TsujikawaA,Kirchhof B, Bursell SE, Adamis AP. 
Leukocyte-mediated endothelial cell injury and death in the diabetic retina. American 
Journal of Pathology 2001; 158: 147-152. 
 
Joussen AM, Poulaki V, Qin W, Kirchhof B, Mitsiades N, Wiegand SJ, Rudge J, 
Yancopoulos GD, Adamis AP. Retinal vascular endothelial growth factor induces 
intercellular adhesion molecule-I and endothelial nitric oxide synthase expression 
and initiates early diabetic retinal leukocyte adhesion in vivo. American Journal of 
Pathology 2002; 160: 501-509. 
 
Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, Schraermeyer U, 
Kociok N, Fauser S, Kirchhof B, Kern TS, Adamis AP. A central role for 
inflammation in the pathogenesis of diabetic retinopathy. The Federation of 
American Societies for Experimental Biology 2004; 18: 1450-1452. 
 
Joy S, Kaplan E, Fein D. Speed and memory in the WAIS-III Digit Symbol—Coding 
subtest across the adult lifespan. Archives of Clinical Neuropsychology 2004; 
19:759–767 
 
Juutilainen A., Lehto S., Ronnemaa T., Pyorala K., Laakso M. Retinopathy predicts 
cardiovascular mortality in type 2 diabetic men and women. Diabetes Care 2007; 30: 
292-299. 
 
Kadoi Y, Saito S, Fujita N, Goto F. Risk factors for cognitive dysfunction after 
coronary artery bypass graft surgery in patients with type 2 diabetes. Journal of 
thoracic and cardiovascular surgery 2005; 129: 576-583. 
 
Kalmijn S, Feskens EJM, Launer LJ, T Stijnen, Kromhout D. Glucose intolerance, 
hyperinsulinaemia and cognitive function in a general population of elderly men, 
Diabetologia 1995; 38: 1096–1102. 
 343 
 
Kalmijn S, Feskens EJ, Launer LJ, Kromhout D. Cerebrovascular disease, the 
apolipoprotein e4 allele, and cognitive decline in a community-based study of elderly 
men. Stroke 1996; 27: 2230 –2235. 
 
Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to 
the pathophysiology of type 2 diabetes. Diabetologia 2003; 46: 3-19. 
 
Kalmijn S, van Boxtel MPJ, Verschuren MWM, Jolles J, Launer LJ. Cigarette 
smoking and alcohol consumption in relation to cognitive performance in middle age. 
American Journal of Epidemiology 2002; 156: 936-944. 
 
Kanaya AM, Barrett-Connor E, Gildengorin G, Yaffe K. Changes in cognitive 
function by glucose tolerance status in older adults. A 4-year prospective study of the 
Rancho Bernardo Study Cohort. Archives of internal medicine 2004; 164: 
1327-1333. 
 
Kang JH, Cook N, Manson J, Buring JE, Grodstein F.Low dose aspirin and cognitive 
function in the women‘s health study cognitive cohort. British Medical Journal 2007; 
334:987-996. 
 
Karapanayiotides T, Piechowski-Jozwiak B, van Melle G, Bogousslavsky J, Devuyst 
G. Stroke patterns, etiology and prognosis in patients with diabetes mellitus. 
Neurology 2004; 62: 1558–1562.  
 
Karlamangla AS, Singer BH, Reuben DB, Seeman TE. Increases in serum 
non-high-density lipoprotein cholesterol may be beneficial in some high-functioning 
older adults: MacArthur studies of successful aging. Journal of the American 
Geriatrics Society 2004; 52: 487– 494. 
 
Kase CS, Wolf PA, Kelly-Hayes M, Kannel WB, Beiser A, D‘Agostino RB. 
Intellectual decline after stroke. The Framingham Study. Stroke 1998; 29: 805-812. 
 344 
 
Kato S, Takemori M, Kitano S, Hori S, Fukushima H, Numaga J, Yamashita H. 
Retinopathy in older patients with diabetes mellitus. Diabetes research and clinical 
practice 2002; 58: 187-192. 
 
Katsilambros N, Tentolouris N. Type 2 diabetes: an overview. In: Pickup JC and 
Williams G (Eds). Texkbook of Diabetes 1, 3
rd
 Edition. Oxford: Blackwell, 2003. pp. 
4.1-4.19. 
 
Kaushik S, Kifley A, Mitchell P, Wang JJ. Age, blood pressure, and retinal vessel 
diameter: separate effects and interaction of blood pressure and age. Investigative 
ophthalmology & visual science 2007; 48: 557-561. 
 
Kawasaki R, Wang JJ, Rochtchina E, Taylor B, Wong TY, Tominaga M, Kato T, 
Daimon M, Oizumi T, Kawata S, Kayama T, Yamashita H, Mitchell P. 
Cardiovascular risk factors and retinal microvascular signs in an adult Japanese 
population: the Funagata study. Ophthalmology 2006;113: 1378-1384. 
 
Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis 
T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, 
Whiting M, Ehnholm C, Laakso M; FIELD study investigators. Effects of long-term 
fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes 
mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 
1849-1861. 
 
Keen H, Lee ET, Russell D, Miki E, Bennett PH, Lu M. The appearance of 
retinopathy and progression to proliferative retinopathy: the WHO Multinational 
Study of Vascular Disease in Diabetes. Diabetologia 2001; 44 (Suppl. 2): 22–23. 
 
Kelley BJ, Petersen RC. Alzheimer‘s disease and mild cognitive impairment. 
Neurologic Clinics 2007; 25: 577-609. 
 
 345 
Kent S. Is diabetes a form of accelerated aging? Geriatrics 1976; 31:140, 145,149-151. 
 
Kern TS, Mohr S. Nonproliferative diabetic retinopathy. In Joussen AM, Gardner 
TW, Bernd K, Stephen R(Eds). Retinal vascular disease Berlin Heidelberg: 
Springer-Verlag, 2007: pp. 303-316. 
 
Kifley A, Wang JJ, Cugati S, Wong TY, Mitchell P Retinal vascular caliber, diabetes, 
and retinopathy. American Journal of Ophthalmology 2007; 143: 1024-1026. 
 
Kilander L, Nyman H, Boberg M, Hansson L, Lithell H. Hypertension is related to 
cognitive impairment: a 20-year follow-up of 999 men. Hypertension 1998; 31:  
780-786. 
 
Kim KW, MacFall JR, Payne ME. Classification of white matter lesions on magnetic 
resonance imaging in elderly persons. Biological psychiatry 2008; 64: 273–280. 
 
Kivipelto M, Helkala EL, Hänninen T, Laakso MP, Hallikainen M, Alhainen K, 
Soininen H, Tuomilehto J, Nissinen A. Midlife vascular risk factors and late-life mild 
cognitive impairment: a populationbased study. Neurology 2001; 56: 1683–1689. 
 
Klaver CC, Ott A, Hofman A, Assink JJ, Breteler MM, de Jong PT. Is age-related 
maulopathy associated with Alzheimer‘s disease? The Rotterdam Study. American 
Journal of Epidemiology1999; 150: 963-968. 
  
Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic 
Study of Diabetic Retinopathy III. Prevalence and risk of diabetic retinopathy when 
age at diagnosis is 30 or more years. Archives of Ophthalmology 1984; 102: 527-532. 
 
Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. Glycosylated hemoglobin 
predicts the incidence and progression of diabetic retinopathy. Journal of the 
American Medical Association 1988; 260: 2864-2871. 
 
 346 
Klein BE, Moss SE, Klein R, Surawicz TS. The Wisconsin Epidemiologic Study of 
Diabetic retinopathy. XIII Relationship of serum cholesterol to retinopathy and hard 
exudate. Ophthalmology 1991; 98: 1261-1265. 
 
Klein R, Klein BEK, Moss SE, Linton KLP. The Beaver Dam Eye Study Retinopathy 
in adults with newly discovered and previously diagnosed diabetes mellitus. 
Ophthalmology 1992a; 99: 58-62. 
 
Klein R, Klein BE, Moss SE. Epidemiology of proliferative diabetic retinopathy. 
Diabetes Care 1992b; 15: 1875-1891. 
 
Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study 
of diabetic retinopathy. XIV. Ten-year incidence and progression of diabetic 
retinopathy. Archives of Ophthalmology 1994a; 112: 1217-1228. 
 
Klein R, Klein BE, Moss SE, Wang Q. Hypertension and retinopathy, arteriolar 
narrowing, and arteriovenous nicking in a population. Archives of ophthalmology 
1994b; 112: 92-98. 
Klein R, Klein BE, Moss SE. Is obesity related to microvascular and macrovascular 
complications in diabetes? The Wisconsin Epidemiologic Study of Diabetic 
Retinopathy. Archives of Internal Medicine 1997; 157: 650–656.  
Klein R., Klein BE, Moss SE., Cruickshanks KJ. Association of ocular disease and 
mortality in a diabetic population. Archives of Ophthalmology 1999; 117: 1487–
1495. 
 
Klein R, Sharrett AR, Klein BE, Chambless LE, Cooper LS, Hubbard LD, Evans G. 
Are retinal arteriolar abnormalities related to atherosclerosis? The Atherosclerosis 
Risk in Communities Study. Arteriosclerosis, thrombosis, and vascular biology 2000; 
20: 1644-1650. 
 
Klein R, Klein BEK. Blood pressure control and diabetic retinopathy. British Journal 
 347 
of Ophthalmology 2002; 86: 365-367. 
 
Klein R, Klein BE, Moss SE, Wong TY, Hubbard L, Cruickshanks KJ, Palta M. 
Retinal vascular abnormalities in persons with type 1 diabetes. The Wisconsin 
Epidemiologic Study of Diabetic retinopathy:XVIII. Ophthalmology 2003; 110: 
2118-2125. 
 
Klein R, Klein BE, Moss SE, Wong TY, Hubbard L, Cruickshanks KJ, Palta M. The 
relation of retinal vessel calibre to the incidence and progression of diabetic 
retinopathy :XIX the Wisconsin Epidemiologic Study of Diabetic retinopathy. 
Archives of Ophthalmology 2004a; 122: 76-83. 
 
Klein BE, Klein R, McBride PE, Cruickshanks KJ, Palta M, Knudtson MD, Moss SE, 
Reinke JO. Cardiovascular disease, mortality, and retinal microvascular 
characteristics in type 1 diabetes: Wisconsin epidemiologica study of diabetic 
retinopathy. Archives of internal medicine 2004b; 164: 1917-1924. 
 
Klein R, Klein BE, Moss SE, Wong TY, Sharrett AR. Retinal vascular calibre in 
persons with type 2 diabetes: the Wisconsin Epidemiological Study of Diabetic 
Retinopathy: XX. Ophthalmology. 2006; 113: 1488-1498. 
 
Klein R, Moss SE, Klein BE. Author reply. Ophthalmology 2007; 114: 2099. 
 
Knapp M, Prince M, Albanese E, Banerjee S, Dhanasiri S, Fernandez JL, Ferri C, 
McCrone P, Snell T, Stewart R. Dementia UK, summary of key findings. 
Alzheimer‘s Society, London, 2007. 
 
Knott RM, Forrester JV. Chapter 48 Pathogenesis of diabetic eye disease. In Pickup 
JC and Williams G (eds). Textbook of Diabetes, 3
rd
 edition. 2003, pp:48.2-48.17. 
 
Knudtson MD, Lee K, Hubbard L, Wong T, Klein R, Klein B. Revised formulas for 
summarizing retinal vessel diameters. Current Eye Research 2003; 27: 143-149. 
 348 
 
Knudtson MD, Klein BE, Klein R, Wong TY, Hubbard LD, Lee KE, Meuer SM, 
Bulla CP. Variation associated with measurement of retinal vessel diameters at 
different points in the pulse cycle. British Journal of Ophthalmology 2004; 88: 
57-61. 
 
Kolodjaschna J, Berisha F, Lung S, Schaller G, Polska E, Jilma B, Wolzt M, 
Schmetterer L. LPS-induced microvascular leukocytosis can be assessed by 
blue-field entoptic phenomenon. American journal of physiology. Heart and 
circulatory physiology 2004; 287: H691–H694. 
 
Kövari E, Gold G, Herrmann FR, Canuto A, Hof PR, Bouras C, Giannakopoulos P. 
Cortical microinfarcts and demyelination affect cognition in cases at high risk for 
dementia. Neurology 2007; 68: 927-931. 
 
Kramer JH, Mungas D, Reed BR, Wetzel ME, Burnett MM, Miller BL, Weiner MW, 
Chui HC. Longitudinal MRI and cognitive change in healthy elderly. 
Neuropsychology 2007; 21: 412-418. 
 
Kristinsson JK, Gottfredsdottir MS, Stefansson E. Retinal vessel dilatation and 
elongation precedes diabetic macular edema. British Journal of Ophthalmology 1997; 
81: 274-278. 
 
Kuo HK, Jones RN, Milberg WP, Tennstedt S, Talbot L, Morris JN, Lipsitz LA. 
Cognitive function in normal-weight, overweight, and obese older adults: an analysis 
of the Advanced Cognitive Training for Independent and Vital Elderly cohort. 
Journal of the American Geriatrics Society. 2006; 54: 97-103. 
 
Kuusisto J, Koivisto K, Mykkänen L, Helkala EL, Vanhanen M, Hänninen T, Pyörälä 
K, Riekkinen P, Laakso M. Essential hypertension and cognitive function. The role of 
hyperinsulinemia. Hypertension 1993; 22: 771-779. 
 
 349 
Kuusisto J, Koivisto K, Mykkänen L, Helkala EL, Vanhanen M, Hänninen T, 
Kervinen K, Kesäniemi YA, Riekkinen PJ, Laakso M. Association between features 
of the insulin resistance syndrome and Alzheimer's disease independently of 
apolipoprotein E4 phenotype: cross sectional population based study. British Medical 
Journal 1997; 315: 1045–1049. 
 
Kwa VI, van der Sande JJ, Stam J, Tijmes N, Vrooland JL; Amsterdam Vascular 
Medicine Group. Retinal arterial changes correlate with cerebral small-vessel disease. 
Neurology 2002; 59: 1536-1540. 
 
Kyllonen PC, Christal RE. Reasoning ability is (little more than) working-memory 
capacity?! Intelligence 1990; 14, 389–433. 
 
Lammie GA. Hypertensive cerebral small vessel disease and stroke. Brain Pathology 
2002; 12: 358-370. 
 
Lammie GA. Pathology of small vessel stroke. British Medical Bulletin 2000; 56: 
296-306. 
 
Larrieu S, Letenneur L, Orgogozo JM, Fabrigoule C, Amieva H, Le Carret N, 
Barberger-Gateau P, Dartigues JF. Incidence and outcome of mild cognitive 
impairment in a population-based prospective cohort. Neurology 2002; 59: 
1594–1599. 
 
Larsen S, Soliman W. Grading of diabetic retinopathy. In Joussen AM, Gardner TW, 
Bernd K, Stephen R(edS). Retinal vascular disease. Berlin Heidelberg: 
Springer-Verlag 2007, pp: 291-302. 
 
Launer LJ, Masaki K, Petrovitch H, Foley D, Havlik RJ. The association between 
midlife blood pressure levels and late-life cognitive function: The Honolulu-Asia 
Aging Study. Journal of the American Medical Association 1995; 274:1846-1851. 
 
 350 
Lee S, Kawachi I, Berkman LF, Grodstein F. Education, other socioeconomic 
indicators, and cognitive function. American Journal of Epidemiology 2003; 157: 
712–720. 
 
Leng GC, Fowkes FG. The Edinburgh Claudication Questionnaire: an improved 
version of the WHO/Rose Questionnaire for use in epidemiological surveys. Journal 
of Clinical Epidemiology 1992; 45: 1101-1109. 
 
Lesage SR, Mosley TH, Wong TY, Szklo M, Knopman D, Catellier DJ, Cole SR, 
Klein R, Coresh J, Coker LH, Sharrett AR. Retinal microvascular abnormalities and 
cognitive decline The ARIC 14-year follow-up study. Neurology 2009; 73: 862-868. 
 
Leung H, Wang JJ, Rochtchina E, Tan AG, Wong TY, Klein R, Hubbard LD, Mitchell 
P. Relationships between age, blood pressure, and retinal vessel diameters in an older 
population. Investigative ophthalmology & visual science. 2003a; 44: 2900-2904. 
 
Leung H, Wang JJ, Rochtchina E, Tan AG, Wong TY, Hubbard LD, Klein R, Mitchell 
P. Computer-assisted retinal vessel measurement in an older population: correlation 
between right and left eyes. Clinical & experimental ophthalmology 2003b; 31: 
326-330. 
 
Leske MC, Wu SY, Hyman L, Li XW, Hennis A, Connell AMS, Schachat AP. 
Diabetic retinopathy in a black population. Ophthalmology 1999; 106: 1893-1899. 
 
Leung H, Wang JJ, Rochtchina E, Wong TY, Klein R, Mitchell P. Impact of current 
and past blood pressure on retinal arteriolar diameter in an older population. Journal 
of Hypertension 2004; 22: 1543-1549. 
 
Leung H, Wang JJ, Rochtchina E, Wong TY, Klein R, Mitchell P. Does hormone 
replacement therapy influence retinal microvascular calibre? Microvascular 
Research 2004; 67: 48-54. 
 
 351 
Lezak MD. Neuropsychological assessment, second edition. New York: Oxford 
University Press, 1983. 
 
Lezak MD. Neuropsychological assessment, third edition. New York: Oxford 
University Press, 1995. 
 
Liew G, Wong TY, Mitchell P, Wang JJ. Are narrower or wider retinal venules 
associated with incident hypertension? Author reply. Hypertension. 2006; 48: e10. 
 
Liew G, Sharrett AR, Kronmal R, Klein R, Wong TY, Mitchell P, Kifley A, Wang JJ. 
Measurement of retinal vascular caliber: issues and alternatives to using the arteriole 
to venule ratio. Investigative ophthalmology & visual science 2007; 48: 52-57. 
 
Liew G, Wang JJ, Mitchell P, Wong TT. Retinal Vascular Imaging: A New Tool in 
Microvascular Disease Research. Circulation. Cardiovascular imaging 2008a; 1: 
156-161. 
 
Liew G, Wang JJ, Cheung N, Zhang YP, Hsu W, Lee ML, Mitchell P, Tikellis G, 
Taylor B, Wong TY. The retinal vasculature as a fractal, methodology, reliability, and 
relationship to blood pressure. Ophthalmology 2008b; 115: 1951-1956. 
 
Liew G, Mitchell P, Wong TY, Lindley RI, Cheung N, Kaushik S, Wang JJ.Retinal 
microvascular signs and cognitive impairment. Journal of the American Geriatrics 
Society 2009; 57: 1892-1896. 
 
Lim SW, Cheung N, Wang JJ, Donaghue KC, Liew G, Islam FMA, Jenkins AJ, Wong 
TY. Retinal vascular fractal dimension and risk of early diabetic retinopathy. A 
prospective study of children and adolescents with type 1 diabetes. Diabetes Care 
2009; 32: 2081-2083. 
 
Lindley RI, Wang JJ, Wong MC, Mitchell P, Liew G, Hand P, Wardlaw J, De Silva 
DA, Baker M, Rochtchina E, Chen C, Hankey GJ, Chang HM, Fung VS, Gomes L, 
 352 
Wong TY; Multi-Centre Retina and Stroke Study (MCRS) Collaborative 
Group.Retinal microvasculature in acute lacunar stroke:a cross-sectional study. 
Lancet Neurology 2009; 8: 628-634. 
 
Ling R, Ramsewak V, Taylor D, Jacob J. Longitudinal study of a cohort of people 
with diabetes screened by the Exeter Diabetic Retinopathy Screening Programme. 
Eye 2002; 16: 140-145. 
 
Lipscombe LL, Hux JE. Trends in diabetes prevalence, incidence, and mortality in 
Ontario, Canada 1995–2005. Lancet 2007; 369: 750-756. 
 
Lloyd CE, Klein R, Maser RE, Kuller LH, Becker DJ, Orchard TJ. The progression 
of retinopathy over 2 years: the Pittsburgh Epidemiology of Diabetes Complications 
(EDC) study. Journal of Diabetes and its Complications 1995; 9: 140-148 
 
Longstreth W, Manolio T, Arnold A, Burke G, Bryan N, Jungreis C, Enright P, 
O‘Leary D, Fried L. Clinical correlates of white matter findings on cranial magnetic 
resonance imaging of 3301 elderly people. The Cardiovascular Health Study. Stroke. 
1996; 27: 1274 –1282. 
 
Longstreth WT, Bernick C, Manolio T, Bryan N, Jungreis CA, Price TR. Lacunar 
infarcts defined by magnetic resonance imaging of 3660 elderly people: the 
Cardiovascular Health Study. Archives of Neurology 1998; 55: 1217-1225. 
 
Longstreth W Jr, Larsen EK, Klein R, Wong TY, Sharrett AR, Lefkowitz D, Manolio 
TA. Associations between findings on cranial magnetic resonance imaging and 
retinal photography in the elderly: the Cardiovascular Health Study. Americna 
Journal of Epidemiology 2007; 165: 78-84. 
 
Loonstra A, Tarlow A, Sellers A. COWAT metanorms across age, education and 
gender. Applied Neuropsychology 2001; 8: 161-166. 
 
 353 
Lorenzi M, Cagliero E. Pathobiology of endothelial and other vascular cells in 
diabetes mellitus. Call for data. Diabetes 1991; 40: 653-659. 
 
Lowe LP, Tranel D, Wallace RB, Welty TK. Type II diabetes and cognitive function. 
Diabetes Care 1994; 17: 891-896. 
 
Luchsinger JA, Tang MX, Shea S, Mayeux R. Hyperinsulinemia and risk of 
Alzheimer disease. Neurology 2004; 63: 1187–1192. 
 
Luchsinger JA, Reitz C, Patel B, Tang MX, Manly JJ, Mayeux R. Relation of 
diabetes to mild cognitive impairment. Archives of neurology 2007; 64: 570-575. 
 
Lusis AJ. Atherosclerosis. Nature 2000; 407: 233-241. 
 
Lyness JM, Caine ED, Cox C, King DA, Conwell Y, Olivares T. Cerebrovascular 
risk factors and later-life major depression. Testing a small-vessel brain disease 
model. American journal of geriatric psychiatry 1998; 6: 5–13. 
 
Lyssenko V, Almgren P, Anevski D, Perfekt R, Lahti K, Nissén M, Isomaa B, Forsen 
B, Homström N, Saloranta C, Taskinen MR, Groop L, Tuomi T; Botnia study group 
Predictors of and longitudinal changes in insulin sensitivity and secretion preceding 
onset of type 2 diabetes. Diabetes 2005; 54: 166-174. 
 
Maggi S, Limongi F, Noale M, Romanato G, Tonin P, Rozzini R, Scafato E, 
Crepaldi G; ILSA Study Group. Diabetes as a risk factor for cognitive decline in 
older patients. Dementia and Geriatric Cognitive Disorders 2009; 27: 24-33. 
 
Malloy P, Correia S, Stebbins G, Laidlaw DH. Neuroimaging of white matter in 
aging and dementia. The Clinical Neuropsychologist 2007; 21: 73-109. 
 
Mandecka A, Dawczynski J, Blum M et al. Influence of flickering light on the retinal 
vessels in diabetic patients. Diabetes Care 2007; 30: 3048-3052. 
 354 
 
Mankovsky BN, Ziegler D. Stroke in patients with diabetes mellitus. 
Diabetes/Metabolism Research and Reviews 2004; 20: 268-287. 
 
Manschot SM, Brands AMA, van der Grond J, Kessels KPC , Algra A, Kappelle LJ, 
Biessels GJ on behalf of the Utrecht Diabetic Encephalopathy Study Group. Brian 
magnetic resonance imaging correlates of impaired cognition in patients with type 2 
diabetes. Diabetes 2006; 55: 1106-1113. 
 
Manschot SM, Biessels GJ, de Valk H, Algra A, Rutten GE, van der Grond J, 
Kappelle LJ; Utrecht Diabetic Encephalopathy Study Group. Metabolic and vascular 
determinants of impaired cognitive performance and abnormalities on brain magnetic 
resonance imaging in patients with type 2 diabetes. Diabetologia 2007; 50: 
2388-2397.  
 
Mazzone T, Chait A, Plutzky J. Cardiovascular disease risk in type 2 diabetes 
meelitus : insights from mechanistic studies. Lancet 2008; 371: 1800-1809. 
 
McCane DR, Hanson RI, Charles MA, Jacobsson LTH , Dj Pettitt D, Bennett PH, 
Knowler WC Comparision of tests for glycated haemoglobin and fasting and two 
hour plasma glucose concentrations as diagnostic methods for diabetes. British 
Medical Journal 1994; 308: 1323-1328. 
 
McCarty CA, Harper CA, Taylor HR. Long term complications: Diabetic retinopathy. 
In: Ekoé JM, Zimmet P, Williams (Eds). The Epidemiology of Diabetes Mellitus: An 
International Perspective. West Sussex: John Wiley & Sons Ltd., 2001.pp.349-366. 
 
McDowell S. ABPI and subclinical cognitive impairment. Unpublished MSc thesis. 
University of Edinburgh, UK. 2004. 
 
McGarry JD. Dysregulation of fatty acid metabolism in the etiology of type 2 
diabetes. Diabetes 2002; 51:7-18. 
 355 
 
McGeechan K, Liew G, Macaskill P, Irwig L, Klein R, Klein BE, Wang JJ, Mitchell 
P, Vingerling JR, de Jong PT, Witteman JC, Breteler MM, Shaw J, Zimmet P, Wong 
TY. Prediction of incident stroke events based on retinal vessel caliber: a systematic 
review and individual-participant meta-analysis. American Journal of Epidemiology 
2009; 170: 1323-1332. 
 
McGuire LC, Ford ES, Ajani UA. The impact of cognitive functioning on mortality 
and the development of functional disability in older adults with diabetes: the second 
longitudinal study on aging BMC Geriatrics 2006; 6: 8. 
 
McGuire LC, Ajani UA, Ford ES. Cognitive Functioning in Late Life: The impact of 
Moderate Alcohol Consumption. Annals of Epidemiology 2007; 17: 93-99. 
 
McGurn B, Starr JM, Topfer JA, Pattie A, Whiteman MC, Lemmon HA, Whalley LJ, 
Deary IJ. Pronunciation of irregular words is preserved in dementia, validating 
premorbid IQ estimation. Neurology 2004; 62: 1184-1186. 
 
Megherbi SE, Milan C, Minier D, Couvreur G, Osseby GV, Tilling K, Di Carlo A, 
Inzitari D, Wolfe CD, Moreau T, Giroud M; European BIOMED Study of Stroke 
Care Group. Association between diabetes and stroke subtype on survival and 
functional outcome 3 months after stroke Stroke 2003; 34: 688–695. 
 
Meneilly GS, Cheung E, Tessier D, Yakura C, Tuokko H. The effect of improved 
glycemic control on cognitive functions in the elderly patient with diabetes. Journal 
of gerontology1993; 48: M117-M121. 
 
Miettinen H., Haffner SM., Lehto S, Ronnemaa T., Pyorala K., Laakso M. 
Retinopathy predicts coronary heart disease events in NIDDM patients. Diabetes 
Care 1996; 19: 1445-1448. 
 
Mikkola K, Ritari N, Tommiska V. Neurodevelopmental outcome at 5 years of age of 
 356 
a National Cohort of Extremely low birth weight infants who were born in 
1996-1997. Pediatrics 2005; 116: 1391-1400. 
 
Mitchell P, Smith W, Wang JJ, Attebo K. Prevalence of diabetic retinopathy in an 
older community. The Blue Mountains Eye Study. Ophthalmology 1998; 
105:406-411 
 
Mitchell P, Wong TY. DIRECT new treatments for diabetic retinopathy. Lancet 2008; 
372: 1361-1363. 
 
Miyamoto K, Ogura Y. Pathogenetic potential of leukocytes in diabetic retinopathy. 
Seminars in Ophthalmology 1999; 14: 233–239. 
 
Miyaoka Y, Miyaoka H, Motomiya T, Kitamura S, Asai M. Impact of 
sociodemographic and diabetes-related characteristics on depressive state among 
non-insulin-dependent diabetic patients. Psychiatry and clinical neurosciences 1997; 
51: 203–206. 
 
Mizutani M, Kern TS, Lorenzi M. Accelerated death of retinal microvascular cells in 
human and experimental diabetic retinopathy. Journal of Clinical Investigation 1996; 
97: 2883-2890. 
 
Moorhouse P, Rockwood K. Vascular cognitive impairment: current concepts and 
clinical developments. The Lancet Neurology 2008; 7: 246-255. 
 
Moorhouse P, Rockwood K. Vascular cognitive impairment: current concepts and 
clinical developments. Lancet Neurology 2008;7: 246-255. 
 
Mori E. Impact of subcortical ischemic lesions on behavior and cognition. Annals of 
the New York Academy of Sciences 2002; 977: 141-148. 
 
Morris MC, Evans DA, Hebert LE, Bienias JL. Methodological issues in the study of 
 357 
cognitive decline. American Journal of Epidemiology 1999; 149: 789-793. 
 
Moss SE, Klein R, Klein BE. Association of cigarette smoking with diabetic 
retinopathy. Diabetes Care. 1991; 14: 119-126. 
 
Moss SE, Klein R, Klein BE. The association of alcohol consumption with the 
incidence and progression of diabetic retinopathy. Ophthalmology 1994; 101: 
1962-1968.  
 
Msall ME, Phelps DL, DiGaudio KM, Dobson V, Tung B, McClead RE, Quinn GE, 
Reynolds JD, Hardy RJ, Palmer EA. Severity of neonatal retinopathy of prematurity 
is predicative of neurodevelopment functional outcome at age 5.5 years. Pediatrics 
2000; 106: 998-1005. 
 
Muhlhauser I, Sawicki P, Berger M. Cigarette smoking as a risk factor for 
macroproteinuria and proliferative retinopathy in type 1 (insulin-dependent) diabetes. 
Diabetologia 1986; 29: 500-502. 
 
Mukamal KJ, Chung H, Jenny NS et al. Mukamal KJ, Chung H, Jenny NS, Kuller 
LH, Longstreth WT Jr, Mittleman MA, Burke GL, Cushman M, Psaty BM, 
Siscovick DS.Alcohol consumption and risk of coronary heart disease in older adults: 
the Cardiovascular Health Study. Journal of American Geriatric Society 2006; 54: 
30-37. 
Murray CD. The Physiological Principle of Minimum Work: I. The Vascular System 
and the Cost of Blood Volume. Proceedings of the National Academy of Sciences of 
the United States of America 1926a; 207-214. 
Murray CD. The physiological principle of minimum work applied to the angle of 
branching arteries. The Journal of General Physiology 1926b; 9: 835-841. 
Munshi M, Grande L, Hayes M, Ayres D, Suhl E, Capelson R, Lin S, Milberg W, 
Weinger K. Cognitive dysfunction is associated with poor diabetes control in older 
 358 
adults. Diabetes Care 2006; 29: 1794-1799. 
 
Nakayama T, Date C, Yokoyama T, Yoshiike N, Yamaguchi M, Tabaka H. A 
15.5-year follow-up study of stroke in a Japanese provincial city. The Shibata Study. 
Stroke 1997; 28: 45-52. 
 
Naor M, Steingrüber HJ, Westhoff K, Schottenfeld-Naor Y, Gries AF. Cognitive 
function in elderly non-insulin-dependent diabetic patients before and after inpatients 
treatment for metabolic control. Journal of diabetes and its complications 1997; 
11:40-46. 
 
Nelson HE, Willison JR. National Adult Reading Test (NART) Test Manual. 2nd ed. 
Windsor, U.K., NFER-Nelson 1991. 
 
Nguyen TT, Wang JJ, Wong TY. Retinal vascular changes in pre-diabetes and 
prehypertension. New findings and their research and clinical implications. Diabetes 
Care 2007; 30: 2708-2715. 
 
Nguyen TT, Wang JJ, Sharrett AR, Islam FM, Klein R, Klein BE, Cotch MF, Wong 
TY. Relationship of retinal vascular caliber with diabetes and retinopathy. The 
Multi-ethnic study of Atherosclerosis (MESA). Daibetes Care 2008a; 31: 544-549. 
 
Nguyen TT, Wong TY, Islam FM, Hubbard L, Miller J, Haroon E, Darwin C, Esser 
B, Kumar A. Is depression associated with microvascular disease in patients with 
type 2 diabetes? Depression and Anxiety 2008b; 25: E158-E162. 
 
Nguyen TT, Wong TT. Retinal vascular changes and diabetic retinopathy. Current 
Diabetes Reports 2009; 9: 277-283. 
 
Nguyen TT, Kawasaki R, Kreis AJ, Wang JJ, Shaw J, Vilser W, Wong TY. 
Correlation of light-flicker-induced retinal vasodilation and retinal vascular caliber 




Nordahl CW, Ranganath C, Yonelinas AP, DeCarli C, Reed BR, Jagust WJ. 
Different mechanisms of episodic memory failure in mild cognitive impairment. 
Neuropsychologia 2005; 43: 1688-1697. 
 
Noren D, Palmer H, Frame M. Predicted wall shear rate gradients in T-type arteriolar 
bifurcations. Biorheology. 2000; 37:325-340. 
 
Norgaz T, Hobikoglu G, Aksu H, Guveli A, Aksoy S, Ozer O, Bolca O, Narin A. 
Retinopathy is related to the angiographically detected severity and extent of 
coronary artery disease in patients with type 2 diabetes mellitus. Internal Heart 
Journal 2005; 46: 639-646.  
 
Norrving B. Lacunar infarcts: no black holes in the brain are benign. Practical 
neurology 2008; 8: 222-228. 
 
Nyberg L, McIntosh A, Cabeza R, Habib R, Houle S, Tulving E. General and 
specific brain regions involved in encoding and retrieval of events: What, where and 
when? Proceedings of the National Academy of Sciences of the United States of 
America1996; 93: 11280-11285. 
 
O‘Brien JT, Wiseman R, Burton EJ, Barber B, Wesnes K, Saxby B, Ford GA. 
Cognitive associations of subcortical white matter lesions in older people. Annals of 
the New York Academy of Sciences 2002; 977: 436-444. 
 
O‘Brien JT, Erkinjuntti T, Reisberg B, Roman G, Sawada T, Pantoni L, Bowler JV, 
Ballard C, DeCarli C, Gorelick PB, Rockwood K, Burns A, Gauthier S, DeKosky ST. 
Vascular cognitive impairment. Lancet Neurology 2003; 2: 89-98. 
 




Okereke OI, Kang JH, Cook NR, Gaziano JM, Manson JE, Buring JE, Grodstein F. 
Type 2 diabetes mellitus and cognitive decline in two large cohorts of 
community-dwelling older adults. Journal of the American Geriatrics Society 2008; 
56: 1028-1036. 
 
Oren S, Grossman E, Frohlich ED. Arterial and venous compliance in obese and 
nonobese subjects. American Journal of Cardiology 1996; 77: 665-667. 
 
Osareh A. Automated Identification of Diabetic Retinal Exudates and the Optic Disc. 
Published doctoral dissertation, University of Bristol, UK. 2004.  
 
Ott A, Andersen K, Dewey ME, Letenneur L, Brayne C, Copeland JRM, Dartigues 
JF, Kragh-Sorensen P, Lobo A, Martinez-Lage JM, Stijnen T, Hofman A, Launer LJ. 
Effect of smoking on global cognitive function in nondemented elderly. Neurology 
2004; 62: 920-924. 
 
Paetkau ME, Boyd TA, Winship B, Grace M. Cigarette smoking and diabetic 
retinopathy. Diabetes 1977; 26: 46-49. 
 
Page MC, Braver SL, Mackinnon DP. Levine’s guide to SPSS for analysis of variance, 
2
nd
 edition. New Jersey: Lawrence Erlbaum Associates, Inc. Publishers. 2003. 
 
Parillo M, Riccardi G. Diet composition and the risk of type 2 diabetes: 
epidemiological and clinical evidence. The British journal of nutrition 2004; 92: 
7-19. 
 
Park DC, Reuter-Lorenz P. The adaptive brain: aging and neurocognitive scaffolding. 
Annual review of psychology 2009; 60: 173–196. 
 
Parr JC, Spears GF. General calibre of the retinal arteries expressed as the equivalent 




Parr JC, Spears GF. Mathematical relationships between the width of a retinal artery 
and the widths of its branches. American Journal of Ophthalmology 1974b; 77: 
478-483. 
 
Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, 
Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, 
Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, 
Joshi R, Travert F, ADVANCE Collaborative Group. Intensive blood glucose control 
and vascular outcomes in patients with type 2 diabetes. New England Journal of 
Medicine 2008; 358: 2560-2572. 
 
Paterniti S, Verdier-Taillefer MH, Dufouil C, Alpérovitch A. Depressive symptoms 
and cognitive decline in elderly people: longitudinal study. British Journal of 
Psychiatry 2002; 181: 406-410. 
 
Patton N, Aslam T, Macgillivray T, Pattie A, Deary IJ, Dhillon B.Retinal vascular 
image analysis as a potential screening tool for cerebrovascular disease: a rationale 
based on homology between cerebral and retinal microvasculatures. Journal of 
anatomy 2005; 206: 319-348. 
 
Patton N. Computerised image analysis of retinal vascular network geometry and its 
association with cognition. Published MD dissertation, Manchester University, UK, 
2006. 
 
Patton N, Aslam T, Macgillivray T, Dhillon B, Constable I. Asymmetry of retinal 
arteriolar branch widths at junctions affects ability of formulae to predict trunk 
arteriolar widths. Investigative ophthalmology & visual science 2006a; 47: 
1329-1333. 
 
Patton N, Aslam T, Macgillivray T, Deary IJ, Dhillon B, Eikelboom RH, Yogesan K, 
 362 
Constable IJ. Retinal image analysis: concepts, applications and potential. Progress 
in Retinal and Eye Research 2006b; 25: 99-127. 
 
Patton N, Pattie A, MacGillivray T, Aslam T, Dhillon B, Gow A, Starr JM, Whalley 
LJ, Deary IJ. The association between retinal vascular network geometry and 
cognitive ability in an elderly population. Investigative ophthalmology & visual 
science 2007;48: 1995-2000. 
 
Pearson TA. Alcohol and heart disease. Circulation 1996; 94: 3023-3025. 
 
Perlmuter LC, Hakami MK, Hodgson-Harrington C, Ginsberg J, Katz J, Singer DE, 
Nathan DM.Decreased cognitive function in aging non-insulin-dependent diabetic 
patients. The American journal of medicine 1984; 77: 1043-1048. 
 
Perlmuter LC, Goldfinger SH, Shore AR, Nathan DM. Cognitive function in 
non-insulin-dependent diabetes. In: Holmes CS, ed. Neuropsychological and 
Behavioural Aspects of Diabetes. New York: Springer-Verlag; 1990: 222-238. 
 
Peters R, Peters J, Warner J, Beckett N, Bulpitt C. Alcohol, dementia and cognitive 
decline in the elderly: a systematic review. Age and ageing 2008; 37: 505-512. 
 
Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild 
cognitive impairment: clinical characterization and outcome. Archives of Neurology 
1999; 56: 303-308. 
 
Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. 
Practice parameter: early detection of dementia: mild cognitive impairment (an 
evidence-based review). Neurology 2001; 56: 1133-1142. 
 
Petersen RC. Mild cognitive impairment as a diagnostic entity. Journal of Internal 
Medicine 2004; 256: 183-194. 
 
 363 
Petitti DB, Bhatt H. Retinopathy as a risk factor for nonembolic stroke in diabetic 
subjects. Stroke 1995; 26: 593-596. 
 
Petrovitch H, White L, Masaki KH, Ross GW, Abbott RD, Rodriguez BL, Lu G, 
Burchfiel CM, Blanchette PL, Curb JD. Influence of myocardial infarction, coronary 
artery bypass surgery, and stroke on cognitive impairment in late life. American 
Journal of Cardiology 1998; 81: 1017-1021. 
 
Phillips NA. Thinking on your feet: a neuropsychological review of peripheral 
vascular disease. In: Waldstein SR, Elias MF (Eds). Neuropsychology of 
cardiovascular disease. New Jersey: Lawrence Erlbaum Associates, 2001. pp. 
121-142. 
 
Piguet O, Grayson DA, Creasey H, Bennett HP, Brooks WS, Waite LM, Broe GA. 
Vascular risk factors, cognition and dementia incidence over 6 years in the Sydney 
Older Persons Study. Neuroepidemiology 2003; 22: 165-171. 
 
Pimenta W, Korytkowski M, Mitrakou A, Jenssen T, Yki-Jarvinen H, Evron W, 
Dailey G, Gerich J. Pancreatic beta-cell dysfunction as the primary genetic lesion in 
NIDDM. Journal of the American Medical Association 1995; 273: 1855-1861. 
 
Porta M, Grosso A, Veglio F. Hypertensive retinopathy: there‘s more than meets the 
eye. Journal of Hypertension 2005; 23: 683-696. 
 
Portin R, Saarijärvi, Joukamaa M, Salokangs RKR. Education, gender and cognitive 
performance in a 62-year-old normal population: results from the Turva Project. 
Psychological Medicine 1995; 25: 1295-1298. 
 
Portet F, Ousset PJ, Touchon J, Frisoni G, Nobili FM, Scheltens PH, Vellas B, 
Visser PJ. Mild cognitive impairment in medical practice: critical review of the 
concept and new diagnostic procedure. Report of the MCI Working Group of the 
European Consortium on Alzheimer's Disease. Journal of Neurology, Neurosurgery 
 364 
and Psychiatry 2006; 77: 714–718.  
 
Posner HB, Tang MX, Luchsinger J, Lantigua R, Stern Y, Mayeux R. The 
relationship of hypertension in the elderly to AD, vascular dementia, and cognitive 
function. Neurology 2002; 58: 1175-1181. 
 
Price JF, McDowell S, Whiteman MC, Deary IJ, Stewart MC, Fowkes FG. Ankle 
brachial index as a predictor of cognitive impairment in the general population: 
ten-year follow-up of the Edinburgh Artery Study. Journal of the American 
Geriatrics Society 2006; 54: 763-69. 
 
Price JF, Reynolds RM, Mitchell RJ, Williamson RM, Fowkes FG, Deary IJ, Lee AJ, 
Frier BM, Hayes PC, Strachan MW. The Edinburgh Type 2 Diabetes Study: study 
protocol. BMC endocrine disorders 2008; 11: 8-18. 
 
Prineas RJ, Crow RS, Blackburn H. The Minnesota code manual of 
electrocardiographic findings: standards and procedures for measurement and 
classification. London: John Wright, 1982. 
 
Prins ND, van Dijk EJ, den Heijer T, Vermeer SE, Jolles J, Koudstaal PJ, Hofman A, 
Breteler MM. Cerebral small-vessel disease and decline in information processing 
speed, executive function and memory. Brain 2005; 128:2034-2041. 
 
PROGRESS Collaborative Group. Randomised trial of a perindopril-based 
blood-pressure-lowering regimen among 6,105 individuals with previous stroke or 
transient ischaemic attack. Lancet 2001; 358: 1033-1041. 
 
Qiu CX, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to 
cognitive function and dementia. Lancet Neurology 2005; 4: 487-499. 
 
Qiu C, Cotch MF, Sigurdsson S, Garcia M, Klein R, Jonasson F, Klein BE, 
Eiriksdottir G, Harris TB, van Buchem MA, Gudnason V, Launer LJ. Retinal and 
 365 
cerebral microvascular signs and diabetes: the Age, gene/environment 
susceptibility-Reykjavik Study. Diabetes 2008; 57: 1645-1650. 
 
Rafnsson SB, Deary IJ, Smith FB, Whiteman MC, Rumley A, Lowe GD, Fowkes 
FG.Cognitive decline and markers of inflammation and hemostasis: the Edinburgh 
Artery Study. Journal of the American Geriatrics Society 2007; 55: 700-707. 
 
Rafnsson SB. Cardiovascular disease, risk factors and cognitive decline in the 
general population. Unpublished doctoral dissertation, Edinburgh University, 
Edinburgh, Scotland, UK, 2006. 
 
Rahman MM, Laher I. Structural and functional alteration of blood vessels caused by 
cigarette smoking: an overview of molecular mechanisms. Current vascular 
pharmacology 2007; 5: 276-292. 
 
Rasmussen LS, Larsen K, Houx P, Skovgaard LT, Hanning CD, Moller JT; ISPOCD 
group. The International Study of Postoperative Cognitive Dysfunction. The 
assessment of postoperative cognitive function. Acta anaesthesiologica Scandinavica 
2001; 45: 275-289. 
 
Rathmann W, Haastert B, Icks A, Löwel H, Meisinger C, Holle R, Giani G. High 
prevalence of undiagnosed diabetes mellitus in Southern Germany: Target 
populations for efficient screening. The KORA survey 2000. Diabetologia 2003; 46: 
182-189 
 
Raven JC, Court JH, Raven J. Manual for Raven‘s Progressive Matrices and 
Vocabulary Scales. London: Lewis, 1977. 
 
Raven J, Raven JC, Court JH. Manual for Raven‘s progressive matrices and 
vocabulary scales Oxford: Oxford Psychologists Press, 1998. 
 
Raz N, Lindenberger U, Rodrigue KM, Kennedy KM, Head D, Williamson A, Dahle 
 366 
C, Gerstorf D, Acker JD. Regional brain changes in aging healthy adults: general 
trends, individual differences and modifiers. Cerebral Cortex 2005; 15: 1676-1689. 
 
Raz N, Rodrigue KM. Differential aging of the brain: patterns, cognitive correlates 
and modifiers. Neuroscience and biobehavioral reviews 2006; 30: 730–748. 
 
Reaven GM, Thompson LW, Nahum D, Haskins E. Relationship between 
hyperglycaemia and cognitive function in older NIDDM patients. Diabetes Care 
1990; 13: 16-21. 
 
Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 
1595-1607. 
 
Reding M, Haycox J, Blass J. Depression in patients referred to a dementia clinic: a 
three year prospective study. Archives of Neurology 1985; 42: 894-896.  
Reita N. Validity of the trail making test as an indicator of organic brain damage. 
Perceptual Motor Skills 1958; 8: 251 –259. 
Reitz C, Luchsinger J, Tang MX, Manly J, Mayeux R. Impact of plasma lipids and 
time on memory performance in healthy elderly without dementia. Neurology 2005; 
64:1378–1383. 
 
Richards M, Jarvis MJ, Thompson N, Wadsworth MEJ. Cigarette smoking and 
cognitive decline in midlife: Evidence from a prospective birth cohort study. 
American Journal of Public Health 2003; 93: 994-998. 
 
Richards M., Shipley B, Fuhrer R, Wadsworth MEJ. Cognitive ability in childhood 
and cognitive decline in mid-life: longitudinal birth cohort study. British Medical 
Journal 2004; 328: 52-554. 
 
Richards M, Deary IJ. A life course approach to cognitive reserve: a model for 
cognitive aging and development? Annals of Neurology 2005; 58: 617-622. 
 367 
 
Ritchie K, Artero S, Touchon J. Classification criteria for mild cognitive impairment. 
A population-based validation study. Neurology 2001; 56: 37-42. 
 
Ritchie K, Lovestone S. The dementias. Lancet 2002; 360: 1759-1766. 
 
Rochtchina E, Wang JJ, Taylor B, Wong TY, Mitchell P. Ethnic variability in retinal 
vessel caliber: a potential source of measurement error from ocular pigmentation? 
The Sydney Childhood Eye Study. Investigative ophthalmology & visual science 
2008; 49: 1362-1366. 
 
Rockwood K. Vascular cognitive impairment and vascular dementia. Journal of the 
Neurological Sciences 2002; 203-204: 23-27. 
 
Rogers SL, Tikellis G, Cheung N, Tapp R, Shaw J, Zimmet PZ, Mitchell P, Wang JJ, 
Wong TY. Retinal arteriolar caliber predicts incident retinopathy. The Australian 
Diabetes, Obesity and Lifestyle (AusDiab) study. Diabetes Care 2008; 31: 761-763. 
 
Román GC, Erkinjuntti T, Wallin A, Pantoni L, Chui HC. Subcortical ischaemic 
vascular dementia. The Lancet Neurology 2002; 17: 426-436. 
 
Román G. Vascular dementia revisited: diagnosis, pathogenesis, treatment, and 
prevention. The Medical Clinics of North America 2002; 86: 477-499. 
 
Rose GA. The diagnosis of ischaemic heart pain and intermittent claudication in field 
surveys. Bulletin of the World Health Organization 1962; 27: 645-658. 
 
Rosenberg ML, Chan DG, Francis IC, Coroneo MT. Smokers‘ veins: a useful 
clinical sign. Clinical & experimental ophthalmology 2005; 33: 107-108. 
 
Ross R. Atherosclerosis-an inflammatory disease. New England Journal of Medicine 
1999; 340: 115-126. 
 368 
 
Rotkiewicz-Piorun AM, Snih SA, Raji MA, Kuo YF, Markides KS. Cognitive 
decline in older Mexican Americans with diabetes. Journal of National Medical 
Association 2006; 98: 1840-1847. 
 
Roy MS, Roy A, Affouf M. Depression is a risk factor for poor glycemic control and 
retinopathy in African-Americans with Type 1 diabetes. Psychosomatic Medicine 
2007; 69: 537-542. 
 
Ruis C, Biessels GJ, Gorter KJ. Cognition in the early stage of type 2 diabetes. 
Diabetes Care 2009; 32: 1261-1265. 
 
Russell RWR. Transient cerebral ischaemia. In: Russell RWR (Ed). Vascular disease 
of the central nervous system. Churchill Livingston, 1983. pp. 204-221. 
 
Ryan CM, Williams TM, Finegold DN, Orchard TJ. Cognitive dysfunction in adults 
with type 1 (insulin-dependent) diabetes mellitus of long duration: effects of 
recurrent hypoglycaemia and other chronic complications. Diabetologia 1993; 36: 
329-334. 
 
Ryan CM, Geckle MO. Circumscribed cognitive dysfunction in middle-aged adults 
with Type 2 diabetes. Diabetes Care 2000; 23: 1486-1493. 
 
Ryan CM. Diabetes-associated cognitive dysfunction. In: Waldstein SR and Elias 
MF (Eds). Neuropsychology of cardiovascular disease. New Jersey: Lawrence 
Erlbaum Associates, Publishers, 2001. pp. 61-82. 
 
Ryan CM, Geckle MO, Orchard TJ. Cognitive efficiency declines over time in adults 
with Type 1 diabetes: effects of micro- and macrovascular complications. 
Diabetologia 2003; 46: 940-948. 
 
Ryan CM, Freed MI, Rood JA, Cobitz AR, Waterhouse BR, Strachan MW. 
 369 
Improving metabolic control leads to better working memory in adults with type 2 
diabetes. Diabetes Care 2006; 29: 345-351. 
 
Sacco SE, Whisnant JP, Broderick JP, Philips SJ, O'Fallon WM. Epidemiological 
characteristics of lacunar infarcts in a population. Stroke 1991; 22: 1236-1241. 
 
Saczynski JS, Jónsdóttir MK, Garcia ME, Jonsson PV, Peila R, Eiriksdottir G, 
Olafsdottir E, Harris TB, Gudnason V, Launer LJ. Cognitive impairment : an 
increasingly important complication of type 2 diabetes. The Age, Gene/Environment 
Susceptibility-Reykjavik Study. American Journal of Epidemiology 2008; 168: 
1132-1139. 
 
Salthouse, TA. Theoretical perspectives on cognitive aging. Hillsdale NJ: Lawrence 
Erlbaum Associates, 1991. 
 
Salthouse, TA. Structural models of the relations between age and measures of 
cognitive function. Intelligence, 2001; 29: 93-115. 
 
Salthouse TA. Localizing age-related individual differences in a hierarchical 
structure. Intelligence 2004; 32: 541-561. 
 
Salthouse TA. When does age-related cognitive decline begin? Neurobiology of 
aging 2009; 30: 507–514. 
 
Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid 
metabolism. Nature 2001; 414: 799-806. 
 
Schaie KW. Intellectual development in adulthood: The Seattle Longitudinal Study. 
Cambridge: Cambridge University Press. 1996. 
 
Schaie KW. Developmental influences on adult intelligence Oxford: Oxford 
University Press, 2005. 
 370 
Schmetterer L, Polak K. Role of nitric oxide in the control of ocular blood flow. 
Progress in retinal and eye research 2001; 20: 823-847. 
 
Schmidt R, Ropele S, Enzinger C, Petrovic K, Smith S, Schmidt H, Matthews P, 
Fazekas F. White matter lesion progression, brain atrophy, and cognitive decline: 
The Austrian Stroke Prevention study. Annals of Neurology 2005; 58: 610–616. 
 
Schneider JA, Wilson RS, Cochran EJ, Bienias JL, Arnold SE, Evans DA, Bennet 
DA. Relation of cerebral infarctions to dementia and cognitive function in older 
persons. Neurology 2003; 60: 1082-1088. 
 
Scottish Index of Multiple Deprivation 2006 http://www. scotland.gov.uk 
/Topics/Statistics/SIMD 
 
Seeman TE, Huang MH, Bretsky P, Crimmins E, Launer L, Guralnik JM. Education 
and APOE-e4 in longitudinal cognitive decline: MacArthur Studies of Sucessful 
Aging. Journal of Gerontology: Psychological Sciences 2005; 60B:74-83. 
 
Segato T, Midena E, Grigoletto F, Zucchetto M, Fedele D, Piermarocchi S, Crepaldi 
G. Veneto Group for Diabetic Retinopathy. The epidemiology and prevalence of 
diabetic retinopathy in the Veneto region of north east Italy. Diabetic Medicine1991; 
8(Spec N): S11-16. 
 
Selnes OA, Vinters HV. Vascular cognitive impairment. Nature Clinical Practice 
Neurology 2006; 2: 538-546. 
 
Shai I, Rimm EB, Schulze MB, Rifai N, Stampfer MJ, Hu FB. Moderate alcohol 
intake and markers of inflammation and endothelial dysfunction among diabetic men. 
Diabetologia 2004; 47:1760-1767. 
 
Sharrett AR, Hubbard LD, Cooper LS, Sorlie PD, Brothers RJ, Nieto FJ, Pinsky JL, 
Klein R. Retinal arteriolar diameters and elevated blood pressure: the Atherosclerosis 
 371 
Risk in Communities Study. American Journal of Epidemiology 1999; 150: 263-270. 
 
Shaw JE, Boyko EJ, de Courten M, Zimmet PZ. Impact of new diagnostic criteria for 
diabetes on different populations. Diabetes Care 1999; 22: 762-766. 
 
Shenkin SD, Bastin ME, Macgillivray TJ, Deary IJ, Starr JM, Rivers CS, Wardlaw 
JM. Cognitive correlates of cerebral white matter lesions and water diffusion tensor 
parameters in community-dwelling older people. Cerebrovascular Diseases 2005; 20: 
310-318. 
 
Sherman T. On connecting large vessels to small: the meaning of Murray‘s law. 
Journal of general physiology 1981; 78: 431-453. 
 
Sherry LM, Wang JJ, Rochtchina E, Wong T, Klein R, Hubbard L, Mitchell P. 
Reliability of computer-assisted retinal vessel measurement in a population. Clinical 
& experimental ophthalmology 2002; 30: 179-182. 
 
Silbert LC, Nelson C, Howieson DB, Moore MM, Kaye JA. Impact of white matter 
hyperintensity volume progression on rate of cognitive and motor decline. Neurology. 
2008; 71: 108-113. 
 
Singh-Manoux A, Britton AR, Marmot M. Vascular disease and cognitive function: 
evidence from the Whitehall II study. Journal of the American Geriatric Society 
2003; 51: 1445-1450. 
 
Smith W, Wang JJ, Wong TY, Rochtchina E, Klein R, Leeder SR, Mitchell P.  
Retinal arteriolar narrowing is associated with 5-year incidence severe hypertension: 
the Blue Mountains Eye Study. Hypertension. 2004; 44: 442-447. 
 
Snaith RP. The Hospital Anxiety and Depression Scale. Health and Quality of Life 
Outcomes 2003; 1: 29 
 
 372 
Snowdon DA, Kemper SJ, Mortimer JA, Greiner LH, Wekstein DR, Markesbery WR. 
Linguistic ability in early life and cognitive function and Alzheimer‘s disease in late 
life. Findings from the Nun study. Journal of the American Medial Association 1996; 
275: 528-532. 
 
Solfrizzi V, Panza F, Colacicco AM, D'Introno A, Capurso C, Torres F, Grigoletto F, 
Maggi S, Del Parigi A, Reiman EM, Caselli RJ, Scafato E, Farchi G, Capurso A; 
Italian Longitudinal Study on Aging Working Group. Vascular risk factors, 
incidence of MCI, and rates of progression to dementia. Neurology 2004; 63: 
1882–1891. 
 
Spearman C. ―General intelligence‖, objectively determined and measured. American 
Journal of Psychology 1904; 15: 201-293. 
 
Spreen, O., and Strauss, E. A compendium of neuropsychological tests. 2nd ed. New 
York, NY: Oxford University Press, 1998. 
 
Srikanth VK, Thrift AG, Saling MM, Anderson JFI, Dewey HM, Macdonell RAL, 
Donnan GA. Increased risk of cognitive impairment 3 months after mild to moderate 
first-ever stroke. A community-based prospective study of nonaphasic 
Englishspeaking survivors. Stroke 2003; 34: 1136-1143. 
 
Staff RT., Murray AD, Deary IJ, Whalley LJ. What provides cerebral reserve? Brain, 
2004; 127: 1191-1199. 
 
Stanton AV, Wasan B, Cerutti A, Ford S, Marsh R, Sever PP, Thom SA, Hughes AD. 
Vascular network changes in the retina with age and hypertension. Journal of 
Hypertension 1995a; 13: 1724-1728. 
 
Stanton A, Mullaney P, Mee F, O'Brien E, O'Malley K. A method for quantifying 
retinal microvascular alterations associated with blood pressure and age. Journal of 
Hypertension 1995b; 13: 41-48. 
 
 373 
Starr JM, Wardlaw J, Ferguson K, MacLullich A, Deary IJ, Marshall I. Increased 
blood-brain barrier permeability in type 2 diabetes demonstrated by gadolinium 
magnetic resonance imaging. Journal of neurology, neurosurgery, and psychiatry 
2003; 74: 70-76. 
 
Starr JM, McGurn B, Whiteman M, Pattie A, Whalley LJ, Deary IJ. Life long 
changes in cognitive ability are associated with prescribed medications in old 
age.International Journal of Geriatric Psychiatry 2004; 19: 327-332. 
 
Stefansson E, Landers MB 3rd, Wolbarsht ML. Oxygenation and vasodilatation in 
relation to diabetic and other proliferative retinopathies. Ophthalmic surgery1983; 14:  
209-226. 
 
Stern Y. Cognitive reserve and Alzheimer disease. Alzheimer Disease & Associated 
Disorders 2006, 20: 112-117. 
 
Stern Y. Cognitive reserve. Neuropsychologia 2009;47: 2015-2028. 
 
Stewart R, Liolitsa D. Type 2 diabetes mellitus, cognitive impairment and dementia. 
Diabetic Medicine 1999; 16: 93-112. 
 
Stewart MCW, Deary IJ, Fowkes FGR, Price JF. Relationship between lifetime 
smoking, smoking status at older age and human cognitive function. 
Neuroepidemiology 2006; 26: 83-92. 
 
Strachan MW, Deary IJ, Ewing FM, Frier BM. Is type II diabetes associated with an 
increased risk of cognitive dysfunction? A critical review of published studies. 
Diabetes Care 1997; 20: 438-445. 
 
Strachan MWJ, Price J, Frier BM. Diabetes, cognitive impairment, and dementia. 
Are strongly linked, but the precise mechanisms are unclear. British Medical Journal 
2008a; 336: 6. 
 374 
 
Strachan MW, Reynolds RM, Frier BM, Mitchell RJ, Price JF. The relationship 
between type 2 diabetes and dementia. British Medical Bulletin 2008b; 88: 131-146. 
 
Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE, 
Matthews DR. UKPDS 50: Risk factors for incidence and progression of retinopathy 
in Type II diabetes over 6 years from diagnosis Diabetologia 2001; 44: 156–163. 
 
Stumvoll M, Goldstein BJ, van Haeft en TW. Type 2 diabetes: principles of 
pathogenesis and therapy. Lancet 2005; 365: 1333-1346. 
 
Sullivan EV, Pfefferbaum A. Diffusion tensor imaging and aging. Neuroscience & 
Biobehavioral Reviews 2006; 30: 749–761. 
 
Sun C, Wang JJ, Mackey DA, Wong TY. Retinal vascular calibre: systemic, 
enviromental and genetic associations. Survey of Ophthalmology 2009; 54: 74-94. 
 
Surmacz E. Obesity hormone leptin: a new target in breast cancer? Breast Cancer 
Research 2007; 9: 301. 
 
Svärdsudd K, Wedel H, Aurell E, Tibblin G. Hypertensive eye ground changes. 
Prevalence, relation to blood pressure and prognostic importance. The study of men 
born in 1913. Acta medica Scandinavica 1978; 204:159-167. 
 
Swan GE, Carmelli D, Larue A. Systolic blood pressure tracking over 25 to 30 years 
and cognitive performance in older adults. Stroke 1998; 29: 2334-2340. 
 
Taguchi A. Vascular factors in diabetes and Alzheimer's disease. American journal of 
Alzheimer's disease and other dementias 2009; 16: 859-864. 
 
Tapp RJ, Shaw JE, Harper CA, de Courten MP, Balkau B, McCarty DJ, Taylor HR, 
Welborn TA, Zimmet PZ; AusDiab Study Group. The prevalence of and factors 
 375 
associated with diabetic retinopathy in the Australian population. Diabetes Care 
2003; 26: 1731-1737. 
 
Tekin S, Cummings JL. Frontal-subcortical neuronal circuits and clinical 
neuropsychiatry. An update. Journal of Psychosomatic Research 2002; 53: 647-654. 
 
Tekin O, Cukur S, Uraldi C, Işik B, Ozkara A, Kurtaran H, Catal F, Ustün I. 
Relationship between retinopathy and cognitive impairment among hypertensive 
subjects. European neurology 2004; 52: 156-161. 
 
The International Diabetes Federation. Diabetes Atlas, third edition. 2006, Brussels. 
 
The Eye Diseases Prevalence Research Group. The prevalence of diabetic 
retinopathy among adults in the United States. Archives of Ophthalmology 2004; 122: 
552-563. 
 
Thomas AJ, Kalaria RN, O‘Brien JT. Depression and vascular disease: what is the 
relationship? Journal of affective disorders 2004; 79: 81–95. 
 
Thomas MC, Walker MK, Emberson JR, Thomson AG, Lawlor DA, Ebrahim S, 
Whincup PH.Prevalence of undiagnosed Type 2 diabetes and impaired fasting 
glucose in older British men and women. Diabetic Medicine 2005; 22: 789-793. 
 
Thomas AJ, O‘Brien JT. Depression and cognition in older adults. Current Opinion 
in Psychiatry 2008; 21: 8-13. 
 
Thompson CS, Hakim AM. Living beyond our physiological means small vessel 
disease of the brain is an expression of a systemic failure in arteriolar function: a 
unifying hypothesis. Stroke 2009; 40: e322. 
 
Tiemeier H, van Dijck W, Hofman A, Witteman JC, Stijnen T, Breteler MM.. 
Relationship between atherosclerosis and latelife depression: the Rotterdam Study. 
 376 
Archives of general psychiatry 2004; 61: 369–376. 
 
Tilvis RS, Kähönen-Väre MH, Jolkkonen J, Valvanne J, Pitkala KH, Strandberg TE. 
Predictors of cognitive decline and mortality of aged people over a 10-year period. 
Journal of Gerontology 2004; 59: 268-274. 
 
Tombaugh TN, McIntyre NJ. The mini-mental state examination: a comprehensive 
review. Journal of American Geriatric Society 1992; 40: 922-935. 
 
Tooth L, Ware R, Bain C, Purdie DM, Dobson A. Quality of reporting of 
observational longitudinal research. American Journal of Epidemiology 2005; 161; 
280-288. 
 
Towler HMA, Lightman S. Chapter 49 Clinical features and management of diabetic 
eye disease. In Pickup JC and Williams G (eds). Textbook of Diabetes, 3
rd
 edition. 
2003, pp: 49.1-49.25. 
 
Townsend MK, Devore E, Kang JH, Grodstein F. The relation between moderate 
alcohol consumption and cognitive function in older women with type 2 diabetes. 
Diabetes Research and Clinical Practice 2009; 85: 322-327. 
 
Tulving E, Markowitsch H. Memory beyond the hippocampus. Current Opinion in 
Neurobiology 1997; 7:209-216. 
 
UK Prospective Diabetes Study Group. Intensive blood glucose control with 
sulphonylureas or insulin compared with conventional treatment and risk of 
complications in patients with type 2 diabetes (UKPDS33). Lancet 1998; 352: 
837-853. 
 
UK Prospective Diabetes Study Group. Tight blood pressure control and risk of 
macrovascular and microvascular complications in type 2 diabetes UKPDS 38 
British Medical Journal 1998; 317: 703-713. 
 377 
 
UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose 
control with metformin on complications in overweight patients with type 2 diabetes 
(UKPDS 34). Lancet 1998; 352: 854–865. 
 
Umegaki H, Iimuro S, Kaneko T, Araki A, Sakurai T, Ohashi Y, Iguchi A, Ito H. 
Factors associated with lower Mini Mental State Examination scores in elderly 
Japanese diabetes mellitus patients. Neurobiology of Aging 2008; 29: 1022-1026. 
 
Ungerleider L. Functional brain imaging studies of cortical mechanisms for memory. 
Science 1995; 270:769-775. 
 
van den Berg E, de Craen AJ, Biessels GJ, Gussekloo J, Westendorp RG. The impact 
of diabetes mellitus on cognitive decline in the oldest of the old: a prospective 
population-based study. Diabetologia 2006; 49: 2015-2023. 
 
van den Heuvel D, ten Dam V, de Craen A, Admiraal-Behloul F, Olofsen H, Bollen 
E, Jolles J, Murray H, Blauw G, Westendorp R, van Buchem M. Increase in 
periventricular white matter hyperintensities parallels decline in mental processing 
speed in a non-demented elderly population. Journal of neurology, neurosurgery, 
and psychiatry 2006; 77: 149-153. 
 
van der Flier WM, Scheltens P. Epidemiology and risk factors of dementia. Journal 
of Neurology, Neurosurgery, and Psychiatry 2005; 76 (suppl.): v2-v7. 
 
van Dijk EJ, Prins ND, Vermeer SE, Vrooman HA, Hofman A, Koudstaal PJ, 
Breteler MM. C-reactive protein and cerebral small-vessel disease: the Rotterdam 
Scan Study. Circulation 2005; 112: 900-905. 
 
van Dijk EJ, Prins ND, Vrooman HA, Hofman A, Peter J. Koudstaal PJ, Breteler 
MM. Progression of cerebral small vessel disease in relation to risk factors and 




van Dijk KR, Van Gerven PW, Van Boxtel MP, Van der Elst W, Jolles J. No 
protective effects of education during normal cognitive aging:results from the 6-year 
follow-up of the Maastricht Aging Study. Psychology and Aging 2008; 23: 119-130. 
 
van Harten B, de Leeuw FE, Weinstein HC, Scheltens P, Biessels GJ. Brain imaging 
in patients with diabetes: a systematic review. Diabetes Care 2006; 29: 2539-2548. 
 
van Harten B, Oosterman J, Muslimovic D, van Loon BJ, Scheltens P, Weinstein HC. 
Cognitive impairment and MRI correlates in the elderly patients with type 2 diabetes 
mellitus. Age and Ageing 2007; 36: 164-170. 
 
van Hecke MV, Dekker JM, Nijpels G, Stolk RP, Henry RM, Heine RJ, Bouter LM, 
Stehouwer CD, Polak BC. Are retinal microvascular abnormalities associated with 
large artery endothelial dysfunction and intima-media thickness? The Hoorn Study. 
Clinical science (London, England : 1979) 2006; 110: 597-604. 
 
van Leiden HA, Dekker JM, Moll AC, Nijpels G, Heine RJ, Bouter LM, Stehouwer 
CD, Polak BC. Blood Pressure, Lipids, and Obesity Are Associated With Retinopathy. 
The Hoorn Study. Diabetes Care 2002; 25: 1320–1325. 
 
van Exel E, Gussekloo J, de Craen AJM, Bootsma-van der Wiel A, Houx P, Knook 
DL, Westendorp RGJ. Cognitive function in the oldest old: women perform better 
than men. Journal of Neurology, Neurosurgery, and Psychiatry 2001; 71:29-32. 
 
Varma R, Torres M, Peña F, Klein R, Azen SP; Los Angeles Latino Eye Study 
Group. Prevalence of diabetic retinopathy in adult Latinos The Los Angeles Latino 
Eye Study. Ophthalmology 2004; 111: 1298-1306. 
 
Vecchione C, Maffei A, Colella S, Aretini A, Poulet R, Frati G, Gentile MT, Fratta L, 
Trimarco V, Trimarco B, Lembo G. Leptin effect on endothelial nitric oxide is 
 379 
mediated through Akt-endothelial nitric oxide synthase phosphorylation pathway. 
Diabetes 2002; 51: 168-173. 
 
Verdelho A, Madureira S, Ferro JM, Basile AM, Chabriat H, Erkinjuntti T, Fazekas 
F, Hennerici M, O'Brien J, Pantoni L, Salvadori E, Scheltens P, Visser MC, Wahlund 
LO, Waldemar G, Wallin A, Inzitari D; LADIS Study.Differential impact of cerebral 
white matter changes, diabetes, hypertension and stroke on cognitive performance 
among non-disabled elderly: the LADIS study. Journal of neurology, neurosurgery, 
and psychiatry 2007; 78: 1325-1330. 
 
Verhaeghen P, Borchelt M, Smith J. Relation between cardiovascular and metabolic 
disease and cognition in very old age: cross-sectional and longitudinal findings from 
the Berlin Aging Study. Health Psychology 2003; 22: 559-569. 
 
Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MMB. 
Silent brain infarcts and the risk of dementia and cognitive decline. New England 
Journal of Medicine 2003; 348: 1215-1222. 
 
Vermeer SE, Longstreth WY, Koudstaal. Silent brain infarcts: a systematic review. 
Lancet Neurology 2007; 6: 611-619. 
Vernooij MW, Ikram MA, Vrooman HA, Wielopolski PA, Krestin GP, Hofman A, 
Niessen WJ, Van der Lugt A, Breteler MM. White matter microstructural integrity 
and cognitive function in a general elderly population. Archives of general psychiatry 
2009; 66: 545-553. 
Victoria CG, Huttly SR, Fuchs SC, Olinto MTA. The role of conceptual frameworks 
in epidemiological analysis: a hierarchical approach. International Journal of 
Epidemiology 1997; 26: 224-227. 
 
Vingerhoets G. Cognitive consequences of myocardial infarction, cardiac 
arrhythmias, and cardiac arrest. In: Waldstein SR, Elias MF (Eds). Neuropsychology 




Virally M, Blicklé JF, Girard J, Halimi S, Simon D, Guillausseau PJ. Type 2 diabetes: 
epidemiology, pathophysiology, unmet needs and therapeutical perspectives. 
Diabetes & Metabolism 2007; 33: 231-244. 
 
Visser PJ, Verhey F, Ponds R. Distinction between preclinical Alzheimer‘s disease 
and depression. Journal of American Geriatric Society 2000; 48: 479-84. 
 
Vogt MT, Wolfson SK, Kuller LH. Lower extremity arterial disease and the aging 
process: a review. Journal of Clinical Epidemiology 1992; 45:529-542. 
 
Wada T, Matsubayashi K, Okumiya K, Kimura S, Osaka Y, Doi Y, Ozawa T. Lower 
serum cholesterol level and later decline in cognitive function in older people living 
in the community, Japan. Journal of the American Geriatrics Society 1997; 45: 
1411–1412. 
 
Wagener HP, Clay GE, Gipner JF. Classification of retinal lesions in the presence of 
vascular hypertension. Transactions of the American Ophthalmological Society 1947; 
45: 57-73. 
 
Wakabayashi I, Kobaba-Wakabayashi R, Masuda H. Relation of drinking alcohol to 
atherosclerotic risk in type 2 diabetes. Diabetes Care 2002; 25: 1223-1228. 
 
Waldstein SR. Hypertension and neuropsychological function: a lifespan perspective. 
Experimental aging research 1995; 21: 321-352. 
 
Waldstein SR, Elias MF. Introduction to the special section on health and cognitive 
function. Health Psychology 2003; 22: 555-558. 
 
Walker N, McConville PM, Hunter D, Deary IJ, Whalley LJ. Childhood mental 
ability and lifetime psychiatric contact a 66-year follow-up study of the 1932 
 381 
Scottish Mental Ability Survey. Intelligence 2002; 30: 233-245. 
 
Wang JJ, Taylor B, Wong TY, Chua B, Rochtchina E, Klein R, Mitchell P. Retinal 
vessel diameters and obesity: a population-based study in older persons. Obesity 
(Silver Spring) 2006; 14: 206-214. 
 
Wardlaw JM, Sandercock PA, Dennis MS, Starr J. Is breakdown of the blood-brain 
barrier responsible for lacunar stroke, leukoaraiosis, and dementia? Stroke 2003; 34: 
806-812. 
 
Wardlaw JM, Farrall A, Armitage PA, Carpenter T, Chappell F, Doubal F, 
Chowdhury D, Cvoro V, Dennis MS. Changes in background blood-brain barrer 
intefrity between lacunar and cortical ischaemic stroke subtypes. Stroke 2008; 39: 
1327-1332. 
 
Wardlaw JM, Doubal F, Armitage P, Chappell F, Carpenter T, Muñoz Maniega S, 
Farrall A, Sudlow C, Dennis M, Dhillon B. Lacunar stroke is associated with diffuse 
blood-brain barrier dysfunction. Annals of neurology 2009; 65: 194-202. 
 
Watari K, Letamendi A, Elderkin-Thompson V et al. Watari K, Letamendi A, 
Elderkin-Thompson V, Haroon E, Miller J, Darwin C, Kumar A. Cognitive function 
in adults with type 2 diabetes and major depression. Archives of Clinical 
Neuropsychology 2006; 21: 787-796. 
 
Way KJ, Katai N, King GL. Protein kinase C and the development of diabetic vascular 
complications. Diabetic Medicine 2001; 18: 945-959. 
 
Wechsler D. Wechsler Adult Intelligence Scale-Revised Manual. San Antonio, TX: 
The Psychological Corporation, 1981. 
 




Wechsler D. Wechsler Test of Adult Reading (WTAR). San Antonio, TX: The 
Psychological Corporation , 2001. 
 
Werring DJ, Frazer DW, Coward LJ, Losseff NA, Watt H, Cipolotti L, Brown MM, 
Jäger HR. Cognitive dysfunction in patients with cerebral microbleeds on 
T2*-weighted gradient-echo MRI. Brain 2004; 127: 2265–2275. 
 
Whalley LJ, Deary IJ, Appleton C, Starr JM. Cognitive reserve and the neurobiology 
of cognitive aging. Aging Research Reviews 2004, 3: 369-382. 
 
Whiteman MC. Relationships between personality traits and cardiovascular diseases 
in the general population. Unpublished doctoral dissertation, Edinburgh University, 
Edinburgh, Scotland, UK, 1996. 
 
Whitmer RA, Sidney S , Selby J, SC Johnston and K Yaffe, Midlife cardiovascular 
risk factors and risk of dementia in late life. Neurology 2005; 64: 277–281. 
 
Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes. 
Diabetes Care 2004; 27: 1047-1053. 
 
Wight RG, Aneshensel CS, Seeman TE. Educational attainment, continued learning 
experience, and cognitive function among older men. Journal of Aging and Health 
2002; 14: 211-236. 
 
Wilkinson CP, Ferris FL 3rd, Klein RE, Lee PP, Agardh CD, DavisM, Dills D, 
Kampik A, Pararajasegaram R, Verdaguer JT. Global Diabetic Retinopathy Project 
Group: Proposed international clinical diabetic retinopathy and diabetic macular 
edema disease severity scales. Ophthalmology 2003; 110: 1677-1682 
 
Wilkinson-Berka JL. Vasoactive factors and diabetic retinopathy: vascular 
endothelial growth factor, cycoloxygenase-2 and nitric oxide. Current 
 383 
pharmaceutical design 2004; 10: 3331–3348. 
 
Wilson RS, Beckett LA, Barnes LL, Schneider JA, Bach J, Evans DA, Bennett DA. 
Individual differences in rates of change in cognitive abilities of older persons. 
Psychololgy and Aging 2002; 17: 179–193. 
 
Wilson RS, de Leon CFM, Bennett DA, Bienias JL, Evans DA. Depressive 
symptoms and cognitive decline in a community population of older persons. 
Journal of Neurology, Neurosurgery, and Psychiatry 2004; 75: 126-129. 
 
Wise GN, Dollery CT, Henkind P. The retinal circulation. New York: Harper and 
Row. 1971. 
 
Witt N, Wong TY, Hughes AD, Chaturvedi N, Klein BE, Evans R, McNamara M, 
Thom SA, Klein R. Abnormalities of retinal microvascular structure and risk of 
mortality from ischemic heart disease and stroke. Hypertension 2006; 47: 975-981. 
 
Wolf PA, Beiser A, Elias MF, Au R, Vasan RS, Seshadri S. Relation of obesity to 
cognitive function: importance of central obesity and synergistic influence of 
concomitant hypertension. The Framingham Heart Study. Current Alzheimer 
research 2007; 4: 111-116. 
 
Woodruff-Pak DS. The neuropsychology of ageing. Oxford: Blackwell Publishers, 
1997. 
 
Woodward Z. Validation of self-reported smoking status: a literature review prepared 
for the Quit Group, 2002. http://www.quit.org.nz/documents/Validation-selfreport. 
pdf. 
 
Wong TY, Klein R, Couper DJ, Cooper LS, Shahar E, Hubbard LD, Wofford MR, 
Sharrett AR Retinal microvascular abnormalities and incident stroke: the 
Atherosclerosis Risk in Communities Study. Lancet 2001a; 358: 1134-1140. 
 384 
 
Wong TY, Klein R, Klein BE, Tielsch JM, Hubbard L, Nieto FJ. Retinal 
microvascular abnormalities and their relationship with hypertension, cardiovascular 
diseases and mortality. Survey of Ophthalmology 2001b; 46: 59-80. 
 
Wong TY, Klein R, Sharrett AR, Schmidt MI, Pankow JS, Couper DJ, Klein BE, 
Hubbard LD, Duncan BB; ARIC Investigators. Retinal arteriolar narrowing and risk 
of diabetes mellitus in middle-aged persons. Journal of the American Medical 
Association 2002a; 287: 2528-2533. 
 
Wong TY, Hubbard LD, Klein R, Marino EK, Kronmal R, Sharrett AR, Siscovick DS, 
Burke G, Tielsch JM. Retinal microvascular abnormalities and blood pressure in 
older people: the Cardiovascular Health Study. British Journal of Ophthalmology 
2002b; 86:  1007-1013. 
 
Wong TY, Klein R, Sharrett AR, Couper DJ, Klein BE, Liao DP, Hubbard LD, 
Mosley TH; ARIC Investigators. Atheroslerosis Risk in Communities Study. 
Cerebral white matter lesions, retinopathy, and incident clinical stroke. Journal of the 
American Medical Association 2002c; 288: 67-74. 
 
Wong TY, Klein R, Nieto FJ, Moraes SA, Mosley TH, Couper DJ, Klein BE, Boland 
LL, Hubbard LD, Sharrett AR. Is early age-related maculopathy related to cognitive 
function? The Atherosclerosis Risk in Communities Study. American Journal of 
Ophthalmology 2002d; 134: 828-835. 
 
Wong TY, Klein R, Sharrett AR, Nieto FJ, Boland LL, Couper DJ, Mosley TH, 
Klein BE, Hubbard LD, Szklo M. Retinal microvascular abnormalities and cognitive 
impairment in middle-aged persons: The Atherosclerosis Risk in Communities Study. 
Stroke 2002e; 33: 1487-1492. 
 
Wong TY, Klein R, Klein BE, Meuer SM, Hubbard LD. Retinal vessel diameters and 
their associations with age and blood pressure. Investigative ophthalmology & visual 
 385 
science 2003a; 44: 4644-4650. 
 
Wong TY, Klein R, Sharrett AR, Manolio TA, Hubbard LD, Marino EK, Kuller L, 
Burke G, Tracy RP, Polak JF, Gottdiener JS, Siscovick DS. The prevalence and risk 
factors of retinal microvascular abnormalities in older persons: the Cardiovascular 
Health Study. Ophthalmology 2003b; 110: 658-666. 
 
Wong TY, Mosley TH Jr, Klein R, Klein BE, Sharrett AR, Couper DJ, Hubbard LD; 
Atherosclerosis Risk in Communities Study. Retinal microvascular changes and MRI 
signs of cerebral atrophy in healthy, middle-aged people. Neurology 2003c; 61:806
–811. 
 
Wong TY, Klein R, Nieto FJ, Klein BE, Sharrett AR, Meuer SM, Hubbard LD, 
Tielsch JM. Retinal microvascular abnormalities and 10-year cardiovascular 
mortality: a population based case-control study. Ophthalmology 2003d; 110: 933–
940. 
 
Wong TY. Is retinal photography useful in the measurement of stroke risk? Lancet 
Neurology 2004; 3: 179-183. 
 
Wong TY, Mitchell P The eye in hypertensive retinopathy. New England Journal 
Medicine 2004; 351: 2310-2317. 
 
Wong TY, Klein R, Sharrett AR, Duncan BB, Couper DJ, Klein BE, Hubbard LD, 
Nieto FJ; Atherosclerosis Risk in Communities Study. Retinal arteriolar diameter and 
risk for hypertension. Annals of Internal Medicine 2004a; 17: 248-255. 
 
Wong TY, Shankar A, Klein R, Klein BE, Hubbard LD. Prospective cohort study of 
retinal vessel diameters and risk of hypertension. British Medical Journal 2004b; 329: 
79-82. 
 
Wong TY, Wang JJ, Rochtchina E, Klein R, Mitchell P. Does refractive error 
 386 
influence the association of blood pressure and retinal vessel diameters? The Blue 
Mountains Eye Study. American Journal of Ophthalmology 2004c; 137: 1050-1055.  
 
Wong TY, Knudtson MD, Klein BE, Klein R, Hubbard LD. Estrogen replacement 
therapy and retinal vascular calibre. Ophthalmology. 2005a; 112: 553-558. 
 
Wong TY, Rosamond W, Chang PP, Couper DJ, Sharrett AR, Hubbard LD, Folsom 
AR, Klein R. Retinopathy and risk of congestive heart failure. Journal of the 
American Medical Association 2005b; 293: 63-69. 
 
Wong TY, Islam FM, Klein R, Klein BE, Cotch MF, Castro C, Sharrett AR, Shahar E. 
Retinal vascular caliber, cardiovascular risk factors, and inflammation: the 
multi-ethnic study of atherosclerosis (MESA). Investigative ophthalmology & visual 
science 2006a; 47: 2341-2350. 
 
Wong TY, Kamineni A, Klein R, Sharrett AR, Klein BE, Siscovick DS, Cushman M, 
Duncan BB. Quantitative retinal venular caliber and risk of cardiovascular disease in 
older persons: the cardiovascular health study. Archives of Internal Medicine 2006b; 
166: 2388-2394. 
 
Wong TY, Mitchell P. The eye in hypertension. Lancet 2007; 369: 425-435 
 
Wong TY, Liew G, Tapp RJ, Schmidt MI, Wang JJ, Mitchell P, Klein R, Klein BE, 
Zimmet P, Shaw J. Relation between fasting glucose and retinopathy for diagnosis of 
diabetes: three population-based cross-sectional studies. Lancet 2008; 371: 736-743. 
 
World Health Organization: Expert Committee on Diabetes Mellitus. Geneva, World 
Health Org., 1980. Tech. Rep. Ser., no. 646: 1-80. 
  
World Health Organization: Diabetes Mellitus: Report of a WHO Study Group. 
Geneva, World Health Org., 1985. Tech. Rep. Ser., no. 727: 1-104. 
 
 387 
World Health Organization: Definition, Diagnosis and Classification of Diabetes 
Mellitus and its Complications: Report of a WHO Consultation. Part 1: Diagnosis 
and Classification of Diabetes Mellitus. Geneva, World Health Org., 1999. 
 
World Health Organization: Definition and diagnosis of diabetes mellitus and 




World Health Organization: Shaping the future. The World Health Report 2003. 
Geneva, World Health Orgization, 2003. 
 
Yaffe K, Blackwell T, Gore R, Sands L, Reus V, Browner WS. Depressive 
symptoms and cognitive decline in nondemented elderly women. Archives of 
General Psychiatry 1999; 56: 425-430. 
 
Yaffe K, Kanaya A, Lindquist K, Simonsick EM, Harris T, Shorr RI, Tylavsky FA, 
Newman AB. The metabolic syndrome, inflammation, and risk of cognitive decline, 
Journal of the American Medical Aassociation 2004a; 292: 2237–2242. 
 
Yaffe K, Blackwell T, Kanaya AM, Davidowitz N, Barrett-Connor E, Krueger K. 
Diabetes, impaired fasting glucose, and development of cognitive impairment in 
older women. Neurology 2004b; 63: 658-663. 
 
Yaffe K, Blackwell T, Whitmer RA, Krueger K, Barrett Connor E. Glycosylated 
hemoglobin level and development of mild cognitive impairment or dementia in 
older women. The journal of nutrition, health & aging 2006; 10: 293-295. 
 
Young T. On the function of the heart and arteries. Philosophical Transactions of the 
Royal Society London 1809; 99: 1-31. 
 
Young RJ, McCulloch DK, Prescott RJ, Clarke BF. Alcohol: another risk factor for 
 388 
diabetic retinopathy? British Medical Journal 1984; 288: 1035-1037. 
 
Younis N, Broadbent DM, Vora JP, Harding SP. Liverpool Diabetic Eye Study. 
Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the 
Liverpool Diabetic Eye Study: a cohort study. The Lancet 2003; 361: 195-200. 
 
Yousem DM, Tasman WS, Grossman RI. Proliferative retinopathy:absence of white 
matter lesions at MR imaging. Radiology 1991;179: 229-230.  
 
Yu DY, Cringle SJ, Alder VA, Su EN. Intraretinal oxygen distribution in rats as a 
function of systemic blood pressure. American Journal of Physiology 1994; 36: 
H2498-H2507. 
 
Zammit S, Allebeck P, David AS, Dalman C, Hemmingsson T, Lundberg I, Lewis G 
A longitudinal study of premorbid IQ score and risk of developing schizophrenia, 
bipolar disorder, severe depression, and other nonaffective psychoses. Archives of 
general psychiatry 2004; 61: 354-460. 
 
Zaslavsky LM, Gross JL, Chaves ML, Machado R. Memory dysfunction and 
autonomic neuropathy in non-insulin-dependent (type 2) diabetic patients. Diabetes 
research and clinical practice 1995; 30: 101–110.  
 
Zelinski EM, Burnight KP. Sixteen-year longitudinal and time lag changes in 
memory and cognition in older adults. Psychological Aging 1997; 12: 503-513. 
 
Zhang L, Krzentowski G, Albert A, Lefebvre PJ. Risk of developing retinopathy in 
Diabetes Control and Complications Trial type 1 diabetic patients with good or poor 
metabolic control. Diabetes Care 2001; 24: 1275–1279. 
 
Zhao W, Alkon DL. Role of insulin and insulin receptor in learning and memory, 
Molecular and cellular endocrinology 2001; 177: 125–134. 
 
 389 
Zhu L, Fratiglioni L, Zhenchao G, Agüero-Torres H, Winblad B, Viitanen M. 
Association of stroke with dementia, cognitive impairment, and functional disability 
in the very old. A population-based study. Stroke 1998; 29: 2094-2099. 
 
Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scales. Acta 
Psychiatrica Scandinavica 1983; 67: 361-370. 
 
Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes 









APPENDIX A: Data extraction sheet for studies on retinal 
microvasuclar disease and cognitive dysfunction 
 
 
     A)  STUDY DESIGN 
 
   Cross-sectional    Case-Control   Prospective cohort    
 
 
B) PARTICIPANTS SELECTION, RECRUITMENT & FOLLOW-UP 
 
(1) Type of sample: General population/ Hospital/ Outpatient Clinic   
 
(2) Principle clinical status of patients: Diabetes (Type 1/ Type 2/ Unspecified) / 
Hypertension / others________________________________________________ 
 
(3) No. of participants________________   (4) Age (mean/range) _______________  
(5) Sex: F/M/both  
 (6) (Baseline) response rate (%): _____________/ Not reported  
 
(7) Follow-up period: ____ / NA (8) Loss to follow-up (%):_______/ Not reported / NA 
 
C) MEASURES OF RETINAL MICROVASCULAR DISEASE 
 
(1) No. of eyes assessed: 1/2/Not reported 
(2) Assessment tools: Photography / Ophthalmoscopy / Medical records/ Questionnaire 
(3) Grading Methods: Adopted from Prior Classification System (name) ___________ 
__________________ ____________________/Computer-assisted / Not Reported    
(4) Abnormalities measured:   
 
  -----Any Retinopathy:  generalized/focal arteriolar narrowing / arteriovenous nicking 
microaneurysm / retinal hemorrhage / soft or hard exudates/ cotton wool spots/ 
background  
   retinopathy / proliferative retinopathy / 
retinopathy/________________________________ 
 
------Retinal vascular network geometry: AVR (the arteriole-to-venule ratio) / CRAE 
(central retinal arterial equivalent) / CRVE (central retinal venular equivalent) / Branching 
Coefficient / Bifurcation Angles /______________________________________________ 
 
    (5)  Assessors blinded: Yes/No/Not reported 
 
D) MEASURES OF COGNITIVE FUNCTION 
 




 (2)  Assessment of Premobid intelligence: occupation / education / word reading test 
/ 
_________________/ Not Reported 
Ref ID: _______________ 
Author: _______________ 
Year:     _______________ 
Reviewer: _____________  
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(3) Cognitive impairment defined as: 
_______________________________________ 

















  CI 
 
    P 
value 
 





























       
       
       




      Domain 
 
 Z scores 
      
   CI 
 
   Effect Size 
 





























      
      
      
      
 
F) POTENTIAL CONFOUNDERS ADJUSTED FOR 
 
     Age / Sex / Premobid intelligence / Hypertension / Diabetes / Medical conditions 
(eg. dementia, depression, hyperlipemia, coronary heart disease, peripheral vascular 
disease and cerebrovascular disease) / Drugs with effects in the central nervous 
system (eg. beta-adrenoreceptor blocking agents and antidepressants) / Alcohol 





Scores:    /          
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APPENDIX B: Documentation relating to the 2006-2007 
survey of Edinburgh Type 2 Diabetes Study 
 
B-1: Subject’s information sheet, letter of invitation and 
reply form  
 
Will my details be kept confidential? 
All data collected from you will be kept confidential.  Samples will be 
coded to remove identifying information before being sent to the 
laboratories. Only members of the research team will have access to 
named data. Data on computer will be accessible only by research team 
members and will be password protected. Written information will be 
stored securely in locked filing cabinets. 
 
If you agree to take part in the study then please: 
1. Complete the Reply Slip at the bottom of the invitation letter and tick 
the box to say you do wish to be contacted. Return in reply paid 
envelope.  
2. Keep this information sheet for your own information and wait for 
the research team to contact you. 
If you do not wish to take part then please: 
1. Complete the Reply Slip and tick the box to say you do not wish to 
be contacted. Return in reply paid envelope (this will avoid you being 
accidentally contacted again). 
If you change your mind 
If you do decide to take part you are still free to withdraw from the study 
at any time without giving a reason.  However, if you do decide to 
withdraw, it would be very helpful if you could contact the study office 
and let us know.  A decision to withdraw at any time, or a decision not to 
take part, will not affect any health care you receive. 
 




INFORMATION SHEET  
  
    Edinburgh Type 2 Diabetes Study 
 
 
Diabetes is a major health problem in Scotland. It is 
important that we try to improve our understanding of the 
complications of diabetes so that new ways of preventing and 
treating these can be developed. 
               
If you have any queries please contact : 
 
Edinburgh Type 2 Diabetes Study Research Office  
The University of Edinburgh 
Teviot Place 
Edinburgh EH8 9AG  





Background information to the study 
The Medical Research Council is funding a major new research project 
into the cause of complications associated with diabetes in Lothian.  This 
study is looking at people with type 2 diabetes who are aged 60 to 75 and 
investigating them for disease of the blood vessels and changes in mental 
sharpness.  We are collecting samples of blood and taking clinical 
measurements to look at which risk factors may contribute to these 
conditions in diabetic people. 
 
Why have I been asked to take part? 
You have been asked to take part because you are one of several 
thousand people living in Lothian who has diabetes and are aged 60 to 
75.  If you agree to take part you will be one of 1000 people we aim to 
recruit into the study. 
 
How can I help with this study? 
If you agree to take part, we will invite you to a research clinic at the 
Western General Hospital in Edinburgh where you will be met by one of 
our study nurses.  They will ask you to: 
1. Give your personal details and sign a consent form. 
2. Give a blood sample of approximately 30mls (6 teaspoons). 
3. Complete a questionnaire about your social and medical history. The 
nurse will offer help with this should you wish. 
4. Undertake some interviews and questionnaires to test your memory, 
thinking skills and other aspects of mental function. 
5. Allow us to take some simple clinical measurements on you, such as 
height, weight, waist and hip circumferences, blood pressure in your 
arm and ankle, an electrocardiogram (ECG, recording of the heart),  
non-invasive tests of feeling in your feet and body fat composition. 
6. Provide us with specimens of urine and saliva. 
7. Allow us to take pictures of the back of your eyes after dilating your 
pupils with eye drops (we will give you a separate 40 minute appoint-
ment at the Princess Alexandra Eye Pavilion in Edinburgh for this). 
 
We will ask you to attend the research clinic in the morning and without 
breakfast (a simple breakfast will be provided in the clinic).  The whole 
appointment should last around 3 hours and we will be happy to 
reimburse your travel expenses.   
 
Blood, urine and saliva samples will be used in the laboratories to 
measure possible risk factors.  Constituents of your blood sample (plasma 
and DNA) will be stored for measurement of additional risk factors at a 
later date, including genetic factors.  Whole blood and/or blood cells will 
also be stored.  The blood cells can be modified to produce cells which 
are capable of continuously renewing themselves and provide an on-
going source of DNA for future analysis of genetic risk factors.  
 
In 4 to 5 years time, we will contact you again to ask you to repeat some 
of the measurements, in order to see whether these have changed.  In the 
intervening years, we will keep in touch with you, either by telephone or 
post.  We may also wish to contact you to ask if you would be willing to 
participate in any additional related studies.  You will not be asked to 
commit to this just now, but we will ask your permission to contact you 
again for this purpose (you will be free to refuse permission). 
 
We will also ask for permission to look at your medical records (both 
your medical notes and any electronic medical records). This will enable 
us to follow your medical history and find out details about your diabetes 
without asking you each time.  
 
Will the research have any implications to my health? 
There is no health risk or risk of significant physical or psychological 
harm associated with participation in this study.  Nevertheless, you 
should know that the University of Edinburgh has indemnity insurance 
cover for research work undertaken by its employees.  Occasionally 
people experience reactions to the eye drops used for pupil dilatation.  
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However, this is very rare and experienced staff and facilities will be on 
hand to deal quickly and effectively with any such problem. Complaints 
from participants about their treatment by individual members of 
research staff will be dealt with sensitively by the research team. 
 
There is no intended clinical benefit to you from taking part in this study.  
Your General Practitioner will be notified of your participation in the 
study and any information collected during the course of the study which 





                                                                                                                                                                   
^Name                   
^Address                  
         
^Date 
 
Dear ^Title ^Name 
 
Edinburgh Type 2 Diabetes Study 
 
A major new research project into the effects of diabetes on blood vessels and mental 
function is taking place in Lothian and is called the Edinburgh Type 2 Diabetes Study.  
This study, which will involve 1000 people with Type 2 diabetes in Lothian, is being 
run by a team of researchers from Edinburgh University in collaboration with diabetes 
specialists in Lothian.  It is funded by the Medical Research Council and has the support 
of NHS Lothian. 
 
The purpose of this letter is to ask whether you would be interested in taking part in this 
research.   Your name has been randomly picked from the Lothian diabetes register and 
will not be passed on to the research team without your permission  If you do give 
permission you will then be invited to attend a clinic run by trained research nurses.  
More information about the project is given in the enclosed patient information sheet.  
Please note however that whether or not you wish to participate is entirely up to you and 
that a decision either way will not affect the care you receive from your GP or your 
hospital diabetes team if you attend hospital as an outpatient. 
 
I would be very grateful if you could complete the slip below and return it in the reply 
paid envelope.  Even if you do not wish to take part, please return the slip so that you 
will not be contacted again for this study.  If you have any queries, you can contact 
the research team directly on 0131-XXX-XXXX. 
 
I do hope that you will be able to help the research team and look forward to hearing 





Miss Julie Bladen 
Lothian Diabetes Register Facilitator (with the support of Mary Scott, Diabetes MCN 
Manager) 
 
^Title ^Name ^DOB 
^Address ^Postcode 
I am interested in taking part in the Edinburgh Type 2 Diabetes Study □ 
I do not wish to take part in the Edinburgh Type 2 Diabetes Study  □ 
 





Please return to: Miss Julie Bladen, Lothian Diabetes Register Facilitator, Blackford 
Pavillion, Astley Ainslie Hospital, 133 Grange Loan, Edinburgh EH9 2HL  Tel: 0131 –
XXX- XXXX  Fax. 0131-XXX- XXXX  
 
For office use:  Study no………… 
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B-2: Letter of appointment and instructions for clinical examination 
 
 






Dear ^Title ^Surname, 
 
Thank you for agreeing to participate in the Edinburgh Type 2 Diabetes Study.  
 
To confirm, we have arranged an appointment for you on:  
 
^Day ^Date ^ Month at 9am, at the Wellcome Trust Clinical Research Facility, Western 
General Hospital (Directions and a map are enclosed). Your appointment is likely to last until 
12:30pm. 
 
So that we can take a fasting blood sample from you, we will need you to fast for twelve hours 
prior to your appointment. If you take insulin or any other medication for diabetes in the 
morning, please bring this with you to the clinic and take it after you have provided a blood 
sample. (Please note: any other medication which is not for diabetes should be taken as normal). 
If you have any concerns or questions about this please call the study team. We will take blood 
samples as early as possible, and we will provide a light breakfast afterwards.  
 
We have enclosed a questionnaire - please complete this and bring it to the clinic. If you are 
unable to complete the questionnaire or if you have any questions about it, a nurse will help you 
at the clinic. 
 
We also need you to bring a small sample of urine to the clinic. We have enclosed a container, 
with instructions, for this purpose. Please follow these instructions carefully.  
 
If you wear glasses for reading, please bring these with you to the clinic.  
 
If you have any queries about the study, or if you are unable to attend your appointment, please 
telephone us at the number above. 
 





Edinburgh Type 2 Diabetes Study Team 
 
 
Please Note: This is a fasted appointment. It is important that you have nothing to eat or 










B-3: Directions to the Wellcome Trust Clinical Research Facility 
 
The Wellcome Trust Clinical Research Facility is at the Western General Hospital, situated 
between Crewe Road South and Telford Road in North Edinburgh. The main entrance to the 
WTCRF is on the ground floor, off the north corridor between the Acute Receiving Unit 






Enter via Porterfield Road; follow the road to the right of the Outpatient building towards the 
Alexander Donald Building (ADB), under the walkway and past the Acute Receiving Unit 
(ARU) on the left. The WTCRF entrance is immediately on your left opposite the large blue 
building (Anne Ferguson Building). Enter through double glass doors and through the next set of 
turquoise doors. 
Public transport: 
The following buses stop at the hospital: 
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Lothian Regional Transport – 19,19A, 27, 28, 28B,29,29A, 37, 37A, 38, X29, X7, 42 For 
information about all bus services, contact Traveline on freephone 0800 232323.  
Arriving by car or taxi: 
Enter by Porterfield Road, as above. You can be dropped off directly outside the WTCRF. The 
hospital operates a pay and display system in public parking areas, as marked on the map. 
Unfortunately, there is restricted parking in the hospital grounds so you may not be able to find a 
parking space easily especially at peak times (8.45am-3pm Monday to Friday). 





















































Edinburgh Type 2 Diabetes Study 








The Eye Pavilion is situated on Chalmers Street, off Lauriston Place. 
 
There is metered parking outside the hospital, or a car park 100 yards away 
at the bottom of the road. LRT Buses nos 23 and 27 go from the bottom of 
the Mound to Lauriston Place.  
 
Once at the Eye Pavilion: 
Go past the reception area and take the lift or stairs to the first floor 
Go through the double doors, turn right and wait in the red chair area 
If you need to ask directions, say that you are from the Edinburgh Type 
2 Diabetes Study and have an appointment with Dr. Halina Kaim 
 
Please Note: Your appointment will take 40 mins to 1 hour. We will use eye 
drops to dilate your pupils, and we do not recommend that you drive for 2-
3 hours afterwards. 
 
Please call the Edinburgh Type 2 Diabetes Study team on 0131-XXX-




B-5: Consent form 
 
The Edinburgh Type 2 Diabetes Study 
 
Co-ordinating Centre    Public Health Sciences    University of Edinburgh 
Teviot Place    Edinburgh    EH8 9AG    Tel/Fax 0131-XXX-XXXX 
 
 




       (Circle YES or NO below) 
 
1. I confirm that I have read and understand the information sheet dated 30
th
 March 2006  YES/NO 
(version 2) for the above study and have had the opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time,  YES/NO 
without giving any reason, without my medical care or legal rights being affected. 
 
3. I give permission for responsible individuals from the research team to gather relevant YES/NO 
 medical information from any of my medical records, including NHS electronic medical 
 records, and any medical information that may be held by the General Register  
 Office for Scotland. 
 
4. I agree that the samples I give and the information gathered about me can be stored by YES/NO 
 the research team and used in future, related research, as described in the information  
 sheet (this excludes the genetic information, for which there is a separate consent form).   
 
5. I understand that my GP will be contacted about my participation in the study and will be  YES/NO 
told about results of the examination which may be important for my clinical care. 
  
6. I agree to take part in the above study.   YES/NO 
 
7. I agree, if selected, to be invited to participate in related studies involving collection of  YES/NO 




________________________ ________________     ____________________ 
Name of Patient  Date Signature 
 
 
_________________________ ________________     ____________________ 














EDINBURGH TYPE 2 DIABETES STUDY 
(Baseline) 
 
Data Collection Form & Checklist 
 
 




PART 1 – Consent and venepuncture  
 
Recorder: DJ GB SL KB CM RM Other…….  (circle initials) 
 
  
General consent form signed? 
 
Genetic consent form signed?   
 
Urine sample received from subject and labelled? 
  
Questionnaire part 1 received from subject, checked and labelled?  
 
Patient fasted and still to take diabetic medication (if appropriate)?  
 
 







               Yes            No 
   
1. Was venepuncture completed and all tubes filled? 
 
2. Was venepuncture difficult/slow? 
 
 




All samples labelled?  
 
Correct brown, yellow and red tubes placed in specimen bag with 
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COMPLETED request form and urine specimen? 
 






   Subject reminded to take medication if necessary? 
 
   Questionnaire part 3 (and pen) given to subject? 
 
PART 2 – Cognitive function testing 
 





           YES NO 
Does subject normally wear glasses/contact lenses for distance vision? 
   
If YES, subject tested wearing glasses/contact lenses? 
 
Right eye    ………………. 
 
Left eye   ………………. 
 
Near vision  
           YES NO 
Does subject normally wear glasses for near vision? 
   
If YES, subject tested wearing glasses? 
 
Right eye    N  …. 
 




             . (If < 4.0, re-arrange appointment) 
 
 
Cognitive Test Battery: 
 
Time tests started………………am 
 
Tick box if complete     If test incomplete/difficulty encountered, 
specify  
 
Hospital Anxiety & Depression Scale 
 ………………………………………………………….. 
 





Logical memory 1 (WMS-III)  
 …………………………………………………………. 
 
Trail-Making Test B (TMB)  
 ………………………………………………………….  
 
Faces 1 (WMS-III)    
 …………………………………………………………. 
 
Matrix Reasoning (WAIS-III)  
 …………………………………………………………. 
 
Digit symbol test (WAIS-III)   
 …………………………………………………………. 
 
Borkowski Verbal Fluency Task  
 …………………………………………………………. 
 
Mill Hill Vocabulary Scale  
 ………………………………………………………….  
 
Letter-number sequencing (WAIS-III) 
 …………………………………………………………. 
 
Logical memory 2 (WMS-III)  
 …………………………………………………………. 
 
Faces 2 (WMS-III)   
 ………………………………………………………….  
 
PART 3 –physiological testing 
 
Time physiological testing started ……………………………… 
 
Tester:  DJ GB SL KB CM Other…….   
 
Group A tests (subject lying down) 
 
ABPI 
BP measurements using doppler 
 
 
Circle lowest ankle and higher arm reading     ABPI =        .  
 
             RESTING BLOOD PRESSURE 
 
Right arm, using stethoscope   
     
                                                Observed        
 
Systolic mmHg     mm/Hg 
 Left Right  
Posterior tibial 
 




















Yes  No 
  ECG recorded and labelled      
 
     
           
 NEUROTHESIOMETRY 
        Right big toe  Left big toe 
     
   Reading 1         .          volts   . volts 
 
   Reading 2         .          volts   . volts  
 
   Reading 3         .          volts   . volts  
 
   Average         .          volts   . volts 
 
 
Is there any obvious FOOT ulceration?    Yes No 
  Right foot 
 
      Left foot 
 
 
Has subject ever had a FOOT ulcer?    Yes No 
  Right foot 
 
      Left foot 
 





Circumference mid-way between lower rib and iliac crest (feet 30cm apart) 
 
          
Reading 1     . cm (to nearest 
0.5cm) 
 










Max circumference at hips (feet together) 
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Reading 1     . cm (to nearest 
0.5cm) 
 




  Average 




Height (without shoes)                                               .         cm 









(Shoes off, feet 30 cm apart)     % fat    
 
Reading 1  . %  
 
Reading 2  . %  
 
Reading 3  . % 
  
Average  . %  
 
 
 PART 4 – questionnaire checks and departure 
 
 
Recorder: DJ GB SL KB CM Other…….   
 
 
Questionnaire part 2 completed with subject? 
 
 




sent home with subject? 
 
 








APPENDIX D: Baseline questionnaire part 1 & 2 
 






PLEASE NOTE:  ONE OF OUR RESEARCH NURSES WILL GO OVER THE 
QUESTIONNAIRE WITH YOU AT THE CLINIC AND MAY ASK A FEW 
ADDITIIONAL QUESTIONS 
 
THE INFORMATION IN THIS QUESTIONNAIRE IS HIGHLY CONFIDENTIAL 
AND IS PART OF A MEDICAL RESEARCH STUDY 
 
 
The information you give in this questionnaire will be treated as strictly confidential 
and will be available only to your own doctor and the study team.  The results of 
the research will appear only in the form of general statistics from which it will be 




Please complete the following: 
 
 








If you have any difficulties in answering some of the questions, you will have a 
chance to discuss these with a member of the study team.   
 
 


















1. Please tick one box:            Male    Female      
                                 
                 
                  Day    Month          Year 
2. Enter your date of birth:         
 
 
3.  Please tick the box showing your present marital status: 
 
  Married and/or living with long-term partner   
  Single        
  Widowed         
Divorced or separated     
 
 
4. Please enter your address (including postcode) and telephone no.   
 
  Address:   …………………………………………………………………. 
 
    …………………………………………………………………. 
 
  Postcode: ……………………………….. 
 
Telephone no: ………………………………… 
 
                        
5. Please enter the details of your GP       
 




  …………………………………………………………………. 
 
EDUCATION 
6. What is the HIGHEST level of education you and your spouse/ex-spouse or long-term 
partner  have completed? 
 Please tick appropriate boxes: 
                  You      Spouse/ex-spouse 
           /partner 
 University/college degree course         




           Secondary school           




7. What is your ethnic group? 
 
 Please choose ONE section from 1 to 5, then tick the appropriate box to indicate your ethnic 
Group 
 
 (i)  White  
 
  
      British 
     
    Any Other White background, please write in   
__________________________________ 
 
 (ii)  Mixed 
 
     
    White and Black Caribbean 
     
    White and Black African 
     
    White and Asian 
     
    Any Other Mixed background, please write in  
__________________________________ 
 
 (iii)  Asian or Asian British 
 
     
    Indian 
     
    Pakistani 
     
    Bangladeshi 
     
    Any Other Asian background, please write in  
__________________________________ 
 
 (iv)  Black or Black British 
 
     
    Caribbean 
     
    African 
     
    Any Other Black background, please write in  
__________________________________ 
 
 (v)  Chinese or other ethnic group 
 
     
    Chinese 
     
    Any Other, please write in  __________________________________ 
 
CURRENT EMPOYMENT STATUS 
8. At the moment, what is the employment status of you and your spouse/ex-spouse or long-
term  partner? 
                                               You            Spouse/ex-spouse/partner 
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 Employed, full-time           Employed, full-time      
 Employed, part-time    
        
Employed, part-time      
 Unemployed     
        
Unemployed       
 
 Retired      
          
Retired        
 A Housewife (full-time)    
          
A Housewife (full-time)      
 Other     
          
Other       
 






9. When was your diabetes diagnosed (if known)?    Year ……..…… 
 
10. What treatment do you receive currently for your diabetes? 
 
Yes No 
(i) Tablets        
 
If „yes‟, please give name(s)  ……………………................................................. 
 
  Yes No 
(ii) Insulin injections    
 
If „yes‟,  
 
(a) give total number of units per day                            
……………….…units/day 
(b) give date (year) when you started insulin       year   ………………… 
 
           Yes       No  Don‟t Know 
11. Have you ever had an episode of low blood glucose (hypoglycaemia)  
      
  
 when you have needed someone else to treat you eg. give sugary  
drink or glucagon?    
 
 If „yes‟, how many times has this ever happened? 
 
  1-2    
3-4    
5 or over  
 
 
 How many times has this happened over the past year? 
 
  1-2    
  3-4    
             5 or over  
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12.  Are you on any regular medical treatment from a doctor as follows:  
                    Yes     No    Don‟t Know 
   Aspirin?        
  
  
   Drugs for angina (including spray)?   
     
  
   Drugs to lower blood pressure?     
               
  
   Drugs to lower cholesterol?     
               
  
   
(If you have answered YES to any of these, please include details below) 
13. Give names of all current medication if possible (including regular skin creams, eye drops, 












                           Yes     No    Don‟t Know 
14. Have you taken any oral steroids, used steroid inhalers or used       
  
   
       
  





15. Have you ever been told by a doctor that you have or have had any of the following? 
 
  
                                                                                                                Yes         No     Don‟t Know 
(i) Heart attack (coronary thrombosis, myocardial infarction)?       
(ii) Angina?             
(iii) Stroke?             
(iv) Hardening of the arteries in the legs?         
(v)    High blood pressure?           
 
If you have answered „yes‟ to any of the above, please give the year in which the event 
occurred and/or condition was diagnosed (as near as you can remember) and the name of 
the hospital/GP surgery where you were/are treated for the condition 
 
Event/condition   Year of event/diagnosis  Hospital/GP surgery  
where treated 
 








16. Have you ever undergone any of the following procedures/operations? 
                                 Don‟t 
                    Yes         No     Know 
(i) An operation or balloon treatment to relieve a blockage in         
the arteries of your heart (coronary by-pass or angioplasty)?     
 
(ii) An operation or balloon treatment to relieve a blockage in        
the arteries of your leg(s) , other than for varicose veins?  
 
(iii) Surgery to remove toes or leg (above or below the knee)?           
 
(iv)   An operation or balloon treatment to relieve a blockage in       
the arteries of your neck (carotid surgery/angioplasty/stenting)? 
 
 
If you have answered „yes‟ to any of the above, please give the year in which the 
procedure was performed and the name of the hospital you attended 
 
Procedure/operation  Year performed   Hospital attended  
 
 …………………………… ……………………….  …………………………. 
 





17. Have you ever been told by a doctor that you have or have had any of the following? 
  
                                                                                                                     Yes       No Don‟t Know 
(i) Hepatitis?             
(ii) Cirrhosis of the liver?            
(iii) Any other disease/medical condition affecting the liver? 
 
      
            
 
If you have answered „yes‟ to any of the above, please give the name of the condition, the 
year in which it was diagnosed (as near as you can remember) and the name of the 
hospital where you were/are treated for the condition 
 
Name of condition  Year of diagnosis  Hospital where treated 
 
 …………………………… ……………………….  …………………………. 
 
 …………………………… ………………………..  …………………………. 
 
 
18. Have you ever had any of the following investigations of your liver 
   
                                                                                                                     Yes       No Don‟t Know 
(i)          Abnormal blood tests of liver function?        
 




(iii)         Scan (ultrasound or CT etc.) of the liver?       
 
  (iv)         Other investigation of the liver?         
 
 
If you have answered „yes‟ to any of the above, please give the name of the investigation, 
the year in which it was done (as near as you can remember) and the name of the hospital 
where the test/investigation was performed 
 
Name of investigation  Year done   Hospital where  
performed 
 
 …………………………… ……………………….  …………………………. 
 
 …………………………… ………………………..  …………………………. 
      
 
Other Medical Conditions         
                                                                                                                     Yes       No   Don‟t Know 
19. Do you suffer from disease of the thyroid gland?        
  
20. Do you have any other medical conditions not mentioned above?      
 





   
                 
ALCOHOL 
 
21. Current alcohol intake 
 
(i)  Think back carefully over the last seven days.  Please write in each column the exact 
number  of alcoholic drinks you consumed on each day during the past week.  If none 
consumed write „0‟  in the boxes. 
 
 Try to remember where and who you were with on each day.  This may help you 
remember what  you had to drink. 
 
            Pints of beer,       Single glasses of        Single glasses of 
           lager, cider etc      whisky, vodka, gin etc       martini, wine, sherry, etc 
 
        
Monday                          
Tuesday                          
Wednesday                       
Thursday                        
Friday                        
Saturday                        
Sunday                         
 
          Yes No 
(ii) Would you say that last week was fairly typical of what you usually 
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have to drink in a week? 
          
          More Less 
(iii) If last week was not typical, would you normally drink more or 
less in a week?  
 
  
22.   Alcohol intake over past year 
 
(i)   How often did you have a drink containing alcohol in the past year?  
 Consider a “drink” to be a can or bottle of beer, a glass of wine, or one cocktail or a 
measure of  spirits (like scotch, gin, or vodka).  
 
never        
monthly or less     
2 to 4 times a month    
2 to 3 times a week     
4 to 5 times a week     
6 or more times a week    
 
 (ii)  How many drinks did you have on a typical day when you were drinking in the past year?  
 
0 drinks      
1 to 2 drinks     
3 to 4 drinks     
5 to 6 drinks        
7 to 9 drinks     




(iii)  How often did you have 6 or more drinks on one occasion in the past year?  
 
never      
less than monthly     
monthly      
weekly      
daily or almost daily    
 
23.   Have you or your doctor ever considered that you suffer/have   Yes No 







Smoking has been linked with many health problems.  It is important that you answer the following 
section as accurately as possible. 
         Yes No 




If no, proceed to Question 29 
 
25. What do you usually smoke now? 
Yes No 
 Cigarettes                  
Pipe             
Cigars            
          
 
26. How many do you usually smoke now? 
 
Cigarettes per day      ……… cigarettes 
 
Ozs. tobacco per week      ……… ozs. 
 
Cigars per week      ……… cigars 
 
 
27. For how many years during your life have you smoked cigarettes? ……… years 
           
 
28. How many cigarettes have you smoked on average per day during  
 the period you have smoked?      ………cigarettes
        
 Now proceed to Question 34      
       Yes No  
29. Have you ever smoked regularly?          
    
   If no, proceed to Question 34 
           
30. What did you usually smoke?       Yes No 
Cigarettes            
Pipe             
Cigars             
 
   
 
31. How much did you smoke on average while you were a smoker? 
 
Cigarettes per day      ……… cigarettes 
 
Ozs. tobacco per week      ……… oz. 
 
Cigars per week      ……… cigars 
 
32. For how many years did you smoke cigarettes?    ……… years 
 
33.        If you smoked cigarettes, how long is it since you finally  
 gave up?   







34. Do you ever get pain or discomfort in your chest?         
                     
 
IF NO, PROCEED TO QUESTION 40 
         Yes No 
35. Do you get this pain or discomfort when you walk uphill or hurry?      
         
  
  IF NO, PROCEED TO QUESTION 40 
            
          Yes No 
36. Do you get it when you walk at an ordinary pace on the level?       
          
           
37. When you get any pain or discomfort in your chest what do you do?  
                      Tick one 
Stop           
 
Slow down         
 
Continue at the same pace        
   
        Yes No 
38. Does it go away when you stand still or sit down?         
 
How soon?                       Tick one 
10 minutes or less         
 
More than 10 minutes         
 
 
39. Where do you get this pain or discomfort?  Mark the place(s) 
with an „X‟ on the diagram 
 
 
         Yes No 
40. (i) Have you ever had a severe pain across the front of your     
  chest lasting for half an hour? 
 






                                                                                                                     Yes      No   I am unable 
                                                                                                                             to walk 
 41.  Do you get a pain or discomfort in your leg(s) when you walk?        
  
 
If you answered ‘yes’ to question 41, please answer the following questions.   
 
           Yes
 No 
 (i) Does this pain ever begin when you are standing still or sitting?   
   
 (ii) Do you get it if you walk uphill or hurry?      
  
 (iii) Do you get it when you walk at an ordinary pace on the level?   
  
 
 (iv) Does the pain ever disappear while you are still walking?    
   
 (v) What do you do if you get it when you are walking?     
   
 
         Tick one 
   Stop          
Slow down         
  Continue at same pace        
 
 
(vi) What happens to it if you stand still? 
        Tick one 
 Usually continues for more than 10 minutes     
 Usually disappears in 10 minutes or less     
 
  
(vii) Where do you get this pain or discomfort? 
          Yes No 
  (i) Do you get this pain in your calf (or calves)?        
  








THANK YOU FOR COMPLETING THIS QUESTIONNAIRE – PLEASE BRING IT WITH YOU TO 












THE INFORMATION IN THIS QUESTIONNAIRE IS HIGHLY CONFIDENTIAL 
AND IS PART OF A MEDICAL RESEARCH STUDY 
 
 
The information you give in this questionnaire will be treated as strictly confidential 
and will be available only to your own doctor and the study team.  The results of 
the research will appear only in the form of general statistics from which it will be 




Please complete the following: 
 
 




























EMPLOYMENT STATUS / OCCUPATION  
The following questions refer to your current main job, or (if you are not working now) to your last 
main job. Please complete for both yourself (I) and for your spouse/ex-spouse or long-term partner 
(II) 
(I) Yourself   (Please tick one box only per question) 
1. What is (was) your employment status? 
Employee   
Self-employed with employees   
Self-employed / freelance without employees 
(go to question 4)    
Housewife 
(go to question 4)    
No previous paid employment (excluding housewife) 
(go to question 4)    
2. Number of employees 
For employees: indicate below how many people work (worked) for your employer at the place where 
you work (worked).  Then go to question 3. 
For self-employed: indicate below how many people you employ (employed). Then go to question 4. 
                                                     1 to 24                                             25 or more   
3. Do (did) you supervise any other employees? 
A supervisor or foreman is responsible for overseeing the work of other employees on a day-to-day 
basis 
                                                            Yes   
  
                                                  No   
4. Please tick one box to show which best describes the sort of work you do. 
(If you are not working now, please tick a box to show what you did in your last job). 
PLEASE TICK ONE BOX ONLY 
Modern professional occupations 
such as: teacher - nurse - physiotherapist - social worker - welfare officer - artist - musician - 




Clerical and intermediate occupations 
such as: secretary - personal assistant - clerical worker - office clerk - call centre agent - nursing 
auxiliary - nursery nurse 
 
 
Senior managers or administrators 
(usually responsible for planning, organising and co-ordinating work and for finance) 
such as: finance manager - chief executive 
 
 
Technical and craft occupations 
such as: motor mechanic - fitter - inspector - plumber - printer - tool maker - electrician - 
gardener - train driver 
 
 
Semi-routine manual and service occupations 
such as: postal worker - machine operative - security guard - caretaker - farm worker - catering 





Routine manual and service occupations 
such as: HGV driver - van driver - cleaner - porter - packer - sewing machinist - messenger - 
labourer - waiter / waitress - bar staff 
 
 
Middle or junior managers 
such as: office manager - retail manager - bank manager - restaurant manager - warehouse 
manager - publican 
 
 
Traditional professional occupations 
such as: accountant - solicitor - medical practitioner - scientist - civil / mechanical engineer  
 
 
EMPLOYMENT STATUS / OCCUPATION (cont.) 
(II) Your spouse/ex-spouse/long term partner   (Please tick one box only per question) 
5. What is (was) his (her) employment status? 
Employee   
Self-employed with employees   
Self-employed / freelance without employees 
(go to question 8)    
Housewife 
(go to question 8)    
No previous paid employment (excluding housewife) 
(go to question 8)    
6. Number of employees 
For employees: indicate below how many people work (worked) for his/her employer at the place 
where he/she work (worked).  Then go to question 7. 
For self-employed: indicate below how many people he/she employs (employed). Then go to 
question 8. 
                                                     1 to 24                                             25 or more   
7. Do (did) he/she supervise any other employees? 
A supervisor or foreman is responsible for overseeing the work of other employees on a day-to-day 
basis 
                                                            No   
  
                                                  Yes   
8. Please tick one box to show which best describes the sort of work he/she does. 
(If not working now, please tick a box to show what he/she did in his/her last job). 
PLEASE TICK ONE BOX ONLY 
Modern professional occupations 
such as: teacher - nurse - physiotherapist - social worker - welfare officer - artist - musician - 
police officer (sergeant or above) - software designer 
 
 
Clerical and intermediate occupations 
such as: secretary - personal assistant - clerical worker - office clerk - call centre agent - nursing 





Senior managers or administrators 
(usually responsible for planning, organising and co-ordinating work and for finance) 
such as: finance manager - chief executive 
 
 
Technical and craft occupations 
such as: motor mechanic - fitter - inspector - plumber - printer - tool maker - electrician - 
gardener - train driver 
 
 
Semi-routine manual and service occupations 
such as: postal worker - machine operative - security guard - caretaker - farm worker - catering 
assistant - receptionist - sales assistant  
 
 
Routine manual and service occupations 
such as: HGV driver - van driver - cleaner - porter - packer - sewing machinist - messenger - 
labourer - waiter / waitress - bar staff 
 
 
Middle or junior managers 
such as: office manager - retail manager - bank manager - restaurant manager - warehouse 
manager - publican 
 
 
Traditional professional occupations 





APPENDIX E: Cognitive test battery 

















































APPENDIX F: Diabetic retinopathy characteristics graded in the 
Edinburgh Type 2 Diabetes Study  
 
 
1.       NUMBER OF MICROANEURYSMS (MA Grade) 
 
Features of a microaneurysm 
 red spot 
 sharp margins 
 even density 
 usually round ( but may be fusiform – sausage shaped) 




 A red spot which is < 150 µ (125 μ ETDRS ) (the width of a major vein at 
the disc margin) with sharp margins and even density is considered to be a 
microaneurysm. Otherwise it is assessed as a retinal haemorrhage. 
 
 A red spot which is > 150 µ is assessed as a retinal haemorrhage unless 














 CODE DEFINITION 
  
0 No MA 
1 Questionable MA 
2 1 MA 
3 2 MA 
4 3 MA 
5 4 MA 
6 5 or more MA 














 Preretinal haemorrhages are excluded 
 
 Subretinal haemorrhages are excluded 
 
 Microaneurysms that appear as white dots with no blood visible in a central 
lumen are graded as hard exudates 
 













GRADE FIELDS 2-7 
 
 
 CODE DEFINITION 
  
0 No H/MA 
1 Questionable H/MA 
2 Definite H/MA < 1 
3 Definite H/MA ≥ 1 < 2A 
4 Definite H/MA ≥ 2A < 2B 
5 Definite H/MA ≥ 2 B 











                                         STANDARD PHOTOS     3   4    5 
 
Notes on Appearance: 
 
 yellowish –white (white if regressing) 
 waxy appearance 
 sharp margins 
 usually irregular shape 
 don’t have a border of pigment 
 can have a varied appearance –    
o dots 
o patches: may be confluent 
o partial or complete rings surrounding microaneurysms 
 














 CODE DEFINITION 
  
0 No hard exudates 
1 Questionable hard exudate 
2 Definite hard exudate < 3 
3 Definite hard exudate ≥ 3 but < 5 
4 Definite hard exudate ≥ 5 but < 4 
5 Definite hard exudate ≥ 4 
















 localised swellings in the nerve fibre layer 
 round or oval 
 white, pale yellow – white or greyish – white 
 “feathery edges” 
 frequently have striations parallel to nerve fibres 
 a large CWS may displace a vessel 
 may be – 
o haemorrhage on the distal side 
o IRMA  on the proximal side 








GRADE ALL FIELDS 
 
 
 CODE DEFINITION 
  
0 No cotton wool spot 
1 Questionable cotton wool spot 
2 Definite CWS < 8A 
3 Definite CWS ≥ 8A < 5 
4 Definite CWS ≥ 5 

















 tortuous intraretinal vascular segments 
 
 vary in calibre from barely visible to 35 μm ( 31 μm ETDRS ) ( ¼ width of a 
major vein at the disc margin ) or occasionally larger. 
 
 Punctate microaneurysms in the retina and new vessels on the surface of the 
retina are excluded. 
 
 Without stereo it may be difficult to distinguish IRMA from new vessels. In 
general IRMA are more:  
 Delicate 
 Angular or jagged in their tortuosity 
 less likely to cross themselves or other retinal vessels 












 CODE DEFINITION 
  
0 No IRMA 
1 Questionable IRMA 
2 Definite IRMA < 8A 
3 IRMA ≥ 8A  but < 8B 
4 IRMA ≥ 8B 














 localised increases in venous calibre which sometimes resemble a string of 
beads 
 























 CODE DEFINITION 
  
0 No beading 
1 Questionable beading 
2 Definite beading < 6A 
3 Beading ≥ 6A but < 6B 
4 Beading  ≥ 6B 








Notes & Definitions: 
 
 
Venous loop:  An abrupt, curving deviation of a vein from its normal path 
 
Venous reduplication: Dilation of a pre-existing channel or the proliferation of a new 
channel of similar calibre adjacent to the original vein. 
 
NB: Grading is based on the calibre of veins involved - 35μm (31μm ETDRS ) = ¼ 


















GRADE FIELDS 3-7 
 
 
 CODE DEFINITION 
  
0 No loops or reduplications 
1 Questionable loop(s) or definite loop(s) in a branch < 31 μm wide if the loop 
< 50% wider than the vein from which it arises. 
2 Loops in a branch ≥ 31 μm wide or loop(s) in a branch < 31μm wide if the loop 
is ≥ 50% wider than the vein 
From which it arises 
3 Reduplication of a small vein < 31 μm wide 
4 Reduplication of a larger vein ≥ 31 μm wide 
X Cannot grade 
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 New vessels that are clearly on the surface of the retina (i.e. not within the 
retina) or further forward in the vitreous cavity – except for those on the disc 
or within 1 disc diameter of its margin ( or in the vitreous anterior to this 
area) 
 
 However if new vessels located mostly elsewhere extend into the area 
between ½ - 1 DD from the disc margin and no other vessels are present 
closer to or on the disc, all the new vessels are included in the NVE category 
 
 Grading is based on the area of retina covered by the new vessels using as 
cut points on the grading scale ½ disc area (DA) and NVE in standard photo 
7 
 
 I the absence of stereo it may be difficult to distinguish subtle new vessels 
from IRMA. In general new vessels are: 
 
 Bolder 
 More curvilinear 
 More likely to cross and recross both themselves and the retinal 
vessels 




GRADE FIELDS 1, 3-7 
 
 
 CODE DEFINITIONS 
  
0 No NVE 
1 Questionable NVE 
2 Definite NVE < ½ DA 
3 NVE ≥ ½ DA < photo 7 
4 NVE ≥ photo 7 












 Fibrous tissue opaque enough to be definitely seen, with or without 
accompanying new vessels including fibrous strands or sheets that comprise 
a thickened posterior hyaloid surface as well as completely atrophied new 
vessels ( no visible red blood column present) 
 
 Fibrous proliferations on the surface of the retina or further forward in the 
vitreous cavity – except for those on the disc or within 1 disc diameter of its 
margin ( or in the vitreous anterior to this area) 
 
 However if fibrous proliferations located mostly elsewhere extend into the 
are between ½ - 1 DD from the disc margin and no other fibrous 
proliferations are present closer to or on the disc, all fibrous proliferations 










GRADE FIELDS 1, 3-7 
 
 
 CODE DEFINITION 
  
0 No FPE 
1 Questionable FPE 
2 Definite FPE < ½ DA 
3 FPE ≥ ½ DA < photo 11 
4 FPE ≥ photo 11 















 Round, oval or linear patches of haemorrhage just anterior to the retina or under 
its internal limiting membrane ( Photo 9) 
 
 Boat-shaped haemorrhage with a fluid level ( Photo 13) 
 
 Haemorrhage on the surface of detached retina is also considered to be PRH 
 
 Grading is based on the area of retina covered by haemorrhage using standard 











GRADE ALL FIELDS 
 
 
 CODE DEFINITION 
  
0 No PRH 
1 Questionable PRH 
2 Definite PRH < photos 9 or 13 
3 PRH ≥ photos 9 or 13 < ½ field 
4 PRH ≥ ½ field 








 Haemorrhage further forward in the vitreous cavity than PRH, including 
haemorrhage on or within fibrovascular proliferations. 
 
 Grade 1 (Questionable) – Assigned when the haziness present could be due to 
haemorrhage, lens opacity, or poor focus. 
 
NB:If definite haemorrhage is present but whether it is PRH or VH is uncertain 
– the grade questionable may not be used for both. The grader must decide 
which definite grade is the best choice. 
 
 Grade 2 (Definite) – When VH is definitely present but interferes with grading 
of < 1 DA of the field. 
- Diffuse VH ( so thin that it does not prevent the grading of the fundus 
abnormalities) covering, but not obscuring, IDA or more of field (occasionally 
all of field) 
 
 Grade 3 (Definite)  – When VH is dense enough to obscure a major retinal 
vessel ( to the extent that beading, narrowing etc cannot be graded) and 
extensive enough to obscure > 1 DA but < ½ field. 
 
 Grade 4 ( Definite) – When VH obscures ½ field but some detail can still be 
graded ( eg fibrovascular proliferations) 
 
 Grade 5 ( Definite) – Only when all fundus details are obscured by VH. 
 
 Grade X  (Cannot grade) – Cannot grade for reasons other than VH with 2 
exceptions ( both in field 2 only): 
1. obscuration of the macula by VH is graded 2, definitely present. 
2. it might be possible to grade posterior vitreous detachment by inference 
from adjacent field ( see below) 
 
GRADE ALL FIELDS 
 
 CODE DEFINITION 
  
0 No VH 
1 Questionable VH 
2 Definite VH obscuring < 1 DA 
3 VH ≥ 1 DA  < ½ field 
4 VH ≥ ½ field, but some characteristics can still be graded 
5 VH obscures the entire field 

















 New vessels on the disc or within 1 disc diameter of its margin ( or in 
the vitreous anterior to this area) 
 NB: NVE can extend into an area between ½ - 1DD from the disc 
margin and as long as no other vessels are present closer to or on the 

















GRADE FIELD 1 ONLY 
 
 
 CODE DEFINITION 
  
0 No NVD 
1 Questionable NVD 
2 Definite NVD < 10 A 
3 NVD ≥ 10 A < 10 C 
4 NVD ≥ 10 C 















 White sheets or fine strands of  fibrous tissue opaque enough to be 
definitely seen, with or without accompanying new vessels, 
including: 
- Fibrous strands or sheets that comprise a thickened posterior 
hyaloid  surface 
- Completely atrophic new vessels ( no visible red blood column 
present) 
 
 Fibrous proliferations on or within IDD of the disc (or in the vitreous 
anterior to this area) 
 
 NB : fibrous proliferations elsewhere can extend into the area 
between ½ - 1DD from the disc margin and as long as no other 
fibrous proliferations are present closer to or on the disc – this would 
be classified as fibrous proliferations elsewhere – FPE) 
 
 Grading is based on the area involved by FPD, not their thickness or 
whiteness, using cut points on the scale 2 DA and standard photo 
10B. 
 
 If the FPD occur in fine strands, the grader mentally compresses 
them into a network of density similar to that of the NVE in standard 
photo 7 and estimates the area that would be covered. 
 
 
GRADE FIELD 1 ONLY 
 
 
 CODE DEFINITION 
  
0 No FPD 
1 Questionable FPD 
2 Definite FPD < photo 10B 
3 FPD ≥ 10 B < 2DA 
4 FPD ≥ 2 DA 
X Cannot grade 









Macular grid laser:          
A grid of laser around the fovea used to treat central serous macular oedema 
(with or without the presence of exudates). 
 
Focal laser:   
                       
o Usually within the temporal arcades but not centered on the fovea. 
o Used to treat areas of leakage (usually exudates are present) away from 
the fovea but still within the temporal arcades 
o May also be used to directly treat NVE in conjunction with pan retinal 
photocoagulation. 
 






















 CODE DEFINITION 
  
0 No photocoagulation scars 
1 Questionable photocoagulation scars 
2 Definite photocoagulation scars 









 Diabetic maculopathy is defined as hard exudates within 1 disc diameter of the 
centre of the macula. 
 
 This characteristic does not form part of the ETDRS grading system, but 
provides a separate variable for use in the ET2DS. 
 
 Hard exudates will be recorded in the same field in addition to this diabetic 


























 CODE DEFINITION 
  
0 No Diabetic Maculopathy 
1 Questionable Diabetic Maculopathy 
2 Definite Diabetic Maculopathy 










 Usually for severe non proliferative or proliferative 
retinopathy 
 
 An uneven pattern of burns in all 4 quadrants sparing the 
macula and the papillomacular bundle. 
 


























 CODE DEFINITION 
  
0 No photocoagulation 
1 Questionable photocoagulation 
2 Definite photocoagulation 










 Graded at the level of each eye, therefore proving a simple 
indication of whether or not PRPs were present for use in 
calculating final level score. (see notes on review of subjects 



























 CODE DEFINITION 
  
0 No photocoagulation 
1 Questionable photocoagulation 
2 Definite photocoagulation 









 Provides an indication at the level of each eye of whether or not the 












































 Graded at the level of each eye, therefore proving a simple 
indication of whether or not retinal haemorrhage was present, 
for use in calculating final level scores (relevant to level 15 































 CODE DEFINITION 
  
0 No Retinal Haemorrhage 
1 Questionable Retinal Haemorrhage 
2 Definite Retinal Haemorrhage 
X Cannot grade 
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APPENDIX G: Comparisons of characteristics between subjects 
with and without missing cognitive data 
 
Table g1: Characteristics in subjects with and without Letter-Number Sequencing 
(LNS) test data  
                                                                                                         Subjects with                     Subjects with missing  
                                                                                                     LNS values (n=1048)
a
             LNS values  (n=18)
b 
Age (years),mean (SD) 
Sex, (% (n) men) 
BMI (kg/m
2
), mean (SD) 
WHR, mean (SD) 
HbA1c, median (IQR) 
Total cholesterol (mmol/L), mean (SD) 





Cardiovascular disease, %(n) 
MI and/or Angina
 
Stroke and/or TIA 
 
Diabetic retinopathy, % (n) 
 
Retinal width parameters 
Central Retinal Arteriolar Equivalent, μm, mean (SD) 
Central Retinal Venular Equivalent, μm, mean (SD) 
Aretrio-venous ratio 
 
Retinal bifurcation parameters 
Median bifurcation angles, degrees, mean (SD) 























































Smoker=current or former smoker; * P <0.05; a Maximum n=1048, minimum n=438 for subjects with LNS data; 






APPENDIX H: Reliability of retinal vessel widths and arteriolar 
bifurcation measurements: Bland-Altman plots 
 
H-1: Intra-rater Reliability  
 
Figure h1: Difference against mean for CRAE data (n=20) 
 
The mean difference was -0.42; the upper and lower limits of agreement (95% limits of 
agreement) were 2.3 and -3.1 respectively. For arteriolar vessels that range between 22.0 -29.0 
pixels, 95% of the repeat measurements fell within ±2.7 pixels of the first measurements. There 
was no systematic bias and the size of differences did not change with increasing CRAE. 
 
 
The mean difference was -0.44; the upper and lower limits of agreement (95% limits of 
agreement) were 2.26 and -3.14 respectively. For venular vessels that range between 30.0 -45.0 
pixels, 95% of the repeat measurements fell within ±2.7 pixels of the first measurements. There 
was no systematic bias and the size of differences did not change with increasing CRVE. 







The mean difference was -0.004; the upper and lower limits of agreement (95% limits of 
agreement) were 0.066 and -0.074 respectively. For AVR that range between 0.58 -0.90, 95% of 
the repeat measurements fell within ±0.07 of the first measurements. There was no systematic 
bias and the size of differences did not change with increasing AVR. 
 
 
Figure h4:  Difference against mean for arteriolar bifurcation angle data (n=20) 
 
 
The mean difference was 1.42; the upper and lower limits of agreement (95% limits of 
agreement) were 14.98 and -12.14 respectively. For bifurcation angle that range between 69-
100
0
, 95% of the repeat measurements fell within ± 13.6
0 
of the first measurements. There was no 
systematic bias and the size of differences did not change with increasing bifurcation angle. 
 






Figure h5:  Difference against mean for arteriolar branching coefficient data (n=20) 
 
The mean difference was 0.016; the upper and lower limits of agreement (95% limits of 
agreement) were 0.38 and -0.34 respectively. For branching coefficient that range between 1.6-
2.3, 95% of the repeat measurements fell within ± 0.36
 
of the first measurements. There was no 
systematic bias and the size of differences did not change with increasing branching coefficient. 
 
 
H-2: Inter-rater Reliability 
 
Figure h6: Difference against mean for CRAE data (n=30) 
 
 
The mean difference was 1.27; the upper and lower limits of agreement (95% limits of 
agreement) were 4.9 and -2.4 respectively. For arteriolar vessels that range between 18-32 pixels, 
95% of the repeat measurements fell within ±3.6 pixels of the first rater (rater of our study) 





Figure h7: Difference against mean for CRVE data (n=30) 
 
The mean difference was -0.82; the upper and lower limits of agreement (95% limits of 
agreement) were 6.5 and -4.8 respectively. For venular vessels that range between 28-42 pixels, 
95% of the repeat measurements fell within ±5.7 pixels of the first rater’s (rater of our study) 




Figure h8:  Difference against mean for AVR data (n=30) 
 
The mean difference was 0.02; the upper and lower limits of agreement (95% limits of 
agreement) were 0.16 and -0.12 respectively. For AVR that range between 0.58 -1.00, 95% of the 
repeat measurements fell within ±0.14 of the first rater’s (rater of our study) measurements. 







Figure h9: Difference against mean for branching coefficient data (n=30) 
 
 
The mean difference was 0.03; the upper and lower limits of agreement (95% limits of 
agreement) were 0.65 and -0.75 respectively. For branching coefficient that range between 1.6-
2.3,  95% of the repeat measurements fell within ±0.7 of the first rater’s (rater of our study) 




APPENDIX I: Multivariate models 
 





Sex (male vs. female) 
MHVS 
Education 
Alcohol intake  
Smoking (yes vs. no)  
Waist to hip ratio (per 0.1 unit increase)  
Systolic blood pressure 
Total cholesterol level  
MI and/or angina 
Stroke and/or TIA 
Depression 
  Model 1 
B     SE     
-0.16
†




-0.07   0.06 
 
 
     Model 2 

















  Model 3 











‡   
 0.01 
0.14





       Model 4 





‡   
0.01 
-0.13*  0.06 
0.10
‡     
 0.01 
0.13
‡     
 0.04 
0.04*    0.02 
-0.10     0.05 
-0.10*   0.04 
 0.00      0.002 
0.004    0.03 
       Model 5 
        B      SE 
-0.11*  0.04 
-0.06
‡    
0.01 
-0.11    0.06 
0.10
‡      
0.01 
0.13
‡     
 0.04 
0.03      0.02 
-0.08     0.05 
-0.09*   0.04 
0.00      0.002 
0.003    0.03 
-0.06     0.06 
-0.29
‡     
0.09 
  Model 6 
  B      SE 
-0.11*  0.04 
-0.06
‡    
0.01 
-0.17 
†   
0.06 
0.10
‡     
 0.01 
0.12 
‡      
0.04 
0.03      0.02 
-0.06     0.05 
-0.06     0.04 
-0.001   0.001 
0.006     0.03 
-0.01      0.06 
-0.26
†   
  0.09 
-0.44 
‡     
0.10 
Model 7 
B      SE 













0.03    0.02 
-0.05   0.05 
-0.08   0.04 
-0.001  0.002 
-0.01   0.03 








Duration of diabetes  
      0.03 0.02 





△R2 (R square change) 
Df 











































































Sex (male vs. female) 
MHVS 
Education 
Alcohol intake  
Smoking (yes vs. no)  
Waist to hip ratio (per 0.1 unit increase)  
Systolic blood pressure 
Total cholesterol level  
MI and/or angina 
Stroke and/or TIA 
Depression 
  Model 1 
B     SE     
-1.46*   0.70 
-0.25
†
   0.10 




B      SE 




-0.32   0.72 
1.07







B      SE 
-1.52*  0.63 
-0.23
†
   0.09 
-0.39   0.72 
0.97
‡   
 0.08 





B      SE 
-1.24  0.65 
-0.20* 0.09 






  0.54 
0.53*   0.25 
0.02   0.79 
-0.65   0.57 
-0.04   0.02 
0.18   0.42 
Model 5 
B      SE 
-1.14  0.65 
-0.22* 0.09 
-0.54  0.91 
0.95




  0.54 
0.54*   0.25 
0.02   0.79 
-0.69   0.57 
-0.04   0.02 
0.19   0.42 
1.49   0.82 
-2.31   1.32 
Model 6 
B      SE 
-1.11  0.65 
-0.22* 0.09 
-0.85  0.91 
0.94





0.52*   0.25 
0.15   0.79 
-0.54   0.57 
-0.04   0.02 
0.21   0.42 
1.72   0.84 
-2.13   1.32 
-2.62   1.41 
Model 7 
B      SE 
-0.23  0.72 
-0.21* 0.09 
-0.85  0.91 
0.93




  0.54 
0.51*   0.25 
0.45   0.79 
-0.03   0.57 
-0.05*  0.02 
 0.08    0.42 
1.89    0.84 
-2.20   1.32 
-2.0    1.41 
HbA1c 
Duration of diabetes  
      -0.15   0.36 





△R2 (R square change) 
Df 







































































Sex (male vs. female) 
MHVS 
Education 
Alcohol intake  
Smoking (yes vs. no)  
Waist to hip ratio (per 0.1 unit increase)  
Systolic blood pressure 
Total cholesterol level  
MI and/or angina 
Stroke and/or TIA 
Depression 
  Model 1 
B     SE     
-0.92*   0.42 
-0.28
‡   
 0.06 
-2.7
‡    




B      SE 















B      SE 








‡     
 0.05 





B      SE 
-0.70   0.42 
-0.28
‡





‡     
 0.04 
0.41      0.34 
0.32      0.16 
-0.11     0.50 
-0.56     0.36 
0.01      0.01 
-0.12     0.27 
    Model 5 
      B      SE 








‡     
0.05 
0.45      0.34 
0.30      0.16 
-0.08      0.50 
-0.53   0.36 
0.01      0.01 
-0.13     0.27 
-0.46      0.53 
-0.14     0.85 
Model 6 
B      SE 








‡     
0.05 
0.42      0.39 
0.29      0.16 
-0.01     0.51 
-0.45     0.37 
0.01       0.01 
-0.12     0.27 
-0.34     0.53 
-0.04     0.85 
-1.34     0.90 
Model 7 
B      SE 








‡    
0.05 
0.52      0.36 
0.32      0.17 
0.03      0.52 
-0.38     0.38 
0.01      0.02 
-0.21     0.28 
-0.16     0.55 
0.03      0.86 
-1.51     0.93 
HbA1c 
Duration of diabetes  
      0.14      0.23 
-0.78






△R2 (R square change) 
Df 








































































Sex (male vs. female) 
MHVS 
Education 
Alcohol intake  
Smoking (yes vs. no)  
Waist to hip ratio (per 0.1 unit increase)  
Systolic blood pressure 
Total cholesterol level  
MI and/or angina 
Stroke and/or TIA 
Depression 
  Model 1 
 B        SE     
0.07
†
   0.02 
0.02
‡    
 0.003 




B          SE 
0.06 
†   
 0.02 
0.02
‡     
 0.003 
0.05*    0.02 
-0.03
‡  






B        SE 
0.06
†
   0.02 
0.02
‡     
0.003 









B       SE 
0.06 
†








-0.01    0.02 
0.01     0.01 
0.05     0.03 
0.05
†
    0.02 
0.00     0.001 
-0.001   0.01 
Model 5 
B      SE 








-0.01   0.02 
0.01     0.01 
0.04    0.03 
0.05
†
   0.02 
0.00    0.001 
-0.001   0.01 
0.01    0.03 
0.11
†
   0.04 
Model 6 
  B        SE 
0.05*    0.02 
0.02
‡  
   0.003 
0.01     0.03 
-0.03
‡ 
   0.003 
-0.002   0.02 
0.01      0.01 
0.03      0.03 
0.04*    0.02 
0.00      0.001 
-0.002   0.01 
-0.01     0.03 
0.10*    0.04 
0.18
‡   
   0.05 
Model 7 
  B      SE 
0.03    0.02 
0.02
‡   
 0.003 
0.01     0.03 
-0.03
‡ 
  0.003 
0.001    0.02 
0.01      0.01 
0.03      0.03 
0.04*    0.02 
0.00     0.001 
0.004     0.01 
-0.01     0.03 
0.11*    0.04 
0.19
‡  
    0.05 
HbA1c 
Duration of diabetes  
      -0.01   0.01 





△R2 (R square change) 
Df 









































































Sex (male vs. female) 
MHVS 
Education 
Alcohol intake  
Smoking (yes vs. no)  
Waist to hip ratio (per 0.1 unit increase)  
Systolic blood pressure 
Total cholesterol level  
MI and/or angina 
Stroke and/or TIA 
Depression 
  Model 1 
     B       SE     
-3.35
‡    
 0.78 
-0.74
‡    
 0.11 
-4.31




    Model 2 
    B        SE 
-3.27
‡    
 0.71 
-0.75
‡    
 0.10 
-5.34
‡    
 0.81 
1.14






   Model 3 
   B        SE 
-3.39
‡    
 0.73 
-0.75 
‡    
0.10 
-5.48
‡    
 0.83 
1.02
‡     
 0.09 




   Model 4 
   B        SE 
-3.33
‡    
 0.73 
-0.79
‡    
 0.10 
-3.77
‡    
 1.02 
1.00 
‡      
0.09 
1.27*     0.61 
0.25       0.28 
-3.27
‡      
0.89 
-1.60*   0.64 
0.01      0.03 
-0.15     0.47 
  Model 5 
  B        SE 
-3.11




   0.10 
-3.42
‡    
 1.02 
0.96
‡      
 0.09 
1.23*     0.61 
0.16      0.28 
-3.00
‡      
0.89 
-1.40*  0.64 
0.01      0.03 
-0.17     0.47 
-1.73     0.92 
-3.79*   1.48 
  Model 6 
  B        SE 
-3.06
‡
    0.73 
-0.76
‡
    0.10 
-4.18
‡
    1.03 
0.94
‡      
 0.09 
1.09       0.60 
0.12       0.28 
-2.69
†
    0.88 
-1.03      0.64 
0.01       0.03 
-0.14      0.47 
-1.14      0.92 
-3.36*    1.47 
-6.21
‡       
1.56 
Model 7 





‡   
 0.10 
-4.22
‡   
 1.05 
0.94
‡       
0.09 
0.94       0.62 
0.19       0.29 
-2.62
†    
 0.90 
-1.31*   0.66 
-0.01      0.03 
-0.32      0.48 
-0.90      0.95 
-3.19*    1.50 
-6.19
‡      
1.62 
HbA1c 
Duration of diabetes  
      0.47       0.40 





△R2 (R square change) 
Df 
















































































Smoking (yes vs. no)  
Waist to hip ratio (per 0.1 unit increase)  
Systolic blood pressure 
Total cholesterol level  
MI and/or angina 
Stroke and/or TIA 
Depression 
    Model 1 










   Model 2 
    B      SE 
-0.25
‡    
0.06 
-0.06
‡   
 0.01 
0.11







  Model 3 
  B        SE 
-0.24
‡    
0.06 
-0.06
‡   
 0.01 
0.11
‡     
 0.01 
0.17





  Model 4 
  B        SE 
-0.22






‡     
0.01 
0.16 




  0.02 
0.01     0.08 
-0.10    0.06 
-0.001  0.002 
0.01     0.04 
 
 
 Model 5 
B          SE 
-0.20
‡    
0.06 
-0.06 
‡   
0.01 
0.09
‡     
 0.01 
0.15
†   
  0.05 
0.05*   0.02 
0.03     0.08 
-0.09    0.06 
-0.001  0.002 
0.00     0.04 





  B        SE 
-0.20
‡    
0.06 
-0.06 
‡   
0.01 
0.09
‡     
 0.01 
0.15 
†   
 0.05 
0.05*    0.02 
0.03     0.08 
-0.06    0.06 
-0.001  0.002 
-0.001   0.04 




-0.34*   0.13 
Model 7 
B        SE 
-0.17*  0.07 
-0.06
‡   
0.01 
0.09




  0.05 
0.05*   0.02 
0.04     0.08 
-0.06    0.06 
-0.002  0.002 
-0.01    0.04 








Duration of diabetes  
      0.002   0.03 





△R2 (R square change) 
Df 














































































Alcohol intake  
Smoking (yes vs. no)  
Waist to hip ratio (per 0.1 unit increase)  
Systolic blood pressure 
Total cholesterol level  
MI and/or angina 
Stroke and/or TIA 
Depression 
  Model 1 
     B      SE     
-2.61
†  
  0.95 




  Model 2 
   B      SE 
-3.10
‡   
 0.87 
-0.28*  0.13 
0.99 







   B      SE 
-3.05
‡
    0.89 
-0.28*    0.13 
0.94 
‡       
0.11 




   Model 4 
    B      SE 
-3.08
‡   
 0.89 
-0.25     0.13 
0.88 
‡      
0.11 
1.17       0.75 
0.75*     0.31 
0.97       1.19 
-0.22      0.86 
-0.09
†    
  0.03 
0.07        0.62 
 
 
  Model 5 
  B        SE 
-2.95
‡   
 0.89 
-0.25*   0.13 
0.88 
‡      
0.11 
1.28       0.75 
0.76*     0.31 
0.98       1.18 
-0.26      0.88 
-0.08*    0.03 
-0.02      0.62 
1.76    1.10 
-3.06      1.64 
  Model 6 
  B         SE 
-2.94
‡    
 0.89 
-0.25      0.13 
0.88 
‡       
0.11 
1.24        0.75 
0.75*      0.31 
1.00        1.18 
-0.06       0.09 
-0.09
†      
 0.03 
-0.03       0.62 
1.77    1.10 
-2.89      1.65 
-2.09      2.04 
Model 7 
B         SE 
-1.99*   1.0 
-0.25     0.13 
0.88
‡      
 0.12 
1.16       0.77 
0.71*     0.32 
1.57       1.22 
-0.15      0.93 
-0.09
†    
  0.03 
-0.06       0.64 
2.04        1.16 
-2.99       1.68 
-1.90       2.12 
HbA1c 
Duration of diabetes  
      -0.25       0.51 





△R2 (R square change) 
Df 










































































Alcohol intake  
Smoking (yes vs. no)  
Waist to hip ratio (per 0.1 unit increase)  
Systolic blood pressure 
Total cholesterol level  
MI and/or angina 
Stroke and/or TIA 
Depression 
  Model 1 
B     SE     
-0.05   0.08 





  B       SE 
-0.05   0.08 
0.10*   0.01 






 B        SE 
-0.06   0.08 
0.10*   0.01 
0.07    0.01 





B      SE 
-0.07   0.08 
0.10*   0.01 
0.07     0.01 
-0.02    0.07 
0.04     0.03 
0.04     0.11 
0.05     0.08 
-0.12
† 
  0.003 




B        SE 
-0.07   0.08 
0.10*   0.01 
0.07     0.01 
-0.02    0.07 
0.04     0.03 
0.04     0.11 
0.05     0.08 
-0.12
† 
  0.003 
0.001    0.06 
0.11*    0.10 
-0.01     0.15 
Model 6 
 B        SE 
-0.07   0.08 
0.10*   0.01 
0.07     0.01 
-0.02    0.07 
0.04      0.03 
0.04      0.11 
0.05      0.08 
-0.12
†
   0.003 
0.001    0.06 
0.11*    0.10 
-0.01     0.15 
0.01      0.18 
Model 7 
B        SE 
-0.03    0.09 
0.09     0.01 
0.08     0.01 
-0.001   0.07 
0.05      0.03 
0.06      0.11 
0.03      0.08 
-0.12*   0.003 
0.001    0.06 
0.11*    0.10 
-0.01     0.15 
0.03      0.18 
HbA1c 
Duration of diabetes  
      -0.04     0.05 





△R2 (R square change) 
Df 

























































Sex (Male vs. Female) 
MHVS 
Education 
Alcohol intake  
Smoking (yes vs. no)  
Waist to hip ratio (per 0.1 unit increase)  
Systolic blood pressure 
Total cholesterol level  
MI and/or angina 
Stroke and/or TIA 
Depression 
  Model 1 
B      SE     
-0.03   0.06 






B         SE 
-0.03   0.06 









  B       SE 
-0.03    0.06 
-0.05    0.01 
-0.17
‡    
0.06 
0.03      0.01 





  B      SE 
-0.02   0.06 
-0.05   0.01 
-0.19
‡   
0.08 
0.02      0.01 
-0.00     0.05 
0.05       0.02 
0.01       0.07 
-0.02      0.05 
0.04       0.002 
-0.01      0.04 
Model 5 
  B       SE 
-0.02    0.06 
-0.05    0.01 
-0.19
‡    
0.08 
0.02      0.01 
-0.00     0.05 
 0.05      0.02 
 0.01      0.07 
-0.02     0.05 
 0.04      0.002 
 -0.01      0.04 
 -0.03      0.07 
 0.03       0.12 
Model 6 
  B       SE 
-0.02    0.06 
-0.05    0.01 
-0.19
‡    
0.08 
0.02      0.01 
-0.00     0.05 
 0.05      0.02 
 0.01       0.07 
-0.02      0.05 
0.04       0.002 
-0.01      0.04 
-0.03      0.07 
 0.03       0.12 
 0.01       0.13 
Model 7 
B        SE 
-0.01    0.06 
-0.04    0.01 
-0.19
‡    
0.08 
0.02      0.01 
0.01      0.05 
0.06      0.02 
0.01      0.07 
-0.00     0.05 
0.03      0.002 
-0.02     0.04 
-0.02     0.08 
0.04      0.12 
0.01      0.13 
HbA1c 
Duration of diabetes  
      0.01      0.13 





△R2 (R square change) 
Df 





































































Sex (Male vs. Female) 
MHVS 
Education 
Alcohol intake  
Smoking (yes vs. no)  
Waist to hip ratio (per 0.1 unit increase)  
Systolic blood pressure 
Total cholesterol level  
MI and/or angina 
Stroke and/or TIA 
Depression 
  Model 1 
B     SE     
0.03    0.06 
0.04    0.06 
-0.02   0.06 
 
Model 2 
B        SE 
0.04    0.06 
0.04    0.06 
-0.03   0.06 
0.14
‡
   0.01 
 
Model 3 
B      SE 
0.03    0.06 
0.04    0.01 
-0.03   0.07 
0.07*   0.01 
0.12





 B       SE 
0.04    0.06 
0.05    0.01 
-0.12
†
  0.08 
0.07      0.01 
0.12
‡     
0.05 
0.13
‡     
0.02 
0.03      0.07 
0.06      0.05 
-0.01    0.002 




  B       SE 
0.03     0.06 
0.05     0.01 
-0.12
†
  0.08 
0.07      0.01 
0.12
‡      
0.05 
0.13
‡       
0.02 
0.03       0.07 
0.06       0.05 
-0.01     0.002 
0.01       0.04 
-0.02      0.07 
0.04       0.12 
Model 6 
 B        SE 
0.03     0.06 
0.05     0.01 
-0.11
†
  0.08 
0.07      0.01 
0.12
‡      
0.05 
0.13
‡      
0.02 
0.03      0.07 
0.06      0.05 
-0.01     0.002 
0.01       0.04 
-0.02      0.07 
0.03        0.12 
0.03        0.12 
Model 7 
 B       SE 
0.03     0.06 
0.07*   0.01 
-0.10*  0.08 
0.07*    0.01 
0.12
‡      
0.05 
0.13
‡      
0.05 
0.03      0.07 
0.05      0.05 
-0.01     0.002 
0.01      0.04 
-0.01     0.07 
0.03      0.12 
0.04      0.13 
HbA1c 
Duration of diabetes  
      -0.02     0.03 




△R2 (R square change) 
Df 









































































Sex (Male vs. Female) 
MHVS 
Education 
Alcohol intake  
Smoking (yes vs. no)  
Waist to hip ratio (per 0.1 unit increase)  
Systolic blood pressure 
Total cholesterol level  
MI and/or angina 
Stroke and/or TIA 
Depression 
  Model 1 
B      SE     
-0.10
†
   0.06 
-0.05     0.01 
-0.18
‡
   0.06 
 
Model 2 




-0.05    0.01 
-0.17
‡
  0.06 





B        SE 
-0.11
‡   
0.06 




-0.08*   0.01 
-0.01    0.05 
 
Model 4 
 B        SE 
-0.11
‡   
0.06 
-0.06    0.01 
-0.17
‡
   0.06 
-0.08*   0.01 
-0.03     0.02 
0.04       0.11 
-0.11
†
     0.07 
-0.03      0.05 
0.02       0.002 
-0.01      0.04 
Model 5 
   B       SE 
-0.11
‡
    0.06 
-0.07*   0.01 
-0.10*   0.08 
-0.09*   0.01 
-0.02     0.05 
0.04      0.11 
-0.11
†
   0.07 
-0.03     0.05 
0.02      0.002 
-0.01     0.04 
-0.07*   0.07 
-0.03     0.12 
Model 6 
   B      SE 
-0.1 
‡     
0.06 
-0.07*   0.01 
-0.10*   0.08 
-0.09*   0.01 
-0.02     0.05 
0.04      0.11 
-0.11
†
    0.07 
-0.03      0.05 
0.02       0.002 
-0.01       0.04 
-0.06       0.07 
-0.03       0.12 
-0.03       0.12 
Model 7 
  B        SE 
-0.11
†
    0.06 
-0.06      0.01 
-0.11*    0.08 
-0.09*    0.01 
-0.03      0.05 
-0.03      0.02 
-0.10
†
     0.07 
-0.03      0.05 
0.004     0.002 
-0.01      0.04 
-0.06      0.08 
-0.02      0.12 
-0.03      0.12 
HbA1c 
Duration of diabetes  
        0.03      0.03 





△R2 (R square change) 
Df 








































































Alcohol intake  
Smoking (yes vs. no)  
Waist to hip ratio (per 0.1 unit increase)  
Systolic blood pressure 
Total cholesterol level  
MI and/or angina 
Stroke and/or TIA 
Depression 
  Model 1 
  
B      SE     
-0.05
‡
   0.01 










-0.11   0.08 
0.51
‡








  B       SE 
-0.05
‡   
0.01 
-0.10    0.08 
0.47
‡
    0.07 






  B        SE 
-0.05
‡ 
  0.01 
-0.10     0.08 
0.45
‡ 
    0.07 
0.67      0.49 
0.31      0.20 
0.89      0.78 
-0.11     0.06 
-0.004    0.02 





 B        SE 
-0.05
‡
  0.01 
-0.08    0.08 
0.45
‡      
0.07 
0.67      0.49 
0.31       0.20 
0.92       0.78 
-0.13      0.06 
-0.004    0.02 
-0.14      0.41 
0.60       0.72 
-1.57      1.10 
Model 6 
 
  B       SE 
-0.05
‡
   0.01 
-0.08    0.08 
0.45
‡
     0.07 
0.67      0.49 
0.31      0.20 
0.97      0.79 
0.07      0.06 
-0.01     0.02 
-0.14     0.41 
0.81      0.74 
-1.42     1.10 
-2.04     1.32 
Model 7        
 




-0.08    0.09 
0.44 
‡   
0.08 
0.60     0.51 
0.28     0.21 
1.0       0.80 
0.05     0.06 
-0.01    0.02 
-0.02    0.43 
0.94      0.77 
-1.49     1.14 
-2.03     1.38 
Model 8        
 
  B        SE 
-0.04*   0.02 
-0.08     0.09 
0.44
‡
     0.08 
0.65       0.51 
0.28       0.21 
1.04       0.81 
0.01       0.06 
-0.01      0.02 
0.01      0.43 
0.98        0.77 
-1.48      1.14 
-2.07       1.39 
HbA1c 
Duration of diabetes  
      -0.55     0.34 
0.24      0.36 
-0.52       0.34 
0.23        0.36 





△R2 (R square change) 
Df 
















































































Alcohol intake  
Smoking (yes vs. no)  
Waist to hip ratio (per 0.1 unit increase)  
Systolic blood pressure 
Total cholesterol level  
MI and/or angina 
Stroke and/or TIA 
Depression 
  Model 1 
B       SE     
-0.03*   0.01 





  B       SE 
-0.03
†
  0.01 
-0.13    0.08 
0.52








  B       SE 
-0.03
† 
  0.01 
-0.12    0.08 
0.47
‡
    0.07 





B        SE 
-0.03
†
  0.01 
-0.10    0.08 
0.46 
‡    
0.07 
0.74      0.50 
0.34      0.20 
1.05      0.79 
0.06      0.06 
-0.002   0.02 








-0.10    0.09 
0.46 
‡     
0.07 
0.79      0.50 
0.34      0.20 
1.08      0.79 
0.04      0.06 
-0.002   0.02 
0.02       0.42 
0.65       0.73 
-1.60      1.11 
Model 6 
 B        SE 
-0.03
†
  0.01 
-0.09    0.09 
0.46 
‡     
0.07 
0.74      0.50 
0.34      0.20 
1.13      0.79 
0.03      0.06 
-0.006   0.02 
0.02       0.42 
0.91       0.75 
-1.42      1.11 
-2.39       1.32 
Model 7        




-0.09    0.09 
0.45
‡
    0.07 
0.67      0.52 
0.31      0.21 
1.12      0.82 
0.02      0.06 
-0.003   0.02 
0.11       0.43 
0.99       0.77 
-1.49      1.14 
-2.32      1.39 
Model 8        
B         SE 
-0.01    0.01 
-0.08    0.09 
0.44
‡
    0.08 
0.65      0.51 
0.28      0.21 
1.04      0.82 
0.01      0.06 
-0.005   0.02 
0.01       0.43 
0.98       0.77 
-1.48      1.14 
-2.07      1.39 
HbA1c 
Duration of diabetes  
      -0.50      0.34 
0.21       0.36 
 -0.52     0.34 
  0.23      0.36 
 
CRAE 
        





△R2 (R square change) 
Df 
















































































Alcohol intake  
Smoking (yes vs. no)  
Waist to hip ratio (per 0.1 unit increase)  
Systolic blood pressure 
Total cholesterol level  
MI and/or angina 
Stroke and/or TIA 
Depression 
  Model 1 
B     SE     
0.01     0.02 





 B         SE 
0.03*   0.01 
-0.15    0.08 
0.57
‡







 B        SE 
0.03    0.02 
-0.14   0.08 
0.52
‡
  0.08 





 B        SE 
0.03    0.02 
-0.12   0.08 
0.49
‡
   0.08 
0.75     0.53 
0.64*   0.31 
-0.15    0.72 
-0.6      0.5 
0.01     0.02 




 B        SE 
0.02    0.02 
-0.13   0.09 
0.49
‡
   0.08 
0.80     0.54 
0.61*   0.31 
-0.10    0.72 
-0.6       0.5 
0.01      0.02 
-0.16     0.38 
0.15      0.85 
-1.73    1.66 
Model 6 
B        SE 
0.02    0.02 
-0.14   0.09 
0.47
‡
   0.08 
0.75     0.54 
0.59     0.31 
0.10     0.73 
-0.5      0.5 
0.01     0.02 
-0.10    0.38 
0.37     0.86 
-1.58   1.66 
-2.33   1.35 
Model 7        
B        SE 
0.02    0.02 
-0.10   0.09 
0.44
‡    
0.08 
0.98     0.55 
0.67*    0.31 
-0.001   0.75 
-0.41     0.52 
0.02      0.02 
-0.32     0.38 
0.68      0.87 
-0.99     1.67 
-2.71     1.39 
Model 8        
B          SE 
-0.004   0.02 
-0.09     0.09 
0.45
‡
     0.08 
0.93      0.54 
0.68*     0.31 
-0.15      0.75 
-0.45      0.52 
0.02       0.02 
-0.28      0.39 
0.62       0.87 
-0.86      1.67 
-2.78*     1.39 
HbA1c 
Duration of diabetes  
      0.41      0.35 
-1.20
†
   0.39 
0.40       0.35 
-1.18 




        





△R2 (R square change) 
Df 














































































Alcohol intake  
Smoking (yes vs. no)  
Waist to hip ratio (per 0.1 unit increase)  
Systolic blood pressure 
Total cholesterol level  
MI and/or angina 
Stroke and/or TIA 
Depression 
  Model 1 
B     SE     
0.03     0.01 





B        SE 
0.03
†
   0.01 
-0.14   0.08 
0.57
‡







 B        SE 
0.03
†
   0.01 
-0.12   0.08 
0.53
‡
   0.08 





  B       SE 
0.03
†
   0.01 
-0.12   0.08 
0.50 
‡   
0.08 
0.71     0.53 
0.66*   0.31 
-0.31    0.72 
-0.63    0.50 
0.02   0.02 




 B        SE 
0.03
†   
 0.01 
-0.12    0.08 
0.50 
‡    
0.08 
0.76      0.53 
0.63*    0.31 
-0.26     0.72 
-0.61     0.50 
0.02     0.02 
-0.07      0.38 
0.11       0.84 
-1.61      1.65 
Model 6 
B        SE 
0.03
†
   0.01 
-0.13   0.09 
0.48
‡
   0.08 
0.71     0.53 
0.61      0.31 
-0.06     0.72 
-0.52     0.51 
0.02     0.02 
-0.05     0.38 
0.33       0.85 
-1.44      1.65 
-2.39      1.34 
Model 7        
B         SE 
0.03*   0.01 
-0.09    0.09 
0.45
‡       
0.08 
0.93       0.54 
0.68*     0.31 
-0.15      0.75 
-0.45      0.52 
0.02      0.02 
-0.29       0.39 
0.61        0.86 
-0.84       1.66 
-2.76*     1.38 
Model 8        
B         SE 
0.03*   0.01 
-0.09    0.09 
0.45
‡
    0.08 
0.93      0.54 
0.68*    0.31 
-0.15     0.75 
-0.45     0.52 
0.02      0.02 
-0.28     0.39 
0.62      0.87 
-0.86     1.67 
-2.78*   1.39 
HbA1c 
Duration of diabetes  
      0.40       0.35 
-1.18      0.39 
  0.40    0.35 
-1.18
†
    0.39 
 
CRVE 
        





△R2 (R square change) 
Df 
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ABSTRACT
Objective: To examine the evidence for an association
between cognitive impairment or dementia and the
presence of retinal microvascular abnormalities.
Methods: A systematic review of observational studies
identified through searching five electronic databases and
reference lists. Studies were required to have both a
recognised cognitive function assessment (either a
structured neuropsychological test or a clinical evaluation
of dementia), and assessment of the retinal microvascu-
lature (either characteristics associated with generalised
retinopathy or changes specific to arterioles or venules).
Results: 6 studies were included. Studies were clinically
and methodologically heterogeneous and of variable
quality. Some degree of cognitive impairment was found
to be associated with the presence of retinal micro-
vascular abnormalities in all studies, although the extent
of the association varied. The presence of retinal vascular
signs was mostly associated with poorer verbal memory,
mental speed and executive function in the general
population, but not consistently associated with other
cognitive modalities.
Conclusions: There is some evidence suggesting a
positive association between retinal microvascular
abnormalities and cognitive impairment or dementia in
elderly people and in patients with diabetes. Findings are
inconclusive, and further better designed studies are
required, with standardised and objective retinal vascular
assessment and a range of sensitive cognitive tests.
Cognitive impairment and dementia are important
causes of morbidity and mortality in elderly people
in Western countries. Apart from the effects of
normal ageing, marked inter-individual differences
in the rate of cognitive decline indicate that other
age-associated pathologies may be involved, such
as macro- or microvascular disease. Current pri-
mary prevention programmes, aimed at reducing
the impact of macrovascular disease, have proved
unsuccessful in reducing the risk of cognitive
decline, other than by preventing major strokes.1–5
Improved prevention of cognitive dysfunction
therefore requires a better understanding of under-
lying pathogenic mechanisms, identification of
novel risk factors and development of new
approaches to recognition of people at high risk.6
Several pathobiological markers have been sug-
gested as potential predictors of cognitive dysfunc-
tion. These include non-invasive measures of
cerebral microvascular disease, such as white-
matter hyperintensities and lacunar infarcts
detected by magnetic resonance imaging (MRI),
and retinal microvascular signs.7–9 Of these, retinal
microvascular signs may offer the most promise as
a potential tool in clinical practice, as they can be
simply and accessibly measured. Based on retinal
photographs, retinal microvascular abnormalities,
such as the presence of microaneurysms, soft
exudates, haemorrhages and generalised arteriolar
narrowing, predict incident stroke as well as MRI-
identified subclinical stroke independent of other
measured risk factors.10–13 Recently, influenced by
the homology between retinal vascular disease and
cerebral small vessels disease, several studies have
investigated retinal microvascular abnormalities
and risk of cognitive impairment and dementia in
patients and in the general population. These
studies are reviewed systematically in this article.
METHODS
We aimed to include all published studies that
investigated the association between retinal micro-
vascular abnormalities and cognitive dysfunction
in adult subjects, available for review by July 2007.
Studies had to meet the following predetermined
inclusion criteria: (a) observational epidemiological
design (ie, cross-sectional, case-control, cohort), (b)
inclusion of a cognitive function assessment tool
that was either a structured neuropsychological
test or a clinical evaluation of dementia, (c)
assessment of the retinal microvasculature (either
characteristics associated with generalised retino-
pathy or changes specific to arterioles or venules,
such as focal arteriolar narrowing or venular
tortuosity) but not other retinal conditions, which
fail to offer a direct measure of retinal vascular
signs (such as age-related maculopathy), (d) provi-
sion of data relating retinal microvascular lesions
to cognitive function. Studies in which participants
were selected on the basis of existing infectious
disease due to a virus or bacteria were excluded
because cognitive dysfunction in these subjects is
likely to have specific pathology peculiar to the
infectious disease.
Studies were identified by computerised searches
of PubMed (Medline), EMBASE, PsycINFO,
BIOSIS Previews, and Web of Science, by checking
the reference lists of relevant original and review
articles, by reference to conference proceedings,
and by tracking articles that cited retrieved studies
using Science Citation Index. A detailed ‘‘topic
only’’ search strategy was adopted, as it proves the
most sensitive. The search string for each database
was similar with the terms ‘‘retinopath* OR
(retina* AND (microvascu* OR arteriol* OR venul*
OR vascu*)) AND (cognit* OR Alzheim* OR
dementi* OR memor* OR neuropsycholog*).’’
Searches were limited to the English language.
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Further details on the search strategy are available from the
authors on request.
The titles and abstracts of studies identified were screened by
one reviewer (JD), and potentially relevant full-text articles
were retrieved and assessed according to the inclusion criteria.
Data were extracted by two reviewers (RJM and JD), who also
independently assessed methodological quality of studies, using
a scoring system based on previously published guidelines.14 15
The following information was extracted from included studies:
method of assessment of retinal microvascular abnormalities,
measurement of cognitive function, and all relevant results,
including adjustment for potential confounding factors. Studies
were assessed for both internal and external validity (Box).
Studies scoring less than six out of a possible maximum nine for
case control or cross-sectional studies, and less than seven out of
11 for cohort studies were excluded for further analysis.
Disagreements in rating were resolved by discussion or
arbitrated by a third reviewer (JP). Owing to a high degree of
heterogeneity between studies, including study designs, type of
population, measures of retinal vascular characteristics, types of
neuropsychological tests and covariates included in analyses,
meta-analysis of study results was not possible. A descriptive
synthesis approach was therefore used.
RESULTS
The numbers of studies identified at each stage of the
systematic review are shown in fig 1. Of the eight studies
meeting our inclusion criteria,16–23 two were subsequently
excluded, as they did not fulfil the quality criteria.16 17 The key
details of the six included studies are summarised in tables 1, 2.
Study design and populations
The six included studies comprised two prospective cohort
studies in which cognitive function was measured both at
baseline (when retinal images were taken) and at follow-up,18 19
and four cross-sectional studies.20–23 Three studies were popula-
tion-based21–23 and three hospital- or clinic-based.18–20 The
populations sampled came from the US, UK and Japan. The
clinic and hospital-based studies involved patients with type 1
or type 218 20 and patients with type 2 diabetes after coronary
artery bypass grafting (CABG).19 The age range of participants
(at baseline) was 18–35 years18 to 83–84 years23 and all studies
included both men and women. In the prospective studies, the
duration of follow-up was 6 months and 7 years, respectively,
with losses to follow-up estimated to be 5%19 and 39%.18
In three of the four cross-sectional studies, a retinal
examination was undertaken at the same time as the cognitive
testing. In the other study, the cognitive function tests were
performed 3 years before or after retinal photography, and the
average test scores were used in the analysis.21 One prospective
study in which cognitive abilities were assessed both at baseline
and at 7 years’ follow-up examined the presence of retinopathy
biennially as well as at baseline.18
Assessment of retinal microvascular abnormalities
Both the techniques and grading methods used to evaluate
retinal microvascular signs varied between the studies. In one
study, the combination of ophthalmoscopic examination with
digital retinal photography was adopted,20 whereas in the
remaining studies, colour fundus photography alone was used.
Prior to retinal photography, pharmacological dilation of the
pupil(s) was performed in two studies.18 23 The angle used for
the field of view in photography differed, ranging from 30u18–20
to 45u21 22 or 50u.23 Three studies reported that only one eye was
assessed21–23 (arbitrarily chosen) but the other studies did not
provide such information.
In the studies using a fully manual grading system, subjects
were categorised either according to the presence of diabetic
retinopathy varying with severity,18–20 or into one of several
defined groups, including the presence of: (1) any specific
retinopathy signs (microaneurysms, retinal haemorrhages,
cotton wool spots, soft exudates, macular oedema, venous
beading, etc); (2) arteriovenous nicking; (3) focal arterial
narrowing (table 3).21 22 At least three different classification
systems for retinal vascular signs were used in five studies.
Computer-assisted imaging techniques were applied in three
studies to quantify retinal vessel calibre and other parameters of
retinal vascular network geometry.21–23 One study focusing on
quantitative measures alone assessed five continuous variables:
the central retinal arterial equivalent (CRAE), central retinal
venular equivalent (CRVE), arteriovenous ratio (AVR), sub-
optimal geometry of arteriolar branching coefficients and angles
(table 3).23
Assessment of cognitive function and impairment
Cognitive function was assessed using four primary methods:
(1) specific cognitive tests; (2) a mean/composite score on two
or more tests in the battery;18 (3) general cognitive ability score
(g) generated by extracting a component reflecting the variance
shared by all tests;23 (4) clinical assessment alone (eg, diagnosis
of dementia).22 Results were reported as either continuous or
categorical outcomes. More than 17 different psychometric tests
were used among these studies. To help organise discussion,
many of these neuropsychological tests can be classified into the
cognitive domains that they examined, including attention/
concentration, information processing speed, manual dexterity,
frontal lobe/executive function, verbal memory, performance
IQ, and mini-mental state examination (table 4).28 29 In one
study, patients with dementia were identified through a
detailed diagnostic examination, and dementia was defined
according to recognised international criteria.22 30
Three of the studies including one of the prospective studies
divided the participants into two groups based on whether or
not they experienced cognitive impairment or decline (during
follow-up). Cognitive impairment was defined in a variety of
ways that included: (1) a decline by a particular amount relative
to the baseline test score;19 (2) test scores below a particular
threshold score;21 or (3) the presence of clinically diagnosed
dementia.
Findings from studies on patients with diabetes
The results of the studies on subjects with diabetes are shown
in table 1.
In 74 patients with type 1 diabetes,20 the presence of retinal
microaneurysms was associated with poorer performance on
some tests of performance IQ (Block Design, Digit Symbol
Test), information-processing speed and attention but not on
other tests of performance IQ or executive function. In a second
study of 103 patients with type 1 diabetes,18 the presence of
proliferative diabetic retinopathy (PDR) at baseline or develop-
ment of the condition during follow-up was associated with
poorer performance on measures of ‘‘psychomotor efficiency’’ (a
composite score based on the results of four tests: Digit
Vigilance, Digit Symbol Test, Grooved Pegboard and Part B of
the Trail Making). Compared with diabetic people without
retinopathy at either assessment, there was a cognitive decline
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either in subjects with PDR at baseline (change in test score
20.50 vs 20.22, p,0.02) or in incident PDR (change in test
score 20.56 vs 20.22, p,0.02) over 7 years. In both studies, the
association remained significant after adjusting for a variety of
demographic and several important diabetes-related variables.
The magnitude of the cognitive deficits observed in these young
adult subjects was moderate to large, with effect sizes for the
group difference ranging from about 0.3 to 0.7 SD (according to
Cohen’s terminology31).
In 180 patients with type 2 diabetes,19 after adjustment for a
number of biomedical and demographic variables, the presence
of diabetic retinopathy assessed prior to CABG surgery was
associated with an increased risk of cognitive decline (compared
with preoperative cognitive performance) after 7 days (OR 2.0,
95% CI 1.3 to 3.0) and 6 months (OR 2.1, 95% CI 1.2 to 2.7)
following surgery.
Findings from studies on population-based samples
The results from population-based studies are shown in table 2.
In the Atherosclerosis Risk in Communities Study of 8,734
middle-aged men and women free of stroke,21 the presence of
any retinopathy, microaneurysms, retinal haemorrhages or soft
exudates was associated with an increased risk of impaired
performance on tests of verbal memory (Delayed Word Recall),
information-processing speed (Digit Symbol Test) and executive
function (Verbal Fluency Test). The presence of arteriolar
narrowing or AV nicking was not associated with these tests.
Subjects with any of these retinal vascular lesions were 2.6 (OR
(95% CI 1.3 to 2.9)) to 3.4 (OR (95% CI 2.0 to 5.8)) times more
likely to have cognitive impairment than people without these
lesions independent of other covariates.
In the Cardiovascular Health Study22 of 2,211 men and
women, the presence of any retinopathy was associated with
poorer performance on information processing speed (Digital
Symbol Test, adjusted mean test scores 39 vs 42, p = 0.02), but
not on the MMSE. No association was found with the presence
of focal arteriolar narrowing, AV nicking or quintiles of retinal
calibre. In a hypertensive subgroup, the presence of any
retinopathy (multivariable-adjusted OR, 2.10 (95% CI 1.04 to
4.24)) or focal arteriolar narrowing (OR, 3.02 (95% CI 1.51 to
6.02)) was associated with an increased risk of dementia, but no
association was found with the presence of other retinal
vascular signs.
In the Lothian Birth Cohort 1921 study23 of 321 elderly men
and women, the deviation from optimality of the retinal
vascular network geometry was associated with lower cognitive
ability scores, but no association was found for retinal arteriolar
or venular calibre. After controlling for a variety of other
covariates, suboptimality of angles at arteriolar bifurcations
(from theoretically derived-optimum values) was associated
Box 1 Quality assessment of studies
Participant selection and recruitment (maximum 2 points)
c Well-defined population sample (the final study sample was
likely to be representative of the target population) (1)
c (Baseline) response rate 70% or more (1)
Participation at follow-up (maximum 2 points)
c Follow-up period more than 1 year (1)
c Loss to follow-up less than 30–40% (death was excluded from
the estimate) (1)
Retinal microvascular abnormalities assessment (maximum 3
points)
c Retinopathy status based on self-report or medical records (0)
or
c Ophthalmoscopic examination (1)
or
c Retinal photography and grading based on a standardised
protocol (2)
c Assessors blinded to cognitive status (1)
Cognitive function and/or dementia assessment (maximum 3
points)
c Only a global functioning test (1)
or
c Neuropsychological battery (2)
or
c Dementia based on medical records (0)
or
c Dementia diagnosed by active screening with specific criteria
(1)
or
c Dementia based on worldwide recognised criteria by a central
consensus committee (2)
c Assessors blinded to ocular findings and other major clinical
disease status (1)
Adjustment for confounding (maximum 1 point)
c Effect of main confounders not investigated (at baseline) (0)
or
c Main confounders reported but not adjusted in the final
analysis (0)
or
c Main confounders reported and adequately adjusted in the
analysis (1)
Eligible studies: scoring >7/11 for cohort studies and >6/9 for
case-control/cross-sectional studies
Figure 1 Flow chart of eligibility of studies.
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with poorer verbal memory (Logical Memory) but not other
cognitive modalities including general cognitive ability (g),
executive function (Verbal Fluency Test) or performance IQ
(Raven’s Matrices); suboptimal branching coefficient (from
theoretically derived-optimum values) was associated with
poorer general cognitive ability and verbal fluency but not
other tests. The effect size of the variance in cognitive test
scores explained by the retinal vascular abnormalities was small,
ranging from 2.6% to 3.7%.
DISCUSSION
This is the first systematic review of the association between
retinal vascular signs and cognitive dysfunction. Findings are
consistent with the hypothesis that retinal microvascular
abnormalities are associated with cognitive impairment or
dementia in patients with diabetes and in the general
population, although findings are not conclusive due to varied
and sometimes limited methodology in the included studies.
The presence of retinal vascular signs was mostly associated
with poorer verbal memory, information-processing speed
(Digit Symbol Test) and executive function (Verbal Fluency
Test) in the general population. Furthermore, the longitudinal
studies in this review may have underestimated the association
with retinal abnormalities and cognitive function in patients
with diabetes because of survival bias. Patients with diabetes
with retinopathy at baseline were more likely not to attend for
follow-up (including deaths), when follow-up success itself
could well be related to good cognitive function, but the two
studies did not report the retinopathy status of individuals lost
to follow-up.18 19 Indeed, one study had a higher proportion of
drop-outs.18
If there is indeed a direct relationship between retinal vascular
abnormalities and cognitive function, this may reflect the
homology between the retinal and cerebral microvasculatures.9
Similar to changes in the retinal vasculature, these microvascular
changes might lead to chronic ischaemia of the brain and the
development of white-matter lesions. In epidemiological studies,
the presence of retinal vascular lesions that reflect a breakdown of
the blood–retinal barrier, including microaneurysms, retinal
haemorrhages and soft exudates, was related most consistently
to stroke, stroke mortality, white-matter lesions and cerebral
atrophy.10–13 Thus, the similar disruption of the blood–brain
barrier of the cerebral microcirculation could be an important
pathophysiological feature in the occurrence of cognitive impair-
ment and dementia.32
Compared with ophthalmoscopic examination, the assess-
ment of retinal photographs has been suggested as a more
reliable method for measuring a number of retinal vascular
signs, including generalised and focal arteriolar narrowing,
arteriovenous (AV) nicking, isolated retinal haemorrhages,
microaneurysms and cotton wool spots.6 33–35 Computer-assisted
measures of retinal vascular widths (to define generalised
arteriolar narrowing, venular dilation and other measures of
retinal vascular network geometry) have been found to detect
subtle microvascular changes with low intra- and inter-observer
variability.10 13 35 36 Grading of other abnormalities (such as focal
arteriolar attenuation and retinal haemorrhages) is still largely
done manually and therefore highly operator-dependent,
though automated techniques are being developed. The
reliability of grading of focal retinal abnormalities has also been
shown to be dependent on the classification system used.37
Despite the use of standardised protocols, differing methods and
grading systems for measuring retinal microvascular abnormal-
ities could explain at least in part some of the inconsistent
findings between studies in this review.
Many observed changes in cognitive function of interest in
studies are generally small,38 and mild cognitive impairment is
an established risk factor for the subsequent development of
dementia39 This requires measurement of cognitive function
that use validated (sensitive to small increments of change) and
Table 3 Terminology and definitions of retinal microvascular abnormalities used in included studies
Retinal microvascular signs Definitions References
Background diabetic retinopathy Presence of two or more microaneurysms in one eye Ferguson et al20
Proliferative diabetic retinopathy (PDR) A grading level at 60 or higher in one eye, or less than 60 but with panretinal photocoagulation scars
consistent with laser therapy*
Ryan et al18
Diabetic retinopathy A grading level greater than 10 (10 = no retinopathy){ Kadoi et al19
Any retinopathy Presence of any of the following lesions (not explicitly arteriolar in nature): microaneurysms, retinal
haemorrhages, soft exudates, hard exudates, macular oedema, intraretinal microvascular abnormalities
(tortuous intraretinal vessels), venous beading, new vessels at the disc or elsewhere, vitreous
haemorrhage, disc swelling, or laser photocoagulation scars{
Wong et al,21 Baker et al22
Focal arteriolar narrowing (FAN) An arteriole estimated to be 50 mm diameter or greater has a constricted area of 2/3 or less the width of
proximal and distal vessel segments{
Wong et al,21 Baker et al22
Arteriovenous nicking (AV nicking) A venule is constricted on both sides of its crossing under an arteriole in a specified region{ Wong et al,21 Baker et al22
Generalised arteriolar narrowing Lowest 20th percentile of the sample arteriole-to-venule ratio (AVR) distribution measured on a continuous
scale via a computer-assisted technique
Wong et al21
Arteriovenous ratio (AVR) A ratio between the summarised calibre measurements of the arterioles (CRAE) with respect to the
venules (CRVE)1
Wong et al,21 Patton et al23
Central retinal arterial equivalent
(CRAE)
Combined calibre measurements of individual arterioles coursing through a circular zone defined as
between 0.5 and 1 disc diameter from the optic disc margin1
Wong et al,21 Baker et al,22
Patton et al23
Central retinal venular equivalent
(CRVE)
Combined calibre measurements of individual venules coursing through a circular zone defined as between
0.5 and 1 disc diameter from the optic disc margin1
Wong et al,21 Baker et al,22
Patton et al23
Arteriolar branching coefficient (BC) A ratio expressing the relationship between trunk vessel (W) and two branch vessels (w1 and w2) on
vessel widths at arteriolar branching points: BC = (w1
2+w22)/w2
Patton et al23
Arteriolar bifurcation angles (BA) An angle (degree) measured at arteriolar branching points between the two branch arterioles Patton et al23
Suboptimal branching coefficient The degree of deviation of the BC from optimality (ie, a theoretical value of 1.26) Patton et al23
Suboptimal angles The difference of the degree of BA from optimality (ie, a theoretical and empirical value of 75u) Patton et al23
*The Wisconsin Epidemiologic Study of Diabetic Retinopathy Classification and Grading System.24
{The Diabetic Retinopathy Study and the Early Treatment Diabetic Retinopathy study grading scale.25
{The Modified Airlie House Classification of Diabetic Retinopathy.26
1Methods for evaluation of retinal microvascular abnormalities associated with Hypertension/Sclerosis in the Atherosclerosis Risk in Communities Study.27
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reliable psychometric tests. In one of the studies, MMSE scores
were used as a measure of cognitive function.22 However, the
MMSE is a relatively insensitive test, which is designed to screen
for dementia but not to measure subtle changes in cognitive
decline.40–42
The majority of cross-sectional studies of cognitive function
relied on cognitive performance at a single time point, which
does not capture the pathological process under study—
cognitive decline or change over time. Premorbid cognitive
ability represents the highest level of ability attained prior to
any cognitive decrements taking place and is also known to
account for a substantial proportion of the variance in cognitive
function scores in old age.28 43 44 Some studies estimated prior
ability by a patient’s education and occupation history, but this
is limited in that these features may be influenced by lack of
opportunity rather than lack of ability.28 45 The National Adult
Reading Test (NART) could be a more useful measure, as word
reading ability is preserved even in generalised cognitive
decline.45 Adjusting scores on a fluid mental test for NART
has been shown to be a valid, instantaneous measure of lifetime
cognitive change or decline.46 47 Only one study adjusted for
premorbid IQ in an attempt to get a direct measure of lifetime
cognitive decline.23
Most studies assessed important potential confounders such
as age, gender, lifestyle factors and medical conditions. Patients
with neurological conditions (including a history of stroke) that
might interfere with cognitive abilities were also excluded from
all studies. However, subjects with a history of chronic alcohol
or drug abuse were only variably excluded. In addition,
inadequate adjustment was generally made for visual acuity
and depression. Some of the cognitive tasks may require at least
moderate visual function to complete and if diabetic people
with severe retinopathy have greatly impaired vision, their
scores on the relevant cognitive testing could be affected. Two
of the studies collected data on visual acuity18 23 and one study
controlled for this.23 Depression may confound the association
between retinal microvascular disease and cognitive dysfunction
because depression can be mistaken for dementia (and vice
versa), and is associated with deficits of memory and learning,
and occurs more frequently in those with diabetes-related
complications including retinopathy.48–53 Two studies assessed
the potential effects of low mood.18 20
It should be noted that we reviewed only published studies,
and it is possible that studies which did not show an association
between retinal vascular disease and cognitive dysfunction may
not have been published as often as studies that did. It was not
possible to test for this formally (eg, by use of a funnel plot)
because studies were too few and too methodologically
heterogeneous. Clinic-based studies on patients with diabetes
used variable inclusion criteria and this limited the generalisa-
bility of the results. Diabetes-related cognitive impairment may
have different underlying mechanisms from cognitive dysfunc-
tion in the general population and may differ in patients with
type 1 diabetes, type 2 diabetes and postoperatively. However,
population-based studies are scarce so far restricted to a cross-
sectional design, which makes it impossible to determine the
temporal relationship between retinal vascular disease and
cognitive dysfunction (though it is perhaps unlikely that
cognitive impairment leads directly to retinal vascular abnorm-
alities). Findings are not consistent regarding the importance of
the association which are limited by substantial differences in
methodology between the studies, small size of some of the
studies, restricted controlling for potential confounding factors
and variability in the range of cognitive domains and retinal
microvascular abnormalities measured. Further better-designed
studies are required, with a common, standardised and objective
retinal vascular assessment, together with a range of sensitive
cognitive tests.
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